<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"><channel rdf:about="http://onlinelibrary.wiley.com/rss/journal/10.1002/(ISSN)1097-0347" xmlns="http://purl.org/rss/1.0/"><title>Head &amp; Neck</title><description> Wiley Online Library : Head &amp; Neck</description><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2F%28ISSN%291097-0347</link><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc</dc:publisher><dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">en</dc:language><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Copyright © 2013 Wiley Periodicals, Inc., A Wiley Company</dc:rights><prism:issn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1043-3074</prism:issn><prism:eIssn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1097-0347</prism:eIssn><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-06-01T00:00:00-05:00</dc:date><prism:coverDisplayDate xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">June 2013</prism:coverDisplayDate><prism:volume xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">35</prism:volume><prism:number xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">6</prism:number><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">E171</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">E201</prism:endingPage><image rdf:resource="http://onlinelibrary.wiley.com/store/10.1002/hed.v35.6/asset/cover.gif?v=1&amp;s=d2317d75ce7fba6621ffb105d87654e011d7d24e"/><items><rdf:Seq><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23376"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23380"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23381"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23378"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23377"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23375"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23374"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23365"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23369"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23372"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23371"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23370"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23368"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23367"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23366"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23364"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23363"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23362"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23361"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23360"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23354"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23350"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23348"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23359"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23358"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23357"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23356"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23355"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23353"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23352"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23351"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23349"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23347"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23346"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23345"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23344"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23343"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23342"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23341"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23340"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23339"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23338"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23337"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23336"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23335"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23260"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23274"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23254"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23257"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23259"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23267"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23253"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23285"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23284"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23266"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23265"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23262"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23249"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23277"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23282"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23280"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23283"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23243"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23258"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23064"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23279"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23218"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23231"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23234"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23235"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23236"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23237"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23239"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23240"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23246"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23228"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23230"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23242"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23244"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23233"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23227"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23226"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23225"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23223"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23210"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23245"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23241"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23238"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23232"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23229"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23220"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23217"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23214"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23213"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23215"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23219"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23190"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23211"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23216"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23209"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23186"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23191"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23197"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23199"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23200"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23201"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23202"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23206"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23158"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23181"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23182"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23183"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23187"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23198"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23195"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23204"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23096"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23194"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23205"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23196"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23059"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23184"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23188"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23189"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23193"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23185"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23175"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23170"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23126"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23144"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23104"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23145"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23160"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23173"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23174"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23172"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23050"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23152"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23159"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22950"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23147"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23164"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23088"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23105"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23153"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23154"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23156"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23169"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23138"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23139"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23150"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23151"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23108"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23120"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23094"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23116"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23131"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23137"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23157"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23161"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23163"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23171"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23140"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23141"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23143"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23146"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23148"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23149"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23155"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23162"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23093"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23130"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23142"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23110"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23106"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23099"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23123"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23124"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23125"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23127"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23128"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23129"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23097"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23112"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23115"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23119"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23082"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23101"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23102"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23103"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23107"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23109"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23111"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23113"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23114"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23002"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23086"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23087"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23092"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23095"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23098"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23089"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23080"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23090"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23051"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23055"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23091"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23117"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23118"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23121"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23065"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23048"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23063"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23085"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23046"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23076"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23077"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23079"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23081"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23083"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23084"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23039"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23060"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23073"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23071"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23072"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23074"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23040"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23061"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23066"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23075"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23027"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23031"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23049"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23062"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23052"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23028"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23015"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23000"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22971"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22976"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22962"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23025"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23030"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23029"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23032"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23033"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23034"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23036"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23035"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23038"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23037"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23043"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23042"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23041"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23054"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23053"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23058"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23057"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23056"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22917"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22923"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22922"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23177"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23180"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22914"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22918"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22931"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22926"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22940"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22955"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22956"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22975"/></rdf:Seq></items></channel><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23376" xmlns="http://purl.org/rss/1.0/"><title>HED-11-0074.R1 - Role of ultrasound-guided core-needle biopsy in the assessment of Head and Neck lesions: A Meta-analysis and Systematic review of the literature</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23376</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">HED-11-0074.R1 - Role of ultrasound-guided core-needle biopsy in the assessment of Head and Neck lesions: A Meta-analysis and Systematic review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eva Novoa, Ehab Y. Hanna</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-22T03:20:02.728795-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23376</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23376</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23376</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Reply to Letter to the Editor</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23380" xmlns="http://purl.org/rss/1.0/"><title>Depth of invasion, tumor budding and worst pattern of invasion classify patients with early stage oral tongue cancer into low- and high-risk categories of mortality</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23380</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Depth of invasion, tumor budding and worst pattern of invasion classify patients with early stage oral tongue cancer into low- and high-risk categories of mortality</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alhadi Almangush, Ibrahim O. Bello, Harri Keski-Säntti, Laura K. Mäkinen, Joonas H. Kauppila, Matti Pukkila, Jaana Hagström, Jussi Laranne, Satu Tommola, Outi Nieminen, Ylermi Soini, Veli-Matti Kosma, Petri Koivunen, Reidar Grénman, Ilmo Leivo, Tuula Salo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-21T02:38:29.179645-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23380</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23380</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23380</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Background</em>. Oral (mobile) tongue squamous cell carcinoma (OTSCC) is characterized by a highly variable prognosis in early stage disease (T1/T2 N0M0). The ability to classify early OTSCCs into low- and high-risk categories would represent a major advancement in their management.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Methods</em>. Depth of invasion, tumor budding, histologic risk-assessment score (HRS) and cancer-associated fibroblasts (CAF) density were studied in 233 cases of T1/T2 N0M0 OTSCC managed in five university hospitals in Finland.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Results</em>. Tumor budding (≥5 clusters at the invasive front of the tumor) and depth of invasion (&gt;4 mm) were associated with poor prognosis in patients with early OTSCC, <span class="underlined ">hazard ratio (HR)</span>, 2.04 with <span class="underlined ">95% confidence interval, CI,</span> (1.17-3.55) and <span class="underlined ">HR,</span> 2.55 (<span class="underlined ">95% CI,</span> 1.25-5.20), respectively after multivariate analysis. The HRS and CAF density did not predict survival. However, high-risk worst pattern of invasion (WPOI), a component of HRS, was also an independent prognostic factor: <span class="underlined ">HR,</span> 4.47 (<span class="underlined ">95% CI,</span> 1.59-12.51).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Conclusion</em>. Analyzing the depth of invasion, tumor budding and/or WPOI in prognostication and treatment planning of T1/T2 N0M0 OTSCC is recommended. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background. Oral (mobile) tongue squamous cell carcinoma (OTSCC) is characterized by a highly variable prognosis in early stage disease (T1/T2 N0M0). The ability to classify early OTSCCs into low- and high-risk categories would represent a major advancement in their management.
Methods. Depth of invasion, tumor budding, histologic risk-assessment score (HRS) and cancer-associated fibroblasts (CAF) density were studied in 233 cases of T1/T2 N0M0 OTSCC managed in five university hospitals in Finland.
Results. Tumor budding (≥5 clusters at the invasive front of the tumor) and depth of invasion (&gt;4 mm) were associated with poor prognosis in patients with early OTSCC, hazard ratio (HR), 2.04 with 95% confidence interval, CI, (1.17-3.55) and HR, 2.55 (95% CI, 1.25-5.20), respectively after multivariate analysis. The HRS and CAF density did not predict survival. However, high-risk worst pattern of invasion (WPOI), a component of HRS, was also an independent prognostic factor: HR, 4.47 (95% CI, 1.59-12.51).
Conclusion. Analyzing the depth of invasion, tumor budding and/or WPOI in prognostication and treatment planning of T1/T2 N0M0 OTSCC is recommended. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23381" xmlns="http://purl.org/rss/1.0/"><title>ACR Appropriateness Criteria® Treatment of Stage 1 T1 Glottic Cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23381</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">ACR Appropriateness Criteria® Treatment of Stage 1 T1 Glottic Cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John A. Ridge, Joshua Lawson, Sue S. Yom, Madhur Kumar Garg, Mark W. McDonald, Harry Quon, Nabil Saba, Joseph K. Salama, Richard V. Smith, Francis Worden, Anamaria Reyna Yeung, Jonathan J. Beitler</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-21T02:36:41.56112-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23381</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23381</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23381</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Background: Controversy surrounds the appropriate therapy for T1 glottic cancer. Both transoral endolaryngeal resection and radiation offer excellent local control and voice quality; some lesions are best addressed resection and others with radiation.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Methods: The American College of Radiology (ACR) Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed by a multidisciplinary expert panel. The guideline development includes an analysis of current literature from peer reviewed journals and the well-established “modified Delphi” consensus methodology to rate the appropriateness of treatment. Where evidence is not definitive, expert opinion informed recommendations.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Results: The ACR Expert Panel on Radiation Oncology – Head and Neck Cancer developed consensus recommendations for treatment of T1 glottic cancer. Treatment planning is complex and decisions nuanced.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Conclusions: Best treatment for a particular cancer cannot be defined without consideration of the lesion's location, extent, depth of invasion, and quality of surgical exposure during direct laryngoscopy. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: Controversy surrounds the appropriate therapy for T1 glottic cancer. Both transoral endolaryngeal resection and radiation offer excellent local control and voice quality; some lesions are best addressed resection and others with radiation.
Methods: The American College of Radiology (ACR) Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed by a multidisciplinary expert panel. The guideline development includes an analysis of current literature from peer reviewed journals and the well-established “modified Delphi” consensus methodology to rate the appropriateness of treatment. Where evidence is not definitive, expert opinion informed recommendations.
Results: The ACR Expert Panel on Radiation Oncology – Head and Neck Cancer developed consensus recommendations for treatment of T1 glottic cancer. Treatment planning is complex and decisions nuanced.
Conclusions: Best treatment for a particular cancer cannot be defined without consideration of the lesion's location, extent, depth of invasion, and quality of surgical exposure during direct laryngoscopy. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23378" xmlns="http://purl.org/rss/1.0/"><title>Conclusions about HPV-Related Malignancies</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23378</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Conclusions about HPV-Related Malignancies</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wendell G. Yarbrough, Eben Rosenthal</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-21T02:32:09.522294-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23378</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23378</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23378</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Editorial Comment</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23377" xmlns="http://purl.org/rss/1.0/"><title>Methodological issues in meta-analysis of diagnostic accuracy studies</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23377</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Methodological issues in meta-analysis of diagnostic accuracy studies</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert L. Schmidt</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-16T02:08:51.374721-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23377</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23377</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23377</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Letter to the Editor</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23375" xmlns="http://purl.org/rss/1.0/"><title>International head and neck cancer epidemiology consortium: Update no. 11</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23375</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">International head and neck cancer epidemiology consortium: Update no. 11</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Erich M. Sturgis</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-16T01:51:27.297956-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23375</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23375</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23375</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Updates</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23374" xmlns="http://purl.org/rss/1.0/"><title>The 3rd salivary gland tumor workshop meeting report</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23374</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The 3rd salivary gland tumor workshop meeting report</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adel K. El-Naggar, Fredrick Kaye, Göran Stenman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-16T01:43:59.573765-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23374</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23374</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23374</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Editorial Comment</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23365" xmlns="http://purl.org/rss/1.0/"><title>Enoral laser microsurgery for squamous cell carcinoma of the oral cavity</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23365</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Enoral laser microsurgery for squamous cell carcinoma of the oral cavity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martin Canis, Friedrich Ihler, Alexios Martin, Hendrik A. Wolff, Christoph Matthias, Wolfgang Steiner</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T05:01:46.245285-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23365</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23365</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23365</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Objectives</b>: To investigate oncological and functional results of enoral laser microsurgery in treatment of cancer of the oral cavity.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Methods</b>: A retrospective chart analysis was carried out. 232 patients with cancer of the oral cavity were treated by enoral laser microsurgery +/- selective neck dissection +/- postoperative radio(chemo-)therapy.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Results</b>: 72 % (n=168) received a uni- or bilateral selective or modified radical neck dissection, 32 % (n=75) received an adjuvant radio(chemo)therapy. The median follow-up period was 71.89 months. The 5-year overall survival was 54.6 %, recurrence-free survival was 60.2 % and disease specific survival was 70.3 %. Nasogastric feeding tubes were needed in 96 patients, only 2 patients required a temporary gastrostomy tube.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusions</b>: Enoral laser microsurgery is an efficient therapeutic option in the treatment of oral cavity cancer. Oncological and functional results are comparable to any other treatment regimen, while morbidity and complications tend to be lower. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Objectives: To investigate oncological and functional results of enoral laser microsurgery in treatment of cancer of the oral cavity.
Methods: A retrospective chart analysis was carried out. 232 patients with cancer of the oral cavity were treated by enoral laser microsurgery +/- selective neck dissection +/- postoperative radio(chemo-)therapy.
Results: 72 % (n=168) received a uni- or bilateral selective or modified radical neck dissection, 32 % (n=75) received an adjuvant radio(chemo)therapy. The median follow-up period was 71.89 months. The 5-year overall survival was 54.6 %, recurrence-free survival was 60.2 % and disease specific survival was 70.3 %. Nasogastric feeding tubes were needed in 96 patients, only 2 patients required a temporary gastrostomy tube.
Conclusions: Enoral laser microsurgery is an efficient therapeutic option in the treatment of oral cavity cancer. Oncological and functional results are comparable to any other treatment regimen, while morbidity and complications tend to be lower. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23369" xmlns="http://purl.org/rss/1.0/"><title>Trends in head and neck cancers in Peru between 1987-2008: Experience from a large public cancer hospital in Lima</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23369</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Trends in head and neck cancers in Peru between 1987-2008: Experience from a large public cancer hospital in Lima</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Leora Walter, Tatiana Vidaurre, Robert H. Gilman, Ebert Poquioma, Carlos Olaechea, Patti E. Gravitt, Morgan A. Marks</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:20:59.100427-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23369</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23369</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23369</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Background</b>: Few studies have evaluated the trends in head and neck cancer (HNC) in developing countries. The goal of this study is to estimate trends in incidence of HPV-associated (HPV-R) and non-associated (HPV-U) HNC in Lima, Peru from 1987-2008.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Methods</b>: Registry data from a single public cancer hospital were used to estimate age and sex-specific incidence rates. Annualized percent change was estimated using poisson regression.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Results</b>: The rate of total HNC, HPV-U and HPV-R HNC was 11.9, 10.9, and 0.8 per 100,000 person-years. Significant increases in HPV-U HNC were observed in male's aged 30-44 (2.5%/ year) and females 15-29 (4.2%/year), 30-44 (3.4%/year) and 60-74(2.0%/ year). Significant increases in HPV-R HNC were observed only among males aged 45-59 (9.6%/ year).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusions</b>: While increased exposure to tobacco, occupational carcinogens, and changing sexual behaviors could be influencing these trends, additional analyses to assess generalizability of these findings to other regions of Peru are needed. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: Few studies have evaluated the trends in head and neck cancer (HNC) in developing countries. The goal of this study is to estimate trends in incidence of HPV-associated (HPV-R) and non-associated (HPV-U) HNC in Lima, Peru from 1987-2008.
Methods: Registry data from a single public cancer hospital were used to estimate age and sex-specific incidence rates. Annualized percent change was estimated using poisson regression.
Results: The rate of total HNC, HPV-U and HPV-R HNC was 11.9, 10.9, and 0.8 per 100,000 person-years. Significant increases in HPV-U HNC were observed in male's aged 30-44 (2.5%/ year) and females 15-29 (4.2%/year), 30-44 (3.4%/year) and 60-74(2.0%/ year). Significant increases in HPV-R HNC were observed only among males aged 45-59 (9.6%/ year).
Conclusions: While increased exposure to tobacco, occupational carcinogens, and changing sexual behaviors could be influencing these trends, additional analyses to assess generalizability of these findings to other regions of Peru are needed. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23372" xmlns="http://purl.org/rss/1.0/"><title>Transoral laser microsurgery for the unknown primary: A role for lingual tonsillectomy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23372</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Transoral laser microsurgery for the unknown primary: A role for lingual tonsillectomy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas H. Nagel, Michael L. Hinni, Richard E. Hayden, David G. Lott</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:20:53.769369-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23372</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23372</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23372</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Background</em>. We conducted a retrospective review of patients with unknown primary head and neck cancer who underwent a transoral laser <b>microsurgery (TLM)</b> assisted search for an occult tumor.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Methods</em>. Fifty-two patients at a single center with unknown primaries of squamous cell carcinoma were treated with a surgical algorithm.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Results</em>. The overall rate of primary tumor identification was 75% (39/52 patients). When selecting those cases in which a <b>TLM</b> algorithm with lingual tonsillectomy was utilized the detection rate was <b>86% (31/36).</b> Tumors were most commonly found in the lingual (65.0%) and palatine tonsils (27.5%). <b>When directed biopsies did not locate a tumor, a higher yield was obtained with the addition of a lingual tonsillectomy in 8 patients.</b></p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Conclusions</em>. A surgical algorithm for the unknown primary that includes <b>TLM</b>-assisted techniques, <b>including a lingual tonsillectomy</b>, offers the greatest likelihood of successfully detecting the location of occult primary tumors. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background. We conducted a retrospective review of patients with unknown primary head and neck cancer who underwent a transoral laser microsurgery (TLM) assisted search for an occult tumor.
Methods. Fifty-two patients at a single center with unknown primaries of squamous cell carcinoma were treated with a surgical algorithm.
Results. The overall rate of primary tumor identification was 75% (39/52 patients). When selecting those cases in which a TLM algorithm with lingual tonsillectomy was utilized the detection rate was 86% (31/36). Tumors were most commonly found in the lingual (65.0%) and palatine tonsils (27.5%). When directed biopsies did not locate a tumor, a higher yield was obtained with the addition of a lingual tonsillectomy in 8 patients.
Conclusions. A surgical algorithm for the unknown primary that includes TLM-assisted techniques, including a lingual tonsillectomy, offers the greatest likelihood of successfully detecting the location of occult primary tumors. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23371" xmlns="http://purl.org/rss/1.0/"><title>Optimal indication of thyroglobulin measurement in fine-needle aspiration for detecting lateral metastatic lymph nodes in patients with papillary thyroid carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23371</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Optimal indication of thyroglobulin measurement in fine-needle aspiration for detecting lateral metastatic lymph nodes in patients with papillary thyroid carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jin Chung, Eun-Kyung Kim, Hyunsun Lim, Eun Ju Son, Jung Hyun Yoon, Ji Hyun Youk, Jeong-Ah Kim, Hee Jung Moon, Jin Young Kwak</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:20:47.927901-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23371</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23371</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23371</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Background</em>. To evaluate optimal indication of thyroglobulin (Tg) measurement in fine-needle aspiration (FNA) for detecting <span class="underlined ">lateral</span> metastatic lymph nodes (LNs) in patients with papillary thyroid carcinoma.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Methods</em>. We performed a retrospective study of 241 LNs of 220 patients who underwent ultrasound-guided FNA (US-FNA) with Tg in FNA washout fluid (FNA-Tg) measurements for suspicious LNs.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Results</em>. On multivariate analysis, hyperechogenicity, cystic change, presence of calcifications, and peripheral vascularity were independent factors predictive of LN. After adding FNA-Tg, sensitivity and accuracy were significantly increased when the LN had one or two suspicious US <span class="underlined ">features.</span> However, sensitivity and accuracy were not significantly increased when the LN had multiple suspicious US features.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Conclusion</em>. Additional FNA-Tg can help diagnose a metastatic LN with one or two suspicious US features. <span class="underlined ">However, additional FNA-Tg is not beneficial in LNs with highly suspicious US features, where FNA alone is sufficient for diagnosis of metastasis.</span> <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background. To evaluate optimal indication of thyroglobulin (Tg) measurement in fine-needle aspiration (FNA) for detecting lateral metastatic lymph nodes (LNs) in patients with papillary thyroid carcinoma.
Methods. We performed a retrospective study of 241 LNs of 220 patients who underwent ultrasound-guided FNA (US-FNA) with Tg in FNA washout fluid (FNA-Tg) measurements for suspicious LNs.
Results. On multivariate analysis, hyperechogenicity, cystic change, presence of calcifications, and peripheral vascularity were independent factors predictive of LN. After adding FNA-Tg, sensitivity and accuracy were significantly increased when the LN had one or two suspicious US features. However, sensitivity and accuracy were not significantly increased when the LN had multiple suspicious US features.
Conclusion. Additional FNA-Tg can help diagnose a metastatic LN with one or two suspicious US features. However, additional FNA-Tg is not beneficial in LNs with highly suspicious US features, where FNA alone is sufficient for diagnosis of metastasis. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23370" xmlns="http://purl.org/rss/1.0/"><title>Craniofacial bone reconstruction with bioactive fibre-reinforced composite implant</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23370</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Craniofacial bone reconstruction with bioactive fibre-reinforced composite implant</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kalle M.J. Aitasalo, Jaakko M. Piitulainen, Jami Rekola, Pekka K. Vallittu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:20:45.933801-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23370</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23370</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23370</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="hed23370-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>A novel, bioactive, fibre-reinforced composite implant is a solution to address the shortcomings in craniofacial bone reconstruction. A longitudinal, clinical investigation with a follow-up time of 4 years, was conducted.</p></div></div>
<div class="section" id="hed23370-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A cranial bone reconstruction with the implant was performed to 12 patients. In these patients, the reasons for craniotomies resulting in craniofacial bone defects, were traumatic and spontaneous intra-cranial bleeding as well as infections to the primary reconstruction material. The implant material consisted of a supporting fibre-reinforced framework, porous inner layers and a bioactive glass (S53P4) filling. The framework and the porous layers were made of a pBisGMA-pTEGDMA resin matrix, which was reinforced with silanized E-glass.</p></div></div>
<div class="section" id="hed23370-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In clinical examinations and skull x-rays, the implants were in original positions providing the expected functional and aesthetic outcome at all time points.</p></div></div>
<div class="section" id="hed23370-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The implants functioned appropriately which would provide a potential solution for craniofacial bone reconstruction in the future. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
A novel, bioactive, fibre-reinforced composite implant is a solution to address the shortcomings in craniofacial bone reconstruction. A longitudinal, clinical investigation with a follow-up time of 4 years, was conducted.


Methods
A cranial bone reconstruction with the implant was performed to 12 patients. In these patients, the reasons for craniotomies resulting in craniofacial bone defects, were traumatic and spontaneous intra-cranial bleeding as well as infections to the primary reconstruction material. The implant material consisted of a supporting fibre-reinforced framework, porous inner layers and a bioactive glass (S53P4) filling. The framework and the porous layers were made of a pBisGMA-pTEGDMA resin matrix, which was reinforced with silanized E-glass.


Results
In clinical examinations and skull x-rays, the implants were in original positions providing the expected functional and aesthetic outcome at all time points.


Conclusions
The implants functioned appropriately which would provide a potential solution for craniofacial bone reconstruction in the future. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23368" xmlns="http://purl.org/rss/1.0/"><title>Effectiveness of transoral laser microsurgery for precancerous lesions and early glottic cancer guided by analysis of voice quality</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23368</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effectiveness of transoral laser microsurgery for precancerous lesions and early glottic cancer guided by analysis of voice quality</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Abdulrahman A. Bahannan, Aleš Slavíček, Libor Černý, Jan Vokřal, Zdenek Valenta, Radka Lohynska, Martin Chovanec, Jan Betka</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:20:42.447993-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23368</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23368</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23368</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Background: Comparison of the quality of voice obtained after superficial transoral endoscopic cordectomies (type I, II and III) according to the European Laryngological Society classification versus the more extended cordectomy (type IV and V) among patients with glottic precancerous lesions or early glottic cancer.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Methods: Sixty two patients underwent vocal assessment after cordectomy (type I-V) for dysplasia, Tis, T1a, T1b, and T2 lesions.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Results: Cordectomy (type I-III) had good vocal outcomes. Cordectomy (type IV-V) showed less favorable outcomes, <em>P</em> &lt; 0.005 in common parameters of voice range profile and symmetry in stroboscopy following cordectomy (type IV-V), with significant voice handicap index.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Recurrences were found in four cases with T1b and T2 cancer. Two cases were managed by higher type of cordectomy, and the other two by total laryngectomy.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Conclusion: Effect of transoral laser microsurgery on quality of voice depends on the type of cordectomy and the site of the lesion. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: Comparison of the quality of voice obtained after superficial transoral endoscopic cordectomies (type I, II and III) according to the European Laryngological Society classification versus the more extended cordectomy (type IV and V) among patients with glottic precancerous lesions or early glottic cancer.
Methods: Sixty two patients underwent vocal assessment after cordectomy (type I-V) for dysplasia, Tis, T1a, T1b, and T2 lesions.
Results: Cordectomy (type I-III) had good vocal outcomes. Cordectomy (type IV-V) showed less favorable outcomes, P &lt; 0.005 in common parameters of voice range profile and symmetry in stroboscopy following cordectomy (type IV-V), with significant voice handicap index.
Recurrences were found in four cases with T1b and T2 cancer. Two cases were managed by higher type of cordectomy, and the other two by total laryngectomy.
Conclusion: Effect of transoral laser microsurgery on quality of voice depends on the type of cordectomy and the site of the lesion. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23367" xmlns="http://purl.org/rss/1.0/"><title>Prognostic significance of bone invasion for oral cavity squamous cell carcinoma considered T1/T2 by AJCC size criteria</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23367</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prognostic significance of bone invasion for oral cavity squamous cell carcinoma considered T1/T2 by AJCC size criteria</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Fried, Brandon Mullins, Mark Weissler, Carol Shores, Adam Zanation, Trevor Hackman, William Shockley, Neil Hayes, Bhishamjit S. Chera</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:20:31.752999-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23367</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23367</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23367</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Background</b>: It is unclear whether bone invasion in small oral cavity squamous cell carcinomas (OCSCC) results in worse prognosis.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Methods</b>: 254 OCSCC were identified and divided into 3 cohorts: 1) ≤ 4 cm with no bone invasion, 2) ≤ 4 cm with bone invasion, 3) ≥4 cm or other factors (e.g. skin invasion, deep muscle invasion, etc.) that would qualify for AJCC T4 classification aside from bone invasion. Depth of bone invasion (none, cortical, medullary) was also recorded.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Results</b>: Cohorts 1 and 2 had similar outcomes. Cohort 3 had lower rates of RC (p = 0.04), DSS (p &lt; 0.01), and OS (p &lt; 0.01). On multivariate analysis, margin status and medullary bone invasion were associated with worse outcomes.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusions</b>: Bone invasion does not appear to significantly influence outcomes in patients with small primaries treated with surgery/radiation. Medullary bone invasion appears to result in reduced rates of control and survival. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: It is unclear whether bone invasion in small oral cavity squamous cell carcinomas (OCSCC) results in worse prognosis.
Methods: 254 OCSCC were identified and divided into 3 cohorts: 1) ≤ 4 cm with no bone invasion, 2) ≤ 4 cm with bone invasion, 3) ≥4 cm or other factors (e.g. skin invasion, deep muscle invasion, etc.) that would qualify for AJCC T4 classification aside from bone invasion. Depth of bone invasion (none, cortical, medullary) was also recorded.
Results: Cohorts 1 and 2 had similar outcomes. Cohort 3 had lower rates of RC (p = 0.04), DSS (p &lt; 0.01), and OS (p &lt; 0.01). On multivariate analysis, margin status and medullary bone invasion were associated with worse outcomes.
Conclusions: Bone invasion does not appear to significantly influence outcomes in patients with small primaries treated with surgery/radiation. Medullary bone invasion appears to result in reduced rates of control and survival. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23366" xmlns="http://purl.org/rss/1.0/"><title>Incidence of HPV-related oropharyngeal cancer and outcomes after chemoradiation in a population of heavy smokers</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23366</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Incidence of HPV-related oropharyngeal cancer and outcomes after chemoradiation in a population of heavy smokers</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cerezo L, López C, de la Torre A, Suárez D, Hervás A, Ruiz A, Ballestín C, Martín M, Sandoval P</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:20:18.614605-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23366</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23366</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23366</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Background</b>: Incidence of HPV-related oropharyngeal carcinomas (OC) is increasing worldwide. Our purpose is to report the incidence in our region, and to determine the influence of HPV status on survival among a heavy smoking population.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Methods</b>: p16 expression was analyzed in 102 patients with stage II-IV treated with chemoradiation. Overall survival, LRC and disease-free survival were compared for HPV+ and HPV-.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Results</b>: The majority of patients were smokers (86%). p16 positivity was found in 26.7%. HPV+ patients were younger (56 vs 59 years old, p = 0.052). No differences were observed regarding tumor stage, gender or smoking between HPV+ and HPV-. Three-year overall survival was 67.4% for HPV+ vs 49.7% for HPV- patients, HR, 0.55; p=0.095).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusions</b>: Incidence of HPV-related OC in Spain is similar to that reported in other European countries. In this sample of heavy smokers, we observed a non-significant trend for better outcomes in HPV+ patients. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: Incidence of HPV-related oropharyngeal carcinomas (OC) is increasing worldwide. Our purpose is to report the incidence in our region, and to determine the influence of HPV status on survival among a heavy smoking population.
Methods: p16 expression was analyzed in 102 patients with stage II-IV treated with chemoradiation. Overall survival, LRC and disease-free survival were compared for HPV+ and HPV-.
Results: The majority of patients were smokers (86%). p16 positivity was found in 26.7%. HPV+ patients were younger (56 vs 59 years old, p = 0.052). No differences were observed regarding tumor stage, gender or smoking between HPV+ and HPV-. Three-year overall survival was 67.4% for HPV+ vs 49.7% for HPV- patients, HR, 0.55; p=0.095).
Conclusions: Incidence of HPV-related OC in Spain is similar to that reported in other European countries. In this sample of heavy smokers, we observed a non-significant trend for better outcomes in HPV+ patients. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23364" xmlns="http://purl.org/rss/1.0/"><title>The efficacy of current regular follow-up policy after treatment for head and neck cancer: The need for individualized and obligatory follow-up strategy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23364</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The efficacy of current regular follow-up policy after treatment for head and neck cancer: The need for individualized and obligatory follow-up strategy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Young Ho Jung, Chang Myeon Song, Joo Hyun Park, Heejin Kim, Wonjae Cha, J. Hun Hah, Tack-Kyun Kwon, Kwang Hyun Kim, Myung-Whun Sung</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:20:01.78964-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23364</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23364</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23364</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Background</b>: The aim of this study is to report the efficacy of routine follow-up after head and neck cancer treatment.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Method</b>: Data of 520 head and neck cancer patients registered with between 2002 and 2008 were reviewed retrospectively.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Results</b>: The mean ± SD follow-up period taken into account was 34.7 ± 22.8 months. The pick- up rate for recurrence using our follow-up protocol in this cohort was one in every 79 visits (1.26%). High pick-up rates were observed in patients older than 70 years and patients with advanced T classification, while low pick-up rates were observed in patients who had received treatment including surgery. The only factor on multivariate analysis to influence follow up visits was surgical treatment (P=0.043).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusion</b><b>s</b>. Individualized and obligatory follow-up policy is desirable considering various factors, especially age, T classification, and whether treatment modality includes surgery or not. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: The aim of this study is to report the efficacy of routine follow-up after head and neck cancer treatment.
Method: Data of 520 head and neck cancer patients registered with between 2002 and 2008 were reviewed retrospectively.
Results: The mean ± SD follow-up period taken into account was 34.7 ± 22.8 months. The pick- up rate for recurrence using our follow-up protocol in this cohort was one in every 79 visits (1.26%). High pick-up rates were observed in patients older than 70 years and patients with advanced T classification, while low pick-up rates were observed in patients who had received treatment including surgery. The only factor on multivariate analysis to influence follow up visits was surgical treatment (P=0.043).
Conclusions. Individualized and obligatory follow-up policy is desirable considering various factors, especially age, T classification, and whether treatment modality includes surgery or not. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23363" xmlns="http://purl.org/rss/1.0/"><title>Radiation induced squamous cell carcinoma of the nasopharynx after radiotherapy for nasopharyngeal carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23363</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Radiation induced squamous cell carcinoma of the nasopharynx after radiotherapy for nasopharyngeal carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jimmy Yu Wai Chan, Victor Shing Howe To, Stanley Thian Sze Wong, William Ignace Wei</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:19:55.906437-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23363</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23363</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23363</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Background</b>: To investigate the treatment outcome of radiation-induced squamous cell carcinoma (SCC) of the nasopharynx after radiotherapy for nasopharyngeal carcinoma (NPC).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Methods</b>: Retrospective review.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Results</b>: Between 1998 and 2011, 24 patients had radiation-induced SCC of the nasopharynx. The median age of diagnosis was 68.2 years. Majority (66.7%) presented with early stage NPC initially, and they were treated with radiotherapy alone (n = 18) or concurrent chemoradiation (n = 6). The mean latency period for the second malignancy was 10.5 years. All were treated with maxillary-swing nasopharyngectomy. Clear resection margin was achieved in 66.7%, and 75% of those with involved margin received adjuvant radiotherapy. The mean follow-up duration was 48.2 months. The overall 5-year actuarial local tumour control was 56% and the overall 5-year disease free survival was 38%.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusions</b>: Radiation-induced SCC of the nasopharynx is rare after radiotherapy for NPC. The prognosis remained poor despite aggressive surgery and adjuvant radiotherapy. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: To investigate the treatment outcome of radiation-induced squamous cell carcinoma (SCC) of the nasopharynx after radiotherapy for nasopharyngeal carcinoma (NPC).
Methods: Retrospective review.
Results: Between 1998 and 2011, 24 patients had radiation-induced SCC of the nasopharynx. The median age of diagnosis was 68.2 years. Majority (66.7%) presented with early stage NPC initially, and they were treated with radiotherapy alone (n = 18) or concurrent chemoradiation (n = 6). The mean latency period for the second malignancy was 10.5 years. All were treated with maxillary-swing nasopharyngectomy. Clear resection margin was achieved in 66.7%, and 75% of those with involved margin received adjuvant radiotherapy. The mean follow-up duration was 48.2 months. The overall 5-year actuarial local tumour control was 56% and the overall 5-year disease free survival was 38%.
Conclusions: Radiation-induced SCC of the nasopharynx is rare after radiotherapy for NPC. The prognosis remained poor despite aggressive surgery and adjuvant radiotherapy. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23362" xmlns="http://purl.org/rss/1.0/"><title>Human papillomavirus 16 detected in nasopharyngeal carcinomas in Caucasian Americans but not in endemic Southern Chinese patients</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23362</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Human papillomavirus 16 detected in nasopharyngeal carcinomas in Caucasian Americans but not in endemic Southern Chinese patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zhixiong Lin, Brian Khong, Shirley Kwok, Hongbin Cao, Robert B. West, Quynh-Thu Le, Christina S. Kong</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:19:51.281166-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23362</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23362</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23362</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>BACKGROUND</b>: We evaluated the relationship of HPV and EBV with race in endemic and non-endemic cohorts of patients with nasopharyngeal carcinoma (NPC), and with smoking status in the non-endemic cohort.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>METHODS</b>: Tissue microarrays (TMA) were constructed using samples from 86 patients treated in southern China and 108 patients from Stanford. TMAs were stained with p16, HPV ISH, and EBV ISH. PCR was used to confirm EBV(-) cases and HPV status in p16(+) cases. Survival data was available for the Stanford cohort only.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>RESULTS</b>: No HPV(+) cases were detected in the Chinese cohort. In the Stanford cohort, 5/11 EBV(-) cases harbored HPV16, 10/10 occurred in Caucasians, and 8/11 were smokers. Patients with EBV(-) NPC also showed a trend towards worse survival.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>CONCLUSIONS</b>: EBV(-) NPC shows an association with the presence of HPV, Caucasian race, and smoking. In contrast, EBV(-) NPC shows no association with HPV in the endemic cohort. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

BACKGROUND: We evaluated the relationship of HPV and EBV with race in endemic and non-endemic cohorts of patients with nasopharyngeal carcinoma (NPC), and with smoking status in the non-endemic cohort.
METHODS: Tissue microarrays (TMA) were constructed using samples from 86 patients treated in southern China and 108 patients from Stanford. TMAs were stained with p16, HPV ISH, and EBV ISH. PCR was used to confirm EBV(-) cases and HPV status in p16(+) cases. Survival data was available for the Stanford cohort only.
RESULTS: No HPV(+) cases were detected in the Chinese cohort. In the Stanford cohort, 5/11 EBV(-) cases harbored HPV16, 10/10 occurred in Caucasians, and 8/11 were smokers. Patients with EBV(-) NPC also showed a trend towards worse survival.
CONCLUSIONS: EBV(-) NPC shows an association with the presence of HPV, Caucasian race, and smoking. In contrast, EBV(-) NPC shows no association with HPV in the endemic cohort. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23361" xmlns="http://purl.org/rss/1.0/"><title>Intraoral nerve sheath myxoma: a case report and systematic review of the literature</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23361</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Intraoral nerve sheath myxoma: a case report and systematic review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rafaela Elvira Rozza-de-Menezes, Raquel Machado Andrade DDS, Mônica Simões Israel, Karin Soares Gonçalves Cunha</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:19:48.829294-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23361</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23361</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23361</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Background</em>: Oral nerve sheath myxoma (NSM) is an uncommon benign neoplasm with Schwann-cell origin, which is frequently mistaken for neurothekeoma. We report a case of NSM on the buccal mucosa in a 42-year-old woman. This case is compared with previously reported cases and a systematic review is performed. <em>Methods and Results</em>: Case report and systematic review of oral cases considered true NSMs. A literature search was performed using Pubmed, Lilacs, Scielo, Cochrane, SciVerse Scopus, Web of Science and Embase electronic database. Twenty-five cases of oral NSM were included in the systematic review. <em>Conclusions</em>: Oral NSM is rare and may represent a diagnosis challenge for pathologists. To confirm the diagnosis of NSM, the evaluation of S-100 protein expression or other neural marker is essential. The use of the terms NSM and neurothekeoma as synonymous or as variants of the same tumor should be avoided, since they are clearly distinct lesions. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: Oral nerve sheath myxoma (NSM) is an uncommon benign neoplasm with Schwann-cell origin, which is frequently mistaken for neurothekeoma. We report a case of NSM on the buccal mucosa in a 42-year-old woman. This case is compared with previously reported cases and a systematic review is performed. Methods and Results: Case report and systematic review of oral cases considered true NSMs. A literature search was performed using Pubmed, Lilacs, Scielo, Cochrane, SciVerse Scopus, Web of Science and Embase electronic database. Twenty-five cases of oral NSM were included in the systematic review. Conclusions: Oral NSM is rare and may represent a diagnosis challenge for pathologists. To confirm the diagnosis of NSM, the evaluation of S-100 protein expression or other neural marker is essential. The use of the terms NSM and neurothekeoma as synonymous or as variants of the same tumor should be avoided, since they are clearly distinct lesions. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23360" xmlns="http://purl.org/rss/1.0/"><title>Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23360</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Steven Habbous, Luke T.G. Harland, Anthony La Delfa, Ehab Fadhel, Wei Xu, Fei-Fei Liu, David Goldstein, John Waldron, Shao-Hui Huang, Brian O-Sullivan, Geoffrey Liu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T04:19:41.029957-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23360</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23360</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23360</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Background</b>: The prognostic utility of comorbidity on HNC may differ by subsite, stage, and human-papillomavirus (HPV) status. <b>Methods</b>: We reviewed the medical records of 4953 HNC patients for comorbidity (Charlson Comorbidity Index, CCI), smoking, and alcohol history. Multivariate proportional hazards assessed the association of CCI with survival. HPV status was determined using p16 immunohistochemistry. <b>Results</b>: After accounting for stage, higher CCI was associated with worse OS in nasopharyngeal [HR 2.93 (1.53-5.62)], oropharyngeal [HR 1.99 (1.63-2.43)], and oral cavity [HR 1.54 (1.27-1.86)], cancers. These associations were most prominent in the early-stage oral cavity [HR 2.11 (1.50-2.96)] and laryngeal [HR 1.87 (1.35-2.58)] cancers, and in advanced-stage oropharyngeal [HR 2.23 (1.81-2.74)] and nasopharyngeal [HR 3.50 (1.76-6.97)] cancers. CCI was INDEPENDENTLY prognostic even in the HPV-adjusted oropharyngeal cancers. <b>Conclusion</b>: Comorbidity was prognostic in subsets of nasopharyngeal, oropharyngeal, oral cavity, and laryngeal cancers. Comorbidity may be a partial surrogate for age and social habits. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: The prognostic utility of comorbidity on HNC may differ by subsite, stage, and human-papillomavirus (HPV) status. Methods: We reviewed the medical records of 4953 HNC patients for comorbidity (Charlson Comorbidity Index, CCI), smoking, and alcohol history. Multivariate proportional hazards assessed the association of CCI with survival. HPV status was determined using p16 immunohistochemistry. Results: After accounting for stage, higher CCI was associated with worse OS in nasopharyngeal [HR 2.93 (1.53-5.62)], oropharyngeal [HR 1.99 (1.63-2.43)], and oral cavity [HR 1.54 (1.27-1.86)], cancers. These associations were most prominent in the early-stage oral cavity [HR 2.11 (1.50-2.96)] and laryngeal [HR 1.87 (1.35-2.58)] cancers, and in advanced-stage oropharyngeal [HR 2.23 (1.81-2.74)] and nasopharyngeal [HR 3.50 (1.76-6.97)] cancers. CCI was INDEPENDENTLY prognostic even in the HPV-adjusted oropharyngeal cancers. Conclusion: Comorbidity was prognostic in subsets of nasopharyngeal, oropharyngeal, oral cavity, and laryngeal cancers. Comorbidity may be a partial surrogate for age and social habits. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23354" xmlns="http://purl.org/rss/1.0/"><title>Cadaver study on the location of suboccipital lymph nodes: Guidance for suboccipital node dissection</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23354</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cadaver study on the location of suboccipital lymph nodes: Guidance for suboccipital node dissection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hidde J. Veenstra, W. Martin C. Klop, Peter J.F.M. Lohuis, Omgo E. Nieweg, M. Loes van Velthuysen, Alfons J.M. Balm</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T05:00:13.02085-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23354</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23354</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23354</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Objectives</b>: To provide anatomical guidance for the extent (technique) of suboccipital node dissection.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Methods</b>: Five human cadaver necks (nine sides) were studied. Boundaries were the superior nuchal line and external occipital protuberance (cranial), the nuchal ligament (medial), an imaginary line through C7 (caudal) and the posterior wall of the auditory channel (anterior). The overlying skin and complete thickness of the cranial part of the trapezius muscle and fascia sheath was included (deep).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Results</b>: An average number of 4 lymph nodes per suboccipital side were found. Diameters ranged from 1 to 6 mm. Twenty nodes (63%) were located in the subcutaneous tissue, twelve (37%) were found just underneath the superficial fascia of the trapezius muscle.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusion</b>: Suboccipital nodes are small and mainly located in the subcutaneous layer, with a minority just underneath the superficial fascia of the trapezius muscle. This anatomical knowledge was used to refine the suboccipital dissection. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Objectives: To provide anatomical guidance for the extent (technique) of suboccipital node dissection.
Methods: Five human cadaver necks (nine sides) were studied. Boundaries were the superior nuchal line and external occipital protuberance (cranial), the nuchal ligament (medial), an imaginary line through C7 (caudal) and the posterior wall of the auditory channel (anterior). The overlying skin and complete thickness of the cranial part of the trapezius muscle and fascia sheath was included (deep).
Results: An average number of 4 lymph nodes per suboccipital side were found. Diameters ranged from 1 to 6 mm. Twenty nodes (63%) were located in the subcutaneous tissue, twelve (37%) were found just underneath the superficial fascia of the trapezius muscle.
Conclusion: Suboccipital nodes are small and mainly located in the subcutaneous layer, with a minority just underneath the superficial fascia of the trapezius muscle. This anatomical knowledge was used to refine the suboccipital dissection. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23350" xmlns="http://purl.org/rss/1.0/"><title>Survival rates and prognostic factors for infiltrating salivary duct carcinoma: An analysis of 228 cases from SEER database</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23350</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Survival rates and prognostic factors for infiltrating salivary duct carcinoma: An analysis of 228 cases from SEER database</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vijayvel Jayaprakash, Mihai Merzianu, Graham W. Warren, Hassan Arshad, Wesley L. Hicks, Nestor R. Rigual, Maureen A. Sullivan, Mukund Seshadri, James R. Marshall, David M. Cohan, Yujie Zhao, Anurag K. Singh</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T05:00:01.035537-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23350</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23350</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23350</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="hed23350-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The survival rates and prognostic factors for salivary duct carcinoma (SDC) are not clear.</p></div></div>
<div class="section" id="hed23350-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Survival estimates and prognostic factors were evaluated for 228 SDC patients identified from the Surveillance, Epidemiology, and End Results database.</p></div></div>
<div class="section" id="hed23350-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Median overall survival duration for SDC patients was 79 months and 5-year disease-specific survival rate (DSS) was 64%. Among SDC patients with lymph node involvement (LNI), larger primary tumor size (&gt;3cm) was associated with twice the risk of death (p&lt;0.03). Factors predictive of improved DSS were age (p=0.01), tumor size (p=0.006), tumor grade (p=0.02) and LNI (p&lt;0.001). Adjuvant radiotherapy did not improve survival when compared to surgery alone for early stage (I-II) disease (p=0.28).</p></div></div>
<div class="section" id="hed23350-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Younger SDC patients (&lt;50 years) showed a better prognosis. Primary tumor size and LNI were independent and additive risk factors for poor prognosis. The role of adjuvant radiotherapy in the treatment of SDC needs to be explored further. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
The survival rates and prognostic factors for salivary duct carcinoma (SDC) are not clear.


Methods
Survival estimates and prognostic factors were evaluated for 228 SDC patients identified from the Surveillance, Epidemiology, and End Results database.


Results
Median overall survival duration for SDC patients was 79 months and 5-year disease-specific survival rate (DSS) was 64%. Among SDC patients with lymph node involvement (LNI), larger primary tumor size (&gt;3cm) was associated with twice the risk of death (p&lt;0.03). Factors predictive of improved DSS were age (p=0.01), tumor size (p=0.006), tumor grade (p=0.02) and LNI (p&lt;0.001). Adjuvant radiotherapy did not improve survival when compared to surgery alone for early stage (I-II) disease (p=0.28).


Conclusion
Younger SDC patients (&lt;50 years) showed a better prognosis. Primary tumor size and LNI were independent and additive risk factors for poor prognosis. The role of adjuvant radiotherapy in the treatment of SDC needs to be explored further. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23348" xmlns="http://purl.org/rss/1.0/"><title>Effects of octreotide therapy in progressive head and neck paragangliomas: Case series</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23348</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effects of octreotide therapy in progressive head and neck paragangliomas: Case series</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">L.T. van Hulsteijn, N. van Duinen, B.M. Verbist, J.C. Jansen, A.A. van der Klaauw, J.W.A. Smit, E.P.M. Corssmit</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T04:59:48.38417-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23348</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23348</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23348</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="hed23348-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Octreotide, a somatostatin analogue, may be beneficial in the treatment of paragangliomas of the head and neck (HNPGLs).</p></div></div>
<div class="section" id="hed23348-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Non-blinded, prospective intervention study. During one year, patients received a monthly intramuscular injection of 30 mg Sandostatin LAR<sup>®</sup>. Pre- and post-treatment tumor volumes were assessed by magnetic resonance imaging, urinary catecholamine secretion was measured and HNPGL-related signs and symptoms were recorded.</p></div></div>
<div class="section" id="hed23348-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In one out of four included HNPGL-patients, a stabilization of tumor growth was observed after octreotide therapy. In one patient, octreotide therapy was discontinued before the end of the study because of potential side-effects.</p></div><div class="para"><p>No improvements in HNPGL-related signs and symptoms were observed.</p></div></div>
<div class="section" id="hed23348-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>In one out of four patients, HNPGL tumor growth velocity was reduced after octreotide therapy. Research assessing the effects of somatostatin analogues targeting different sst subtypes or combined with other therapies may offer new possibilities for the treatment of HNPGLs. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
Octreotide, a somatostatin analogue, may be beneficial in the treatment of paragangliomas of the head and neck (HNPGLs).


Methods
Non-blinded, prospective intervention study. During one year, patients received a monthly intramuscular injection of 30 mg Sandostatin LAR®. Pre- and post-treatment tumor volumes were assessed by magnetic resonance imaging, urinary catecholamine secretion was measured and HNPGL-related signs and symptoms were recorded.


Results
In one out of four included HNPGL-patients, a stabilization of tumor growth was observed after octreotide therapy. In one patient, octreotide therapy was discontinued before the end of the study because of potential side-effects.
No improvements in HNPGL-related signs and symptoms were observed.


Conclusion
In one out of four patients, HNPGL tumor growth velocity was reduced after octreotide therapy. Research assessing the effects of somatostatin analogues targeting different sst subtypes or combined with other therapies may offer new possibilities for the treatment of HNPGLs. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23359" xmlns="http://purl.org/rss/1.0/"><title>A comparative study on prophylactic irradiation to the whole neck and to the upper neck for neck lymph node-negative nasopharyngeal carcinoma patients</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23359</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A comparative study on prophylactic irradiation to the whole neck and to the upper neck for neck lymph node-negative nasopharyngeal carcinoma patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lei Zeng, Xue-Ming Sun, Chun-Yan Chen, Fei Han, Ying Huang, Wei-Wei Xiao, Shuai Liu, Yun-Ming Tian, Xiao-Wu Deng, Tai-Xiang Lu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T04:01:23.289961-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23359</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23359</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23359</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Background: To investigate the prophylactic irradiation volume to neck drainage areas for N0 classification nasopharyngeal carcinoma(NPC) patients treated by intensity-modulated radiotherapy(IMRT).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Methods: From January 2003 to October 2008,270 N0 classification (AJCC 2002 staging system) NPC patients who had undergone IMRT were retrospectively analyzed. Among all the patients, 171 patients received prophylactic upper-neck irradiation, and 99 patients received prophylactic whole-neck irradiation.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Results: At a median follow-up of 65.1 months(range,4-106 months). The 5-year overall survival(OS), nodal recurrence-free survival(NRFS) and distant metastasis-free survival (DMFS) rates of the upper neck group and the whole neck group were 93.6% vs 90.9%(P=0.553), 99.4% vs 99.0%(P=0.278), 98.8% vs 94.9%(P=0.128). A total of three neck recurrences were found, including two from the whole neck group and one from the upper neck group. The latter (0.6%)was out-of-field recurrence.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusions</b>: Prophylactic irradiation to the upper neck(level II,III,VA) may be feasible for neck lymph node-negative NPC patients. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: To investigate the prophylactic irradiation volume to neck drainage areas for N0 classification nasopharyngeal carcinoma(NPC) patients treated by intensity-modulated radiotherapy(IMRT).
Methods: From January 2003 to October 2008,270 N0 classification (AJCC 2002 staging system) NPC patients who had undergone IMRT were retrospectively analyzed. Among all the patients, 171 patients received prophylactic upper-neck irradiation, and 99 patients received prophylactic whole-neck irradiation.
Results: At a median follow-up of 65.1 months(range,4-106 months). The 5-year overall survival(OS), nodal recurrence-free survival(NRFS) and distant metastasis-free survival (DMFS) rates of the upper neck group and the whole neck group were 93.6% vs 90.9%(P=0.553), 99.4% vs 99.0%(P=0.278), 98.8% vs 94.9%(P=0.128). A total of three neck recurrences were found, including two from the whole neck group and one from the upper neck group. The latter (0.6%)was out-of-field recurrence.
Conclusions: Prophylactic irradiation to the upper neck(level II,III,VA) may be feasible for neck lymph node-negative NPC patients. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23358" xmlns="http://purl.org/rss/1.0/"><title>Prophylactic total thyroidectomy using the minimally invasive video assisted (MIVAT) approach in children with multiple endocrine neoplasia (MEN) type 2</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23358</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prophylactic total thyroidectomy using the minimally invasive video assisted (MIVAT) approach in children with multiple endocrine neoplasia (MEN) type 2</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ronan W. Glynn, Emma C. Cashman, Jaime Doody, Eimear Phelan, John D. Russell, Conrad Timon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T04:01:17.941296-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23358</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23358</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23358</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="hed23358-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>There have been few reports of prophylactic thyroidectomy using the MIVAT approach in children with MEN2.</p></div></div>
<div class="section" id="hed23358-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Retrospective review of a prospectively maintained database of patients who underwent MIVAT for total thyroidectomy.</p></div></div>
<div class="section" id="hed23358-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Six children underwent MIVAT; RET codon mutations identified were 634, 620, 611, and 918. Mean operative time was 93 minutes(range 68-105). Five patients were discharged on the first postoperative day; one patient suffered a postoperative haematoma and was discharged 2 days postoperatively. There were no cases of laryngeal nerve palsy or post-operative hypoparathyroidism. High levels of satisfaction with post-operative cosmesis were reported. Calcitonin levels have been undetectable at follow-up, thusfar (mean follow-up 42.8 months).</p></div></div>
<div class="section" id="hed23358-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Whilst our outcomes are similar to those reported using the traditional approach, it is important to note that MIVAT is essentially the same operation, just performed through a smaller incision, with resulting benefits in terms of pain, cosmesis and, perhaps, morbidity. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
There have been few reports of prophylactic thyroidectomy using the MIVAT approach in children with MEN2.


Methods
Retrospective review of a prospectively maintained database of patients who underwent MIVAT for total thyroidectomy.


Results
Six children underwent MIVAT; RET codon mutations identified were 634, 620, 611, and 918. Mean operative time was 93 minutes(range 68-105). Five patients were discharged on the first postoperative day; one patient suffered a postoperative haematoma and was discharged 2 days postoperatively. There were no cases of laryngeal nerve palsy or post-operative hypoparathyroidism. High levels of satisfaction with post-operative cosmesis were reported. Calcitonin levels have been undetectable at follow-up, thusfar (mean follow-up 42.8 months).


Conclusions
Whilst our outcomes are similar to those reported using the traditional approach, it is important to note that MIVAT is essentially the same operation, just performed through a smaller incision, with resulting benefits in terms of pain, cosmesis and, perhaps, morbidity. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23357" xmlns="http://purl.org/rss/1.0/"><title>Influence of pretreatment ideal body weight percentile and albumin on the prognosis of nasopharyngeal carcinoma: Long-term outcomes of 512 patients from a single institution</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23357</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Influence of pretreatment ideal body weight percentile and albumin on the prognosis of nasopharyngeal carcinoma: Long-term outcomes of 512 patients from a single institution</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guo Li, Jin Gao, Zhi-Gang Liu, Ya-Lan Tao, Bing-Qing Xu, Zi-Wei Tu, Xiu-Ping Zhang, Mu-Sheng Zeng, Yun-Fei Xia</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T04:01:16.722733-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23357</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23357</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23357</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b><em>Background</em></b>: This study was to investigate <b><span class="underlined ">the relationship between pretreatment nutritional status and prognosis of nasopharyngeal carcinoma (NPC)</span></b>.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b><em>Methods</em></b>: Pretreatment nutritional status was evaluated by ideal body weight <b><span class="underlined ">percentile</span></b> (IBW %) and serum albumin for 512 NPC patients received radical radiotherapy. Kaplan-Meier methods, log-rank test, and a Cox model were applied for survival analysis.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b><em>Results</em></b>: Before radiotherapy, <b><span class="underlined ">IBW% &lt; 90%</span></b> was related to poorer overall survival (OS) <b><span class="underlined ">and distant metastasis free survival (DMFS)</span></b> (P=0.031, <b><span class="underlined ">P = 0.012</span></b>); albumin ≤ 43.0 g/ L was related to poorer OS and DMFS (P &lt; 0.001, P = 0.042); both IBW% and albumin were independent prognostic factors for OS; those patients with <b><span class="underlined ">IBW% &lt; 90%</span></b> and albumin ≤ 43.0 g/ L simultaneously had the worst OS and DMFS.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b><em>Conclusions</em></b>: <b><span class="underlined ">Decrease of pretreatment IBW% and albumin was related to poorer survival of NPC</span></b>. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: This study was to investigate the relationship between pretreatment nutritional status and prognosis of nasopharyngeal carcinoma (NPC).
Methods: Pretreatment nutritional status was evaluated by ideal body weight percentile (IBW %) and serum albumin for 512 NPC patients received radical radiotherapy. Kaplan-Meier methods, log-rank test, and a Cox model were applied for survival analysis.
Results: Before radiotherapy, IBW% &lt; 90% was related to poorer overall survival (OS) and distant metastasis free survival (DMFS) (P=0.031, P = 0.012); albumin ≤ 43.0 g/ L was related to poorer OS and DMFS (P &lt; 0.001, P = 0.042); both IBW% and albumin were independent prognostic factors for OS; those patients with IBW% &lt; 90% and albumin ≤ 43.0 g/ L simultaneously had the worst OS and DMFS.
Conclusions: Decrease of pretreatment IBW% and albumin was related to poorer survival of NPC. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23356" xmlns="http://purl.org/rss/1.0/"><title>Sinonasal cancer: Analysis of oncological failures in 156 consecutive cases</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23356</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Sinonasal cancer: Analysis of oncological failures in 156 consecutive cases</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Haïtham Mirghani, Geoffrey Mortuaire, Gian Luca Armas, Dana Hartl, Anne Aupérin, Sophie El Bedoui, Dominique Chevalier, Jean Louis Lefebvre</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T04:01:14.101723-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23356</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23356</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23356</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="section" id="hed23356-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Sinonasal cancers are rare and associated with a poor prognosis. The aim of this study was to report our experience and analyze the risk factors for oncologic failures.</p></div></div>
<div class="section" id="hed23356-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective review of 156 consecutive patients treated with curative intent for sinonasal malignancy between 1995 and 2005 at tertiary cancer center was performed. Demographic, clinical, morphological and pathological parameters were correlated with oncologic outcomes.</p></div></div>
<div class="section" id="hed23356-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p><b>Complete response</b> was obtained for 134 patients. Sixty-eight patients relapsed among which 51 had local recurrence. Nine of these 51 patients (17.6%) underwent successful salvage therapy. Five years local failure and overall survival rates were 50.0% and 61.1%. Maxillary sinus tumors, <b>intracranial</b> invasion and N&gt;0 stage at initial diagnosis were significantly and independently associated with local failure and survival in multivariant analysis.</p></div></div>
<div class="section" id="hed23356-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Local control following initial treatment is primordial to optimizing outcomes due to the poor results of salvage therapy. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
Sinonasal cancers are rare and associated with a poor prognosis. The aim of this study was to report our experience and analyze the risk factors for oncologic failures.


Methods
A retrospective review of 156 consecutive patients treated with curative intent for sinonasal malignancy between 1995 and 2005 at tertiary cancer center was performed. Demographic, clinical, morphological and pathological parameters were correlated with oncologic outcomes.


Results
Complete response was obtained for 134 patients. Sixty-eight patients relapsed among which 51 had local recurrence. Nine of these 51 patients (17.6%) underwent successful salvage therapy. Five years local failure and overall survival rates were 50.0% and 61.1%. Maxillary sinus tumors, intracranial invasion and N&gt;0 stage at initial diagnosis were significantly and independently associated with local failure and survival in multivariant analysis.


Conclusion
Local control following initial treatment is primordial to optimizing outcomes due to the poor results of salvage therapy. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23355" xmlns="http://purl.org/rss/1.0/"><title>Treatment and prognosis in sinonasal mucosal melanoma: A retrospective analysis of 65 patients from a single cancer center</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23355</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Treatment and prognosis in sinonasal mucosal melanoma: A retrospective analysis of 65 patients from a single cancer center</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chuan-Zheng Sun, Qiu-Li Li, Ze-Dong Hu, Yu-E Jiang, Ming Song, An-Kui Yang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T04:01:07.3742-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23355</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23355</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23355</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Background</b>: To evaluate outcome in sinonasal mucosal melanoma (SMM). <b>Methods</b>: A retrospective analysis of clinicopathological data from January 1976 to December 2005 was performed. Survival curve, univariate and multivariate analyses were undertaken. <b>Results</b>: Sixty-eight patients with SMM were enrolled, three patients refused treatment. The 3-year and 5-year overall survival (OS) rates in the remaining 65 cases of SMM were 36.5% and 29.7%, respectively. Patients who underwent surgery had better 3- and 5-year OS rates than those treated without surgery (40.7% &amp; 34.1% vs. 21.4% &amp; 14.3%), and the same was true for patients treated with and without biotherapy (58.2% &amp; 50.9% vs. 30.0% &amp; 23.4%). Distant metastasis at presentation was associated with a worse prognosis. Those patients managed with multimodality treatment had better OS rates. <b>Conclusions</b>: The prognosis in SMM is poor, particularly for those with distant metastasis or without surgery. Multimodality treatment may improve survival. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: To evaluate outcome in sinonasal mucosal melanoma (SMM). Methods: A retrospective analysis of clinicopathological data from January 1976 to December 2005 was performed. Survival curve, univariate and multivariate analyses were undertaken. Results: Sixty-eight patients with SMM were enrolled, three patients refused treatment. The 3-year and 5-year overall survival (OS) rates in the remaining 65 cases of SMM were 36.5% and 29.7%, respectively. Patients who underwent surgery had better 3- and 5-year OS rates than those treated without surgery (40.7% &amp; 34.1% vs. 21.4% &amp; 14.3%), and the same was true for patients treated with and without biotherapy (58.2% &amp; 50.9% vs. 30.0% &amp; 23.4%). Distant metastasis at presentation was associated with a worse prognosis. Those patients managed with multimodality treatment had better OS rates. Conclusions: The prognosis in SMM is poor, particularly for those with distant metastasis or without surgery. Multimodality treatment may improve survival. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23353" xmlns="http://purl.org/rss/1.0/"><title>A reconstructive algorithm and classification system for transoral oropharyngeal defects</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23353</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A reconstructive algorithm and classification system for transoral oropharyngeal defects</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John R. de Almeida, Richard Chan Woo Park, Nathaniel L. Villanueva, Brett A. Miles, Marita S. Teng, Eric M. Genden</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T04:00:58.198867-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23353</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23353</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23353</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="hed23353-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Transoral techniques for oropharyngeal tumors, such as transoral robotic surgery (TORS) and transoral laser microsurgery (TLM), require new reconstructive considerations.</p></div></div>
<div class="section" id="hed23353-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Defects from 92 patients undergoing TORS were classified into 4 classes. A reconstruction algorithm was followed. Perioperative outcomes and complications were assessed. Forty seven patients completed the MD Anderson Dysphagia Inventory (MDADI) swallowing questionnaire and a modified Velopharyngeal Insufficiency Quality of Life questionnaire (VPIQL) post-operatively.</p></div></div>
<div class="section" id="hed23353-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The most common reconstructions involved velopharyngoplasties with local flaps (39%), local flaps alone (25%), or secondary healing (20%). More advanced defects (Class III and IV defects) required regional and free flaps more often. No significant differences were found in MDADI scores or VPIQL scores among the four defect classes. Only adjuvant radiotherapy was a predictor of poor swallowing (p = 0.02).</p></div></div>
<div class="section" id="hed23353-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The classification system for transoral oropharyngeal defects maps defects into four classes and guides the reconstructive thought process. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
Transoral techniques for oropharyngeal tumors, such as transoral robotic surgery (TORS) and transoral laser microsurgery (TLM), require new reconstructive considerations.


Methods
Defects from 92 patients undergoing TORS were classified into 4 classes. A reconstruction algorithm was followed. Perioperative outcomes and complications were assessed. Forty seven patients completed the MD Anderson Dysphagia Inventory (MDADI) swallowing questionnaire and a modified Velopharyngeal Insufficiency Quality of Life questionnaire (VPIQL) post-operatively.


Results
The most common reconstructions involved velopharyngoplasties with local flaps (39%), local flaps alone (25%), or secondary healing (20%). More advanced defects (Class III and IV defects) required regional and free flaps more often. No significant differences were found in MDADI scores or VPIQL scores among the four defect classes. Only adjuvant radiotherapy was a predictor of poor swallowing (p = 0.02).


Conclusions
The classification system for transoral oropharyngeal defects maps defects into four classes and guides the reconstructive thought process. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23352" xmlns="http://purl.org/rss/1.0/"><title>Multidisciplinary therapy including proton beam radiotherapy for an Ewing's sarcoma family tumor of maxillary sinus in a 4-year-old girl</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23352</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Multidisciplinary therapy including proton beam radiotherapy for an Ewing's sarcoma family tumor of maxillary sinus in a 4-year-old girl</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Masayoshi Yamaoka, Masaharu Akiyama, Yuichi Yokokawa, Yoko Terao, Kentaro Yokoi, Takakuni Kato, Takashi Fukushima, Hideyuki Sakurai, Hiroyuki Ida</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T04:00:43.716024-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23352</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23352</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23352</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Background</em>: Although complete resection offers the best chance for controlling head and neck Ewing's sarcoma family tumor (ESFT), it is occasionally unfeasible because of possible functional and cosmetic side effects. Planning multidisciplinary treatment for head and neck ESFT is challenging.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Methods and Results</em>: A 4-year-old girl had had left-sided excessive tearing, nasal obstruction, and exophthalmos for 4 months. Computed tomography showed a mass filling the left maxillary sinus and extending to the left orbital wall. After a diagnosis of ESFT was established with biopsy, the patient was treated with the VDC/IE regimen over 50 weeks; partial maxillectomy was performed at week 15 and was followed by proton radiotherapy. The patient has remained tumor-free for 16 months, with preservation of facial form and function.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Conclusion</em>: Partial resection combined with proton radiotherapy may enable maximal tumor control and minimal functional and cosmetic side effects in children with head and neck ESFT. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: Although complete resection offers the best chance for controlling head and neck Ewing's sarcoma family tumor (ESFT), it is occasionally unfeasible because of possible functional and cosmetic side effects. Planning multidisciplinary treatment for head and neck ESFT is challenging.
Methods and Results: A 4-year-old girl had had left-sided excessive tearing, nasal obstruction, and exophthalmos for 4 months. Computed tomography showed a mass filling the left maxillary sinus and extending to the left orbital wall. After a diagnosis of ESFT was established with biopsy, the patient was treated with the VDC/IE regimen over 50 weeks; partial maxillectomy was performed at week 15 and was followed by proton radiotherapy. The patient has remained tumor-free for 16 months, with preservation of facial form and function.
Conclusion: Partial resection combined with proton radiotherapy may enable maximal tumor control and minimal functional and cosmetic side effects in children with head and neck ESFT. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23351" xmlns="http://purl.org/rss/1.0/"><title>Predictive value of HPV in oropharyngeal carcinoma treated with radiotherapy: An updated systematic review and meta-analysis of 30 trials</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23351</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Predictive value of HPV in oropharyngeal carcinoma treated with radiotherapy: An updated systematic review and meta-analysis of 30 trials</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fausto Petrelli, Enrico Sarti, Sandro Barni</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T04:00:34.84393-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23351</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23351</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23351</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Background</b>: Human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OSCC) is emerging as a different subtype of head and neck cancer. The authors conducted a systematic review and meta-analysis to examine the predictive role of HPV in OSCC patients treated with radiotherapy-based modality therapy.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Methods</b>: The authors performed a PubMed search to identify published trials that evaluated the outcome of HPV+ OSCC treated with radiotherapy. Hazard ratios (HRs) were extracted and pooled by using random or fixed effects models. The primary endpoints were overall, disease-specific and disease-free survival (OS, DSS and DFS).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Results</b>: Thirty trials were available for HPV analysis. HPV+ status is associated with better OS (<b><span class="underlined ">HR = 0.33</span></b>; p &lt; 0.00001), DSS (HR = 0.24; p &lt; 0.00001) and DFS (<b><span class="underlined ">HR = 0.31</span></b>; p &lt; 0.00001).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusions</b>: HPV+ OSCC has a better survival compared to HPV-negative disease when treated with radiotherapy-based modality therapy. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: Human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OSCC) is emerging as a different subtype of head and neck cancer. The authors conducted a systematic review and meta-analysis to examine the predictive role of HPV in OSCC patients treated with radiotherapy-based modality therapy.
Methods: The authors performed a PubMed search to identify published trials that evaluated the outcome of HPV+ OSCC treated with radiotherapy. Hazard ratios (HRs) were extracted and pooled by using random or fixed effects models. The primary endpoints were overall, disease-specific and disease-free survival (OS, DSS and DFS).
Results: Thirty trials were available for HPV analysis. HPV+ status is associated with better OS (HR = 0.33; p &lt; 0.00001), DSS (HR = 0.24; p &lt; 0.00001) and DFS (HR = 0.31; p &lt; 0.00001).
Conclusions: HPV+ OSCC has a better survival compared to HPV-negative disease when treated with radiotherapy-based modality therapy. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23349" xmlns="http://purl.org/rss/1.0/"><title>Comparative study of a gasless transaxillary approach versus a bilateral axillo-breast approach for endoscopic thyroidectomy in a single institute</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23349</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Comparative study of a gasless transaxillary approach versus a bilateral axillo-breast approach for endoscopic thyroidectomy in a single institute</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Myung-Chul Lee, Hoon Park, Ik Joon Choi, Byeong-Cheol Lee, Guk-Haeng Lee</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-22T03:57:59.115621-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23349</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23349</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23349</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="hed23349-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Gasless transaxillary approach (TA) and bilateral axillo-breast approach (BABA) are two distinctive approaches for endoscopic thyroidectomy. The aim of this study was to evaluate and compare these 2 procedures.</p></div></div>
<div class="section" id="hed23349-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>From May 2008 to July 2011, we performed endoscopic hemi-thyroidectomy via gasless TA (83 cases) and BABA (45 cases). The following variables were evaluated: operation time, postoperative pain score, drainage amount, drainage day, postoperative complications, and cosmetic satisfaction score.</p></div></div>
<div class="section" id="hed23349-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>There were no significant differences between two approaches in terms of clinicopathologic characteristics and surgical outcomes except postoperative pain and cosmetic satisfaction. As for postoperative pain and cosmetic satisfaction, gasless TA group complained of less pain and BABA group had a better cosmetic outcome.</p></div></div>
<div class="section" id="hed23349-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>These findings will contribute to providing guidelines for the choice of surgeons between gasless TA and BABA techniques for endoscopic thyroidectomy. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
Gasless transaxillary approach (TA) and bilateral axillo-breast approach (BABA) are two distinctive approaches for endoscopic thyroidectomy. The aim of this study was to evaluate and compare these 2 procedures.


Methods
From May 2008 to July 2011, we performed endoscopic hemi-thyroidectomy via gasless TA (83 cases) and BABA (45 cases). The following variables were evaluated: operation time, postoperative pain score, drainage amount, drainage day, postoperative complications, and cosmetic satisfaction score.


Results
There were no significant differences between two approaches in terms of clinicopathologic characteristics and surgical outcomes except postoperative pain and cosmetic satisfaction. As for postoperative pain and cosmetic satisfaction, gasless TA group complained of less pain and BABA group had a better cosmetic outcome.


Conclusions
These findings will contribute to providing guidelines for the choice of surgeons between gasless TA and BABA techniques for endoscopic thyroidectomy. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23347" xmlns="http://purl.org/rss/1.0/"><title>Optimizing perioperative management of geriatric head and neck cancer patients</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23347</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Optimizing perioperative management of geriatric head and neck cancer patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrew G. Shuman, Snehal G. Patel, Jatin P. Shah, Beatriz Korc-Grodzicki</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:24:28.988662-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23347</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23347</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23347</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Given emerging demographic trends, many more elderly patients are being diagnosed with head and neck cancers. The surgical care paradigm for this cohort of patients must take into account specific challenges inherent to geriatric perioperative management. This manuscript attempts to summarize the existing body of literature relevant to the geriatric head and neck cancer population, and to extrapolate relevant data from geriatric perioperative medicine in order to better understand and guide management decisions. The involvement of geriatricians and of patients' primary care providers may be invaluable in assisting in complex perioperative decision-making and in participating in longitudinal management. Preoperative risk stratification and assessment of medical, social and functional variables are critical for appropriate decision-making in this challenging patient population. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Given emerging demographic trends, many more elderly patients are being diagnosed with head and neck cancers. The surgical care paradigm for this cohort of patients must take into account specific challenges inherent to geriatric perioperative management. This manuscript attempts to summarize the existing body of literature relevant to the geriatric head and neck cancer population, and to extrapolate relevant data from geriatric perioperative medicine in order to better understand and guide management decisions. The involvement of geriatricians and of patients' primary care providers may be invaluable in assisting in complex perioperative decision-making and in participating in longitudinal management. Preoperative risk stratification and assessment of medical, social and functional variables are critical for appropriate decision-making in this challenging patient population. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23346" xmlns="http://purl.org/rss/1.0/"><title>Unusual metastases from tall cell variant (TCV) of papillary thyroid cancer (PTC)</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23346</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Unusual metastases from tall cell variant (TCV) of papillary thyroid cancer (PTC)</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Loredana Pagano, Marina Caputo, Maria Teresa Samà, Marco Zavattaro, Flavia Prodam, Maria Grazia Mauri, Francesco Pia, Amedeo Alonzo, Guido Valente, Gianluca Aimaretti</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:24:22.789184-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23346</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23346</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23346</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><span class="underlined ">Background</span>: TCV is considered more aggressive than classical variant of PTC. Distant metastases are more common among this variant and affect survival. Little is known about the molecular pattern of this histotype.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b><span class="underlined ">Methods</span></b>: We reported 2 cases of unusual metastases from TCV, BRAF V600E positive.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b><span class="underlined ">Results</span></b>: A 38-years-old-woman developed subcutaneous metastases during short term follow-up; at medium term follow-up, patient showed detectable stimulated serum Thyroglobulin without disease evidence at imaging. A 33 years-old-man, presented incidental thymic metastases at time of surgical treatment; this is the first case of not-ectopic thymic metastases from PTC.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><span class="underlined ">Conclusions</span>: TCV may present with unusual metastases already during early follow-up. The more aggressive behavior could be linked to the higher prevalence of BRAF point mutations, but only a long-term follow-up might clarify if this association could worsen the prognosis. Moreover, skin metastases have been predictive factors of worse outcome in our patient, while not thymic metastates. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: TCV is considered more aggressive than classical variant of PTC. Distant metastases are more common among this variant and affect survival. Little is known about the molecular pattern of this histotype.
Methods: We reported 2 cases of unusual metastases from TCV, BRAF V600E positive.
Results: A 38-years-old-woman developed subcutaneous metastases during short term follow-up; at medium term follow-up, patient showed detectable stimulated serum Thyroglobulin without disease evidence at imaging. A 33 years-old-man, presented incidental thymic metastases at time of surgical treatment; this is the first case of not-ectopic thymic metastases from PTC.
Conclusions: TCV may present with unusual metastases already during early follow-up. The more aggressive behavior could be linked to the higher prevalence of BRAF point mutations, but only a long-term follow-up might clarify if this association could worsen the prognosis. Moreover, skin metastases have been predictive factors of worse outcome in our patient, while not thymic metastates. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23345" xmlns="http://purl.org/rss/1.0/"><title>Evaluation of the methylation profile of exfoliated cell samples from head and neck squamous cell carcinoma patients</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23345</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Evaluation of the methylation profile of exfoliated cell samples from head and neck squamous cell carcinoma patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ana Luiza Bomfim Longo, Marianna M. Rettori, Ana Carolina de Carvalho, Luiz Paulo Kowalski, André Lopes Carvalho, André Luiz Vettore</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:24:10.030417-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23345</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23345</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23345</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Background: Silencing of tumor suppressor genes plays a vital role in head and neck carcinogenesis. The aims of this study were to determine the methylation profile of exfoliated tumors cells collected from head and neck squamous cell carcinoma (HNSCC) patients and to evaluate its prognostic significance. Methods: The methylation profile and level of a 20 genes-panel were evaluated by QMSP in exfoliated tumor cell samples from 96 HNSCC patients. Results: <em>CCNA1</em> (60.4%)<em>, DCC</em> (54.2%) and <em>TIMP3</em> (35.4%) were frequently methylated in these samples. Patients with exfoliated tumors cells positive for <em>DCC</em> methylation showed a trend toward a lower local recurrence-free survival.. Conclusions: These findings indicate that a low invasive method could be used to access the methylation profile of exfoliated cells from HNSCC patients. Moreover, our data provide evidence that hypermethylation of <em>DCC</em> could be useful as prognostic indicator for this malignance. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: Silencing of tumor suppressor genes plays a vital role in head and neck carcinogenesis. The aims of this study were to determine the methylation profile of exfoliated tumors cells collected from head and neck squamous cell carcinoma (HNSCC) patients and to evaluate its prognostic significance. Methods: The methylation profile and level of a 20 genes-panel were evaluated by QMSP in exfoliated tumor cell samples from 96 HNSCC patients. Results: CCNA1 (60.4%), DCC (54.2%) and TIMP3 (35.4%) were frequently methylated in these samples. Patients with exfoliated tumors cells positive for DCC methylation showed a trend toward a lower local recurrence-free survival.. Conclusions: These findings indicate that a low invasive method could be used to access the methylation profile of exfoliated cells from HNSCC patients. Moreover, our data provide evidence that hypermethylation of DCC could be useful as prognostic indicator for this malignance. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23344" xmlns="http://purl.org/rss/1.0/"><title>Accuracy of intra-operative frozen section analysis of nasopharyngeal carcinoma resection margins</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23344</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Accuracy of intra-operative frozen section analysis of nasopharyngeal carcinoma resection margins</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richie C. Chan, Jimmy Y. Chan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:24:05.243377-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23344</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23344</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23344</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="hed23344-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Frozen section analysis (FSA) is frequently employed in salvage surgery for recurrent or residual nasopharyngeal carcinoma after radiotherapy (rNPC) to ensure adequate tumour removal. However, the diagnostic accuracy of FSA in rNPC has never been clearly established. This was the first study to specifically address these issues.</p></div></div>
<div class="section" id="hed23344-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Patients with rNPC who underwent nasopharyngectomy in Queen Mary Hospital from 2006 to 2011 were identified. Clinical data, FSA results, and permanent histological results were analyzed.</p></div></div>
<div class="section" id="hed23344-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In the tissue-based analysis, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 70.6%, 100%, 100%, 95.2%, and 95.7% respectively. Only 37% of inconclusive FSA turned out negative on permanent histology. Presence of inconclusive (<em>p</em>=0.000) or positive (<em>p</em>=0.000) FSA results in the same operation significantly lowered the NPV of FSA.</p></div></div>
<div class="section" id="hed23344-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>FSA is useful in ensuring clear resection margins for rNPC. Further resection is advisable in cases of inconclusive FSA results. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
Frozen section analysis (FSA) is frequently employed in salvage surgery for recurrent or residual nasopharyngeal carcinoma after radiotherapy (rNPC) to ensure adequate tumour removal. However, the diagnostic accuracy of FSA in rNPC has never been clearly established. This was the first study to specifically address these issues.


Methods
Patients with rNPC who underwent nasopharyngectomy in Queen Mary Hospital from 2006 to 2011 were identified. Clinical data, FSA results, and permanent histological results were analyzed.


Results
In the tissue-based analysis, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 70.6%, 100%, 100%, 95.2%, and 95.7% respectively. Only 37% of inconclusive FSA turned out negative on permanent histology. Presence of inconclusive (p=0.000) or positive (p=0.000) FSA results in the same operation significantly lowered the NPV of FSA.


Conclusions
FSA is useful in ensuring clear resection margins for rNPC. Further resection is advisable in cases of inconclusive FSA results. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23343" xmlns="http://purl.org/rss/1.0/"><title>Tracheal reconstruction with asymmetrically porous polycaprolactone/pluronic F127 membranes</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23343</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Tracheal reconstruction with asymmetrically porous polycaprolactone/pluronic F127 membranes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Seong Keun Kwon, Jae-Jun Song, Chang Gun Cho, Seok-Won Park, Jin Rae Kim, Se Heang Oh, Jin Ho Lee</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:23:56.157803-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23343</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23343</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23343</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Backgrounds: Congenital and acquired tracheal stenosis continues to be challenging problems. The purpose of this study was to evaluate the efficacy of an asymmetrically porous membrane (APM) to induce tracheal reconstruction by inhibition of granulation tissue growth into the tracheal lumen while minimizing graft failure.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Methods: The APM was fabricated with polycaprolactone (PCL) and Pluronic F127 to have nano-size pores at top side, whereas the bottom side had micro-size pores. Fifteen rabbits underwent tracheal defect, which was then reconstructed with the APM. Rabbits were euthanized 1, 4, and 12 weeks postoperatively, and endoscopic, histologic, and radiologic evaluations were conducted.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Results: Endoscopy did not reveal granulation ingrowth into tracheal lumen. APM was well incorporated into the surrounding tissue on histologic evaluation. CT scans showed well maintained airways.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Conclusion: Off the shelf use of APM for tracheal reconstruction appears to be a promising strategy in the treatment of tracheal defects. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Backgrounds: Congenital and acquired tracheal stenosis continues to be challenging problems. The purpose of this study was to evaluate the efficacy of an asymmetrically porous membrane (APM) to induce tracheal reconstruction by inhibition of granulation tissue growth into the tracheal lumen while minimizing graft failure.
Methods: The APM was fabricated with polycaprolactone (PCL) and Pluronic F127 to have nano-size pores at top side, whereas the bottom side had micro-size pores. Fifteen rabbits underwent tracheal defect, which was then reconstructed with the APM. Rabbits were euthanized 1, 4, and 12 weeks postoperatively, and endoscopic, histologic, and radiologic evaluations were conducted.
Results: Endoscopy did not reveal granulation ingrowth into tracheal lumen. APM was well incorporated into the surrounding tissue on histologic evaluation. CT scans showed well maintained airways.
Conclusion: Off the shelf use of APM for tracheal reconstruction appears to be a promising strategy in the treatment of tracheal defects. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23342" xmlns="http://purl.org/rss/1.0/"><title>Risk of fatal cerebrovascular accidents after external beam radiation therapy for early stage glottic larynx cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23342</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Risk of fatal cerebrovascular accidents after external beam radiation therapy for early stage glottic larynx cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Samuel Swisher-McClure, Nandita Mitra, Alexander Lin, Peter Ahn, Fei Wan, Bert O'Malley, Gregory S. Weinstein, Justin E. Bekelman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:23:44.445218-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23342</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23342</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23342</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b><span class="underlined ">Background:</span></b> This study compared the risk of fatal cerebrovascular accidents (CVA) in patients with early stage glottic larynx cancer receiving surgery or external beam radiation therapy (EBRT).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b><span class="underlined ">Methods and Materials:</span></b> Using a competing risks survival analysis, we compared the risk of death due to CVA among patients with early stage glottic larynx cancer receiving surgery or EBRT in the SEER database.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b><span class="underlined ">Results:</span></b> The cumulative incidence of fatal CVA at 15 years was higher in patients receiving EBRT (2.8 %; 95% CI 2.3%-3.4%) compared to surgery (1.5 %; 95% CI 0.8 %-2.3%, p= 0.024). In multivariable competing risks regression models, EBRT remained associated with an increased risk of fatal CVA compared to surgery (adjusted HR 1.75; 95% CI 1.04-2.96, p= 0.037).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b><span class="underlined ">Conclusion:</span></b> Treatment of early stage glottic larynx cancer with EBRT was associated with a small increase in the risk of late fatal CVA events relative to surgery. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: This study compared the risk of fatal cerebrovascular accidents (CVA) in patients with early stage glottic larynx cancer receiving surgery or external beam radiation therapy (EBRT).
Methods and Materials: Using a competing risks survival analysis, we compared the risk of death due to CVA among patients with early stage glottic larynx cancer receiving surgery or EBRT in the SEER database.
Results: The cumulative incidence of fatal CVA at 15 years was higher in patients receiving EBRT (2.8 %; 95% CI 2.3%-3.4%) compared to surgery (1.5 %; 95% CI 0.8 %-2.3%, p= 0.024). In multivariable competing risks regression models, EBRT remained associated with an increased risk of fatal CVA compared to surgery (adjusted HR 1.75; 95% CI 1.04-2.96, p= 0.037).
Conclusion: Treatment of early stage glottic larynx cancer with EBRT was associated with a small increase in the risk of late fatal CVA events relative to surgery. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23341" xmlns="http://purl.org/rss/1.0/"><title>Oncocytic schneiderian papillomas: Clinical behaviour and outcomes of the endoscopic endonasal approach in 33 cases</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23341</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Oncocytic schneiderian papillomas: Clinical behaviour and outcomes of the endoscopic endonasal approach in 33 cases</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Apostolos Karligkiotis, Maurizio Bignami, Paola Terranova, Stefania Gallo, Francesco Meloni, Giovanni Padoan, Davide Lombardi, Piero Nicolai, Paolo Castelnuovo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:23:33.95573-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23341</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23341</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23341</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Background</em>: the aim of this study was to evaluate the clinical behaviour of oncocytic Schneiderian papillomas in relation to the rate of malignant transformation and recurrences and to report the long-term results of the endoscopic endonasal treatment.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Methods</em>: a retrospective analysis was carried out on patients with oncocytic papilloma, endoscopically managed over the past 20 years, at two university centres following a uniform policy.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Results</em>: thirty-three patients were treated between November 1991 and December 2010. The mean follow-up period was 62 months. We observed 2 cases of persistence (6%) at maxillary sinus level. Both of these patients underwent endoscopic surgical revision. Squamous cell carcinoma was observed in one patient (3%).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Conclusion</em>: the endonasal endoscopic technique proved to be a safe and effective approach for the treatment of oncocytic papillomas. An oncocytic papilloma is not to be considered a negative prognostic factor in terms of malignant transformation or recurrence. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: the aim of this study was to evaluate the clinical behaviour of oncocytic Schneiderian papillomas in relation to the rate of malignant transformation and recurrences and to report the long-term results of the endoscopic endonasal treatment.
Methods: a retrospective analysis was carried out on patients with oncocytic papilloma, endoscopically managed over the past 20 years, at two university centres following a uniform policy.
Results: thirty-three patients were treated between November 1991 and December 2010. The mean follow-up period was 62 months. We observed 2 cases of persistence (6%) at maxillary sinus level. Both of these patients underwent endoscopic surgical revision. Squamous cell carcinoma was observed in one patient (3%).
Conclusion: the endonasal endoscopic technique proved to be a safe and effective approach for the treatment of oncocytic papillomas. An oncocytic papilloma is not to be considered a negative prognostic factor in terms of malignant transformation or recurrence. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23340" xmlns="http://purl.org/rss/1.0/"><title>Preferences and utilities for health states following treatment for oropharyngeal cancer: Transoral robotic surgery versus definitive (chemo)radiotherapy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23340</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Preferences and utilities for health states following treatment for oropharyngeal cancer: Transoral robotic surgery versus definitive (chemo)radiotherapy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John R. de Almeida, Nathaniel L. Villanueva, Alan J. Moskowitz, Brett A. Miles, Marita S. Teng, Andrew Sikora, Vishal Gupta, Marshall Posner, Eric M. Genden</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:23:21.48525-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23340</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23340</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23340</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="hed23340-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4><span class="underlined ">Background</span></h4><div class="para"><p>Treatment of oropharyngeal cancer with Transoral Robotic Surgery (TORS) or definitive (chemo)radiotherapy impacts quality of life. Utility scores are needed for quality of life and economic comparisons.</p></div></div>
<div class="section" id="hed23340-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4><span class="underlined ">Methods</span></h4><div class="para"><p>Fifty healthy subjects and 9 experts reviewed scenarios describing treatment (TORS alone or with adjuvant radiotherapy or chemoradiotherapy, definitive radiotherapy, and chemoradiotherapy), complications, remission, and recurrences. Utilities were assessed using visual analogue scales (VAS) and standard gamble (SG) techniques. Treatments were compared using paired comparisons. Demographic variability was assessed.</p></div></div>
<div class="section" id="hed23340-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4><span class="underlined ">Results</span></h4><div class="para"><p>TORS had higher SG utilities than radiotherapy (p = 0.001) and chemoradiotherapy (p &lt; 0.001) and was preferred in paired comparisons (p &lt; 0.001 for both) for healthy subjects. Utilities did not vary by demographic group and correlated between experts and subjects (VAS r = 0.95, p &lt; 0.001; SG r = 0.97, p &lt; 0.001).</p></div></div>
<div class="section" id="hed23340-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4><span class="underlined ">Conclusion</span></h4><div class="para"><p>TORS has higher utility scores than chemoradiotherapy. Utilities can be used for cost-utility analyses. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
Treatment of oropharyngeal cancer with Transoral Robotic Surgery (TORS) or definitive (chemo)radiotherapy impacts quality of life. Utility scores are needed for quality of life and economic comparisons.


Methods
Fifty healthy subjects and 9 experts reviewed scenarios describing treatment (TORS alone or with adjuvant radiotherapy or chemoradiotherapy, definitive radiotherapy, and chemoradiotherapy), complications, remission, and recurrences. Utilities were assessed using visual analogue scales (VAS) and standard gamble (SG) techniques. Treatments were compared using paired comparisons. Demographic variability was assessed.


Results
TORS had higher SG utilities than radiotherapy (p = 0.001) and chemoradiotherapy (p &lt; 0.001) and was preferred in paired comparisons (p &lt; 0.001 for both) for healthy subjects. Utilities did not vary by demographic group and correlated between experts and subjects (VAS r = 0.95, p &lt; 0.001; SG r = 0.97, p &lt; 0.001).


Conclusion
TORS has higher utility scores than chemoradiotherapy. Utilities can be used for cost-utility analyses. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23339" xmlns="http://purl.org/rss/1.0/"><title>Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV positive and HPV negative locally advanced squamous cell carcinoma of the oropharynx (SCCOP)</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23339</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV positive and HPV negative locally advanced squamous cell carcinoma of the oropharynx (SCCOP)</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Irina Y. Dobrosotskaya, Emily Bellile, Matthew E. Spector, Bhavna Kumar, Felix Feng, Avraham Eisbruch, Gregory T. Wolf, Mark E. P. Prince, Jeffrey S. Moyer, Theodoros Teknos, Douglas B. Chepeha, Heather M. Walline, Jonathan B. McHugh, Kitrina G. Cordell, P. Daniel Ward, Serena Byrd, Jessica H. Maxwell, Susan Urba, Carol R. Bradford, Thomas E. Carey, Francis P. Worden</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:23:15.451891-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23339</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23339</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23339</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Background</em>: Optimal treatment for locally advanced SCCOP is not well defined. Here we retrospectively compare survival and toxicities from two different organ preservation protocols.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Methods</em>: The matched dataset consisted of 35 patients from each trial matched for age, stage, smoking, and tumor HPV status. Patients on University of Michigan Cancer Center (UMCC) trial 9921 were treated with induction chemotherapy followed by high-dose cisplatin and radiation in responders, or surgery in non-responders. Patients on UMCC trial 0221 were treated with weekly carboplatin and paclitaxel and radiation.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Results</em>: Survival was comparable for both studies and did not differ significantly across each trial after stratifying by HPV status. Grade 3 and 4 toxicities were more frequent in UMCC 9921. At 6 months post-treatment, G-tube dependence was not statistically different.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Conclusions</em>: These data suggest that survival outcomes in patients with locally advanced SCCOP are not compromised with weekly chemotherapy and RT, and such treatment is generally more tolerable. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Background: Optimal treatment for locally advanced SCCOP is not well defined. Here we retrospectively compare survival and toxicities from two different organ preservation protocols.
Methods: The matched dataset consisted of 35 patients from each trial matched for age, stage, smoking, and tumor HPV status. Patients on University of Michigan Cancer Center (UMCC) trial 9921 were treated with induction chemotherapy followed by high-dose cisplatin and radiation in responders, or surgery in non-responders. Patients on UMCC trial 0221 were treated with weekly carboplatin and paclitaxel and radiation.
Results: Survival was comparable for both studies and did not differ significantly across each trial after stratifying by HPV status. Grade 3 and 4 toxicities were more frequent in UMCC 9921. At 6 months post-treatment, G-tube dependence was not statistically different.
Conclusions: These data suggest that survival outcomes in patients with locally advanced SCCOP are not compromised with weekly chemotherapy and RT, and such treatment is generally more tolerable. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23338" xmlns="http://purl.org/rss/1.0/"><title>Results of 226 patients with T3 laryngeal carcinoma after treatment with transoral laser microsurgery</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23338</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Results of 226 patients with T3 laryngeal carcinoma after treatment with transoral laser microsurgery</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martin Canis, Friedrich Ihler, Alexios Martin, Hendrik A. Wolff, Christoph Matthias, Wolfgang Steiner</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:23:10.610301-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23338</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23338</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23338</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Objective</b>: to assess the feasibility of Transoral Laser Microsurgery (TLM) in treatment of pT3 laryngeal cancer</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Design</b>: retrospective case-series study.<b>Patients</b>: 226 patients with pT3 glottic (n=122, 54 %) or supraglottic laryngeal carcinoma (n=104, 46 %) were included.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Interventions</b>: All patients were treated by TLM in combination with neck dissection (63%) and with postoperative radiotherapy (18%).</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Main outcome measures</b>: local control, organ preservation, functional outcome, overall, recurrence-free, and disease specific survival</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Results</b>: median follow-up period was 57.8 months. 5-year organ preservation and local control rate for all patients were 87 % and 71.4 %, 5-year overall, recurrence-free and disease specific survival were 64.4 %, 63.0 % and 83.3 %.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusions</b>: Results are comparable to partial or total laryngectomy, while being superior to primary chemo(radio)therapy. TLM results in low morbidity, rapid recovery and good function and can be a valid option for organ preserving surgery of pT3 glottic and supraglottic cancer. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Objective: to assess the feasibility of Transoral Laser Microsurgery (TLM) in treatment of pT3 laryngeal cancer
Design: retrospective case-series study.Patients: 226 patients with pT3 glottic (n=122, 54 %) or supraglottic laryngeal carcinoma (n=104, 46 %) were included.
Interventions: All patients were treated by TLM in combination with neck dissection (63%) and with postoperative radiotherapy (18%).
Main outcome measures: local control, organ preservation, functional outcome, overall, recurrence-free, and disease specific survival
Results: median follow-up period was 57.8 months. 5-year organ preservation and local control rate for all patients were 87 % and 71.4 %, 5-year overall, recurrence-free and disease specific survival were 64.4 %, 63.0 % and 83.3 %.
Conclusions: Results are comparable to partial or total laryngectomy, while being superior to primary chemo(radio)therapy. TLM results in low morbidity, rapid recovery and good function and can be a valid option for organ preserving surgery of pT3 glottic and supraglottic cancer. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23337" xmlns="http://purl.org/rss/1.0/"><title>Pharyngocutaneous fistula after salvage laryngectomy: Impact of interval between radiotherapy and surgery, and performance of bilateral neck dissection</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23337</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pharyngocutaneous fistula after salvage laryngectomy: Impact of interval between radiotherapy and surgery, and performance of bilateral neck dissection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Naveed Basheeth, Gerard O'Leary, Patrick Sheahan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:20:58.702313-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23337</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23337</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23337</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">ABSTRACT</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Introduction</b>: Pharyngocutaneous fistula is a serious complication of total laryngectomy. Our objective was to study predisposing factors at our institution.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Methods</b>: Retrospective review of 94 consecutive patients undergoing total laryngectomy. Cases with hypopharyngeal primary tumours or undergoing extended hypopharyngeal resection with flap augmentation of the pharynx were excluded.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Results</b>: Seventy-four cases met inclusion criteria. 25.7% developed a pharyngocutaneous fistula. The fistula rate was higher after salvage laryngectomy than after primary surgery (34.0% versus 11.1%, p=0.05). Among salvage laryngectomies, performance of laryngectomy within one year of completion of radiotherapy (p=0.006), and performance of concomitant bilateral neck dissection (p=0.02), were significant risk factors for development of fistula. Radiation dose, addition of chemotherapy, use of pectoralis major myofascial flap, preoperative tracheostomy, primary puncture, primary tumour subsite, and initial T-stage, were not significant.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><b>Conclusions</b>: Interval between completion of radiotherapy and surgery is significantly associated with pharyngocutaneous fistula after salvage total laryngectomy <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>

Introduction: Pharyngocutaneous fistula is a serious complication of total laryngectomy. Our objective was to study predisposing factors at our institution.
Methods: Retrospective review of 94 consecutive patients undergoing total laryngectomy. Cases with hypopharyngeal primary tumours or undergoing extended hypopharyngeal resection with flap augmentation of the pharynx were excluded.
Results: Seventy-four cases met inclusion criteria. 25.7% developed a pharyngocutaneous fistula. The fistula rate was higher after salvage laryngectomy than after primary surgery (34.0% versus 11.1%, p=0.05). Among salvage laryngectomies, performance of laryngectomy within one year of completion of radiotherapy (p=0.006), and performance of concomitant bilateral neck dissection (p=0.02), were significant risk factors for development of fistula. Radiation dose, addition of chemotherapy, use of pectoralis major myofascial flap, preoperative tracheostomy, primary puncture, primary tumour subsite, and initial T-stage, were not significant.
Conclusions: Interval between completion of radiotherapy and surgery is significantly associated with pharyngocutaneous fistula after salvage total laryngectomy Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23336" xmlns="http://purl.org/rss/1.0/"><title>Validity of bioelectrical impedance analysis to assess fat-free mass in head and neck cancer patients: an exploratory study</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23336</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Validity of bioelectrical impedance analysis to assess fat-free mass in head and neck cancer patients: an exploratory study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Harriët Jager-Wittenaar, Pieter U. Dijkstra, Carrie P. Earthman, Wim P. Krijnen, Johannes A. Langendijk, Bernard F.A.M. van der Laan, Jan Pruim, Jan L.N. Roodenburg</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-18T00:20:56.225971-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23336</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23336</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23336</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="hed23336-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>We aimed to validate bioelectrical impedance analysis (BIA) using the Geneva equation for fat-free mass (FFM) in head and neck cancer (HNC) patients.</p></div></div>
<div class="section" id="hed23336-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In 24 HNC patients, agreement between BIA (FFM<sub>BIA</sub>) and dual energy x-ray absorptiometry (FFM<sub>DXA</sub>) one week before (T<sub>0</sub>), one month (T<sub>1</sub>) and four months (T<sub>2</sub>) after cancer treatment was analyzed.</p></div></div>
<div class="section" id="hed23336-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>FFM<sub>BIA</sub> did not differ from FFM<sub>DXA</sub> (mean difference 0.71±1.9, 0.30±1.9 and 0.02±2.1 kg) at any time point. Only at T<sub>0</sub>, mean FFM correlated to the difference between FFM<sub>DXA</sub> and FFM<sub>BIA</sub> (<em>r</em>=0.48, <em>P</em>=0.017). Limits of agreement were 3.8, 3.7 and 4.1 kg respectively. Concordance Correlation Coefficients were 0.98 at all time points.</p></div></div>
<div class="section" id="hed23336-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>BIA may be used to assess FFM with reasonable validity based on mean-level comparisons, but differences between BIA and DXA may vary by about 4 kg in an individual patient. These results require confirmation in a larger sample of HNC patients. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
We aimed to validate bioelectrical impedance analysis (BIA) using the Geneva equation for fat-free mass (FFM) in head and neck cancer (HNC) patients.


Methods
In 24 HNC patients, agreement between BIA (FFMBIA) and dual energy x-ray absorptiometry (FFMDXA) one week before (T0), one month (T1) and four months (T2) after cancer treatment was analyzed.


Results
FFMBIA did not differ from FFMDXA (mean difference 0.71±1.9, 0.30±1.9 and 0.02±2.1 kg) at any time point. Only at T0, mean FFM correlated to the difference between FFMDXA and FFMBIA (r=0.48, P=0.017). Limits of agreement were 3.8, 3.7 and 4.1 kg respectively. Concordance Correlation Coefficients were 0.98 at all time points.


Conclusions
BIA may be used to assess FFM with reasonable validity based on mean-level comparisons, but differences between BIA and DXA may vary by about 4 kg in an individual patient. These results require confirmation in a larger sample of HNC patients. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23335" xmlns="http://purl.org/rss/1.0/"><title>Complex adult laryngotracheal reconstruction with a prefabricated flap: A case series</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23335</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Complex adult laryngotracheal reconstruction with a prefabricated flap: A case series</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kara Y. Detwiller, Joshua S. Schindler, Daniel S. Schneider, Robert Lindau, Mark K. Wax</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-15T09:51:34.199708-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23335</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23335</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23335</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="hed23335-sec-0001" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Laryngotracheal stenosis (LTS) can cause persistent or recurrent airway obstruction. While there is extensive literature on surgical techniques to treat LTS at onset, there are few techniques described for complex adult LTS after failed prior airway surgery. We describe a procedure used successfully in three patients who required structural augmentation for complex LTS.</p></div></div>
<div class="section" id="hed23335-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Patients were treated with staged reconstruction using a prefabricated composite graft consisting of auricular cartilage and a radial forearm free flap.</p></div></div>
<div class="section" id="hed23335-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>All patients were reconstructed successfully with good wound healing and are tolerating oral diets. Two patients have been successfully decannulated.</p></div></div>
<div class="section" id="hed23335-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>A delayed prefabricated graft using auricular cartilage in a radial forearm free flap is a viable surgical intervention in patients with complex adult LTS who are not candidates for conventional approaches. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>


Background
Laryngotracheal stenosis (LTS) can cause persistent or recurrent airway obstruction. While there is extensive literature on surgical techniques to treat LTS at onset, there are few techniques described for complex adult LTS after failed prior airway surgery. We describe a procedure used successfully in three patients who required structural augmentation for complex LTS.


Methods
Patients were treated with staged reconstruction using a prefabricated composite graft consisting of auricular cartilage and a radial forearm free flap.


Results
All patients were reconstructed successfully with good wound healing and are tolerating oral diets. Two patients have been successfully decannulated.


Conclusions
A delayed prefabricated graft using auricular cartilage in a radial forearm free flap is a viable surgical intervention in patients with complex adult LTS who are not candidates for conventional approaches. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23260" xmlns="http://purl.org/rss/1.0/"><title>Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: A study in Wistar rats</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23260</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: A study in Wistar rats</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Soraya A. Berti–Couto, Ana Carolina U. Vasconcelos, Júlia E. Iglesias, Maria Antonia Z. Figueiredo, Fernanda G. Salum, Karen Cherubini</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-04T11:34:33.90357-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23260</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23260</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23260</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23260-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to investigate the influence of diabetes and corticotherapy on the development of osteonecrosis of the jaws associated with sodium alendronate.</p></div></div>
<div class="section" id="hed23260-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Rats were allocated into 4 groups of 11 animals each, representing different treatments: (1) alendronate; (2) alendronate and corticotherapy; (3) alendronate and diabetes; and (4) control. Tooth extractions were performed in all animals, and histological analysis was performed by hematoxylin and eosin staining and immunohistochemistry using anti-bone morphogenetic protein (BMP)-4 and anti-matrix metalloproteinase (MMP)-13 antibodies.</p></div></div>
<div class="section" id="hed23260-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>On hematoxylin and eosin analysis, proportions of inflammatory infiltrate, microbial colonies, and osteonecrosis were significantly greater in the diabetes group. BMP-4 expression in connective tissue was higher in the corticosteroid group than the alendronate group. There were no significant differences between the other groups. MMP-13 expression did not differ between the groups analyzed.</p></div></div>
<div class="section" id="hed23260-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Diabetes but not corticotherapy is associated with jaw osteonecrosis in rats undergoing alendronate therapy and subjected to tooth extractions. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
The purpose of this study was to investigate the influence of diabetes and corticotherapy on the development of osteonecrosis of the jaws associated with sodium alendronate.


Methods
Rats were allocated into 4 groups of 11 animals each, representing different treatments: (1) alendronate; (2) alendronate and corticotherapy; (3) alendronate and diabetes; and (4) control. Tooth extractions were performed in all animals, and histological analysis was performed by hematoxylin and eosin staining and immunohistochemistry using anti-bone morphogenetic protein (BMP)-4 and anti-matrix metalloproteinase (MMP)-13 antibodies.


Results
On hematoxylin and eosin analysis, proportions of inflammatory infiltrate, microbial colonies, and osteonecrosis were significantly greater in the diabetes group. BMP-4 expression in connective tissue was higher in the corticosteroid group than the alendronate group. There were no significant differences between the other groups. MMP-13 expression did not differ between the groups analyzed.


Conclusion
Diabetes but not corticotherapy is associated with jaw osteonecrosis in rats undergoing alendronate therapy and subjected to tooth extractions. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23274" xmlns="http://purl.org/rss/1.0/"><title>Clinical response and tumor control based on long-term follow-up and patient-reported outcomes in patients with chemodectomas of the skull base and head-and-neck region treated with highly conformal radiation therapy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23274</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clinical response and tumor control based on long-term follow-up and patient-reported outcomes in patients with chemodectomas of the skull base and head-and-neck region treated with highly conformal radiation therapy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stephanie E. Combs, Bahar Salehi–Allameh, Daniel Habermehl, Kerstin A. Kessel, Thomas Welzel, Jürgen Debus</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-04T11:33:34.81807-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23274</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23274</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23274</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23274-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to evaluate long-term outcome after radiation therapy (RT) for skull base or head-and-neck chemodectomas.</p></div></div>
<div class="section" id="hed23274-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We treated 39 patients with chemodectomas with RT. Patients were treated with either single dose stereotactic radiosurgery, fractionated stereotactic radiotherapy, or intensity modulated radiotherapy (IMRT), depending on the size and anatomy of the lesion. At primary diagnosis, 16 patients were treated with surgical resection (41%), 4 with interventional embolization (10%), and 19 with primary RT (49%). Single doses of 18 Gy/80% isodose were applied. For fractionated treatments delivered as primary RT, a median total dose of 57.6 Gy was delivered. Five patients were treated with re-irradiation, of which 4 were treated with fractionated regimens; total dose was 28.8 Gy, 30 Gy, 40 Gy, and 56 Gy in 1.8 to 2 Gy single fractions.</p></div></div>
<div class="section" id="hed23274-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Clinical symptoms improved in 18 patients (46%), remained unchanged in 10 patients (26%), and worsening of sequelae was observed in only 1 patient, which was associated with tumor progression. Actuarial local control was 97% at 10 years. Overall survival was 89% at 5 years and 87% at 10 years. Deaths were not disease-related except in 3 patients with tumor progression. No secondary malignancies were observed.</p></div></div>
<div class="section" id="hed23274-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>RT has been established as a treatment alternative for patients with glomus tumors. Long-term local control is very high, with good clinical response to treatment. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
The purpose of this study was to evaluate long-term outcome after radiation therapy (RT) for skull base or head-and-neck chemodectomas.


Methods
We treated 39 patients with chemodectomas with RT. Patients were treated with either single dose stereotactic radiosurgery, fractionated stereotactic radiotherapy, or intensity modulated radiotherapy (IMRT), depending on the size and anatomy of the lesion. At primary diagnosis, 16 patients were treated with surgical resection (41%), 4 with interventional embolization (10%), and 19 with primary RT (49%). Single doses of 18 Gy/80% isodose were applied. For fractionated treatments delivered as primary RT, a median total dose of 57.6 Gy was delivered. Five patients were treated with re-irradiation, of which 4 were treated with fractionated regimens; total dose was 28.8 Gy, 30 Gy, 40 Gy, and 56 Gy in 1.8 to 2 Gy single fractions.


Results
Clinical symptoms improved in 18 patients (46%), remained unchanged in 10 patients (26%), and worsening of sequelae was observed in only 1 patient, which was associated with tumor progression. Actuarial local control was 97% at 10 years. Overall survival was 89% at 5 years and 87% at 10 years. Deaths were not disease-related except in 3 patients with tumor progression. No secondary malignancies were observed.


Conclusion
RT has been established as a treatment alternative for patients with glomus tumors. Long-term local control is very high, with good clinical response to treatment. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23254" xmlns="http://purl.org/rss/1.0/"><title>Vascularized free forearm flap versus free anterolateral thigh perforator flaps for reconstruction in patients with head and neck cancer: Assessment of quality of life</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23254</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Vascularized free forearm flap versus free anterolateral thigh perforator flaps for reconstruction in patients with head and neck cancer: Assessment of quality of life</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wenlu Li, Zhongfei Xu, Fayu Liu, Shaohui Huang, Wei Dai, Changfu Sun</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-03T02:45:09.544576-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23254</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23254</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23254</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23254-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>This study investigated the quality of life of Chinese patients with malignant tumors who had undergone immediate free flap reconstruction surgery. In addition, we compared 2 groups of patients: those who had received radial forearm free flap surgery and others who had received free anterolateral thigh perforator flap surgery.</p></div></div>
<div class="section" id="hed23254-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Quality of life was assessed using the Medical Outcomes Study-Short Form-36 (MOS SF-36) and the University of Washington Quality of Life (UW-QOL) questionnaires 12 months after reconstruction.</p></div></div>
<div class="section" id="hed23254-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>A total of 121 of 163 questionnaires were returned (74.2%). There were significant differences between the 2 groups in the T classification (<em>p</em> &lt; .005). Patients reconstructed with free anterolateral thigh perforator flaps performed better in the appearance and shoulder domains, and the role emotion and social functioning domains.</p></div></div>
<div class="section" id="hed23254-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Using either radial forearm free flaps or free anterolateral thigh perforator flaps for reconstruction of head and neck defects after cancer resection significantly influences a patient's quality of life. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
This study investigated the quality of life of Chinese patients with malignant tumors who had undergone immediate free flap reconstruction surgery. In addition, we compared 2 groups of patients: those who had received radial forearm free flap surgery and others who had received free anterolateral thigh perforator flap surgery.


Methods
Quality of life was assessed using the Medical Outcomes Study-Short Form-36 (MOS SF-36) and the University of Washington Quality of Life (UW-QOL) questionnaires 12 months after reconstruction.


Results
A total of 121 of 163 questionnaires were returned (74.2%). There were significant differences between the 2 groups in the T classification (p &lt; .005). Patients reconstructed with free anterolateral thigh perforator flaps performed better in the appearance and shoulder domains, and the role emotion and social functioning domains.


Conclusions
Using either radial forearm free flaps or free anterolateral thigh perforator flaps for reconstruction of head and neck defects after cancer resection significantly influences a patient's quality of life. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23257" xmlns="http://purl.org/rss/1.0/"><title>Radiotherapy for a repeatedly recurrent ameloblastoma with malignant transformation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23257</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Radiotherapy for a repeatedly recurrent ameloblastoma with malignant transformation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chun-Ming Huang, Jin-Yi Chen, Chung-Ho Chen, Chih-Jen Huang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T08:31:59.562292-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23257</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23257</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23257</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23257-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The role of radiation therapy (RT) for ameloblastoma remains controversial and undetermined due to the rarity of the disease.</p></div></div>
<div class="section" id="hed23257-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A case of repeatedly recurrent ameloblastoma with malignant transformation is presented. The clinical course and managements are described.</p></div></div>
<div class="section" id="hed23257-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The 63-year-old man had a recurrent ameloblastoma in the left mandible. Five years after the first surgical resection, he underwent 8 more rounds of surgical excision of the recurrent tumors. The malignant transformation occurred and the unresectable tumor invaded the masticator space, parapharyngeal space, and skull base. He received 3-dimensional conformal RT, at the dose of 66 Gray (Gy) in 33 fractions. The ulcerative exophytic mass had regressed gradually. After follow-up of 28 months, the tumor was well controlled.</p></div></div>
<div class="section" id="hed23257-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>RT seems to be a feasible treatment option for recurrent ameloblastoma with malignant transformation. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
The role of radiation therapy (RT) for ameloblastoma remains controversial and undetermined due to the rarity of the disease.


Methods
A case of repeatedly recurrent ameloblastoma with malignant transformation is presented. The clinical course and managements are described.


Results
The 63-year-old man had a recurrent ameloblastoma in the left mandible. Five years after the first surgical resection, he underwent 8 more rounds of surgical excision of the recurrent tumors. The malignant transformation occurred and the unresectable tumor invaded the masticator space, parapharyngeal space, and skull base. He received 3-dimensional conformal RT, at the dose of 66 Gray (Gy) in 33 fractions. The ulcerative exophytic mass had regressed gradually. After follow-up of 28 months, the tumor was well controlled.


Conclusions
RT seems to be a feasible treatment option for recurrent ameloblastoma with malignant transformation. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23259" xmlns="http://purl.org/rss/1.0/"><title>Genetic relationship between multiple squamous cell carcinomas arising in the oral cavity</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23259</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Genetic relationship between multiple squamous cell carcinomas arising in the oral cavity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lucio Montebugnoli, Elisa Leonardi, Luca Morandi, Anna Farnedi, Davide Bartolomeo Gissi, Claudio Marchetti, Achille Tarsitano, Tiziana Balbi, Luciano Gentile, Roberto Cocchi, Maria Pia Foschini</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T07:57:19.994932-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23259</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23259</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23259</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23259-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Histological and clinical criteria are generally used to differentiate second primary tumors (SPTs) from local recurrences. The purpose of the present study was to apply mitochondrial DNA (mtDNA) D-loop analysis to differentiate SPTs from local recurrences and to validate the clinical classification.</p></div></div>
<div class="section" id="hed23259-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The study population consisted of 20 consecutive patients presenting multiple oral neoplastic lesions for a total of 25 paired lesions. The mtDNA D-loop analysis was performed by direct sequencing and phylogenetic clusterization.</p></div></div>
<div class="section" id="hed23259-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Agreement between mtDNA analysis and clinical classification was found in 19 cases. Discrepancies arose in 6 cases in which the clinical criteria based only on the spatial or temporal distance of the second lesion from the index tumor had led to a diagnosis of SPT (2 cases) or local recurrence (4 cases).</p></div></div>
<div class="section" id="hed23259-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>The present data highlight the value of mtDNA analysis in establishing the clonal relationship between the index tumor and the second neoplastic lesion. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
Histological and clinical criteria are generally used to differentiate second primary tumors (SPTs) from local recurrences. The purpose of the present study was to apply mitochondrial DNA (mtDNA) D-loop analysis to differentiate SPTs from local recurrences and to validate the clinical classification.


Methods
The study population consisted of 20 consecutive patients presenting multiple oral neoplastic lesions for a total of 25 paired lesions. The mtDNA D-loop analysis was performed by direct sequencing and phylogenetic clusterization.


Results
Agreement between mtDNA analysis and clinical classification was found in 19 cases. Discrepancies arose in 6 cases in which the clinical criteria based only on the spatial or temporal distance of the second lesion from the index tumor had led to a diagnosis of SPT (2 cases) or local recurrence (4 cases).


Conclusion
The present data highlight the value of mtDNA analysis in establishing the clonal relationship between the index tumor and the second neoplastic lesion. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23267" xmlns="http://purl.org/rss/1.0/"><title>Molecular profiling of sinonasal undifferentiated carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23267</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Molecular profiling of sinonasal undifferentiated carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexander Gelbard, Katherine S. Hale, Yoko Takahashi, Michael Davies, Michael E. Kupferman, Adel K. El-Naggar, Jeffrey N. Myers, Ehab Y. Hanna</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T07:51:01.206369-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23267</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23267</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23267</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23267-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Sinonasal undifferentiated carcinoma (SNUC) remains a poorly characterized malignancy at both the clinical and molecular level, and, consequently, the optimal treatment strategy remains undefined.</p></div></div>
<div class="section" id="hed23267-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We used a mass spectroscopy–based approach (Sequenom) to evaluate 95 hallmark single nucleotide variations (SNVs) within 12 oncogenes or tumor suppressor genes (AKT, BRAF, CDK4, Beta-catenin, epidermal growth factor receptor [EGFR], FBXW7, JAK2, c-KIT, KRAS, PDGFR, PI3K, and vascular endothelial growth factor [VEGF]) in 13 histologically confirmed SNUC cases.</p></div></div>
<div class="section" id="hed23267-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>None of the samples demonstrated activating mutations in any of the 95 SNVs.</p></div></div>
<div class="section" id="hed23267-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Select clinically relevant activating genomic mutations were not identified in the 13 patient samples. However, polymorphisms were noted within the promoter region of VEGF. These may merit future studies as predictive biomarkers for treatment response or overall survival. Additionally, future studies focusing on larger tumor sets and utilizing whole genome or exome sequencing may help define genetic aberrations in SNUC that can be clinically targeted with available or emerging biological agents. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
Sinonasal undifferentiated carcinoma (SNUC) remains a poorly characterized malignancy at both the clinical and molecular level, and, consequently, the optimal treatment strategy remains undefined.


Methods
We used a mass spectroscopy–based approach (Sequenom) to evaluate 95 hallmark single nucleotide variations (SNVs) within 12 oncogenes or tumor suppressor genes (AKT, BRAF, CDK4, Beta-catenin, epidermal growth factor receptor [EGFR], FBXW7, JAK2, c-KIT, KRAS, PDGFR, PI3K, and vascular endothelial growth factor [VEGF]) in 13 histologically confirmed SNUC cases.


Results
None of the samples demonstrated activating mutations in any of the 95 SNVs.


Conclusion
Select clinically relevant activating genomic mutations were not identified in the 13 patient samples. However, polymorphisms were noted within the promoter region of VEGF. These may merit future studies as predictive biomarkers for treatment response or overall survival. Additionally, future studies focusing on larger tumor sets and utilizing whole genome or exome sequencing may help define genetic aberrations in SNUC that can be clinically targeted with available or emerging biological agents. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23253" xmlns="http://purl.org/rss/1.0/"><title>Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23253</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A. Dimitrios Colevas</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T07:50:18.255671-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23253</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23253</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23253</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23253-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The influences of socioeconomic status (SES) on the incidence rates of oropharyngeal squamous cell carcinoma (OPSCC) are unclear.</p></div></div>
<div class="section" id="hed23253-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Data from the California Cancer Registry and U.S. Census were used to compare incidence rates and trends of OPSCC and other human papillomavirus–related and –unrelated cancer sites by neighborhood SES, race/ethnicity, and sex.</p></div></div>
<div class="section" id="hed23253-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The incidence of OPSCC rose in both higher and lower SES neighborhoods. Absolute rates were greater in the latter. Only non-Hispanic white males with OPSCC demonstrated a significant increase in the incidence rate of squamous cell carcinoma of the head and neck (SCCHN). The incidence rate for this group increased from 4.5/100,000 person-years between 1988 and 1992 to 7.1 between 2003 and 2009. Regression analysis demonstrated an annual percentage change of 1% from 1988 to 1997 and 4% thereafter.</p></div></div>
<div class="section" id="hed23253-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Increases in incidence rates are SES independent. Incidence rates are higher in lower-SES groups. The rise in OPSCC incidence is limited to non-Hispanic white males. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
The influences of socioeconomic status (SES) on the incidence rates of oropharyngeal squamous cell carcinoma (OPSCC) are unclear.


Methods
Data from the California Cancer Registry and U.S. Census were used to compare incidence rates and trends of OPSCC and other human papillomavirus–related and –unrelated cancer sites by neighborhood SES, race/ethnicity, and sex.


Results
The incidence of OPSCC rose in both higher and lower SES neighborhoods. Absolute rates were greater in the latter. Only non-Hispanic white males with OPSCC demonstrated a significant increase in the incidence rate of squamous cell carcinoma of the head and neck (SCCHN). The incidence rate for this group increased from 4.5/100,000 person-years between 1988 and 1992 to 7.1 between 2003 and 2009. Regression analysis demonstrated an annual percentage change of 1% from 1988 to 1997 and 4% thereafter.


Conclusions
Increases in incidence rates are SES independent. Incidence rates are higher in lower-SES groups. The rise in OPSCC incidence is limited to non-Hispanic white males. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23285" xmlns="http://purl.org/rss/1.0/"><title>Longitudinal study on the correlations of thyroid antibody and thyroid hormone levels after radiotherapy in patients with nasopharyngeal carcinoma with radiation-induced hypothyroidism</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23285</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Longitudinal study on the correlations of thyroid antibody and thyroid hormone levels after radiotherapy in patients with nasopharyngeal carcinoma with radiation-induced hypothyroidism</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zhixiong Lin, Linxing Chen, Yusen Fang, Aiqun Cai, Tuodan Zhang, Vincent W. C. Wu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T07:14:16.337806-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23285</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23285</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23285</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23285-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to evaluate the correlations of thyroid antibody and thyroid hormone in postradiotherapy (post-RT) patients with nasopharyngeal carcinoma (NPC).</p></div></div>
<div class="section" id="hed23285-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Serum thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), thyroperoxidase antibody (anti-TPO), and thyroglobulin antibody (anti-TG) levels of 55 patients with NPC were taken before RT and at 3, 6, 12, and 18 months after RT. Patients with hypothyroidism at 18 months after RT and those with normal thyroid function were categorized into the hypo and normal groups, respectively. The thyroid antibody levels were compared between the 2 groups, and the correlations of thyroid antibody and thyroid hormone were evaluated for the hypo group.</p></div></div>
<div class="section" id="hed23285-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The anti-TPO and anti-TG of the hypo group were higher than the normal group. In the hypo group, there was a positive correlation (<em>r</em> = 0.51) between TSH and anti-TG and a negative correlation between fT4 and anti-TPO (<em>r</em> = −0.55).</p></div></div>
<div class="section" id="hed23285-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>There were correlations of the thyroid antibody and thyroid hormone levels in patients with radiation-induced hypothyroidism. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
The purpose of this study was to evaluate the correlations of thyroid antibody and thyroid hormone in postradiotherapy (post-RT) patients with nasopharyngeal carcinoma (NPC).


Methods
Serum thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), thyroperoxidase antibody (anti-TPO), and thyroglobulin antibody (anti-TG) levels of 55 patients with NPC were taken before RT and at 3, 6, 12, and 18 months after RT. Patients with hypothyroidism at 18 months after RT and those with normal thyroid function were categorized into the hypo and normal groups, respectively. The thyroid antibody levels were compared between the 2 groups, and the correlations of thyroid antibody and thyroid hormone were evaluated for the hypo group.


Results
The anti-TPO and anti-TG of the hypo group were higher than the normal group. In the hypo group, there was a positive correlation (r = 0.51) between TSH and anti-TG and a negative correlation between fT4 and anti-TPO (r = −0.55).


Conclusion
There were correlations of the thyroid antibody and thyroid hormone levels in patients with radiation-induced hypothyroidism. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23284" xmlns="http://purl.org/rss/1.0/"><title>Neck spasm after chemoradiotherapy for head and neck cancer: Natural history and dosimetric correlates</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23284</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Neck spasm after chemoradiotherapy for head and neck cancer: Natural history and dosimetric correlates</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Klaudia U. Hunter, Francis Worden, Carol Bradford, Mark Prince, Scott McLean, Gregory Wolf, Douglas B. Chepeha, Avraham Eisbruch</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T07:14:12.068571-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23284</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23284</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23284</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23284-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Little is known about the determinants of postradiation neck spasms in patients with head and neck cancer.</p></div></div>
<div class="section" id="hed23284-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Patients with head and neck cancer treated with radiation therapy (RT) from 2004 to 2010 who experienced neck spasms werereviewed. Radiation doses were generated for their sternocleidomastoid (SCM) muscles bilaterally. Unaffected SCMs were used as controls.</p></div></div>
<div class="section" id="hed23284-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Thirty-four patients reported neck spasms. Thirty had received definitive chemoradiation, and 4 had RT alone. Seven also had an ipsilateral neck dissection. Median time to onset was 23 months (range, 6–67 months). There were significantly higher radiation doses to the affected SCMs with a median of the mean dose to the affected and unaffected SCM of 62.3 Gy (range, 29–71 Gy) and 53.7 Gy (range, 27–65 Gy), respectively (<em>p</em> &lt; .0001). Other dosimetric variables were also statistically significant but were highly correlated with the mean SCM dose. Neck dissection did not affect our results.</p></div></div>
<div class="section" id="hed23284-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Neck spasms after chemotherapy intensity-modulated radiation therapy (IMRT) shows a strong dose–response relationship. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
Little is known about the determinants of postradiation neck spasms in patients with head and neck cancer.


Methods
Patients with head and neck cancer treated with radiation therapy (RT) from 2004 to 2010 who experienced neck spasms werereviewed. Radiation doses were generated for their sternocleidomastoid (SCM) muscles bilaterally. Unaffected SCMs were used as controls.


Results
Thirty-four patients reported neck spasms. Thirty had received definitive chemoradiation, and 4 had RT alone. Seven also had an ipsilateral neck dissection. Median time to onset was 23 months (range, 6–67 months). There were significantly higher radiation doses to the affected SCMs with a median of the mean dose to the affected and unaffected SCM of 62.3 Gy (range, 29–71 Gy) and 53.7 Gy (range, 27–65 Gy), respectively (p &lt; .0001). Other dosimetric variables were also statistically significant but were highly correlated with the mean SCM dose. Neck dissection did not affect our results.


Conclusion
Neck spasms after chemotherapy intensity-modulated radiation therapy (IMRT) shows a strong dose–response relationship. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23266" xmlns="http://purl.org/rss/1.0/"><title>Relationship between postoperative complications and survival after free flap reconstruction for oral cavity squamous cell carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23266</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Relationship between postoperative complications and survival after free flap reconstruction for oral cavity squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sydney Ch'ng, Vincent Choi, Michael Elliott, Jonathan R. Clark</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T07:14:10.442845-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23266</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23266</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23266</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23266-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Current literature on the effect of postoperative complications on survival outcomes in head and neck cancers remains contradictory. This study assesses whether postoperative complications adversely affect survival in cases of complex surgical ablation and reconstruction of oral squamous cell carcinoma.</p></div></div>
<div class="section" id="hed23266-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In all, 255 consecutive patients with complete clinicopathologic data were included. Survival was determined using the log-rank test and Kaplan–Meier survival curves were generated. A Cox proportional hazards model was used to adjust for the effect of other significant covariates to determine the independent effect of complication variables for overall survival (OS). A competing risk model was used for disease-specific survival (DSS).</p></div></div>
<div class="section" id="hed23266-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>On multivariable analysis, major complications independently prognosticated for reduced OS [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.1–3.2, <em>p</em> = .02]. There was no evidence for an association between any complication-variable and DSS or recurrence.</p></div></div>
<div class="section" id="hed23266-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Major postoperative complications are independently associated with decreased OS. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
Current literature on the effect of postoperative complications on survival outcomes in head and neck cancers remains contradictory. This study assesses whether postoperative complications adversely affect survival in cases of complex surgical ablation and reconstruction of oral squamous cell carcinoma.


Methods
In all, 255 consecutive patients with complete clinicopathologic data were included. Survival was determined using the log-rank test and Kaplan–Meier survival curves were generated. A Cox proportional hazards model was used to adjust for the effect of other significant covariates to determine the independent effect of complication variables for overall survival (OS). A competing risk model was used for disease-specific survival (DSS).


Results
On multivariable analysis, major complications independently prognosticated for reduced OS [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.1–3.2, p = .02]. There was no evidence for an association between any complication-variable and DSS or recurrence.


Conclusions
Major postoperative complications are independently associated with decreased OS. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23265" xmlns="http://purl.org/rss/1.0/"><title>Nutritional status, food intake, and dysphagia in long-term survivors with head and neck cancer treated with chemoradiotherapy: A cross-sectional study</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23265</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Nutritional status, food intake, and dysphagia in long-term survivors with head and neck cancer treated with chemoradiotherapy: A cross-sectional study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Manon G. A. Berg, Heidi Rütten, Ellen L. Rasmussen-Conrad, Simone Knuijt, Robert P Takes, Carla M. L. Herpen, Geert J. A. Wanten, Johannes H. A. M. Kaanders, Matthias A. W. Merkx</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T07:14:01.508927-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23265</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23265</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23265</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23265-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The aim of this study was to evaluate nutritional status, food intake, and dysphagia in long-term head and neck cancer survivors.</p></div></div>
<div class="section" id="hed23265-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Thirty-two patients with stage III–IV head and neck cancer treated by chemoradiotherapy were invited to evaluate nutritional status (malnutrition, relative weight loss), food intake (food modification; quality), and dysphagia.</p></div></div>
<div class="section" id="hed23265-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>At a median follow up of 44 months, 6 of 32 patients were at risk for malnutrition. Women (<em>p</em> = .049) and patients with high body mass index before treatment (<em>p</em> = .024) showed more weight loss. None of the 32 patients could eat a “full diet.” Six patients used nutritional supplements/tube feeding. Low dysphagia-related quality of life scores were significantly correlated to increased food modification (<em>r</em> = 0.405; <em>p</em> = .024).</p></div></div>
<div class="section" id="hed23265-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Nutritional advice in patients with head and neck cancer is still necessary years after chemoradiation and should focus on nutritional status, food modification, and quality, in accord with recommended food groups. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
The aim of this study was to evaluate nutritional status, food intake, and dysphagia in long-term head and neck cancer survivors.


Methods
Thirty-two patients with stage III–IV head and neck cancer treated by chemoradiotherapy were invited to evaluate nutritional status (malnutrition, relative weight loss), food intake (food modification; quality), and dysphagia.


Results
At a median follow up of 44 months, 6 of 32 patients were at risk for malnutrition. Women (p = .049) and patients with high body mass index before treatment (p = .024) showed more weight loss. None of the 32 patients could eat a “full diet.” Six patients used nutritional supplements/tube feeding. Low dysphagia-related quality of life scores were significantly correlated to increased food modification (r = 0.405; p = .024).


Conclusions
Nutritional advice in patients with head and neck cancer is still necessary years after chemoradiation and should focus on nutritional status, food modification, and quality, in accord with recommended food groups. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23262" xmlns="http://purl.org/rss/1.0/"><title>Factors affecting swallow outcome following treatment for advanced oral and oropharyngeal malignancies</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23262</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Factors affecting swallow outcome following treatment for advanced oral and oropharyngeal malignancies</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicholas Kalavrezos, Stefano Cotrufo, Roganie Govender, Pauline Rogers, Phil Pirgousis, Sathesh Balasundram, Bagrat Lalabekyan, Colin Liew</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T07:13:50.679915-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23262</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23262</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23262</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23262-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Treatment for tumors of the oral cavity and the oropharynx disrupts normal swallow function. The ability for oral diet postoperatively varies and may be influenced by surgery and patient-related factors.</p></div></div>
<div class="section" id="hed23262-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In all, 114 patients treated with surgery with and without chemoradiotherapy for advanced oral/oropharyngeal cancer were recruited. Clinicopathologic tumor parameters and reconstruction modalities were recorded. Swallow function was determined by oral intake, using the Functional Oral Intake Scale (FOIS) pretreatment and posttreatment.</p></div></div>
<div class="section" id="hed23262-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The median time to first attaining swallow function was 14 days. Patients were less likely to attain tube independence within 1 year of surgery if they received radiotherapy or had a low FOIS score preoperatively. Patients' time to first attaining swallow function postsurgery was inversely related to the FOIS score presurgery.</p></div></div>
<div class="section" id="hed23262-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Swallow function recovery postsurgery is better in patients with higher FOIS presurgery, smaller tumors, and no requirement for radiotherapy. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
Treatment for tumors of the oral cavity and the oropharynx disrupts normal swallow function. The ability for oral diet postoperatively varies and may be influenced by surgery and patient-related factors.


Methods
In all, 114 patients treated with surgery with and without chemoradiotherapy for advanced oral/oropharyngeal cancer were recruited. Clinicopathologic tumor parameters and reconstruction modalities were recorded. Swallow function was determined by oral intake, using the Functional Oral Intake Scale (FOIS) pretreatment and posttreatment.


Results
The median time to first attaining swallow function was 14 days. Patients were less likely to attain tube independence within 1 year of surgery if they received radiotherapy or had a low FOIS score preoperatively. Patients' time to first attaining swallow function postsurgery was inversely related to the FOIS score presurgery.


Conclusions
Swallow function recovery postsurgery is better in patients with higher FOIS presurgery, smaller tumors, and no requirement for radiotherapy. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23249" xmlns="http://purl.org/rss/1.0/"><title>Recent trends in the management of minor salivary gland carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23249</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Recent trends in the management of minor salivary gland carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vincent Poorten, Jennifer Hunt, Patrick J. Bradley, Missak Haigentz, Alessandra Rinaldo, William M. Mendenhall, Carlos Suarez, Carl Silver, Robert P. Takes, Alfio Ferlito</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T07:13:43.100753-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23249</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23249</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23249</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The current management of minor salivary gland cancer is reviewed. These malignancies often present as a submucosal swelling and have been reported at all anatomic subsites of the head and neck. Modern imaging is essential in evaluating the location and the anatomic extent of disease. An incisional or punch biopsy determines the histologic type and grade. Recent advances in molecular biology have yielded diagnostic and potential therapeutic targets that may change our treatment in the future. Complete resection is the treatment of choice. Unfortunately, given the proximity of essential structures, the need to balance functional and cosmetic with oncologic consequences can interfere with an adequate “clear margin.” The neck should be treated when there is evidence of regional metastasis or when subclinical metastatic risk exceeds 15%. Surgery alone cures most low-stage, low-grade tumors, all other stages and grades require postoperative radiotherapy. Systemic treatment for locoregional and distant failure remains disappointing. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div>
]]></content:encoded><description>
The current management of minor salivary gland cancer is reviewed. These malignancies often present as a submucosal swelling and have been reported at all anatomic subsites of the head and neck. Modern imaging is essential in evaluating the location and the anatomic extent of disease. An incisional or punch biopsy determines the histologic type and grade. Recent advances in molecular biology have yielded diagnostic and potential therapeutic targets that may change our treatment in the future. Complete resection is the treatment of choice. Unfortunately, given the proximity of essential structures, the need to balance functional and cosmetic with oncologic consequences can interfere with an adequate “clear margin.” The neck should be treated when there is evidence of regional metastasis or when subclinical metastatic risk exceeds 15%. Surgery alone cures most low-stage, low-grade tumors, all other stages and grades require postoperative radiotherapy. Systemic treatment for locoregional and distant failure remains disappointing. © 2013 Wiley Periodicals, Inc. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23277" xmlns="http://purl.org/rss/1.0/"><title>Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23277</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Lesnik, Mary Elizabeth Cunnane, David Zurakowski, Gul Ozbilen Acar, Cenk Ecevit, Alasdair Mace, Dipti Kamani, Gregory W. Randolph</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-02T02:53:18.100448-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23277</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23277</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23277</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>To study the diagnostic accuracy of physical examination (PE), ultrasonography (US), contrastenhanced computed tomography (CT) and in preoperative detection of macroscopic nodal metastasis in primary/recurrent papillary thyroid carcinoma (PTC) patients to determine if the routine addition of CT would be beneficial in accurate preoperative lymph-node surgery planning.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In a tertiary center prospective study, 162 PTC patients underwent preoperative lymph-node evaluation by PE, US, and CT. Sensitivity, specificity, positive/negative predictive value (PPV/NPV) of each nodal detection technique were calculated in central/lateral cervical compartments. The gold standard for diagnostic-accuracy was surgical pathology.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In patients undergoing primary (Group I)/revision (Group II) surgical treatment for PTC, combined US/CT yielded significantly higher sensitivity for macroscopic lymph-node detection in both lateral and central neck, most marked in Group I-central compartment.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Combined preoperative US/CT provides reliable, objective, preoperative macroscopic nodal metastasis map to design rational nodal surgery in primary/revision PTC patients. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
To study the diagnostic accuracy of physical examination (PE), ultrasonography (US), contrastenhanced computed tomography (CT) and in preoperative detection of macroscopic nodal metastasis in primary/recurrent papillary thyroid carcinoma (PTC) patients to determine if the routine addition of CT would be beneficial in accurate preoperative lymph-node surgery planning.


Methods
In a tertiary center prospective study, 162 PTC patients underwent preoperative lymph-node evaluation by PE, US, and CT. Sensitivity, specificity, positive/negative predictive value (PPV/NPV) of each nodal detection technique were calculated in central/lateral cervical compartments. The gold standard for diagnostic-accuracy was surgical pathology.


Results
In patients undergoing primary (Group I)/revision (Group II) surgical treatment for PTC, combined US/CT yielded significantly higher sensitivity for macroscopic lymph-node detection in both lateral and central neck, most marked in Group I-central compartment.


Conclusions
Combined preoperative US/CT provides reliable, objective, preoperative macroscopic nodal metastasis map to design rational nodal surgery in primary/revision PTC patients. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23282" xmlns="http://purl.org/rss/1.0/"><title>Internet-mediated physician–patient interaction focusing on extracranial hemangiomas and vascular malformations</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23282</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Internet-mediated physician–patient interaction focusing on extracranial hemangiomas and vascular malformations</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susanne Wiegand, Johannes Marggraf, Thomas Wilhelm, Behfar Eivazi, Jochen A. Werner</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-02T02:00:53.357997-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23282</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23282</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23282</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23282-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Internet-mediated communication in health care is becoming increasingly important. The purpose of this study was to analyze internet-mediated physician–patient interaction in an angioma center.</p></div></div>
<div class="section" id="hed23282-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Patient-related e-mails received between January 2002 and June 2009 were retrospectively analyzed regarding the diagnosis of hemangiomas or vascular malformations. Additionally, the visitors' statistics of the corresponding website ‘‘<!--TODO: clickthrough URL--><a href="http://www.angiome.de" title="Link to external resource: http://www.angiome.de">www.angiome.de</a>” was evaluated.</p></div></div>
<div class="section" id="hed23282-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Five hundred forty-eight e-mails matched the criteria of the study. From 2002 to 2008, the number of messages registered annually increased by a factor of 20 and the average number of e-mails per patient tripled. The number of new patients contacting the center via e-mail increased from 12 to 72 per year. The website ‘‘<!--TODO: clickthrough URL--><a href="http://www.angiome.de" title="Link to external resource: http://www.angiome.de">www.angiome.de</a>” was visited 8490 times in 2008 and 13,291 times in 2009.</p></div></div>
<div class="section" id="hed23282-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>The presence of the internet is relevant to get in touch with new patients and to provide information for nonprofessionals and experts especially in diseases with low incidence. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
Internet-mediated communication in health care is becoming increasingly important. The purpose of this study was to analyze internet-mediated physician–patient interaction in an angioma center.


Methods
Patient-related e-mails received between January 2002 and June 2009 were retrospectively analyzed regarding the diagnosis of hemangiomas or vascular malformations. Additionally, the visitors' statistics of the corresponding website ‘‘www.angiome.de” was evaluated.


Results
Five hundred forty-eight e-mails matched the criteria of the study. From 2002 to 2008, the number of messages registered annually increased by a factor of 20 and the average number of e-mails per patient tripled. The number of new patients contacting the center via e-mail increased from 12 to 72 per year. The website ‘‘www.angiome.de” was visited 8490 times in 2008 and 13,291 times in 2009.


Conclusion
The presence of the internet is relevant to get in touch with new patients and to provide information for nonprofessionals and experts especially in diseases with low incidence. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23280" xmlns="http://purl.org/rss/1.0/"><title>Incidence and risk factors of significant carotid artery stenosis in asymptomatic survivors of head and neck cancer after radiotherapy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23280</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Incidence and risk factors of significant carotid artery stenosis in asymptomatic survivors of head and neck cancer after radiotherapy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jennifer A. Dorth, Pretesh R. Patel, Gloria Broadwater, David M. Brizel</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-02T02:00:39.855522-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23280</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23280</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23280</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23280-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The incidence and risk factors of carotid artery stenosis in asymptomatic patients after head and neck radiation therapy (RT) are unknown.</p></div></div>
<div class="section" id="hed23280-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>This retrospective study reviewed asymptomatic patients treated with RT for head and neck cancer from 2000 to 2009 who underwent screening carotid ultrasound.</p></div></div>
<div class="section" id="hed23280-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Two hundred twenty-four patients were included, the majority of whom had stage III to IV disease and received cisplatin-based chemotherapy. Median time from RT completion to last carotid ultrasound was 3 years. Actuarial rate of carotid artery stenosis at 4 years was 14% (95% confidence interval [CI], 4% to 22%). Multivariate analysis revealed that carotid artery stenosis was associated with Framingham risk factors (hazard ratio [HR], 1.6 per factor; 95% CI, 1.2–2.2; <em>p</em> = .003). Among 135 patients treated with intensity-modulated radiation therapy (IMRT), the HR for carotid artery stenosis was 1.4 for every 10 Gy increase in mean RT dose to the carotid bulb plus 2 cm (95% CI, 0.8–2.4; <em>p</em> = .35).</p></div></div>
<div class="section" id="hed23280-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Prevention and screening programs should be considered for head and neck cancer survivors given the high risk of carotid artery stenosis. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
The incidence and risk factors of carotid artery stenosis in asymptomatic patients after head and neck radiation therapy (RT) are unknown.


Methods
This retrospective study reviewed asymptomatic patients treated with RT for head and neck cancer from 2000 to 2009 who underwent screening carotid ultrasound.


Results
Two hundred twenty-four patients were included, the majority of whom had stage III to IV disease and received cisplatin-based chemotherapy. Median time from RT completion to last carotid ultrasound was 3 years. Actuarial rate of carotid artery stenosis at 4 years was 14% (95% confidence interval [CI], 4% to 22%). Multivariate analysis revealed that carotid artery stenosis was associated with Framingham risk factors (hazard ratio [HR], 1.6 per factor; 95% CI, 1.2–2.2; p = .003). Among 135 patients treated with intensity-modulated radiation therapy (IMRT), the HR for carotid artery stenosis was 1.4 for every 10 Gy increase in mean RT dose to the carotid bulb plus 2 cm (95% CI, 0.8–2.4; p = .35).


Conclusion
Prevention and screening programs should be considered for head and neck cancer survivors given the high risk of carotid artery stenosis. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23283" xmlns="http://purl.org/rss/1.0/"><title>Cancer of the head and neck region in solid organ transplant recipients</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23283</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cancer of the head and neck region in solid organ transplant recipients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Naomi Rabinovics, Aviram Mizrachi, Tuvia Hadar, Dean Ad-El, Raphael Feinmesser, Dan Guttman, Thomas Shpitzer, Gideon Bachar</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-02T02:00:25.204308-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23283</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23283</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23283</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23283-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Solid organ recipients are at an increased risk of developing various malignancies. We investigated the incidence, clinical features, and outcome of patients diagnosed with head and neck cancer after organ transplantation.</p></div></div>
<div class="section" id="hed23283-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective analysis was undertaken of patients who underwent solid organ transplantation (kidney, liver, lung, heart) treated at our institution from 1992 to 2010.</p></div></div>
<div class="section" id="hed23283-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Of 2817 organ recipients, 175 patients (6.1%) developed 391 head and neck malignancies. Cutaneous malignancies were the most common (93%): squamous cell carcinoma (SCC; 51%) and basal cell carcinoma (BCC; 42%). The average interval from transplantation to diagnosis of head and neck malignancy was 7.3 years, with liver recipients diagnosed earlier. Eighteen percent of patients presented with an aggressive pattern of head and neck cancer, including 24% of patients with cutaneous SCC.</p></div></div>
<div class="section" id="hed23283-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Organ transplantation recipients are at a higher risk to develop head and neck cancer with an aggressive behavior characterized by multiple recurrences and decreased survival. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
Solid organ recipients are at an increased risk of developing various malignancies. We investigated the incidence, clinical features, and outcome of patients diagnosed with head and neck cancer after organ transplantation.


Methods
A retrospective analysis was undertaken of patients who underwent solid organ transplantation (kidney, liver, lung, heart) treated at our institution from 1992 to 2010.


Results
Of 2817 organ recipients, 175 patients (6.1%) developed 391 head and neck malignancies. Cutaneous malignancies were the most common (93%): squamous cell carcinoma (SCC; 51%) and basal cell carcinoma (BCC; 42%). The average interval from transplantation to diagnosis of head and neck malignancy was 7.3 years, with liver recipients diagnosed earlier. Eighteen percent of patients presented with an aggressive pattern of head and neck cancer, including 24% of patients with cutaneous SCC.


Conclusion
Organ transplantation recipients are at a higher risk to develop head and neck cancer with an aggressive behavior characterized by multiple recurrences and decreased survival. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23243" xmlns="http://purl.org/rss/1.0/"><title>Scoping review of the literature on shoulder impairments and disability after neck dissection</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23243</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Scoping review of the literature on shoulder impairments and disability after neck dissection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David P Goldstein, Jolie Ringash, Eric Bissada, Yves Jaquet, Jonathan Irish, Douglas Chepeha, Aileen M. Davis</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-31T23:15:32.112475-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23243</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23243</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23243</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23243-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this article was to provide a review of the literature on shoulder disability after neck dissection.</p></div></div>
<div class="section" id="hed23243-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A literature review was performed using Ovid Medline and Embase databases. A total of 306 abstracts and 78 full-text articles were reviewed. Forty-two articles were eligible for inclusion.</p></div></div>
<div class="section" id="hed23243-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Patients undergoing nerve-sacrifice neck dissections have greater disability and lower quality of life scores than those undergoing neck dissections with the least manipulation (ie, selective neck dissections). Shoulder impairments can still occur in patients undergoing selective neck dissections. Disability typically improves over time in patients undergoing nerve-sparing neck dissections.</p></div></div>
<div class="section" id="hed23243-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>There was significant variability in the literature in terms of the prevalence and recovery of shoulder morbidity after neck dissection. This variability may not just be related to surgical technique or rehabilitation, but also to study design, definitions, and the variability in disability questionnaires used. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
The purpose of this article was to provide a review of the literature on shoulder disability after neck dissection.


Methods
A literature review was performed using Ovid Medline and Embase databases. A total of 306 abstracts and 78 full-text articles were reviewed. Forty-two articles were eligible for inclusion.


Results
Patients undergoing nerve-sacrifice neck dissections have greater disability and lower quality of life scores than those undergoing neck dissections with the least manipulation (ie, selective neck dissections). Shoulder impairments can still occur in patients undergoing selective neck dissections. Disability typically improves over time in patients undergoing nerve-sparing neck dissections.


Conclusion
There was significant variability in the literature in terms of the prevalence and recovery of shoulder morbidity after neck dissection. This variability may not just be related to surgical technique or rehabilitation, but also to study design, definitions, and the variability in disability questionnaires used. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23258" xmlns="http://purl.org/rss/1.0/"><title>Transoral robotic surgery for the management of oropharyngeal minor salivary gland tumors</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23258</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Transoral robotic surgery for the management of oropharyngeal minor salivary gland tumors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nathaniel L. Villanueva, John R. Almeida, Andrew G. Sikora, Brett A. Miles, Eric M. Genden</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-31T23:14:59.860184-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23258</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23258</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23258</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23258-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>In this study we report our preliminary experience with the use of transoral robotic surgery (TORS) for the management of minor salivary gland malignancies of the oropharynx and outcomes.</p></div></div>
<div class="section" id="hed23258-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>This was a retrospective review of 10 patients followed over a 5-year period at a single tertiary academic medical center. Patient, tumor, clinicopathologic, functional, and oncologic outcomes were collected and analyzed.</p></div></div>
<div class="section" id="hed23258-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>All cancers treated were either T1 (40%) or T2 (60%). Negative margins were achieved in all patients. Four patients received adjuvant radiation therapy (40%). No patients experienced surgical complications and all had excellent functional outcomes. Mean follow-up was 24 months (range, 2–60 months) with locoregional and distant control achieved in 8 patients (80%) and 9 patients (90%), respectively.</p></div></div>
<div class="section" id="hed23258-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Minor salivary malignancies of the oropharynx are a surgical disease. Short-term follow-up data demonstrate feasibility, low morbidity, good functional, and oncologic results for TORS management of these malignancies. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
In this study we report our preliminary experience with the use of transoral robotic surgery (TORS) for the management of minor salivary gland malignancies of the oropharynx and outcomes.


Methods
This was a retrospective review of 10 patients followed over a 5-year period at a single tertiary academic medical center. Patient, tumor, clinicopathologic, functional, and oncologic outcomes were collected and analyzed.


Results
All cancers treated were either T1 (40%) or T2 (60%). Negative margins were achieved in all patients. Four patients received adjuvant radiation therapy (40%). No patients experienced surgical complications and all had excellent functional outcomes. Mean follow-up was 24 months (range, 2–60 months) with locoregional and distant control achieved in 8 patients (80%) and 9 patients (90%), respectively.


Conclusions
Minor salivary malignancies of the oropharynx are a surgical disease. Short-term follow-up data demonstrate feasibility, low morbidity, good functional, and oncologic results for TORS management of these malignancies. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23064" xmlns="http://purl.org/rss/1.0/"><title>Method to help ensure survival of a very small skin paddle of pectoralis major musculocutaneous flap in head and neck reconstruction</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23064</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Method to help ensure survival of a very small skin paddle of pectoralis major musculocutaneous flap in head and neck reconstruction</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eun Key Kim, Sung Jun Yang, Seung Ho Choi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-29T01:53:36.740584-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23064</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23064</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23064</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23064-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>When the required dimension of skin paddle of a pectoralis major musculocutaneous (PMMC) flap is very small, its survival often becomes questionable. We introduce a simple technique which enlarges the practical dimension of a very small skin paddle, leading to ensure the survival of a PMMC flap.</p></div></div>
<div class="section" id="hed23064-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Method and Result</h4><div class="para"><p>A PMMC flap size of 1.5 × 4 cm was required for repair of leakage which developed 2 weeks after the primary ablative surgery for hypopharyngeal cancer. The skin paddle was designed in the size of 4.5 × 7 cm and was deepithelized except the original dimension. After the skin edge was sutured to the defect margin, the deepithelized dermal portion covered the repair site to enhance the suture.</p></div></div>
<div class="section" id="hed23064-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>The effective dimension of a very small skin paddle can be quite enlarged thus increasing the possibility of capturing perforators. This could decrease the risk of avulsion during flap transfer and provide backing of the repair site. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>

Background
When the required dimension of skin paddle of a pectoralis major musculocutaneous (PMMC) flap is very small, its survival often becomes questionable. We introduce a simple technique which enlarges the practical dimension of a very small skin paddle, leading to ensure the survival of a PMMC flap.


Method and Result
A PMMC flap size of 1.5 × 4 cm was required for repair of leakage which developed 2 weeks after the primary ablative surgery for hypopharyngeal cancer. The skin paddle was designed in the size of 4.5 × 7 cm and was deepithelized except the original dimension. After the skin edge was sutured to the defect margin, the deepithelized dermal portion covered the repair site to enhance the suture.


Conclusion
The effective dimension of a very small skin paddle can be quite enlarged thus increasing the possibility of capturing perforators. This could decrease the risk of avulsion during flap transfer and provide backing of the repair site. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23279" xmlns="http://purl.org/rss/1.0/"><title>Transoral laser microsurgery followed by radiation therapy for oropharyngeal tumors: The mayo clinic arizona experience</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23279</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Transoral laser microsurgery followed by radiation therapy for oropharyngeal tumors: The mayo clinic arizona experience</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Samir H. Patel, Michael L. Hinni, Richard E. Hayden, William W. Wong, Amylou C. Dueck, Matthew A. Zarka, Kelly K. Curtis, Michele Y. Halyard</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-26T03:29:56.837681-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23279</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23279</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23279</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="hed23279-sec-0001" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to report the treatment outcomes of patients with advanced oropharyngeal cancer treated with transoral laser microsurgery (TLM) followed by radiation therapy (RT) at Mayo Clinic in Arizona.</p></div></div>
<div class="section" id="hed23279-sec-0002" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective study of 80 patients treated from January 1, 2000 to November 7, 2011 was performed. All patients had stage III/IV oropharyngeal tumors and underwent TLM with neck dissection. Adjuvant RT was then given. Thirty-seven patients received concurrent adjuvant chemotherapy. The primary outcome was locoregional control.</p></div></div>
<div class="section" id="hed23279-sec-0003" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Median follow-up was 47.3 months (range, 9.7–139.2 months). The 3-year locoregional control, recurrence-free survival, and overall survival rates were 98.6% (95% confidence interval [CI], 91% to 100%), 91.1% (95% CI, 81% to 96%), and 93.7% (95% CI, 84% to 98%), respectively. There were a total of 5 treatment failures, 1 regional and 4 distant. Twenty-six patients underwent neck only RT with exclusion of the primary site.</p></div></div>
<div class="section" id="hed23279-sec-0004" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>TLM followed by RT for advanced oropharyngeal cancer results in excellent locoregional control rates. © 2013 Wiley Periodicals, Inc. <em>Head Neck</em>, 2013</p></div></div>
]]></content:encoded><description>

Background
The purpose of this study was to report the treatment outcomes of patients with advanced oropharyngeal cancer treated with transoral laser microsurgery (TLM) followed by radiation therapy (RT) at Mayo Clinic in Arizona.


Methods
A retrospective study of 80 patients treated from January 1, 2000 to November 7, 2011 was performed. All patients had stage III/IV oropharyngeal tumors and underwent TLM with neck dissection. Adjuvant RT was then given. Thirty-seven patients received concurrent adjuvant chemotherapy. The primary outcome was locoregional control.


Results
Median follow-up was 47.3 months (range, 9.7–139.2 months). The 3-year locoregional control, recurrence-free survival, and overall survival rates were 98.6% (95% confidence interval [CI], 91% to 100%), 91.1% (95% CI, 81% to 96%), and 93.7% (95% CI, 84% to 98%), respectively. There were a total of 5 treatment failures, 1 regional and 4 distant. Twenty-six patients underwent neck only RT with exclusion of the primary site.


Conclusion
TLM followed by RT for advanced oropharyngeal cancer results in excellent locoregional control rates. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23218" xmlns="http://purl.org/rss/1.0/"><title>Local resection of the mass to treat the osteochondroma of the mandibular condyle: Indications and different methods with 38-case series</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23218</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Local resection of the mass to treat the osteochondroma of the mandibular condyle: Indications and different methods with 38-case series</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Min-jie Chen, Chi Yang, Maimaitituxun Tuerdi, Ya-ting Qiu, Dong-mei He, Qin Zhou, Dong Huang, Hui-min Shi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-18T10:50:34.534309-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23218</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23218</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23218</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Local resection of the mass was reported to treat the condylar osteochodroma in some cases. The purpose of this study was to evaluate the feasibility and the indications of the local resection.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In all, 47 patients with osteochondroma of the mandibular condyle were treated from January 2002 to March 2012. The decision to perform local resection depended on 2 factors: there was a stalk existing between the mass and the condyle, and the condylar surface was involved less than 1/2.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Local resection of the mass was performed in 38 cases (80.1%). These masses were removed by 4 methods: direct removal (18 cases), pushed-out by a screw and steel wire (14 cases), excision in multiple pieces (3 cases), and temporary osteotomy of the zygomatic arch (3 cases). In the follow-up period, there was no recurrence.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Local resection of the mass was a more conservative procedure to treat the solitary osteochondroma with a stalk. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Local resection of the mass was reported to treat the condylar osteochodroma in some cases. The purpose of this study was to evaluate the feasibility and the indications of the local resection.


Methods
In all, 47 patients with osteochondroma of the mandibular condyle were treated from January 2002 to March 2012. The decision to perform local resection depended on 2 factors: there was a stalk existing between the mass and the condyle, and the condylar surface was involved less than 1/2.


Results
Local resection of the mass was performed in 38 cases (80.1%). These masses were removed by 4 methods: direct removal (18 cases), pushed-out by a screw and steel wire (14 cases), excision in multiple pieces (3 cases), and temporary osteotomy of the zygomatic arch (3 cases). In the follow-up period, there was no recurrence.


Conclusion
Local resection of the mass was a more conservative procedure to treat the solitary osteochondroma with a stalk. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23231" xmlns="http://purl.org/rss/1.0/"><title>Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23231</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martina A. Broglie, Alex Soltermann, David Rohrbach, Sarah R. Haile, Michael Pawlita, Gabriela Studer, Gerard F. Huber, Holger Moch, Sandro J. Stoeckli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-18T10:50:12.895494-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23231</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23231</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23231</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Analysis of the impact of risk factors on survival in patients with oropharyngeal squamous cell carcinoma (OPSCC) treated by primary intensity-modulated radiotherapy (IMRT).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>One hundred forty patients were included with tissue microarray (TMA) construction and immunohistochemical analysis in 124 patients (87%).</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Survival analysis of patients classified into 3 risk categories according to an algorithm based on p16, smoking, T classification, and N classification revealed significant differences with a low, intermediate, and high-risk group. There was a significant impact of p53 expression as surrogate marker for smoking on outcome. In multivariate analysis, p16-positivity was a positive predictor and alcohol as well as N classification was a negative predictor for survival. The algorithm was modified based on alcohol instead of smoking with even more significant differences between the groups.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>A risk model based on multiple factors instead of p16 as single marker can define different risk groups to select patients for treatment deintensification in future prospective clinical trials. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Analysis of the impact of risk factors on survival in patients with oropharyngeal squamous cell carcinoma (OPSCC) treated by primary intensity-modulated radiotherapy (IMRT).


Methods
One hundred forty patients were included with tissue microarray (TMA) construction and immunohistochemical analysis in 124 patients (87%).


Results
Survival analysis of patients classified into 3 risk categories according to an algorithm based on p16, smoking, T classification, and N classification revealed significant differences with a low, intermediate, and high-risk group. There was a significant impact of p53 expression as surrogate marker for smoking on outcome. In multivariate analysis, p16-positivity was a positive predictor and alcohol as well as N classification was a negative predictor for survival. The algorithm was modified based on alcohol instead of smoking with even more significant differences between the groups.


Conclusions
A risk model based on multiple factors instead of p16 as single marker can define different risk groups to select patients for treatment deintensification in future prospective clinical trials. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23234" xmlns="http://purl.org/rss/1.0/"><title>Metastasis at a tracheostomy site as the presenting sign of late recurrent breast cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23234</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Metastasis at a tracheostomy site as the presenting sign of late recurrent breast cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicola Rotolo, Lorenzo Dominioni, Lavinia De Monte, Valentina Conti, Stefano La Rosa, Andrea Imperatori</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-18T10:49:54.750679-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23234</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23234</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23234</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Metastasis in a tracheostomy site occurs rarely, usually from head and neck primary tumors. Breast cancer relapse to a tracheostomy has not been described to date.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>A 71-year-old women presented with symptoms typical of central airway obstruction, 10 years after mastectomy for breast cancer. Fifteen months before admission, when cancer follow-up was negative, she also had surgery for cerebral aneurysm and a tracheostomy. On admission, CT showed a solid mass infiltrating the tracheostomy tract and projecting into the airway. Tracheal obstruction palliation was achieved by laser resection of the endotracheal growth and stenting. Histology documented breast cancer metastasis.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Tracheostomy site metastasis was the presenting sign of late-onset relapse of breast cancer. This case supports the concept of surgery-driven interruption of micrometastatic cancer dormancy, in that the initial recurrence developed in a tracheostomy that was surgically created several years after resection of the primary tumor. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Metastasis in a tracheostomy site occurs rarely, usually from head and neck primary tumors. Breast cancer relapse to a tracheostomy has not been described to date.


Methods and Results
A 71-year-old women presented with symptoms typical of central airway obstruction, 10 years after mastectomy for breast cancer. Fifteen months before admission, when cancer follow-up was negative, she also had surgery for cerebral aneurysm and a tracheostomy. On admission, CT showed a solid mass infiltrating the tracheostomy tract and projecting into the airway. Tracheal obstruction palliation was achieved by laser resection of the endotracheal growth and stenting. Histology documented breast cancer metastasis.


Conclusions
Tracheostomy site metastasis was the presenting sign of late-onset relapse of breast cancer. This case supports the concept of surgery-driven interruption of micrometastatic cancer dormancy, in that the initial recurrence developed in a tracheostomy that was surgically created several years after resection of the primary tumor. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23235" xmlns="http://purl.org/rss/1.0/"><title>Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: A 4-year cohort study</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23235</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: A 4-year cohort study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jang-Jaer Lee, Shih-Jung Cheng, Jai-Jen Wang, Chun-Pin Chiang, Hao-Hueng Chang, Hsin-Ming Chen, Sang-Heng Kok</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-18T10:49:26.974638-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23235</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23235</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23235</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Studies concerning prognostic factors specific for alendronate-related osteonecrosis of the jaws (ONJ) are rare.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We surveyed a cohort of 100 osteoporotic patients with 111 alendronate-related ONJ lesions treated during a 4-year period. Prognostic values of clinical variables and serum markers of bone turnover were assessed by univariate and multivariate analyses.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The cumulative complete response rate at 6 months was 48.65%. Serum bone-specific alkaline phosphatase (BSAP) level &gt;10 μg/L, lesion depth ≦ 10 mm, and lesions in anterior regions denoted a better chance of healing within 6 months and the adjusted hazard ratios were 2.48 (95% confidence interval [CI], 1.41–4.37), 2.71 (95% CI, 1.57–4.70), and 3.94 (95% CI, 1.87–8.30), respectively.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Early discovery of lesions and prevention of their deeper extension are crucial for improving the prognosis of alendronate-related ONJ. A higher pretreatment level of BSAP indicates a better prognosis. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Studies concerning prognostic factors specific for alendronate-related osteonecrosis of the jaws (ONJ) are rare.


Methods
We surveyed a cohort of 100 osteoporotic patients with 111 alendronate-related ONJ lesions treated during a 4-year period. Prognostic values of clinical variables and serum markers of bone turnover were assessed by univariate and multivariate analyses.


Results
The cumulative complete response rate at 6 months was 48.65%. Serum bone-specific alkaline phosphatase (BSAP) level &gt;10 μg/L, lesion depth ≦ 10 mm, and lesions in anterior regions denoted a better chance of healing within 6 months and the adjusted hazard ratios were 2.48 (95% confidence interval [CI], 1.41–4.37), 2.71 (95% CI, 1.57–4.70), and 3.94 (95% CI, 1.87–8.30), respectively.


Conclusions
Early discovery of lesions and prevention of their deeper extension are crucial for improving the prognosis of alendronate-related ONJ. A higher pretreatment level of BSAP indicates a better prognosis. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23236" xmlns="http://purl.org/rss/1.0/"><title>Evaluating the significance of level IIb neck dissection for hypopharyngeal cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23236</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Evaluating the significance of level IIb neck dissection for hypopharyngeal cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Akihiro Sakai, Kenji Okami, Ryousuke Sugimoto, Koji Ebisumoto, Hikaru Yamamoto, Daisuke Maki, Taku Atsumi, Kosuke Saito, Masahiro Iida</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-18T10:49:02.969051-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23236</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23236</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23236</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>This study evaluated cervical lymph node metastases at level IIb in cases of hypopharyngeal cancer and analyzed the possibility of preservation of level IIb during neck dissection.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In total, 34 patients (51 neck sides) with hypopharyngeal cancer that underwent neck dissection from April 2008 to April 2011 were retrospectively analyzed. We evaluated the distribution of metastatic lymph nodes at various levels (particularly level IIb) in cases treated with therapeutic neck dissection and elective neck dissection.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The incidence of metastases in level IIb was 13.3% (4 of 30 patients) for therapeutic neck dissection and 0% (0 of 21 patients) for elective neck dissection. All the level IIb metastases were found on the ipsilateral side in the cases treated with therapeutic neck dissection.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The results suggest that preservation of level IIb during neck dissection was possible in N0 cases of hypopharyngeal cancer. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
This study evaluated cervical lymph node metastases at level IIb in cases of hypopharyngeal cancer and analyzed the possibility of preservation of level IIb during neck dissection.


Methods
In total, 34 patients (51 neck sides) with hypopharyngeal cancer that underwent neck dissection from April 2008 to April 2011 were retrospectively analyzed. We evaluated the distribution of metastatic lymph nodes at various levels (particularly level IIb) in cases treated with therapeutic neck dissection and elective neck dissection.


Results
The incidence of metastases in level IIb was 13.3% (4 of 30 patients) for therapeutic neck dissection and 0% (0 of 21 patients) for elective neck dissection. All the level IIb metastases were found on the ipsilateral side in the cases treated with therapeutic neck dissection.


Conclusions
The results suggest that preservation of level IIb during neck dissection was possible in N0 cases of hypopharyngeal cancer. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23237" xmlns="http://purl.org/rss/1.0/"><title>Redefining classification of central neck dissection in differentiated thyroid cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23237</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Redefining classification of central neck dissection in differentiated thyroid cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Edward D. McAlister, David P. Goldstein, Lorne E. Rotstein</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-18T10:48:42.495444-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23237</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23237</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23237</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Therapeutic central neck dissection for differentiated thyroid cancer is recommended in the setting of clinically positive disease. The role of lymphadenectomy in patients with clinically negative disease is a matter of controversy and therefore extent of surgery varies. The boundaries of the central neck are variably described, as are the components of a central neck dissection. Patients with aggressive disease are managed with a comprehensive dissection, yet there is no classification system to distinguish this from a less rigorous operation. Therefore, there is variability in reporting and difficulty in the interpretation of results in the published literature. Here we propose a novel classification system for central neck dissection in thyroid cancer that allows accurate reporting of extent of surgery. The objectives are to reduce ambivalence and allow documentation of extent of lymphadenectomy, such that comparisons can be made between the varied strategies in the management of the central compartment. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div>
]]></content:encoded><description>

Therapeutic central neck dissection for differentiated thyroid cancer is recommended in the setting of clinically positive disease. The role of lymphadenectomy in patients with clinically negative disease is a matter of controversy and therefore extent of surgery varies. The boundaries of the central neck are variably described, as are the components of a central neck dissection. Patients with aggressive disease are managed with a comprehensive dissection, yet there is no classification system to distinguish this from a less rigorous operation. Therefore, there is variability in reporting and difficulty in the interpretation of results in the published literature. Here we propose a novel classification system for central neck dissection in thyroid cancer that allows accurate reporting of extent of surgery. The objectives are to reduce ambivalence and allow documentation of extent of lymphadenectomy, such that comparisons can be made between the varied strategies in the management of the central compartment. © 2013 Wiley Periodicals, Inc. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23239" xmlns="http://purl.org/rss/1.0/"><title>Extracapsular spread in hypopharyngeal squamous cell carcinoma: Diagnostic value of FDG PET/CT</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23239</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Extracapsular spread in hypopharyngeal squamous cell carcinoma: Diagnostic value of FDG PET/CT</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Young-Hoon Joo, Ie-Ryung Yoo, Kwang-Jae Cho, Jun-Ook Park, In-Chul Nam, Min-Sik Kim</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-18T10:48:18.488812-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23239</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23239</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23239</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to evaluate the use of fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT for the identification of extracapsular spread (ECS) with supporting histologic correlation in hypopharyngeal cancer.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Method</h4><div class="para"><p>We retrospectively reviewed the medical records of 57 patients who underwent FDG PET/CT for hypopharyngeal cancer.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>ECS was present in 79% dissected necks (45 of 57 patients) and in 64% dissected cervical levels (55 of 86). A significant difference in standardized uptake value maximum (SUV<sub>max</sub>) values was found between cervical lymph nodes with and without ECS (6.10 ± 3.51 vs 1.75 ± 1.46, respectively; <em>p</em> &lt; .001). The cutoff value of SUV<sub>max</sub> for differentiating with and without ECS was 2.65 with a sensitivity of 80% and a specificity of 74%. The presence of ECS and median SUV<sub>max</sub> were found to have a significant adverse effect on 5-year disease-specific survival.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Median FDG PET/CT SUV<sub>max</sub> cutoff values of 2.65 or greater are associated with a greater risk of ECS in cervical lymph node metastasis from hypopharyngeal squamous cell carcinoma (SCC). © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to evaluate the use of fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT for the identification of extracapsular spread (ECS) with supporting histologic correlation in hypopharyngeal cancer.


Method
We retrospectively reviewed the medical records of 57 patients who underwent FDG PET/CT for hypopharyngeal cancer.


Results
ECS was present in 79% dissected necks (45 of 57 patients) and in 64% dissected cervical levels (55 of 86). A significant difference in standardized uptake value maximum (SUVmax) values was found between cervical lymph nodes with and without ECS (6.10 ± 3.51 vs 1.75 ± 1.46, respectively; p &lt; .001). The cutoff value of SUVmax for differentiating with and without ECS was 2.65 with a sensitivity of 80% and a specificity of 74%. The presence of ECS and median SUVmax were found to have a significant adverse effect on 5-year disease-specific survival.


Conclusion
Median FDG PET/CT SUVmax cutoff values of 2.65 or greater are associated with a greater risk of ECS in cervical lymph node metastasis from hypopharyngeal squamous cell carcinoma (SCC). © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23240" xmlns="http://purl.org/rss/1.0/"><title>Ewing sarcoma of the thyroid: Report of 2 cases and review of the literature</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23240</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ewing sarcoma of the thyroid: Report of 2 cases and review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jon M. Chan, Elizabeth Bilodeau, Scott Celin, Yuri Nikiforov, Jonas T. Johnson</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-18T10:47:47.474496-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23240</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23240</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23240</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Neuroendocrine tumors of the thyroid encompass a wide differential diagnosis. The most common is medullary thyroid carcinoma. One must consider other possibilities when a neuroendocrine thyroid tumor is calcitonin negative. We report 2 cases of Ewing sarcoma of the thyroid and discuss the differential diagnosis and workup of a calcitonin-negative neuroendocrine tumor of the thyroid.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods/Results</h4><div class="para"><p>This is a retrospective review of 2 patients diagnosed with Ewing sarcoma of the thyroid and a review of the literature.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Ewing sarcoma of the thyroid is an exceedingly rare diagnosis, but should be included in the differential diagnosis for a thyroidal neuroendocrine lesion (especially in the absence of calcitonin). The use and interpretation of immunohistochemistry (IHC) and fluorescent in situ hybridization are essential in making the correct diagnosis. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Neuroendocrine tumors of the thyroid encompass a wide differential diagnosis. The most common is medullary thyroid carcinoma. One must consider other possibilities when a neuroendocrine thyroid tumor is calcitonin negative. We report 2 cases of Ewing sarcoma of the thyroid and discuss the differential diagnosis and workup of a calcitonin-negative neuroendocrine tumor of the thyroid.


Methods/Results
This is a retrospective review of 2 patients diagnosed with Ewing sarcoma of the thyroid and a review of the literature.


Conclusions
Ewing sarcoma of the thyroid is an exceedingly rare diagnosis, but should be included in the differential diagnosis for a thyroidal neuroendocrine lesion (especially in the absence of calcitonin). The use and interpretation of immunohistochemistry (IHC) and fluorescent in situ hybridization are essential in making the correct diagnosis. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23246" xmlns="http://purl.org/rss/1.0/"><title>Practical considerations in reducing swallowing dysfunction following concurrent chemoradiotherapy with intensity-modulated radiotherapy for head and neck cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23246</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Practical considerations in reducing swallowing dysfunction following concurrent chemoradiotherapy with intensity-modulated radiotherapy for head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sukhjeet S. Batth, Jimmy J. Caudell, Allen M. Chen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-18T10:47:21.282462-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23246</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23246</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23246</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Data have emerged that the addition of concurrent chemotherapy to radiation can lead to swallowing dysfunction that may have an impact on patient quality of life and lead to significant morbidities such as poor nutritional status, enteral feeding tube dependence, and aspiration pneumonia. Although intensity-modulated radiation therapy (IMRT) for head and neck cancer was initially developed to spare the parotid gland to reduce xerostomia, attention has recently focused on its utility to selectively decrease radiation dose to specified anatomic structures responsible for a functional swallow. Recent reports have proposed a variety of dose thresholds or constraints to these swallowing-related structures, which may guide IMRT planning with the aim of reducing dysphagia. This critical review of the current literature assesses the feasibility of IMRT to maintain swallowing function and appraises the various dosimetric parameters that have been proposed to help minimize long-term dysphagia. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div>
]]></content:encoded><description>

Data have emerged that the addition of concurrent chemotherapy to radiation can lead to swallowing dysfunction that may have an impact on patient quality of life and lead to significant morbidities such as poor nutritional status, enteral feeding tube dependence, and aspiration pneumonia. Although intensity-modulated radiation therapy (IMRT) for head and neck cancer was initially developed to spare the parotid gland to reduce xerostomia, attention has recently focused on its utility to selectively decrease radiation dose to specified anatomic structures responsible for a functional swallow. Recent reports have proposed a variety of dose thresholds or constraints to these swallowing-related structures, which may guide IMRT planning with the aim of reducing dysphagia. This critical review of the current literature assesses the feasibility of IMRT to maintain swallowing function and appraises the various dosimetric parameters that have been proposed to help minimize long-term dysphagia. © 2013 Wiley Periodicals, Inc. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23228" xmlns="http://purl.org/rss/1.0/"><title>Clinical outcomes of patients with salivary gland carcinomas preoperatively misdiagnosed as benign lesions</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23228</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clinical outcomes of patients with salivary gland carcinomas preoperatively misdiagnosed as benign lesions</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">In Sun Ryu, Jong-Lyel Roh, Kyung-Ja Cho, Sang-wook Lee, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-09T02:54:34.548712-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23228</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23228</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23228</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>We compared clinical outcomes between patients with salivary gland carcinomas preoperatively misdiagnosed as benign lesion and properly diagnosed as malignant lesion.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The outcomes were compared between patients with benign lesion and malignant lesion (44 each) on preoperative fine-needle aspiration cytology diagnosis who underwent conservative or radical surgery.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Five-year lesion-free survival (DFS) rates were 86.8% for benign lesion and 76.3% for malignant lesion (<em>p</em> = .128). Surgical extent did not significantly affect locoregional recurrence and DFS (<em>p</em> = .360). Univariate analysis showed that sublingual gland tumor, positive resection margin, and extraparenchymal extension (EPE) were significantly associated with DFS (<em>p</em> &lt; .05 each). On multivariate analysis, EPE remained an independent variable (<em>p</em> = .047, hazard ratio = 6.621, 95% confidence interval = 1.393–31.474).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The clinical outcomes of patients with salivary gland carcinomas misdiagnosed as benign are relatively favorable. Conservative surgery may be sufficient for patients with low-grade and T1–2 salivary gland carcinomas. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
We compared clinical outcomes between patients with salivary gland carcinomas preoperatively misdiagnosed as benign lesion and properly diagnosed as malignant lesion.


Methods
The outcomes were compared between patients with benign lesion and malignant lesion (44 each) on preoperative fine-needle aspiration cytology diagnosis who underwent conservative or radical surgery.


Results
Five-year lesion-free survival (DFS) rates were 86.8% for benign lesion and 76.3% for malignant lesion (p = .128). Surgical extent did not significantly affect locoregional recurrence and DFS (p = .360). Univariate analysis showed that sublingual gland tumor, positive resection margin, and extraparenchymal extension (EPE) were significantly associated with DFS (p &lt; .05 each). On multivariate analysis, EPE remained an independent variable (p = .047, hazard ratio = 6.621, 95% confidence interval = 1.393–31.474).


Conclusions
The clinical outcomes of patients with salivary gland carcinomas misdiagnosed as benign are relatively favorable. Conservative surgery may be sufficient for patients with low-grade and T1–2 salivary gland carcinomas. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23230" xmlns="http://purl.org/rss/1.0/"><title>Effects of tumor staging and treatment modality on functional outcome and quality of life after treatment for laryngeal cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23230</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effects of tumor staging and treatment modality on functional outcome and quality of life after treatment for laryngeal cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stuart M. Robertson, Justin C. L. Yeo, Lesley Sabey, David Young, Kenneth MacKenzie</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-09T02:54:09.649736-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23230</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23230</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23230</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>An earlier stage of primary disease at diagnosis is associated with better survival from laryngeal cancer. It remains unproven whether earlier stage is also associated with improved end-organ function and quality of life after treatment.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Questionnaire packs were posted to 250 patients with laryngeal cancer treated between January 2006 and December 2008 within the West of Scotland. Packs contained the Voice Symptom Scale (VoiSS), MD Anderson Dysphagia Inventory (MDADI), and University of Washington Quality of Life Questionnaire (UW-QOL).</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>One hundred forty-seven eligible patients provided data for analysis (59% of original cohort). Patients with an earlier stage of primary disease reported significantly better VoiSS, MDADI, and UW-QOL scores (<em>p</em> &lt; .05). No differences were found between scores of patients with T1 laryngeal disease treated with endoscopic laser resection (ELR) and radiotherapy.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>An earlier stage at diagnosis is associated with significantly better end-organ function and quality of life after treatment for laryngeal cancer. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
An earlier stage of primary disease at diagnosis is associated with better survival from laryngeal cancer. It remains unproven whether earlier stage is also associated with improved end-organ function and quality of life after treatment.


Methods
Questionnaire packs were posted to 250 patients with laryngeal cancer treated between January 2006 and December 2008 within the West of Scotland. Packs contained the Voice Symptom Scale (VoiSS), MD Anderson Dysphagia Inventory (MDADI), and University of Washington Quality of Life Questionnaire (UW-QOL).


Results
One hundred forty-seven eligible patients provided data for analysis (59% of original cohort). Patients with an earlier stage of primary disease reported significantly better VoiSS, MDADI, and UW-QOL scores (p &lt; .05). No differences were found between scores of patients with T1 laryngeal disease treated with endoscopic laser resection (ELR) and radiotherapy.


Conclusion
An earlier stage at diagnosis is associated with significantly better end-organ function and quality of life after treatment for laryngeal cancer. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23242" xmlns="http://purl.org/rss/1.0/"><title>Survival analysis of patients with oral squamous cell carcinoma with simultaneous second primary tumors</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23242</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Survival analysis of patients with oral squamous cell carcinoma with simultaneous second primary tumors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shuo–Hsiu Hsu, Yong–Kie Wong, Ching-Ping Wang, Chen–Chi Wang, Rong–San Jiang, Fun–Jou Chen, Shih–An Liu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-09T02:53:53.141516-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23242</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23242</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23242</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to investigate the rate of simultaneous second primary tumor (SPT) in patients with oral squamous cell carcinoma. The survival of patients with simultaneous SPT was also compared with patients without.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The presence of SPT was documented along with the patients' demographic data, tumor-related features, and survival status. Kaplan–Meier method was used for survival analysis. Relevant factors influencing the survival were examined by the Cox proportional hazard model.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>A total of 897 patients' medical records were obtained. Among them, 43 patients (4.8%) had simultaneous SPT and their prognosis was poorer than that of patients without. The Cox proportional hazard model revealed that patients with simultaneous SPT tended to have a higher probability of death (relative risk [RR], 1.694; <em>p</em> = .015).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Simultaneous SPT is an independent prognostic factor for patients with oral squamous cell carcinoma. Those with simultaneous SPT have poorer survival when compared to those without. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to investigate the rate of simultaneous second primary tumor (SPT) in patients with oral squamous cell carcinoma. The survival of patients with simultaneous SPT was also compared with patients without.


Methods
The presence of SPT was documented along with the patients' demographic data, tumor-related features, and survival status. Kaplan–Meier method was used for survival analysis. Relevant factors influencing the survival were examined by the Cox proportional hazard model.


Results
A total of 897 patients' medical records were obtained. Among them, 43 patients (4.8%) had simultaneous SPT and their prognosis was poorer than that of patients without. The Cox proportional hazard model revealed that patients with simultaneous SPT tended to have a higher probability of death (relative risk [RR], 1.694; p = .015).


Conclusions
Simultaneous SPT is an independent prognostic factor for patients with oral squamous cell carcinoma. Those with simultaneous SPT have poorer survival when compared to those without. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23244" xmlns="http://purl.org/rss/1.0/"><title>Intensity-modulated radiotherapy followed by a brachytherapy boost for oropharyngeal cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23244</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Intensity-modulated radiotherapy followed by a brachytherapy boost for oropharyngeal cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Abrahim Al-Mamgani, Peter C. Levendag, Peter van Rooij, Cees A. Meeuwis, Aniel Sewnaik, David N. Teguh</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-09T02:53:40.085223-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23244</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23244</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23244</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to reduce the incidence of radiation-induced toxicity in patients with early-stage oropharyngeal cancer, using highly conformal radiation techniques.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Between 2000 and 2011, 167 patients with T1-3N0-3 oropharyngeal cancer were treated with 46-Gy intensity-modulated radiation therapy (IMRT) followed by 22-Gy brachytherapy boost. In patients with node-positive disease, neck dissection was performed.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The 5-year Kaplan–Meier estimates of local control, regional control, disease-free survival (DFS), and overall survival (OS) were 94%, 97%, 84%, and 72%, respectively. Feeding tubes were required in 26% of the patients. Grade ≥2 late xerostomia and dysphagia were 11% and 8%, respectively. Chemotherapy, tumor subsite, and bilateral neck irradiation correlate significantly with toxicity. Quality of life (QOL) scores deteriorate during and shortly after treatment but returned in all scales to baseline scores within 6 to 12 months, with the exception of xerostomia.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Brachytherapy boost and neck dissection (in node-positive oropharyngeal cancer) after 46-Gy of IMRT resulted in excellent outcomes with low incidence of late toxicity and good QOL scores. © 2013 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to reduce the incidence of radiation-induced toxicity in patients with early-stage oropharyngeal cancer, using highly conformal radiation techniques.


Methods
Between 2000 and 2011, 167 patients with T1-3N0-3 oropharyngeal cancer were treated with 46-Gy intensity-modulated radiation therapy (IMRT) followed by 22-Gy brachytherapy boost. In patients with node-positive disease, neck dissection was performed.


Results
The 5-year Kaplan–Meier estimates of local control, regional control, disease-free survival (DFS), and overall survival (OS) were 94%, 97%, 84%, and 72%, respectively. Feeding tubes were required in 26% of the patients. Grade ≥2 late xerostomia and dysphagia were 11% and 8%, respectively. Chemotherapy, tumor subsite, and bilateral neck irradiation correlate significantly with toxicity. Quality of life (QOL) scores deteriorate during and shortly after treatment but returned in all scales to baseline scores within 6 to 12 months, with the exception of xerostomia.


Conclusion
Brachytherapy boost and neck dissection (in node-positive oropharyngeal cancer) after 46-Gy of IMRT resulted in excellent outcomes with low incidence of late toxicity and good QOL scores. © 2013 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23233" xmlns="http://purl.org/rss/1.0/"><title>Association between skin flap thickness and Frey's syndrome in parotid surgery</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23233</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Association between skin flap thickness and Frey's syndrome in parotid surgery</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Osman Durgut, Oguz Basut, Uygar Levent Demir, Ömer A. Özmen, Fikret Kasapoglu, Hakan Coskun</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-08T03:35:43.538829-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23233</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23233</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23233</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Frey's Syndrome is a frequent complication of parotid surgery. The aim of this study was to evaluate the association between skin flap thickness and Frey's Syndrome in patients who underwent superficial parotidectomy.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Thirty adult patients were randomized into 2 groups: subcutaneous and subsuperficial musculoaponeurotic (sub-SMAS) skin elevation. In both groups skin flap thickness was measured by a micrometer at defined points. The patients were queried for subjective Frey's Syndrome and Minor's test was performed for objective Frey's Syndrome.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The thickness of skin flap in the subcutaneous group was significantly less than that in the sub-SMAS group. There was no statistical significance between skin flap thickness and objective Frey's Syndrome, although the dimension of the colored area in the subcutaneous group was larger compared with that of the sub-SMAS group: 7.5 cm<sup>2</sup> (0–48 cm<sup>2</sup>) and 0.5 cm<sup>2</sup> (0–18 cm<sup>2</sup>), respectively.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>In conclusion, sub-SMAS elevation of the skin flap in parotid surgery provides better results regarding Frey's Syndrome. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Frey's Syndrome is a frequent complication of parotid surgery. The aim of this study was to evaluate the association between skin flap thickness and Frey's Syndrome in patients who underwent superficial parotidectomy.


Methods
Thirty adult patients were randomized into 2 groups: subcutaneous and subsuperficial musculoaponeurotic (sub-SMAS) skin elevation. In both groups skin flap thickness was measured by a micrometer at defined points. The patients were queried for subjective Frey's Syndrome and Minor's test was performed for objective Frey's Syndrome.


Results
The thickness of skin flap in the subcutaneous group was significantly less than that in the sub-SMAS group. There was no statistical significance between skin flap thickness and objective Frey's Syndrome, although the dimension of the colored area in the subcutaneous group was larger compared with that of the sub-SMAS group: 7.5 cm2 (0–48 cm2) and 0.5 cm2 (0–18 cm2), respectively.


Conclusions
In conclusion, sub-SMAS elevation of the skin flap in parotid surgery provides better results regarding Frey's Syndrome. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23227" xmlns="http://purl.org/rss/1.0/"><title>Decision making in the management of recurrent head and neck cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23227</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Decision making in the management of recurrent head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Allen S. Ho, Dennis H. Kraus, Ian Ganly, Nancy Y. Lee, Jatin P. Shah, Luc G. T. Morris</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-08T03:35:14.35804-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23227</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23227</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23227</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Despite substantial improvements in head and neck squamous cell carcinoma (HNSCC) treatment, the major obstacle to long-term survival remains disease recurrence. Salvage options are often limited due to prior therapy and the escalated morbidity of retreatment. The costs of treatment must be measured against the anticipated quality and quantity of life recovered, even with resectable disease. This review surveys the recurrent HNSCC literature to better guide decision making. Across multiple studies, negative prognostic factors include impaired performance status, advanced recurrent stage, brief disease-free interval, previous chemotherapy, and nonlaryngeal sites of recurrence. When possible, surgical salvage remains the principal option for durable disease control, quality of life preservation, and cure. Nonsurgical therapies have also demonstrated measurable improvements in locoregional control. Interpretation of salvage literature must be tempered by recognition of significant selection bias. The decision for salvage therapy must be individualized, with management that involves well-informed patients resulting in the best outcomes. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div>
]]></content:encoded><description>

Despite substantial improvements in head and neck squamous cell carcinoma (HNSCC) treatment, the major obstacle to long-term survival remains disease recurrence. Salvage options are often limited due to prior therapy and the escalated morbidity of retreatment. The costs of treatment must be measured against the anticipated quality and quantity of life recovered, even with resectable disease. This review surveys the recurrent HNSCC literature to better guide decision making. Across multiple studies, negative prognostic factors include impaired performance status, advanced recurrent stage, brief disease-free interval, previous chemotherapy, and nonlaryngeal sites of recurrence. When possible, surgical salvage remains the principal option for durable disease control, quality of life preservation, and cure. Nonsurgical therapies have also demonstrated measurable improvements in locoregional control. Interpretation of salvage literature must be tempered by recognition of significant selection bias. The decision for salvage therapy must be individualized, with management that involves well-informed patients resulting in the best outcomes. © 2013 Wiley Periodicals, Inc. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23226" xmlns="http://purl.org/rss/1.0/"><title>Transoral robotic total laryngectomy: Report of 3 cases</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23226</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Transoral robotic total laryngectomy: Report of 3 cases</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Samuel Dowthwaite, Anthony C Nichols, John Yoo, Richard V. Smith, Sandeep Dhaliwal, John Basmaji, Jason H. Franklin, Kevin Fung</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-08T03:34:48.495663-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23226</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23226</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23226</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Because of the significant toxicity of chemoradiation regimens, there has been a resurgence of interest in the primary surgical management of head and neck cancer and, in particular, the use of minimally invasive surgery. One such technique is transoral robotic surgery (TORS). We aim to discuss the potential role of TORS in patients requiring total laryngectomy (TL).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>Three patients underwent TORS-assisted narrow-field TL. Relative data on preoperative, intraoperative, and postoperative management were collated including postoperative complications.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>We present 3 cases of transoral robotic surgery (TORS)–assisted TL in patients requiring narrow field laryngectomy without requirement for neck dissection. In reviewing these cases we provide a discussion of pertinent preoperative and intraoperative considerations that can assist in facilitating successful completion of the procedure. In particular, appropriate assessment at the pinsertlinePOLA_Del_Blank_PgPOLA_Shift_FramePORT_rem_fpg_underremovelinetabminilanning endoscopy in addition to a methodical surgical approach are vital to the successful use of the robot in TORS-assisted TL. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Because of the significant toxicity of chemoradiation regimens, there has been a resurgence of interest in the primary surgical management of head and neck cancer and, in particular, the use of minimally invasive surgery. One such technique is transoral robotic surgery (TORS). We aim to discuss the potential role of TORS in patients requiring total laryngectomy (TL).


Methods and Results
Three patients underwent TORS-assisted narrow-field TL. Relative data on preoperative, intraoperative, and postoperative management were collated including postoperative complications.


Conclusions
We present 3 cases of transoral robotic surgery (TORS)–assisted TL in patients requiring narrow field laryngectomy without requirement for neck dissection. In reviewing these cases we provide a discussion of pertinent preoperative and intraoperative considerations that can assist in facilitating successful completion of the procedure. In particular, appropriate assessment at the pinsertlinePOLA_Del_Blank_PgPOLA_Shift_FramePORT_rem_fpg_underremovelinetabminilanning endoscopy in addition to a methodical surgical approach are vital to the successful use of the robot in TORS-assisted TL. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23225" xmlns="http://purl.org/rss/1.0/"><title>Leptomeningeal carcinomatosis in sinonasal undifferentiated carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23225</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Leptomeningeal carcinomatosis in sinonasal undifferentiated carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stephen V. Liu, Naveed Wagle, Gabriel Zada, Bonnie Sun, John Go, Afshin Rashtian</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-08T03:34:26.36287-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23225</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23225</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23225</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Sinonasal undifferentiated carcinoma (SNUC) is an uncommon neoplasm characterized by local extension and an aggressive course. Treatment often includes a combination of chemotherapy, radiation therapy, and surgery, although the optimal strategy remains unclear. Here, we present the first reported case of leptomeningeal carcinomatosis from SNUC.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>A 28-year-old man with rapidly progressive headaches, congestion, and exophthalmos was found to have a nasal mass. Biopsy revealed sinonasal undifferentiated carcinoma. He had a transient response to chemotherapy followed by a sustained response to concurrent chemoradiation. At the completion of radiation, he developed subtle neurologic findings and MRI revealed diffuse, bulky leptomeningeal spread. He was able to receive only a single fraction of external beam radiation to his spinal axis before his disease rapidly progressed, leading to respiratory failure and death.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Sinonasal undifferentiated carcinoma can be associated with leptomeningeal carcinomatosis, which can lead to a fulminant clinical course. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Sinonasal undifferentiated carcinoma (SNUC) is an uncommon neoplasm characterized by local extension and an aggressive course. Treatment often includes a combination of chemotherapy, radiation therapy, and surgery, although the optimal strategy remains unclear. Here, we present the first reported case of leptomeningeal carcinomatosis from SNUC.


Methods and Results
A 28-year-old man with rapidly progressive headaches, congestion, and exophthalmos was found to have a nasal mass. Biopsy revealed sinonasal undifferentiated carcinoma. He had a transient response to chemotherapy followed by a sustained response to concurrent chemoradiation. At the completion of radiation, he developed subtle neurologic findings and MRI revealed diffuse, bulky leptomeningeal spread. He was able to receive only a single fraction of external beam radiation to his spinal axis before his disease rapidly progressed, leading to respiratory failure and death.


Conclusions
Sinonasal undifferentiated carcinoma can be associated with leptomeningeal carcinomatosis, which can lead to a fulminant clinical course. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23223" xmlns="http://purl.org/rss/1.0/"><title>Safety of robotic thyroidectomy approaches: Meta-analysis and systematic review</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23223</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Safety of robotic thyroidectomy approaches: Meta-analysis and systematic review</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicole R. Jackson, Lu Yao, Ralph P. Tufano, Emad H. Kandil</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-08T03:33:55.044113-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23223</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23223</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23223</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>This study compared the efficacy of robotic thyroidectomy via a gasless, axillary approach with conventional cervical and endoscopic techniques by meta-analysis.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Articles were identified from the following keyword searches: robotic/robot-assisted thyroidectomy/thyroid surgery. Outcomes included operative time, hospital stay, complications, and cosmetic satisfaction after surgery. Between-group outcome differences were calculated using random-effects models.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In all, 87 publications were identified and 9 studies met inclusion criteria, totaling 2881 patients, 1122 of whom underwent robotic thyroidectomy. Those who underwent robotic surgery reported greater cosmetic satisfaction, with a pooled net mean difference of −1.35 (95% confidence interval [CI]: −1.69, −1.09). Robotic approach operative time was longer than that of the conventional approach (95% CI: 29.23, 54.87), with a trend to be shorter than the endoscopic approaches. Robotic surgery had similar risks to open and endoscopic approaches.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Our meta-analysis suggests that robotic thyroidectomy is as safe, feasible, and efficacious as conventional cervical and endoscopic thyroidectomy, showing superior cosmetic satisfaction than that of conventional thyroidectomy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
This study compared the efficacy of robotic thyroidectomy via a gasless, axillary approach with conventional cervical and endoscopic techniques by meta-analysis.


Methods
Articles were identified from the following keyword searches: robotic/robot-assisted thyroidectomy/thyroid surgery. Outcomes included operative time, hospital stay, complications, and cosmetic satisfaction after surgery. Between-group outcome differences were calculated using random-effects models.


Results
In all, 87 publications were identified and 9 studies met inclusion criteria, totaling 2881 patients, 1122 of whom underwent robotic thyroidectomy. Those who underwent robotic surgery reported greater cosmetic satisfaction, with a pooled net mean difference of −1.35 (95% confidence interval [CI]: −1.69, −1.09). Robotic approach operative time was longer than that of the conventional approach (95% CI: 29.23, 54.87), with a trend to be shorter than the endoscopic approaches. Robotic surgery had similar risks to open and endoscopic approaches.


Conclusions
Our meta-analysis suggests that robotic thyroidectomy is as safe, feasible, and efficacious as conventional cervical and endoscopic thyroidectomy, showing superior cosmetic satisfaction than that of conventional thyroidectomy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23210" xmlns="http://purl.org/rss/1.0/"><title>Endoglin (CD105) expression on microvessel endothelial cells in juvenile nasopharyngeal angiofibroma: Tissue microarray analysis and association with prognostic significance</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23210</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Endoglin (CD105) expression on microvessel endothelial cells in juvenile nasopharyngeal angiofibroma: Tissue microarray analysis and association with prognostic significance</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jing-Jing Wang, Xi-Cai Sun, Li Hu, Zhuo-Fu Liu, Hua-Peng Yu, Han Li, Shu-Yi Wang, De-Hui Wang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-08T03:33:09.187031-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23210</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23210</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23210</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to examine endoglin (CD105) expression on microvessel endothelial cells (ECs) in juvenile nasopharyngeal angiofibroma (JNA) and its relationship with recurrence.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Immunohistochemistry was performed to detect CD105 expression in a tissue microarray from 70 patients with JNA. Correlation between CD105 expression on microvessel ECs and clinicopathological features, as well as tumor recurrence, were analyzed.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Immunohistochemistry revealed CD105 expression on ECs but not in stroma of patients with JNA. Chi-square analysis indicated CD105-based microvessel density (MVD) was correlated with JNA recurrence (<em>p</em> = .013). Univariate and multivariate analyses determined that MVD was a significant predictor of time to recurrence (<em>p</em> = .009). The CD105-based MVD was better for predicting disease recurrence (AUROC: 0.673; <em>p</em> = .036) than other clinicopathological features.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>MVD is a useful predictor for poor prognosis of patients with JNA after curative resection. Angiogenesis, which may play an important role in the occurrence and development of JNA, is therefore a potential therapeutic target for JNA. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to examine endoglin (CD105) expression on microvessel endothelial cells (ECs) in juvenile nasopharyngeal angiofibroma (JNA) and its relationship with recurrence.


Methods
Immunohistochemistry was performed to detect CD105 expression in a tissue microarray from 70 patients with JNA. Correlation between CD105 expression on microvessel ECs and clinicopathological features, as well as tumor recurrence, were analyzed.


Results
Immunohistochemistry revealed CD105 expression on ECs but not in stroma of patients with JNA. Chi-square analysis indicated CD105-based microvessel density (MVD) was correlated with JNA recurrence (p = .013). Univariate and multivariate analyses determined that MVD was a significant predictor of time to recurrence (p = .009). The CD105-based MVD was better for predicting disease recurrence (AUROC: 0.673; p = .036) than other clinicopathological features.


Conclusions
MVD is a useful predictor for poor prognosis of patients with JNA after curative resection. Angiogenesis, which may play an important role in the occurrence and development of JNA, is therefore a potential therapeutic target for JNA. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23245" xmlns="http://purl.org/rss/1.0/"><title>Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23245</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James T. May, Nikhil Rao, Roberto D. Sabater, Hinda Boutrid, Jimmy J. Caudell, Faisal Merchant, Gang Han, Tapan A. Padhya, Judith C. McCaffrey, Tawee Tanvetyanon, Ronald Deconti, Julie Kish, Thomas V. McCaffrey, Andy Trotti</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-06T09:02:54.89662-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23245</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23245</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23245</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Over the past decade, intensity-modulated radiation therapy (IMRT) has gained widespread use in the treatment of head and neck cancer.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>All patients with squamous cell carcinoma of the oropharynx treated with primary IMRT with or without chemotherapy over a 5-year period were reviewed. Outcomes and morbidity were analyzed and compared with previously published data.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In all, 170 patients were included in the analysis. The 3-year local control, locoregional control, disease-free survival, and overall survival rates were 92%, 91%, 80%, and 87%, respectively. Feeding tubes were present in 55% of patients during treatment, but remained in only 1% 2 years following treatment.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>This study confirms that IMRT yields excellent treatment outcomes for oropharyngeal carcinoma. Although acute toxicity remains a problem, late toxicity rates are low and long-term feeding tube dependence is rare compared with conventional radiation therapy. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Over the past decade, intensity-modulated radiation therapy (IMRT) has gained widespread use in the treatment of head and neck cancer.


Methods
All patients with squamous cell carcinoma of the oropharynx treated with primary IMRT with or without chemotherapy over a 5-year period were reviewed. Outcomes and morbidity were analyzed and compared with previously published data.


Results
In all, 170 patients were included in the analysis. The 3-year local control, locoregional control, disease-free survival, and overall survival rates were 92%, 91%, 80%, and 87%, respectively. Feeding tubes were present in 55% of patients during treatment, but remained in only 1% 2 years following treatment.


Conclusions
This study confirms that IMRT yields excellent treatment outcomes for oropharyngeal carcinoma. Although acute toxicity remains a problem, late toxicity rates are low and long-term feeding tube dependence is rare compared with conventional radiation therapy. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23241" xmlns="http://purl.org/rss/1.0/"><title>Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: Report of a case and a literature review of tandem RET mutations with in silico analysis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23241</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: Report of a case and a literature review of tandem RET mutations with in silico analysis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kanako–Tanase Nakao, Takeshi Usui, Mayumi Ikeda, Yusuke Mori, Tetsuro Yamamoto, Sachiko–Tsukamoto Kawashima, Kazutaka Nanba, Akiko Yuno, Tamiko Tamanaha, Tetsuya Tagami, Mitsuhide Naruse, Ryo Asato, Akira Shimatsu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-06T09:02:35.523629-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23241</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23241</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23241</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Multiple endocrine neoplasia type 2B (MEN2B) is the rarest and most aggressive form of MEN2. MEN2B cases usually carry either an M918T or A883T mutation of the <em>RET</em>, but to date, there are 3 atypical MEN2B caused by tandem mutations.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>A 32-year-old woman with no family history of medullary thyroid carcinoma (MTC) presented with a neck tumor and multiple mucosal nodules. She was diagnosed with MEN2B. Genetic analyses of <em>RET</em> revealed that she had 2 mutations, Q781R and V804M. Subclone and genetic analyses revealed that Q781R was on the paternal allele and V804M was a <em>de novo</em>. <em>In silico</em> analysis of the tandem mutations showed a high prediction score.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>We describe a novel combination of tandem <em>RET</em> mutations (Q781R/V804M) in a MEN2B-like patient. <em>In silico</em> analysis showed a high prediction score, which was compatible with the clinical phenotype in the present case. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Multiple endocrine neoplasia type 2B (MEN2B) is the rarest and most aggressive form of MEN2. MEN2B cases usually carry either an M918T or A883T mutation of the RET, but to date, there are 3 atypical MEN2B caused by tandem mutations.


Methods and Results
A 32-year-old woman with no family history of medullary thyroid carcinoma (MTC) presented with a neck tumor and multiple mucosal nodules. She was diagnosed with MEN2B. Genetic analyses of RET revealed that she had 2 mutations, Q781R and V804M. Subclone and genetic analyses revealed that Q781R was on the paternal allele and V804M was a de novo. In silico analysis of the tandem mutations showed a high prediction score.


Conclusions
We describe a novel combination of tandem RET mutations (Q781R/V804M) in a MEN2B-like patient. In silico analysis showed a high prediction score, which was compatible with the clinical phenotype in the present case. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23238" xmlns="http://purl.org/rss/1.0/"><title>Combined transoral robotic surgery and endoscopic endonasal approach for the resection of extensive malignancies of the skull base</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23238</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Combined transoral robotic surgery and endoscopic endonasal approach for the resection of extensive malignancies of the skull base</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ricardo L. Carrau, Daniel M. Prevedello, Danielle de Lara, Kasim Durmus, Enver Ozer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-06T09:02:15.70701-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23238</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23238</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23238</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Oncologic resection of the clivus, nasopharynx, craniovertebral junction, and infratemporal fossa is a challenging endeavor because of their complex and protected anatomy. Our goals were to design a cadaveric model and identify advantages and limitations of combining the transoral robotic surgery (TORS) and endoscopic endonasal approach (EEA) techniques.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Cadaveric specimens were dissected using a da Vinci surgical robot and endoscopic endonasal instruments in a fashion that mimicked our operating room environment. We then applied these techniques clinically.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>EEA was performed to provide a detailed dissection of the infratemporal fossa, nasopharynx, posterior skull base (clivus), and craniovertebral junction. Using TORS, we dissected the parapharyngeal space, infratemporal fossa, and nasopharynx below the eustachian tube, which represented a transition zone that delineated the most effective resection field of each approach.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>TORS and EEA seem to be complementary techniques; thus, their combined use seems advantageous for selected advanced tumors in these complex areas. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Oncologic resection of the clivus, nasopharynx, craniovertebral junction, and infratemporal fossa is a challenging endeavor because of their complex and protected anatomy. Our goals were to design a cadaveric model and identify advantages and limitations of combining the transoral robotic surgery (TORS) and endoscopic endonasal approach (EEA) techniques.


Methods
Cadaveric specimens were dissected using a da Vinci surgical robot and endoscopic endonasal instruments in a fashion that mimicked our operating room environment. We then applied these techniques clinically.


Results
EEA was performed to provide a detailed dissection of the infratemporal fossa, nasopharynx, posterior skull base (clivus), and craniovertebral junction. Using TORS, we dissected the parapharyngeal space, infratemporal fossa, and nasopharynx below the eustachian tube, which represented a transition zone that delineated the most effective resection field of each approach.


Conclusions
TORS and EEA seem to be complementary techniques; thus, their combined use seems advantageous for selected advanced tumors in these complex areas. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23232" xmlns="http://purl.org/rss/1.0/"><title>Survival impact of pulmonary metastasectomy for patients with head and neck cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23232</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Survival impact of pulmonary metastasectomy for patients with head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takuya Miyazaki, Yasuhisa Hasegawa, Nobuhiro Hanai, Taijirou Ozawa, Hitoshi Hirakawa, Atsushi Suzuki, Hiroki Okamoto, Ikuma Harata</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-06T09:01:41.14327-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23232</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23232</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23232</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to evaluate the survival impact and prognostic factors of pulmonary metastasectomy in patients with pulmonary metastasis from head and neck cancer.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective study of 69 patients was analyzed. Twenty-four patients (35%) underwent pulmonary metastasectomy, and the remaining 45 patients (65%) were treated with chemotherapy or best supportive care.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The 1-year overall survival (OS) of 69 patients was 28%. Pulmonary metastasectomy (<em>p</em> = .01) and histology (<em>p</em> &lt; .001) had a significant impact on the prognosis. One-year OS of patients who underwent metastasectomy and those who did not was 90% and 35%, respectively. In the metastasectomy group, recurrence of primary ahead of lung metastasis (<em>p</em> = .006) and disease-free interval (DFI; ≤21.4 months; <em>p</em> = .046) were significant negative prognostic factors.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Pulmonary metastasectomy has an impact on survival in carefully selected patients, especially for those with a long DFI and with no recurrence of primary cancer ahead of lung metastasis. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to evaluate the survival impact and prognostic factors of pulmonary metastasectomy in patients with pulmonary metastasis from head and neck cancer.


Methods
A retrospective study of 69 patients was analyzed. Twenty-four patients (35%) underwent pulmonary metastasectomy, and the remaining 45 patients (65%) were treated with chemotherapy or best supportive care.


Results
The 1-year overall survival (OS) of 69 patients was 28%. Pulmonary metastasectomy (p = .01) and histology (p &lt; .001) had a significant impact on the prognosis. One-year OS of patients who underwent metastasectomy and those who did not was 90% and 35%, respectively. In the metastasectomy group, recurrence of primary ahead of lung metastasis (p = .006) and disease-free interval (DFI; ≤21.4 months; p = .046) were significant negative prognostic factors.


Conclusion
Pulmonary metastasectomy has an impact on survival in carefully selected patients, especially for those with a long DFI and with no recurrence of primary cancer ahead of lung metastasis. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23229" xmlns="http://purl.org/rss/1.0/"><title>Prognostic factors in limited (T1–2, N0–1) oropharyngeal carcinoma treated with surgery ± adjuvant therapy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23229</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prognostic factors in limited (T1–2, N0–1) oropharyngeal carcinoma treated with surgery ± adjuvant therapy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Georgios Psychogios, Konstantinos Mantsopoulos, Abbas Agaimy, Michael Koch, Johannes Zenk, Frank Waldfahrer, Heinrich Iro</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-06T09:01:22.711334-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23229</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23229</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23229</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Surgical therapy for early oropharyngeal carcinoma leads to excellent oncologic results but often requires adjuvant radiotherapy. The purpose of this study was to identify prognostic factors that worsen the outcome of limited oropharyngeal carcinoma treated with surgery ± adjuvant therapy.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Two hundred sixty-six patients were retrospectively evaluated between 1980 and 2007.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Overall 5-year disease-specific survival (DSS) was 88.7% and local control (LC) was 93.3%. The univariate analysis showed a significant difference in DSS between pT1 and pT2 oropharyngeal carcinoma (DSS, 94.0% vs 81.2%; <em>p</em> = .008) and patients with tumor depth greater than 5 mm (DSS, 94.5% vs 78.9%; <em>p</em> = .031). No difference could be found as to N classification, marginal status, p16 human papillomavirus (HPV) status, type of treatment, and adjuvant radiotherapy.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Primary surgical treatment is an effective therapy of limited oropharyngeal carcinoma. Patients with pT2 status and tumor depth of more than 5 mm show a significantly worse survival rate and should be further investigated in future clinical trials. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Surgical therapy for early oropharyngeal carcinoma leads to excellent oncologic results but often requires adjuvant radiotherapy. The purpose of this study was to identify prognostic factors that worsen the outcome of limited oropharyngeal carcinoma treated with surgery ± adjuvant therapy.


Methods
Two hundred sixty-six patients were retrospectively evaluated between 1980 and 2007.


Results
Overall 5-year disease-specific survival (DSS) was 88.7% and local control (LC) was 93.3%. The univariate analysis showed a significant difference in DSS between pT1 and pT2 oropharyngeal carcinoma (DSS, 94.0% vs 81.2%; p = .008) and patients with tumor depth greater than 5 mm (DSS, 94.5% vs 78.9%; p = .031). No difference could be found as to N classification, marginal status, p16 human papillomavirus (HPV) status, type of treatment, and adjuvant radiotherapy.


Conclusion
Primary surgical treatment is an effective therapy of limited oropharyngeal carcinoma. Patients with pT2 status and tumor depth of more than 5 mm show a significantly worse survival rate and should be further investigated in future clinical trials. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23220" xmlns="http://purl.org/rss/1.0/"><title>Endocopic approaches to the skull base</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23220</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Endocopic approaches to the skull base</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrea Chamczuk</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-06T09:01:04.340762-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23220</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23220</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23220</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Book Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23217" xmlns="http://purl.org/rss/1.0/"><title>Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23217</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sébastien Albert, Maria Eugenia Riveiro, Caroline Halimi, Muriel Hourseau, Anne Couvelard, Maria Serova, Béatrix Barry, Eric Raymond, Sandrine Faivre</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-06T09:00:10.256094-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23217</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23217</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23217</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Basic Science Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The human chemokine system includes approximately 48 chemokines and 19 chemokine receptors. The CXCL12/CXCR4 system is one of the most frequently studied that is also found overexpressed in a large variety of tumors. The CXCL12/CXCR4 axis has been increasingly identified as an important target in cancer growth, metastasis, relapse, and resistance to therapy. In this review, we highlight current knowledge of the molecular mechanisms involving chemokines CXCL12/CXCR4 and their consequences in head and neck squamous cell carcinoma (HNSCC). Overexpression of CXCL12/CXCR4 in HNSCC appears to activate cellular functions, including motility, invasion, and metastatic processes. Current findings suggest that CXCR4 and epithelial–mesenchymal transition markers are associated with tumor aggressiveness and a poor prognosis, and may be suitable biomarkers for head and neck tumors with high metastatic potential. Furthermore, knowledge of the role of CXCR4 in HNSCC could influence the development of new targeted therapies for treatment, aimed at improving the prognosis of this disease. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div>
]]></content:encoded><description>

The human chemokine system includes approximately 48 chemokines and 19 chemokine receptors. The CXCL12/CXCR4 system is one of the most frequently studied that is also found overexpressed in a large variety of tumors. The CXCL12/CXCR4 axis has been increasingly identified as an important target in cancer growth, metastasis, relapse, and resistance to therapy. In this review, we highlight current knowledge of the molecular mechanisms involving chemokines CXCL12/CXCR4 and their consequences in head and neck squamous cell carcinoma (HNSCC). Overexpression of CXCL12/CXCR4 in HNSCC appears to activate cellular functions, including motility, invasion, and metastatic processes. Current findings suggest that CXCR4 and epithelial–mesenchymal transition markers are associated with tumor aggressiveness and a poor prognosis, and may be suitable biomarkers for head and neck tumors with high metastatic potential. Furthermore, knowledge of the role of CXCR4 in HNSCC could influence the development of new targeted therapies for treatment, aimed at improving the prognosis of this disease. © 2013 Wiley Periodicals, Inc. Head Neck, 2013
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23214" xmlns="http://purl.org/rss/1.0/"><title>Surgical salvage for recurrent retropharyngeal lymph node metastasis in nasopharyngeal carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23214</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Surgical salvage for recurrent retropharyngeal lymph node metastasis in nasopharyngeal carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jimmy Yu Wai Chan, Velda Ling Yu Chow, Stanley Tien Sze Wong, William Ignace Wei</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-06T08:59:42.892286-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23214</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23214</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23214</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to analyze the surgical management of recurrent retropharyngeal lymph node metastasis after radiotherapy for nasopharyngeal carcinoma (NPC).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We conducted a prospective analysis of preoperative imaging, surgical approach, and oncological results.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Between 1990 and 2011, 82 patients were included. The mean size of the retropharyngeal lymph node on MRI was 1.6 cm, and the mean standardized uptake value maximum (SUVmax) on positron emission tomography (PET) scan was 6.8. All the retropharyngeal lymph nodes were resected via the maxillary swing approach. Among the resected retropharyngeal lymph nodes, 87.8% contained viable tumor cells. The rate of microscopic extracapsular spread was 30.6%. The mean follow-up duration was 38 months. The 5-year actuarial tumor control and the overall disease-free survival of patients who underwent surgeries for isolated recurrent retropharyngeal lymph node metastasis was 79.6% and 59%, respectively.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>A PET scan is potentially useful in diagnosing persistent or recurrent retropharyngeal lymph node after previous radiotherapy for NPC. The maxillary swing approach allows surgical resection with clear margins in order to achieve the best oncological outcome. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to analyze the surgical management of recurrent retropharyngeal lymph node metastasis after radiotherapy for nasopharyngeal carcinoma (NPC).


Methods
We conducted a prospective analysis of preoperative imaging, surgical approach, and oncological results.


Results
Between 1990 and 2011, 82 patients were included. The mean size of the retropharyngeal lymph node on MRI was 1.6 cm, and the mean standardized uptake value maximum (SUVmax) on positron emission tomography (PET) scan was 6.8. All the retropharyngeal lymph nodes were resected via the maxillary swing approach. Among the resected retropharyngeal lymph nodes, 87.8% contained viable tumor cells. The rate of microscopic extracapsular spread was 30.6%. The mean follow-up duration was 38 months. The 5-year actuarial tumor control and the overall disease-free survival of patients who underwent surgeries for isolated recurrent retropharyngeal lymph node metastasis was 79.6% and 59%, respectively.


Conclusion
A PET scan is potentially useful in diagnosing persistent or recurrent retropharyngeal lymph node after previous radiotherapy for NPC. The maxillary swing approach allows surgical resection with clear margins in order to achieve the best oncological outcome. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23213" xmlns="http://purl.org/rss/1.0/"><title>Single-port endoscopic thyroidectomy via a submental approach: Report of an initial experience</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23213</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Single-port endoscopic thyroidectomy via a submental approach: Report of an initial experience</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zheng Ding, XianZhao Deng, YouBen Fan, Bo Wu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-21T05:57:42.836913-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23213</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23213</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23213</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Based on our experience of trans-areola single-site endoscopic thyroidectomy and a preclinical study in the porcine model, we attempted to develop a new approach called trans-submental single-port endoscopic thyroidectomy (TSSPET).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Two female patients (43 and 27 years old, respectively) were selected for TSSPET. Both were preoperatively diagnosed with benign thyroid nodule by ultrasonography and fine-needle aspiration cytology (FNAC). Two mini-incisions were made in the submental area. The isthmectomy was performed for 1 patient and a right lobectomy for the other.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>This procedure was successfully accomplished in 2 cases. The operative time was 108 minutes and 150 minutes, respectively. No complications occurred. Postoperative hospital stay was 2 days. After 3 months, cosmetic result was satisfactory.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Our initial experience demonstrates that the TSSPET is feasible and safe for selected patients. Nevertheless, large series and comparative studies could be necessary to further confirm its effectiveness. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Based on our experience of trans-areola single-site endoscopic thyroidectomy and a preclinical study in the porcine model, we attempted to develop a new approach called trans-submental single-port endoscopic thyroidectomy (TSSPET).


Methods
Two female patients (43 and 27 years old, respectively) were selected for TSSPET. Both were preoperatively diagnosed with benign thyroid nodule by ultrasonography and fine-needle aspiration cytology (FNAC). Two mini-incisions were made in the submental area. The isthmectomy was performed for 1 patient and a right lobectomy for the other.


Results
This procedure was successfully accomplished in 2 cases. The operative time was 108 minutes and 150 minutes, respectively. No complications occurred. Postoperative hospital stay was 2 days. After 3 months, cosmetic result was satisfactory.


Conclusion
Our initial experience demonstrates that the TSSPET is feasible and safe for selected patients. Nevertheless, large series and comparative studies could be necessary to further confirm its effectiveness. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23215" xmlns="http://purl.org/rss/1.0/"><title>Superficial musculoaponeurotic system flap in partial parotidectomy and clinical and subclinical Frey's syndrome. Cosmesis and quality of life</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23215</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Superficial musculoaponeurotic system flap in partial parotidectomy and clinical and subclinical Frey's syndrome. Cosmesis and quality of life</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rafael Barberá, Felipe Castillo, Claudio D'Oleo, Susana Benítez, Ignacio Cobeta</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-04T06:13:28.852989-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23215</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23215</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23215</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Frey's syndrome (FS), facial depression, and noticeable scar may have an impact on patient's quality of life after a parotidectomy. The superficial musculoaponeurotic system (SMAS) flap has been used to ameliorate those effects.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Forty-seven consecutive parotidectomies were analyzed; SMAS flap was performed in 26 of them. We investigated clinical FS, subclinical FS, and cosmetic satisfaction, and compared SMAS flap versus cases where this was not done.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>By performing the SMAS flap, the occurrence of clinical FS was reduced; however, there was no significant difference. Nonetheless, there was a significant difference in the perspiration intensity in favor of the group with SMAS flaps. In the cases we studied, the cosmetic satisfaction was high, even though facial contour-filling techniques were not used.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Provided that the intensity of sweating is the main factor affecting the quality of life after surgery in patients, performing a SMAS flap renders the intervention worthwhile. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Frey's syndrome (FS), facial depression, and noticeable scar may have an impact on patient's quality of life after a parotidectomy. The superficial musculoaponeurotic system (SMAS) flap has been used to ameliorate those effects.


Methods
Forty-seven consecutive parotidectomies were analyzed; SMAS flap was performed in 26 of them. We investigated clinical FS, subclinical FS, and cosmetic satisfaction, and compared SMAS flap versus cases where this was not done.


Results
By performing the SMAS flap, the occurrence of clinical FS was reduced; however, there was no significant difference. Nonetheless, there was a significant difference in the perspiration intensity in favor of the group with SMAS flaps. In the cases we studied, the cosmetic satisfaction was high, even though facial contour-filling techniques were not used.


Conclusions
Provided that the intensity of sweating is the main factor affecting the quality of life after surgery in patients, performing a SMAS flap renders the intervention worthwhile. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23219" xmlns="http://purl.org/rss/1.0/"><title>Hypofractionated palliative radiotherapy for advanced head and neck cancer: The IHF2SQ regimen</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23219</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Hypofractionated palliative radiotherapy for advanced head and neck cancer: The IHF2SQ regimen</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laurie Monnier, Emmanuel Touboul, Catherine Durdux, Philippe Lang, Jean Lacau St Guily, Florence Huguet</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-29T01:05:35.29761-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23219</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23219</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23219</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Standard treatment for unresectable advanced head and neck squamous cell carcinoma is chemoradiotherapy, which can be toxic, particularly among patients with coexisting medical conditions. We report our experience with the hypofractionated radiotherapy regimen Irradiation HypoFractionnée 2 Séances Quotidiennes (IHF2SQ).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We retrospectively reviewed 78 patients treated with the IHF2SQ regimen. Radiotherapy was administrated as 2 fractions of 3 Gy per day (days 1 and 3), during the first, third, fifth, and seventh week of treatment with concurrent platinum-based chemotherapy.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Tolerance was excellent. Forty-one patients had complete or partial response. Median overall survival (OS) was 12.9 months and median progression-free survival (PFS) was 10.3 months. One-year OS, specific survival (SS), and PFS were 58%, 71%, 51.5%, respectively. Independent predictive factors increasing the PFS were response to chemoradiotherapy, male sex, and laryngeal tumor location.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>This regimen is an alternative to conventional chemoradiotherapy with good response rates and acceptable toxicity for selected patients. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Standard treatment for unresectable advanced head and neck squamous cell carcinoma is chemoradiotherapy, which can be toxic, particularly among patients with coexisting medical conditions. We report our experience with the hypofractionated radiotherapy regimen Irradiation HypoFractionnée 2 Séances Quotidiennes (IHF2SQ).


Methods
We retrospectively reviewed 78 patients treated with the IHF2SQ regimen. Radiotherapy was administrated as 2 fractions of 3 Gy per day (days 1 and 3), during the first, third, fifth, and seventh week of treatment with concurrent platinum-based chemotherapy.


Results
Tolerance was excellent. Forty-one patients had complete or partial response. Median overall survival (OS) was 12.9 months and median progression-free survival (PFS) was 10.3 months. One-year OS, specific survival (SS), and PFS were 58%, 71%, 51.5%, respectively. Independent predictive factors increasing the PFS were response to chemoradiotherapy, male sex, and laryngeal tumor location.


Conclusions
This regimen is an alternative to conventional chemoradiotherapy with good response rates and acceptable toxicity for selected patients. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23190" xmlns="http://purl.org/rss/1.0/"><title>p16 Expression in carcinoma of unknown primary: Diagnostic indicator and prognostic marker</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23190</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">p16 Expression in carcinoma of unknown primary: Diagnostic indicator and prognostic marker</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julia Vent, Bastian Haidle, Inga Wedemeyer, Christian Huebbers, Oliver Siefer, Robert Semrau, Simon F. Preuss, Jens Klussmann</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-23T12:47:34.594055-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23190</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23190</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23190</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Carcinoma of unknown primary (CUP) of the neck are heterogeneous tumors in their clinical and biological characteristics, and a preoperative prognostic marker is desirable to optimize staging and therapy and to improve outcome and survival. For CUP syndrome, no optimized diagnostic and treatment strategy or biomarker have yet been determined.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Forty-seven patients presenting with CUP syndrome were analyzed after thorough standard diagnostic staging procedures. All patients were surgically treated with tonsillectomy, neck dissection of the diseased neck, as well as adjuvant chemoradiation. The tissue of lymph node metastases (and, if found, of the primary tumor) was analyzed regarding expression of p16, epidermal growth factor receptor (EGFR), and presence of human papillomavirus (HPV) DNA.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In 39% of all cases (20 of 47), the primary cancer was found during diagnostic workup. If HPV DNA was detected in the neck lymph node metastasis, the primary cancer was significantly more frequently found in the oropharynx (<em>p</em> = .002). Patients with a p16-positive tumor had a significantly higher 5-year overall survival (OS; 33% vs 69%; <em>p</em> = .045, disease-free survival [DSF] 77% vs 89%; <em>p</em> = not significant [NS]). Patients with p16-positive neck metastasis and no detectable primary cancer had a better prognosis. Expression of EGFR in this series did not have a significant effect on prognosis.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>In patients presenting with CUP syndrome, p16 immunohistochemistry can serve to locate the primary cancer in the oropharynx. It is a positive prognostic indicator in patients with those heterogeneous cancers. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Carcinoma of unknown primary (CUP) of the neck are heterogeneous tumors in their clinical and biological characteristics, and a preoperative prognostic marker is desirable to optimize staging and therapy and to improve outcome and survival. For CUP syndrome, no optimized diagnostic and treatment strategy or biomarker have yet been determined.


Methods
Forty-seven patients presenting with CUP syndrome were analyzed after thorough standard diagnostic staging procedures. All patients were surgically treated with tonsillectomy, neck dissection of the diseased neck, as well as adjuvant chemoradiation. The tissue of lymph node metastases (and, if found, of the primary tumor) was analyzed regarding expression of p16, epidermal growth factor receptor (EGFR), and presence of human papillomavirus (HPV) DNA.


Results
In 39% of all cases (20 of 47), the primary cancer was found during diagnostic workup. If HPV DNA was detected in the neck lymph node metastasis, the primary cancer was significantly more frequently found in the oropharynx (p = .002). Patients with a p16-positive tumor had a significantly higher 5-year overall survival (OS; 33% vs 69%; p = .045, disease-free survival [DSF] 77% vs 89%; p = not significant [NS]). Patients with p16-positive neck metastasis and no detectable primary cancer had a better prognosis. Expression of EGFR in this series did not have a significant effect on prognosis.


Conclusion
In patients presenting with CUP syndrome, p16 immunohistochemistry can serve to locate the primary cancer in the oropharynx. It is a positive prognostic indicator in patients with those heterogeneous cancers. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23211" xmlns="http://purl.org/rss/1.0/"><title>Tracheo-innominate artery fistula: Diagnosis and surgical management</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23211</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Tracheo-innominate artery fistula: Diagnosis and surgical management</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiao-lei Wang, Zhen-gang Xu, Ping-zhang Tang, Yue Yu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-23T12:47:14.998174-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23211</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23211</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23211</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Tracheo-innominate artery fistula (TIF) is a rare and fatal complication after tracheostomy. The diagnosis, treatment, and possible prevention of this disease are discussed in this study.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>From 1976 to 2008, 14 patients with TIF were studied retrospectively.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>All patients underwent open surgical tracheostomy. Before TIF, herald events occurred in 10 patients (8 had slight hemoptysis and 2 had innominate artery exposure). When TIF occurred, bedside aid was administered, and 5 patients lived long enough to reach the operating room. Four patients accepted median sternotomy and ligation of innominate arteries. After surgery, mediastinal infection caused the rebleeding and death of 3 patients. In conducting follow-up for 11 months, the last patient was still alive without neurological complications. The survival rate was only 7.1%.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Prompt diagnosis and surgical intervention can save the life of a patient with TIF. Prevention is vital because of the high mortality of this disease. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Tracheo-innominate artery fistula (TIF) is a rare and fatal complication after tracheostomy. The diagnosis, treatment, and possible prevention of this disease are discussed in this study.


Methods
From 1976 to 2008, 14 patients with TIF were studied retrospectively.


Results
All patients underwent open surgical tracheostomy. Before TIF, herald events occurred in 10 patients (8 had slight hemoptysis and 2 had innominate artery exposure). When TIF occurred, bedside aid was administered, and 5 patients lived long enough to reach the operating room. Four patients accepted median sternotomy and ligation of innominate arteries. After surgery, mediastinal infection caused the rebleeding and death of 3 patients. In conducting follow-up for 11 months, the last patient was still alive without neurological complications. The survival rate was only 7.1%.


Conclusion
Prompt diagnosis and surgical intervention can save the life of a patient with TIF. Prevention is vital because of the high mortality of this disease. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23216" xmlns="http://purl.org/rss/1.0/"><title>Role of parathyroid hormone therapy in reversing radiation-induced nonunion and normalization of radiomorphometrics in a murine mandibular model of distraction osteogenesis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23216</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Role of parathyroid hormone therapy in reversing radiation-induced nonunion and normalization of radiomorphometrics in a murine mandibular model of distraction osteogenesis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">K. Kelly Gallagher, Sagar Deshpande, Catherine N. Tchanque-Fossuo, Alexis Donneys, Deniz Sarhaddi, Noah S. Nelson, Douglas B. Chepeha, Steven R. Buchman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-17T23:25:44.56455-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23216</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23216</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23216</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The use of mandibular distraction osteogenesis (MDO) for tissue replacement after oncologic resection or for defects caused by osteoradionecrosis has been described but, in fact, has seen limited clinical utility. Previous laboratory work has shown that radiation (XRT) causes decreased union formation, decreased cellularity, and decreased mineral density in an animal model of MDO. Our global hypothesis is that radiation-induced bone damage is partly driven by the pathologic depletion of both the number and function of osteogenic cells. Parathyroid hormone (PTH) is a U.S. Food and Drug Administration–approved anabolic hormonal therapy that has demonstrated efficacy for increasing bone mineral density for the treatment of osteoporosis. We postulate that intermittent systemic administration of PTH will serve as an anabolic stimulant to cellular function that will act to reverse radiation-induced damage and enhance bone regeneration in a murine mandibular model of DO.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A total of 20 isogenic male Lewis rats were randomly assigned into 3 groups. Group 1 (XRT-DO, <em>n</em> = 7) and group 2 (XRT-DO-PTH, <em>n</em> = 5) received a human bioequivalent dose of 70 Gy fractionated over 5 days. All groups including group 3 (DO, <em>n</em> = 8) underwent a left unilateral mandibular osteotomy with bilateral external fixator placement. Four days later, mandibular DO was performed at a rate of 0.3 mm every 12 hours to reach a maximum gap of 5.1 mm. Group 2 was injected PTH (60 μg/kg) subcutaneously daily for 3 weeks following the start of MDO. On postoperative day 41, all left hemimandibles were harvested. Micro-CT at 45-μm voxel size was performed and radiomorphometrics parameters of bone mineralization were generated. Union quality was evaluated on a 4-point qualitative grading scale. Radiomorphometric data were analyzed using 1-way ANOVA, and union quality assessment was analyzed via the Mann–Whitney test. Statistical significance was considered at <em>p</em> ≤ .05.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Groups 1 and 2 appropriately demonstrated clinical signs of radiation-induced stress ranging from alopecia to mucositis. Union quality was significantly higher in PTH-treated XRT-DO animals, compared with XRT-DO group animals (<em>p</em> = .02). Mineralization metrics, including bone volume fraction (BVF) and bone mineral density (BMD), also showed statistically significant improvement. The groups that were treated with PTH showed no statistical differences in union or radiomorphometrics when compared with DO in nonradiated animals.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>We have successfully demonstrated the therapeutic efficacy of PTH to stimulate and enhance bone regeneration in our irradiated murine mandibular model of DO. Our investigation effectively resulted in statistically significant increases in BMD, BVF, and clinical unions in PTH-treated mandibles. PTH demonstrates immense potential to treat clinical pathologies where remediation of bone regeneration is essential. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
The use of mandibular distraction osteogenesis (MDO) for tissue replacement after oncologic resection or for defects caused by osteoradionecrosis has been described but, in fact, has seen limited clinical utility. Previous laboratory work has shown that radiation (XRT) causes decreased union formation, decreased cellularity, and decreased mineral density in an animal model of MDO. Our global hypothesis is that radiation-induced bone damage is partly driven by the pathologic depletion of both the number and function of osteogenic cells. Parathyroid hormone (PTH) is a U.S. Food and Drug Administration–approved anabolic hormonal therapy that has demonstrated efficacy for increasing bone mineral density for the treatment of osteoporosis. We postulate that intermittent systemic administration of PTH will serve as an anabolic stimulant to cellular function that will act to reverse radiation-induced damage and enhance bone regeneration in a murine mandibular model of DO.


Methods
A total of 20 isogenic male Lewis rats were randomly assigned into 3 groups. Group 1 (XRT-DO, n = 7) and group 2 (XRT-DO-PTH, n = 5) received a human bioequivalent dose of 70 Gy fractionated over 5 days. All groups including group 3 (DO, n = 8) underwent a left unilateral mandibular osteotomy with bilateral external fixator placement. Four days later, mandibular DO was performed at a rate of 0.3 mm every 12 hours to reach a maximum gap of 5.1 mm. Group 2 was injected PTH (60 μg/kg) subcutaneously daily for 3 weeks following the start of MDO. On postoperative day 41, all left hemimandibles were harvested. Micro-CT at 45-μm voxel size was performed and radiomorphometrics parameters of bone mineralization were generated. Union quality was evaluated on a 4-point qualitative grading scale. Radiomorphometric data were analyzed using 1-way ANOVA, and union quality assessment was analyzed via the Mann–Whitney test. Statistical significance was considered at p ≤ .05.


Results
Groups 1 and 2 appropriately demonstrated clinical signs of radiation-induced stress ranging from alopecia to mucositis. Union quality was significantly higher in PTH-treated XRT-DO animals, compared with XRT-DO group animals (p = .02). Mineralization metrics, including bone volume fraction (BVF) and bone mineral density (BMD), also showed statistically significant improvement. The groups that were treated with PTH showed no statistical differences in union or radiomorphometrics when compared with DO in nonradiated animals.


Conclusion
We have successfully demonstrated the therapeutic efficacy of PTH to stimulate and enhance bone regeneration in our irradiated murine mandibular model of DO. Our investigation effectively resulted in statistically significant increases in BMD, BVF, and clinical unions in PTH-treated mandibles. PTH demonstrates immense potential to treat clinical pathologies where remediation of bone regeneration is essential. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23209" xmlns="http://purl.org/rss/1.0/"><title>Definitive radiation therapy without chemotherapy for human papillomavirus–positive head and neck cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23209</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Definitive radiation therapy without chemotherapy for human papillomavirus–positive head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Allen M. Chen, Talia Zahra, Megan E. Daly, D. Gregory Farwell, Quang Luu, Regina Gandour-Edwards, Andrew T. Vaughan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-17T23:25:35.217802-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23209</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23209</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23209</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>To report a single institutional experience with definitive radiation therapy alone for human papillomavirus (HPV)–positive head and neck cancer.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A total of 67 patients were treated by radiation therapy alone to a median dose of 70 Gy (range, 66–72 Gy) for squamous cell carcinoma of the head and neck. Paraffin-embedded, formalin-fixed pretreatment tumor tissues were used to establish HPV-positivity using standardized techniques of immunohistochemistry for p16 and polymerase chain reaction for HPV.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In all, 23 patients with HPV-positive cancers were identified. With a median follow-up of 28 months (range, 6–85 months), the 3-year actuarial rates of overall survival, locoregional control, and distant metastasis-free survival were 83%, 90%, and 88%, respectively.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>These findings attest to the exquisite radiosensitivity of HPV-positive head and neck cancer. The clinical outcomes observed from this selected series compare favorably with historical controls treated by more intensive chemoradiotherapy strategies. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
To report a single institutional experience with definitive radiation therapy alone for human papillomavirus (HPV)–positive head and neck cancer.


Methods
A total of 67 patients were treated by radiation therapy alone to a median dose of 70 Gy (range, 66–72 Gy) for squamous cell carcinoma of the head and neck. Paraffin-embedded, formalin-fixed pretreatment tumor tissues were used to establish HPV-positivity using standardized techniques of immunohistochemistry for p16 and polymerase chain reaction for HPV.


Results
In all, 23 patients with HPV-positive cancers were identified. With a median follow-up of 28 months (range, 6–85 months), the 3-year actuarial rates of overall survival, locoregional control, and distant metastasis-free survival were 83%, 90%, and 88%, respectively.


Conclusion
These findings attest to the exquisite radiosensitivity of HPV-positive head and neck cancer. The clinical outcomes observed from this selected series compare favorably with historical controls treated by more intensive chemoradiotherapy strategies. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23186" xmlns="http://purl.org/rss/1.0/"><title>Outcome of resection of infratemporal fossa tumors</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23186</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Outcome of resection of infratemporal fossa tumors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Babak Givi, Jeffrey Liu, Mark Bilsky, Babak Mehrara, Joseph Disa, Andrea Pusic, Peter Cordeiro, Jatin P. Shah, Dennis H. Kraus</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-16T02:35:51.600257-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23186</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23186</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23186</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>A variety of tumors arise in or extend to the infratemporal fossa. We investigated the outcome of surgical management of these tumors.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We conducted a retrospective review of a craniofacial approach to resection of infratemporal fossa tumors from 1992 to 2008 in a cancer center.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Forty-three patients underwent resection of a infratemporal fossa tumors (68% men). Median age was 46 years (range, 1–81 years). The most common pathology was sarcoma (13; 30%). Twenty-two tumors (51%) were recurrent. Twenty patients (46%) underwent resection of tumors from the infratemporal fossa, 5 (12%) required resection of the anterior skull base, and 18 (42%) required orbital exenteration, additionally. Thirty-one patients (72%) required reconstruction with free tissue transfer. Twenty-seven patients (62.8%) required further treatment with radiation and/or chemotherapy. Complications occurred in 9 patients (21%). Six patients (14%) underwent salvage operations. Median follow-up was 24 months. Median overall survival and 3-year survival were 40 months and 59.6%.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Tumors involving the infratemporal fossa can be resected with acceptable morbidity and long-term survival. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
A variety of tumors arise in or extend to the infratemporal fossa. We investigated the outcome of surgical management of these tumors.


Methods
We conducted a retrospective review of a craniofacial approach to resection of infratemporal fossa tumors from 1992 to 2008 in a cancer center.


Results
Forty-three patients underwent resection of a infratemporal fossa tumors (68% men). Median age was 46 years (range, 1–81 years). The most common pathology was sarcoma (13; 30%). Twenty-two tumors (51%) were recurrent. Twenty patients (46%) underwent resection of tumors from the infratemporal fossa, 5 (12%) required resection of the anterior skull base, and 18 (42%) required orbital exenteration, additionally. Thirty-one patients (72%) required reconstruction with free tissue transfer. Twenty-seven patients (62.8%) required further treatment with radiation and/or chemotherapy. Complications occurred in 9 patients (21%). Six patients (14%) underwent salvage operations. Median follow-up was 24 months. Median overall survival and 3-year survival were 40 months and 59.6%.


Conclusion
Tumors involving the infratemporal fossa can be resected with acceptable morbidity and long-term survival. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23191" xmlns="http://purl.org/rss/1.0/"><title>In vitro cytokine release profile: Predictive value for metastatic potential in head and neck squamous cell carcinomas</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23191</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">In vitro cytokine release profile: Predictive value for metastatic potential in head and neck squamous cell carcinomas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Omar Shkeir, Maria Athanassiou–Papaefthymiou, Martian Lapadatescu, Petros Papagerakis, Michael J. Czerwinski, Carol R. Bradford, Thomas E. Carey, Mark E. P. Prince, Gregory T. Wolf, Silvana Papagerakis</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-16T02:35:36.429811-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23191</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23191</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23191</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Head and neck squamous cell carcinomas (HNSCCs) have devastating morbidity rates with mortality mainly because of metastasis.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Multiplex enzyme-linked immunosorbent assay (ELISA) to assay a variety of cytokine levels secreted by a panel of stage-specific and anatomic site-specific primary, and recurrent and metastatic University of Michigan-HNSCC cell lines over a 72-hour time course.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Conditioned medium from metastatic or recurrent HNSCC showed significantly higher amounts of interleukin (IL)-6, IL-6 receptor, tumor growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) than nonmetastatic cells or normal oral keratinocytes. Tumor necrosis factor (TNF) was only secreted by stage IV, metastatic, or recurrence-derived cell lines.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>The cytokine profile of cultured HNSCC cells suggests that high levels of IL-6 and IL-6R, TGF-β, and VEGF are significantly related with their metastatogenic potential and provide rationale for determining if serum testing for a combination of these 4 soluble factors could be of predictive value for the HNSCC tumor progression and clinical outcome. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Head and neck squamous cell carcinomas (HNSCCs) have devastating morbidity rates with mortality mainly because of metastasis.


Methods
Multiplex enzyme-linked immunosorbent assay (ELISA) to assay a variety of cytokine levels secreted by a panel of stage-specific and anatomic site-specific primary, and recurrent and metastatic University of Michigan-HNSCC cell lines over a 72-hour time course.


Results
Conditioned medium from metastatic or recurrent HNSCC showed significantly higher amounts of interleukin (IL)-6, IL-6 receptor, tumor growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) than nonmetastatic cells or normal oral keratinocytes. Tumor necrosis factor (TNF) was only secreted by stage IV, metastatic, or recurrence-derived cell lines.


Conclusion
The cytokine profile of cultured HNSCC cells suggests that high levels of IL-6 and IL-6R, TGF-β, and VEGF are significantly related with their metastatogenic potential and provide rationale for determining if serum testing for a combination of these 4 soluble factors could be of predictive value for the HNSCC tumor progression and clinical outcome. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23197" xmlns="http://purl.org/rss/1.0/"><title>Surgical extent of central lymph node dissection in clinically node-negative papillary thyroid cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23197</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Surgical extent of central lymph node dissection in clinically node-negative papillary thyroid cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wan Wook Kim, Ho Yong Park, Jin Hyang Jung</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-16T02:35:00.243848-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23197</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23197</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23197</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The indications for elective bilateral central node dissection for patients with unilateral papillary thyroid carcinoma (PTC) who are clinically node negative are still not verified. We investigated the predictive factors of lymph node metastasis and formulated guidelines for surgical extent.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>From 2004 to 2009, 325 patients diagnosed with unilateral PTC who had undergone total thyroidectomy with bilateral central lymph node dissection (CLND) were enrolled retrospectively.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Central node metastasis was found in 45.2%, ipsilateral and contralateral lymph node metastasis was found in 40.0% and 16.0%, respectively. Tumor size larger than 1.0 cm and extrathyroidal extension were significant factors in predicting ipsilateral node metastasis (<em>p</em> = .004, &lt; .001, respectively), and extrathyroidal extension and ipsilateral lymph node metastasis predicted contralateral node metastasis in multivariable analysis (<em>p</em> = .039, &lt; .001, respectively).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Elective bilateral central node dissection may be considered in unilateral PTC with extrathyroidal extension or ipsilateral node metastasis. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
The indications for elective bilateral central node dissection for patients with unilateral papillary thyroid carcinoma (PTC) who are clinically node negative are still not verified. We investigated the predictive factors of lymph node metastasis and formulated guidelines for surgical extent.


Methods
From 2004 to 2009, 325 patients diagnosed with unilateral PTC who had undergone total thyroidectomy with bilateral central lymph node dissection (CLND) were enrolled retrospectively.


Results
Central node metastasis was found in 45.2%, ipsilateral and contralateral lymph node metastasis was found in 40.0% and 16.0%, respectively. Tumor size larger than 1.0 cm and extrathyroidal extension were significant factors in predicting ipsilateral node metastasis (p = .004, &lt; .001, respectively), and extrathyroidal extension and ipsilateral lymph node metastasis predicted contralateral node metastasis in multivariable analysis (p = .039, &lt; .001, respectively).


Conclusion
Elective bilateral central node dissection may be considered in unilateral PTC with extrathyroidal extension or ipsilateral node metastasis. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23199" xmlns="http://purl.org/rss/1.0/"><title>Gastrostomy tube placement in patients with hypopharyngeal cancer treated with radiotherapy or chemoradiotherapy: Factors affecting placement and dependence</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23199</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Gastrostomy tube placement in patients with hypopharyngeal cancer treated with radiotherapy or chemoradiotherapy: Factors affecting placement and dependence</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mihir K. Bhayani, Katherine A. Hutcheson, Denise A. Barringer, Dianna B. Roberts, Jan S. Lewin, Stephen Y. Lai</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-16T02:34:44.97086-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23199</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23199</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23199</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Placement of gastrostomy tubes (g-tubes) in patients with hypopharyngeal cancers undergoing radiation and chemotherapy is generally empirically determined. We examined our experience to identify predictive factors for g-tube placement and length of dependence.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We performed a retrospective review of all patients with primary hypopharyngeal cancer treated with nonsurgical modalities at a tertiary care center between 2002 and 2008. Rates of g-tube placement and length of dependence on enteral feedings were analyzed in relationship to multiple risk factors.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Forty-three patients with hypopharyngeal primary tumors (77%) who had a complete response at the primary site after treatment were included. Thirteen patients (30%) never required g-tube placement. At 1-year follow-up, 11 patients (28%) maintained a g-tube. No clinical variables were significantly associated with g-tube placement. Duration of g-tube dependence was significantly longer in patients with a posterior hypopharyngeal wall primary tumors (<em>p</em> = .026), current smokers (<em>p</em> = .001), and patients with &gt;40 pack-years (<em>p</em> = .010). The duration of g-tube dependence was significantly shorter in those who maintained oral intake at the end of treatment (<em>p</em> = .05), and those who reported adherence to dysphagia exercise regimens (<em>p</em> = .048).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Approximately one third of patients with hypopharyngeal tumors treated on organ preservation regimens may be able to avoid g-tube placement, but further research is needed to identify clinical factors that predict g-tube placement in this population. A posterior hypopharyngeal wall primary and smoking history correlated with longer gastrostomy tube dependence. Adherence to aggressive targeted swallowing exercise regimens may help to prevent long-term dependence on feeding tubes. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Placement of gastrostomy tubes (g-tubes) in patients with hypopharyngeal cancers undergoing radiation and chemotherapy is generally empirically determined. We examined our experience to identify predictive factors for g-tube placement and length of dependence.


Methods
We performed a retrospective review of all patients with primary hypopharyngeal cancer treated with nonsurgical modalities at a tertiary care center between 2002 and 2008. Rates of g-tube placement and length of dependence on enteral feedings were analyzed in relationship to multiple risk factors.


Results
Forty-three patients with hypopharyngeal primary tumors (77%) who had a complete response at the primary site after treatment were included. Thirteen patients (30%) never required g-tube placement. At 1-year follow-up, 11 patients (28%) maintained a g-tube. No clinical variables were significantly associated with g-tube placement. Duration of g-tube dependence was significantly longer in patients with a posterior hypopharyngeal wall primary tumors (p = .026), current smokers (p = .001), and patients with &gt;40 pack-years (p = .010). The duration of g-tube dependence was significantly shorter in those who maintained oral intake at the end of treatment (p = .05), and those who reported adherence to dysphagia exercise regimens (p = .048).


Conclusion
Approximately one third of patients with hypopharyngeal tumors treated on organ preservation regimens may be able to avoid g-tube placement, but further research is needed to identify clinical factors that predict g-tube placement in this population. A posterior hypopharyngeal wall primary and smoking history correlated with longer gastrostomy tube dependence. Adherence to aggressive targeted swallowing exercise regimens may help to prevent long-term dependence on feeding tubes. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23200" xmlns="http://purl.org/rss/1.0/"><title>Gastrostomy tube placement in patients with oropharyngeal carcinoma treated with radiotherapy or chemoradiotherapy: Factors affecting placement and dependence</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23200</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Gastrostomy tube placement in patients with oropharyngeal carcinoma treated with radiotherapy or chemoradiotherapy: Factors affecting placement and dependence</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mihir K. Bhayani, Katherine A. Hutcheson, Denise A. Barringer, Asher Lisec, Clare P. Alvarez, Dianna B. Roberts, Stephen Y. Lai, Jan S. Lewin</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-01-16T02:34:29.93305-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23200</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23200</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23200</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Although many patients require nutritional support during radiotherapy or chemoradiotherapy for oropharyngeal cancer, little is known regarding the risk factors that predispose to gastrostomy tube (g-tube) placement and prolonged dependence, or the therapeutic interventions that may abrogate these effects.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We performed a retrospective medical chart review of patients who were treated for primary oropharyngeal cancer at a tertiary care center from 2003 to 2008. Patients who had a complete response at the primary site at 1-year posttreatment were included. G-tube placement and dependence ≥6 months were evaluated in relationship to site and stage of primary tumor, baseline characteristics, treatment type, smoking status, and swallowing intervention.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>We evaluated 474 patients (79%) with oropharyngeal cancer; 215 patients (40%) had concurrent chemotherapy, 73 patients (15%) had induction chemotherapy, and 69 patients (15%) had induction chemotherapy followed by concurrent chemotherapy. Two hundred ninety-three patients (62%) received g-tubes, of which 238 (81%) received the g-tube during radiation. At 1-year follow-up, 41 patients (9%) remained dependent on enteral feedings. Placement of g-tubes and prolonged g-tube dependence were significantly more likely in patients with T3 to 4 tumors (<em>p</em> &lt; .001), baseline self-reported dysphagia (<em>p</em> &lt; .001), odynophagia (<em>p</em> &lt; .001), &gt;10% baseline weight loss (<em>p</em> &lt; .001), and in those treated with concurrent chemoradiotherapy. Patients who reported adherence to exercises had significantly lower rates of g-tube placement (<em>p</em> &lt; .001), and duration of dependence was significantly shorter in those who reported adherence to swallowing exercises (<em>p</em> &lt; .001).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Almost 40% of patients with oropharyngeal cancer treated with nonsurgical organ preservation modalities may avoid feeding tube placement. Factors that predispose to g-tube placement and prolonged dependence include T3 to T4 tumors, concurrent chemotherapy, current smoking status, and baseline swallowing dysfunction or weight loss. Adherence to an aggressive swallowing regimen may reduce long-term dependence on enteral nutrition and limit the rate of g-tube placement overall. © 2013 Wiley Periodicals, Inc. Head Neck, 2013</p></div></div>
]]></content:encoded><description>


Background
Although many patients require nutritional support during radiotherapy or chemoradiotherapy for oropharyngeal cancer, little is known regarding the risk factors that predispose to gastrostomy tube (g-tube) placement and prolonged dependence, or the therapeutic interventions that may abrogate these effects.


Methods
We performed a retrospective medical chart review of patients who were treated for primary oropharyngeal cancer at a tertiary care center from 2003 to 2008. Patients who had a complete response at the primary site at 1-year posttreatment were included. G-tube placement and dependence ≥6 months were evaluated in relationship to site and stage of primary tumor, baseline characteristics, treatment type, smoking status, and swallowing intervention.


Results
We evaluated 474 patients (79%) with oropharyngeal cancer; 215 patients (40%) had concurrent chemotherapy, 73 patients (15%) had induction chemotherapy, and 69 patients (15%) had induction chemotherapy followed by concurrent chemotherapy. Two hundred ninety-three patients (62%) received g-tubes, of which 238 (81%) received the g-tube during radiation. At 1-year follow-up, 41 patients (9%) remained dependent on enteral feedings. Placement of g-tubes and prolonged g-tube dependence were significantly more likely in patients with T3 to 4 tumors (p &lt; .001), baseline self-reported dysphagia (p &lt; .001), odynophagia (p &lt; .001), &gt;10% baseline weight loss (p &lt; .001), and in those treated with concurrent chemoradiotherapy. Patients who reported adherence to exercises had significantly lower rates of g-tube placement (p &lt; .001), and duration of dependence was significantly shorter in those who reported adherence to swallowing exercises (p &lt; .001).


Conclusion
Almost 40% of patients with oropharyngeal cancer treated with nonsurgical organ preservation modalities may avoid feeding tube placement. Factors that predispose to g-tube placement and prolonged dependence include T3 to T4 tumors, concurrent chemotherapy, current smoking status, and baseline swallowing dysfunction or weight loss. Adherence to an aggressive swallowing regimen may reduce long-term dependence on enteral nutrition and limit the rate of g-tube placement overall. © 2013 Wiley Periodicals, Inc. Head Neck, 2013

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23201" xmlns="http://purl.org/rss/1.0/"><title>Characteristics of radiation-induced sensorineural hearing loss in head and neck cancer: A systematic review</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23201</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Characteristics of radiation-induced sensorineural hearing loss in head and neck cancer: A systematic review</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mario Mujica–Mota, Sofia Waissbluth, Sam J. Daniel</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-12-22T07:16:39.515544-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23201</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23201</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23201</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Patients receiving radiotherapy (RT) for head and neck tumors are at risk of developing sensorineural hearing loss. The objective of this study was to analyze the literature regarding sensorineural hearing loss after RT for head and neck cancer.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Seven databases were searched to identify eligible studies. Eligible articles were independently assessed for quality by 2 authors.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Fourteen articles were evaluated. There was considerable heterogeneity among studies. The reported incidence of sensorineural hearing loss (SNHL) varied from 0% to 85% for the speech frequencies and from 27% to 95% for high frequencies. As the follow-up increased, an increase in the incidence of SNHL was observed. The minimum cochlear dose reported to be a risk factor for SNHL was 45 Gy.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>High quality literature in the topic is lacking. Radiation-induced SNHL is progressive, permanent, and dose-dependent. Total dose and follow-up time are important factors affecting incidence rates. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Patients receiving radiotherapy (RT) for head and neck tumors are at risk of developing sensorineural hearing loss. The objective of this study was to analyze the literature regarding sensorineural hearing loss after RT for head and neck cancer.


Methods
Seven databases were searched to identify eligible studies. Eligible articles were independently assessed for quality by 2 authors.


Results
Fourteen articles were evaluated. There was considerable heterogeneity among studies. The reported incidence of sensorineural hearing loss (SNHL) varied from 0% to 85% for the speech frequencies and from 27% to 95% for high frequencies. As the follow-up increased, an increase in the incidence of SNHL was observed. The minimum cochlear dose reported to be a risk factor for SNHL was 45 Gy.


Conclusions
High quality literature in the topic is lacking. Radiation-induced SNHL is progressive, permanent, and dose-dependent. Total dose and follow-up time are important factors affecting incidence rates. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23202" xmlns="http://purl.org/rss/1.0/"><title>Emerging insights into head and neck cancer metastasis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23202</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Emerging insights into head and neck cancer metastasis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Clint T. Allen, Jonathan H. Law, Gavin P. Dunn, Ravindra Uppaluri</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-12-22T07:16:27.484032-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23202</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23202</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23202</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Basic Science Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The purpose of this review was to provide biological concepts of head and neck cancer metastasis. To attain this goal, we analyzed peer-reviewed articles related to head and neck cancer metastasis obtained though PubMed and archived articles. Articles related to the biologic principles of head and neck cancer metastasis were reviewed and summarized. As locoregional control has improved for patients with head and neck cancer, rates of distant metastasis have not decreased. As patients live longer, many will die of complications related to the development of disease at sites below the clavicles. Emerging evidence now suggests a more complicated framework of metastatic behavior for head and neck cancer. Here, we review the role of regional lymph nodes in containing advanced head and neck cancer, evidence for active as opposed to passive tumor cell metastasis, and clinical implications these concepts have on both treatment of head and neck cancer and future research. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div>
]]></content:encoded><description>

The purpose of this review was to provide biological concepts of head and neck cancer metastasis. To attain this goal, we analyzed peer-reviewed articles related to head and neck cancer metastasis obtained though PubMed and archived articles. Articles related to the biologic principles of head and neck cancer metastasis were reviewed and summarized. As locoregional control has improved for patients with head and neck cancer, rates of distant metastasis have not decreased. As patients live longer, many will die of complications related to the development of disease at sites below the clavicles. Emerging evidence now suggests a more complicated framework of metastatic behavior for head and neck cancer. Here, we review the role of regional lymph nodes in containing advanced head and neck cancer, evidence for active as opposed to passive tumor cell metastasis, and clinical implications these concepts have on both treatment of head and neck cancer and future research. © 2012 Wiley Periodicals, Inc. Head Neck, 2012
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23206" xmlns="http://purl.org/rss/1.0/"><title>In situ mantle cell lymphoma in the nasopharynx</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23206</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">In situ mantle cell lymphoma in the nasopharynx</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Triantafyllia Koletsa, Konstantinos Markou, Sevasti Ouzounidou, Fani Tsiompanou, Georgios Karkavelas, Ioannis Kostopoulos</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-12-22T07:16:14.050103-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23206</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23206</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23206</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Mantle cell lymphoma (MCL) is a B-cell neoplasm with an aggressive clinical course. Recently, an indolent type of MCL has been described under the term in situ MCL.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>We report a case of a 70-year-old woman who presented with nasal obstruction. A mass, located in the nasopharynx, was found. Histologic examination revealed lymphoid hyperplasia characterized by CD5 and cyclin D1–positive mantle zone cells, findings consistent with in situ MCL. Three years later, a new biopsy was performed, which showed the same histologic and immunohistochemical (IHC) findings to those observed in the first biopsy. The diagnosis of in situ MCL was confirmed by fluorescence in situ hybridization (FISH) analysis for t(11;14). Since then, the patient has remained free of an overt lymphoma.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>In situ MCL may be observed in the nasopharynx, and it would be appropriate to perform cyclin D1 immunostain in cases with marked follicular hyperplasia accompanied by clinical suspicion of lymphoma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Mantle cell lymphoma (MCL) is a B-cell neoplasm with an aggressive clinical course. Recently, an indolent type of MCL has been described under the term in situ MCL.


Methods and Results
We report a case of a 70-year-old woman who presented with nasal obstruction. A mass, located in the nasopharynx, was found. Histologic examination revealed lymphoid hyperplasia characterized by CD5 and cyclin D1–positive mantle zone cells, findings consistent with in situ MCL. Three years later, a new biopsy was performed, which showed the same histologic and immunohistochemical (IHC) findings to those observed in the first biopsy. The diagnosis of in situ MCL was confirmed by fluorescence in situ hybridization (FISH) analysis for t(11;14). Since then, the patient has remained free of an overt lymphoma.


Conclusions
In situ MCL may be observed in the nasopharynx, and it would be appropriate to perform cyclin D1 immunostain in cases with marked follicular hyperplasia accompanied by clinical suspicion of lymphoma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23158" xmlns="http://purl.org/rss/1.0/"><title>Safety of thromboprophylaxis after oncologic head and neck surgery. Study of 1018 patients</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23158</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Safety of thromboprophylaxis after oncologic head and neck surgery. Study of 1018 patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Haim Gavriel, Evan Thompson, Stephen Kleid, SorWay Chan, Andrew Sizeland</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-20T09:40:41.210889-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23158</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23158</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23158</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Deep venous thrombosis (DVT) and pulmonary embolism (PE) are significantly reduced with appropriate use of thromboprophylaxis and scarcely evaluated in patients undergoing oncologic head and neck surgery (OHNS).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective study on 1018 patients who underwent oncologic head and neck surgery. The records of patients with venous thromboembolism (VTE) or postoperative bleeding were reviewed for the cancer grading, management, previous known coagulopathy, anticoagulation, and general demographics.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Of a total of 1018 patients undergoing oncologic head and neck surgery, 450 patients had no chemoprophylaxis and 568 received it. The rate of a VTE event in our cohort was 0%. Twelve patients presented with hematoma or bleeding from the surgical site, 11 in the group that received chemoprophylaxis (<em>p</em> = .006).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Our analysis shows no benefit from chemoprophylaxis in oncologic head and neck surgery patients, with no VTE events. Our analysis shows higher rates of morbid side effects from using chemoprophylaxis, and we therefore conclude that chemoprophylaxis should not be routinely used. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Deep venous thrombosis (DVT) and pulmonary embolism (PE) are significantly reduced with appropriate use of thromboprophylaxis and scarcely evaluated in patients undergoing oncologic head and neck surgery (OHNS).


Methods
A retrospective study on 1018 patients who underwent oncologic head and neck surgery. The records of patients with venous thromboembolism (VTE) or postoperative bleeding were reviewed for the cancer grading, management, previous known coagulopathy, anticoagulation, and general demographics.


Results
Of a total of 1018 patients undergoing oncologic head and neck surgery, 450 patients had no chemoprophylaxis and 568 received it. The rate of a VTE event in our cohort was 0%. Twelve patients presented with hematoma or bleeding from the surgical site, 11 in the group that received chemoprophylaxis (p = .006).


Conclusions
Our analysis shows no benefit from chemoprophylaxis in oncologic head and neck surgery patients, with no VTE events. Our analysis shows higher rates of morbid side effects from using chemoprophylaxis, and we therefore conclude that chemoprophylaxis should not be routinely used. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23181" xmlns="http://purl.org/rss/1.0/"><title>High symptom burden prior to radiation therapy for head and neck cancer: A patient-reported outcomes study</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23181</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">High symptom burden prior to radiation therapy for head and neck cancer: A patient-reported outcomes study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">G. Brandon Gunn, Tito R. Mendoza, Clifton D. Fuller, Ibrahima Gning, Steven J. Frank, Beth M. Beadle, Ehab Y. Hanna, Charles Lu, Charles S. Cleeland, David I. Rosenthal</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-20T09:40:07.908427-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23181</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23181</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23181</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>As a first step toward developing effective strategies to control symptoms associated with head and neck cancer (head and neck cancer) and its treatment, we sought to describe the pattern of symptoms experienced before radiation therapy.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Subjects completed the MD Anderson Symptom Inventory–Head and Neck Module before beginning radiation therapy.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In all, 270 patients participated. Symptom severity and interference varied between treatment-naïve patients and those with prior treatment. Cluster analyses revealed that 33% of patients had high symptom burden. Symptoms most often rated moderate-to-severe were fatigue, sleep disturbance, distress, pain, and problems chewing and swallowing. Poorer performance status, higher T classification, and receipt of previous treatment correlated with higher symptom burden.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>A substantial proportion of patients were experiencing high symptom burden. Because few interventions currently exist for several of the most problematic symptoms, research in symptom reduction that targets the pattern of symptoms described here is greatly needed. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
As a first step toward developing effective strategies to control symptoms associated with head and neck cancer (head and neck cancer) and its treatment, we sought to describe the pattern of symptoms experienced before radiation therapy.


Methods
Subjects completed the MD Anderson Symptom Inventory–Head and Neck Module before beginning radiation therapy.


Results
In all, 270 patients participated. Symptom severity and interference varied between treatment-naïve patients and those with prior treatment. Cluster analyses revealed that 33% of patients had high symptom burden. Symptoms most often rated moderate-to-severe were fatigue, sleep disturbance, distress, pain, and problems chewing and swallowing. Poorer performance status, higher T classification, and receipt of previous treatment correlated with higher symptom burden.


Conclusions
A substantial proportion of patients were experiencing high symptom burden. Because few interventions currently exist for several of the most problematic symptoms, research in symptom reduction that targets the pattern of symptoms described here is greatly needed. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23182" xmlns="http://purl.org/rss/1.0/"><title>Sharing a diagnosis of HPV-related head and neck cancer: The emotions, the confusion, and what patients want to know</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23182</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Sharing a diagnosis of HPV-related head and neck cancer: The emotions, the confusion, and what patients want to know</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shrujal S. Baxi, Andrew G. Shuman, Geoffrey W. Corner, Elyse Shuk, Eric J. Sherman, Elena B. Elkin, Jennifer L. Hay, David G. Pfister</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-20T09:39:51.286227-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23182</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23182</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23182</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Oropharyngeal cancers are increasingly associated with human papillomavirus (HPV). Little is known about the experience of patients receiving this diagnosis.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Semistructured interviews were conducted with ten survivors of HPV-related oropharyngeal cancer. The interviews were transcribed, and recurring themes were identified.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Physicians were a trusted source of information regarding HPV. Framing the diagnosis in terms of prognosis resonated with patients. The uncertainty about transmission, latency, and communicability colored the dialogue about HPV. Despite some understanding of prevalence and transmission, patients worried about their partner's risk. Patients sought information about HPV on the Internet, but it was not easily navigable. Emotional reactions to the diagnosis remained mostly cancer-centric rather than HPV-centric. A patient-education handout was developed in response to patient questions.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Additional educational resources explaining the facts about HPV in HNSCC in a consistent way including content of highest priority to patients may improve understanding of HPV. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Oropharyngeal cancers are increasingly associated with human papillomavirus (HPV). Little is known about the experience of patients receiving this diagnosis.


Methods
Semistructured interviews were conducted with ten survivors of HPV-related oropharyngeal cancer. The interviews were transcribed, and recurring themes were identified.


Results
Physicians were a trusted source of information regarding HPV. Framing the diagnosis in terms of prognosis resonated with patients. The uncertainty about transmission, latency, and communicability colored the dialogue about HPV. Despite some understanding of prevalence and transmission, patients worried about their partner's risk. Patients sought information about HPV on the Internet, but it was not easily navigable. Emotional reactions to the diagnosis remained mostly cancer-centric rather than HPV-centric. A patient-education handout was developed in response to patient questions.


Conclusions
Additional educational resources explaining the facts about HPV in HNSCC in a consistent way including content of highest priority to patients may improve understanding of HPV. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23183" xmlns="http://purl.org/rss/1.0/"><title>Speech rehabilitation during the first year after total laryngectomy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23183</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Speech rehabilitation during the first year after total laryngectomy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susanne Singer, Dorit Wollbrück, Andreas Dietz, Juliane Schock, Friedemann Pabst, Hans-Joachim Vogel, Jens Oeken, Annett Sandner, Sven Koscielny, Karl Hormes, Kerstin Breitenstein, Heike Richter, Andreas Deckelmann, Sarah Cook, Michael Fuchs, Sylvia Meuret</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-20T09:39:36.308755-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23183</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23183</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23183</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Gaining a new voice is one of the major aims after total laryngectomy. The objective of this study was to describe the process and results of speech rehabilitation during the first year after surgery.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Speech intelligibility was measured 6 months (<em>n</em> = 273) and 1 year (<em>n</em> = 225) after total laryngectomy.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Objective (23.4 to 47.5 points, <em>p</em> &lt; .0001) and subjective (51.6 to 64.7 points, <em>p</em> &lt; .0001) speech intelligibility improved between 6 months and 1 year after total laryngectomy. Patients who used tracheoesophageal puncture (TEP) had the best results in speech intelligibility 6 months and 1 year after total laryngectomy. In all, 12% of the patients who used TEP initially no longer used it 1 year later. Patients who had received rehabilitation had better objective speech intelligibility than those who did not.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Speech improves considerably between 6 months and 1 year after total laryngectomy. Nonattendance of rehabilitation is associated with a worse functional outcome in speech rehabilitation. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Gaining a new voice is one of the major aims after total laryngectomy. The objective of this study was to describe the process and results of speech rehabilitation during the first year after surgery.


Methods
Speech intelligibility was measured 6 months (n = 273) and 1 year (n = 225) after total laryngectomy.


Results
Objective (23.4 to 47.5 points, p &lt; .0001) and subjective (51.6 to 64.7 points, p &lt; .0001) speech intelligibility improved between 6 months and 1 year after total laryngectomy. Patients who used tracheoesophageal puncture (TEP) had the best results in speech intelligibility 6 months and 1 year after total laryngectomy. In all, 12% of the patients who used TEP initially no longer used it 1 year later. Patients who had received rehabilitation had better objective speech intelligibility than those who did not.


Conclusions
Speech improves considerably between 6 months and 1 year after total laryngectomy. Nonattendance of rehabilitation is associated with a worse functional outcome in speech rehabilitation. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23187" xmlns="http://purl.org/rss/1.0/"><title>Continuous intraoperative vagus nerve stimulation for identification of imminent recurrent laryngeal nerve injury</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23187</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Continuous intraoperative vagus nerve stimulation for identification of imminent recurrent laryngeal nerve injury</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rick Schneider, Gregory W. Randolph, Carsten Sekulla, Eimear Phelan, Phuong Nguyen Thanh, Michael Bucher, Andreas Machens, Henning Dralle, Kerstin Lorenz</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-20T09:39:15.554867-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23187</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23187</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23187</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Conventional intraoperative nerve monitoring, predicated on intermittent stimulation, can predict recurrent laryngeal nerve (RLN) palsy only after the damage has been done.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Fifty-two patients (52 nerves at risk) who underwent continuous intraoperative nerve monitoring (CIONM) for thyroid surgery via vagus nerve stimulation had their electromyographic (EMG) tracings recorded and correlated with surgical maneuvers and postoperative RLN function.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>There was 1 imminent loss of signal (LOS) with intraoperative signal recovery and there were 4 losses of signal with corresponding unilateral transient RLN palsy. When EMG amplitude decreased &gt;50% and EMG latency increased &gt;10%, LOS and postoperative RLN palsy were noted in 4 of 8 patients (50%) who had multiple combined events. In 9 of 13 patients (70%) who developed adverse EMG changes, modification of the causative surgical maneuver resulted in recovery of those EMG changes and aversion of impending RLN palsy.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>CIONM reliably signaled impending nerve injury, enabling immediate corrective action. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Conventional intraoperative nerve monitoring, predicated on intermittent stimulation, can predict recurrent laryngeal nerve (RLN) palsy only after the damage has been done.


Methods
Fifty-two patients (52 nerves at risk) who underwent continuous intraoperative nerve monitoring (CIONM) for thyroid surgery via vagus nerve stimulation had their electromyographic (EMG) tracings recorded and correlated with surgical maneuvers and postoperative RLN function.


Results
There was 1 imminent loss of signal (LOS) with intraoperative signal recovery and there were 4 losses of signal with corresponding unilateral transient RLN palsy. When EMG amplitude decreased &gt;50% and EMG latency increased &gt;10%, LOS and postoperative RLN palsy were noted in 4 of 8 patients (50%) who had multiple combined events. In 9 of 13 patients (70%) who developed adverse EMG changes, modification of the causative surgical maneuver resulted in recovery of those EMG changes and aversion of impending RLN palsy.


Conclusion
CIONM reliably signaled impending nerve injury, enabling immediate corrective action. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23198" xmlns="http://purl.org/rss/1.0/"><title>Reliability and validity of the Italian self-evaluation of communication experiences after laryngeal cancer questionnaire</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23198</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Reliability and validity of the Italian self-evaluation of communication experiences after laryngeal cancer questionnaire</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antonio Schindler, Francesco Mozzanica, Francesca Brignoli, Patrizia Maruzzi, Paul Evitts, Francesco Ottaviani</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-20T09:38:53.837503-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23198</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23198</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23198</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The Self-Evaluation of Communication Experiences after Laryngeal Cancer (SECEL) questionnaire assesses the impact of total laryngectomy on communication-related quality of life (QOL). This study evaluates the Italian version of the SECEL (I-SECEL), including reliability, concurrent validity, and differences in scores between patients who undergo either total laryngectomy or partial laryngectomy.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Eighty patients who underwent either total laryngectomy or partial laryngectomy completed the I-SECEL twice and the Voice Handicap Index (VHI) and Short Form Health Survey (SF-36) questionnaires once. Voice recordings were used for objective and perceptual assessment.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The I-SECEL demonstrated good test–retest reliability and internal consistency for 2 of 3 subscales. Correlations were moderate to strong between most of the I-SECEL scales and the VHI/SF-36 scales. The I-SECEL scales demonstrated moderate associations with most perceptual and objective measures.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Preliminary evidence supports the convergent validity, test-retest reliability, and internal consistency of the I-SECEL, notwithstanding low internal consistency and test–retest reliability for 1 subscale. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The Self-Evaluation of Communication Experiences after Laryngeal Cancer (SECEL) questionnaire assesses the impact of total laryngectomy on communication-related quality of life (QOL). This study evaluates the Italian version of the SECEL (I-SECEL), including reliability, concurrent validity, and differences in scores between patients who undergo either total laryngectomy or partial laryngectomy.


Methods
Eighty patients who underwent either total laryngectomy or partial laryngectomy completed the I-SECEL twice and the Voice Handicap Index (VHI) and Short Form Health Survey (SF-36) questionnaires once. Voice recordings were used for objective and perceptual assessment.


Results
The I-SECEL demonstrated good test–retest reliability and internal consistency for 2 of 3 subscales. Correlations were moderate to strong between most of the I-SECEL scales and the VHI/SF-36 scales. The I-SECEL scales demonstrated moderate associations with most perceptual and objective measures.


Conclusion
Preliminary evidence supports the convergent validity, test-retest reliability, and internal consistency of the I-SECEL, notwithstanding low internal consistency and test–retest reliability for 1 subscale. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23195" xmlns="http://purl.org/rss/1.0/"><title>Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23195</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jin Young Kwak, Jong Ju Jeong, Sang–Wook Kang, Seulkee Park, Jong Rak Choi, Seo–Jin Park, Eun Kyung Kim, Woong Youn Chung</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-17T00:02:38.902486-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23195</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23195</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23195</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The BRAF<sup>V600E</sup> mutation can be detected peripherally in the serum of patients with thyroid cancer. The purpose of this study was to establish the value of detecting the peripheral BRAF<sup>V600E</sup> mutation as a serum tumor marker in this population.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In this study, we obtained 94 serum samples from patients with papillary thyroid cancer positive for the BRAF<sup>V600E</sup> mutation in the tumor itself. The serum samples were analyzed for BRAF<sup>V600E</sup> mutation using real-time polymerase chain reaction (PCR).</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Sixty-seven patients (71.3%) had papillary thyroid microcarcinoma and 26 patients (27.7%) had underlying lymphocytic thyroiditis. Forty-three patients (45.7%) were found to have stage III or stage IV thyroid cancer. None of the patients had a detectable serum BRAF<sup>V600E</sup> mutation.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>We were unable to identify peripheral BRAF<sup>V600E</sup> mutations in patients with papillary thyroid cancer using real-time PCR. Further studies will be needed to validate our results using various diagnostic methods. © Wiley Periodicals Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The BRAFV600E mutation can be detected peripherally in the serum of patients with thyroid cancer. The purpose of this study was to establish the value of detecting the peripheral BRAFV600E mutation as a serum tumor marker in this population.


Methods
In this study, we obtained 94 serum samples from patients with papillary thyroid cancer positive for the BRAFV600E mutation in the tumor itself. The serum samples were analyzed for BRAFV600E mutation using real-time polymerase chain reaction (PCR).


Results
Sixty-seven patients (71.3%) had papillary thyroid microcarcinoma and 26 patients (27.7%) had underlying lymphocytic thyroiditis. Forty-three patients (45.7%) were found to have stage III or stage IV thyroid cancer. None of the patients had a detectable serum BRAFV600E mutation.


Conclusion
We were unable to identify peripheral BRAFV600E mutations in patients with papillary thyroid cancer using real-time PCR. Further studies will be needed to validate our results using various diagnostic methods. © Wiley Periodicals Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23204" xmlns="http://purl.org/rss/1.0/"><title>Clinical ethics consultation in patients with head and neck cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23204</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clinical ethics consultation in patients with head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrew G. Shuman, Mary S. McCabe, Joseph J. Fins, Dennis H. Kraus, Jatin P. Shah, Snehal G. Patel</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-17T00:02:24.892856-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23204</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23204</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23204</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to describe the impact of clinical ethics consultations among patients with head and neck cancer in order to better anticipate and manage clinical challenges.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A database was queried to identify patients with head and neck cancer for whom ethics consultation was performed at a comprehensive cancer center (<em>n</em> = 14). Information from the database was verified via data abstraction and analyzed qualitatively and quantitatively.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Common requests for ethics consultation involved code status (6 of 14) and withdrawal/withholding life-sustaining treatments (6 of 14). Common contextual features were interpersonal conflicts (6 of 14) and communication barriers (5 of 14). Airway management concerns were frequent (5 of 14). Whereas 21% of patients had do not resuscitate (DNR) orders before ethics consultation, 79% were DNR subsequently.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Ethics consultations among patients with head and neck cancer reflect distinctive complexities inherent to their disease, but are entirely consistent with global clinical ethical themes. Consideration of communication barriers, social isolation/stigma, symptom control, and airway management are critical. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to describe the impact of clinical ethics consultations among patients with head and neck cancer in order to better anticipate and manage clinical challenges.


Methods
A database was queried to identify patients with head and neck cancer for whom ethics consultation was performed at a comprehensive cancer center (n = 14). Information from the database was verified via data abstraction and analyzed qualitatively and quantitatively.


Results
Common requests for ethics consultation involved code status (6 of 14) and withdrawal/withholding life-sustaining treatments (6 of 14). Common contextual features were interpersonal conflicts (6 of 14) and communication barriers (5 of 14). Airway management concerns were frequent (5 of 14). Whereas 21% of patients had do not resuscitate (DNR) orders before ethics consultation, 79% were DNR subsequently.


Conclusion
Ethics consultations among patients with head and neck cancer reflect distinctive complexities inherent to their disease, but are entirely consistent with global clinical ethical themes. Consideration of communication barriers, social isolation/stigma, symptom control, and airway management are critical. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23096" xmlns="http://purl.org/rss/1.0/"><title>Prognostic significance of disease-free interval in head and neck cutaneous squamous cell carcinoma with nodal metastases</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23096</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prognostic significance of disease-free interval in head and neck cutaneous squamous cell carcinoma with nodal metastases</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ardalan Ebrahimi, Jonathan R. Clark, Nazanin Ahmadi, Carsten E. Palme, Gary J. Morgan, Michael J. Veness</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-14T00:23:52.232013-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23096</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23096</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23096</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to determine whether the disease-free interval (DFI) between treatment of primary head and neck cutaneous squamous cell carcinoma (SCC) and the development of regional metastases is an independent prognostic factor.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective analysis of 229 patients with metastatic nodal head and neck cutaneous SCC, treated with curative intent by surgery ± adjuvant radiotherapy was conducted.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>After adjusting for the effect of nodal staging, extracapsular spread, involved margins, adjuvant radiotherapy, and immunosuppression, a short DFI (≤9 months vs &gt;9 months) was a significant predictor of disease-related mortality (hazard ratio [HR], 3.0; 95% confidence interval [CI], 1.4–6.5; <em>p</em> = .004) and locoregional relapse (HR, 2.0; 95% CI, 1.1–4.0; <em>p</em> = .044).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>The DFI is a potentially powerful independent prognostic factor in patients with regional metastases secondary to head and neck cutaneous SCC. It provides information before definitive treatment that may ultimately assist clinicians in applying a risk-adapted management paradigm. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to determine whether the disease-free interval (DFI) between treatment of primary head and neck cutaneous squamous cell carcinoma (SCC) and the development of regional metastases is an independent prognostic factor.


Methods
A retrospective analysis of 229 patients with metastatic nodal head and neck cutaneous SCC, treated with curative intent by surgery ± adjuvant radiotherapy was conducted.


Results
After adjusting for the effect of nodal staging, extracapsular spread, involved margins, adjuvant radiotherapy, and immunosuppression, a short DFI (≤9 months vs &gt;9 months) was a significant predictor of disease-related mortality (hazard ratio [HR], 3.0; 95% confidence interval [CI], 1.4–6.5; p = .004) and locoregional relapse (HR, 2.0; 95% CI, 1.1–4.0; p = .044).


Conclusion
The DFI is a potentially powerful independent prognostic factor in patients with regional metastases secondary to head and neck cutaneous SCC. It provides information before definitive treatment that may ultimately assist clinicians in applying a risk-adapted management paradigm. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23194" xmlns="http://purl.org/rss/1.0/"><title>Use of a combined latissimus dorsi scapular free flap revascularized with vein grafting to the internal mammary artery in a vessel-depleted and previously irradiated neck</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23194</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Use of a combined latissimus dorsi scapular free flap revascularized with vein grafting to the internal mammary artery in a vessel-depleted and previously irradiated neck</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William E. Karle, Sumeet M. Anand, Jason B. Clain, Sophie Scherl, Daniel Buchbinder, Mark L. Smith, Mark L. Urken</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-14T00:23:40.998952-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23194</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23194</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23194</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>For patients who have extensive prior treatment, use of the internal mammary artery/vein (IMA/IMV) or cephalic vein has been shown to be a reliable option. Additionally, for those patients who require vascularized bone and extensive soft tissue reconstruction, the combined latissimus dorsi scapular free flap (mega-flap) is an excellent option.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We reviewed 3 cases in which extensive prior surgery and radiation precluded the use of traditional recipient vessels in the neck.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Three patients with major jaw deformities were reconstructed using a mega-flap. In all cases, saphenous vein grafting succeeded in achieving arterial inflow from the IMA to the subscapular artery. Venous egress was achieved using a vein graft to the IMV in 1 patient and a transposed cephalic vein in the remaining 2 patients.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>This approach of restoring large oral cavity defects for patients with extensive prior therapy and comorbid conditions has proven to be reliable and reproducible. © Wiley Periodicals Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
For patients who have extensive prior treatment, use of the internal mammary artery/vein (IMA/IMV) or cephalic vein has been shown to be a reliable option. Additionally, for those patients who require vascularized bone and extensive soft tissue reconstruction, the combined latissimus dorsi scapular free flap (mega-flap) is an excellent option.


Methods
We reviewed 3 cases in which extensive prior surgery and radiation precluded the use of traditional recipient vessels in the neck.


Results
Three patients with major jaw deformities were reconstructed using a mega-flap. In all cases, saphenous vein grafting succeeded in achieving arterial inflow from the IMA to the subscapular artery. Venous egress was achieved using a vein graft to the IMV in 1 patient and a transposed cephalic vein in the remaining 2 patients.


Conclusions
This approach of restoring large oral cavity defects for patients with extensive prior therapy and comorbid conditions has proven to be reliable and reproducible. © Wiley Periodicals Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23205" xmlns="http://purl.org/rss/1.0/"><title>Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER–Medicare analysis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23205</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER–Medicare analysis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Beth M. Beadle, Kai-Ping Liao, Mark S. Chambers, Linda S. Elting, Thomas A. Buchholz, K. Kian Ang, Adam S. Garden, B. Ashleigh Guadagnolo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-14T00:23:27.092819-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23205</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23205</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23205</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Jaw complications, including osteoradionecrosis, are significant sequelae of radiation therapy (RT) for oral cancers. This study identifies the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated with RT.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The Surveillance, Epidemiology, and End Results (SEER)–Medicare database was used to identify patients treated with RT for oral cancers from 1999 to 2007. Jaw complications were identified by International Classification of Diseases 9th revision (ICD-9) diagnosis codes and/or related procedures using Current Procedural Terminology (CPT) and ICD-9 codes.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>A total of 1848 patients were identified. With a median follow-up of 2.5 years, 297 patients (16.1%) developed jaw complications: 226 patients had a diagnosis, 41 patients had a procedure, and 30 patients had both. On multivariate analysis, female sex, lack of chemotherapy use, and fewer comorbidities were associated with a statistically significant increase in jaw complications.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Even with modern techniques, jaw complications are a notable and potentially devastating side effect of RT for oral cancers. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Jaw complications, including osteoradionecrosis, are significant sequelae of radiation therapy (RT) for oral cancers. This study identifies the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated with RT.


Methods
The Surveillance, Epidemiology, and End Results (SEER)–Medicare database was used to identify patients treated with RT for oral cancers from 1999 to 2007. Jaw complications were identified by International Classification of Diseases 9th revision (ICD-9) diagnosis codes and/or related procedures using Current Procedural Terminology (CPT) and ICD-9 codes.


Results
A total of 1848 patients were identified. With a median follow-up of 2.5 years, 297 patients (16.1%) developed jaw complications: 226 patients had a diagnosis, 41 patients had a procedure, and 30 patients had both. On multivariate analysis, female sex, lack of chemotherapy use, and fewer comorbidities were associated with a statistically significant increase in jaw complications.


Conclusions
Even with modern techniques, jaw complications are a notable and potentially devastating side effect of RT for oral cancers. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23196" xmlns="http://purl.org/rss/1.0/"><title>Comparative functional cell biological analysis of mesenchymal stem cells of the head and neck region: Potential impact on wound healing, trauma, and infection</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23196</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Comparative functional cell biological analysis of mesenchymal stem cells of the head and neck region: Potential impact on wound healing, trauma, and infection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mark Jakob, Hatim Hemeda, Kirsten Bruderek, Andreas O. H. Gerstner, Friedrich Bootz, Stephan Lang, Sven Brandau</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-11-14T00:23:14.282708-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23196</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23196</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23196</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Mesenchymal stem cells (MSCs) are multipotent mesenchymal progenitor cells, originally identified in bone-marrow. Little is known about MSCs of the head and neck region. We investigated cell biological properties with a potential impact on wound healing of 2 different tissue-resident MSC populations.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>MSCs were isolated from human nasal mucosa (nmMSCs) and parotid gland (pgMSCs). Clonogenic potential, cell surface markers, cytokine secretion, chemokine receptor expression, mobility, and adhesion to extracellular matrix were examined in unstimulated and stimulated MSCs.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>NmMSCs had the higher clonogenic potential. PgMSCs showed a broader panel of chemokine receptor expression and displayed higher mobility, especially after challenge with bacterial lipopolysaccharide (LPS). NmMSCs were less mobile and showed increased LPS-induced secretion of the inflammatory cytokine interleukin-8 (IL-8) compared with pgMSCs.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>These data highlight functional differences between tissue-resident MSCs of the head and neck region, which may impact functional properties of these cells in response to trauma or infection. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Mesenchymal stem cells (MSCs) are multipotent mesenchymal progenitor cells, originally identified in bone-marrow. Little is known about MSCs of the head and neck region. We investigated cell biological properties with a potential impact on wound healing of 2 different tissue-resident MSC populations.


Methods
MSCs were isolated from human nasal mucosa (nmMSCs) and parotid gland (pgMSCs). Clonogenic potential, cell surface markers, cytokine secretion, chemokine receptor expression, mobility, and adhesion to extracellular matrix were examined in unstimulated and stimulated MSCs.


Results
NmMSCs had the higher clonogenic potential. PgMSCs showed a broader panel of chemokine receptor expression and displayed higher mobility, especially after challenge with bacterial lipopolysaccharide (LPS). NmMSCs were less mobile and showed increased LPS-induced secretion of the inflammatory cytokine interleukin-8 (IL-8) compared with pgMSCs.


Conclusion
These data highlight functional differences between tissue-resident MSCs of the head and neck region, which may impact functional properties of these cells in response to trauma or infection. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23059" xmlns="http://purl.org/rss/1.0/"><title>Primary intestinal-like adenocarcinoma of major salivary glands: 2 instances of previously undocumented phenotype</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23059</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Primary intestinal-like adenocarcinoma of major salivary glands: 2 instances of previously undocumented phenotype</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ann M. Gillenwater, Steven J. Frank, Hanadi Fatani, Adel K. El–Naggar</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-29T04:41:40.768652-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23059</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23059</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23059</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Primary intestinal-like adenocarcinoma of the major salivary glands has not previously been reported.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The clinical and radiological findings of 2 patients with primary submandibular and sublingual tumors are presented. Histopathologic and immunohistochemical examinations of tumor sections were performed. Metastatic workup for distant occult primary was carried out.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The light-optic and the immunomarkers revealed intestinal-like adenocarcinoma consistent with upper respiratory tract origin. Metastatic workup of both patients was negative for primary gastro-intestinal primary.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Primary intestinal-like adenocarcinoma can develop in major salivary glands and should be considered in the differential diagnosis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Primary intestinal-like adenocarcinoma of the major salivary glands has not previously been reported.


Methods
The clinical and radiological findings of 2 patients with primary submandibular and sublingual tumors are presented. Histopathologic and immunohistochemical examinations of tumor sections were performed. Metastatic workup for distant occult primary was carried out.


Results
The light-optic and the immunomarkers revealed intestinal-like adenocarcinoma consistent with upper respiratory tract origin. Metastatic workup of both patients was negative for primary gastro-intestinal primary.


Conclusion
Primary intestinal-like adenocarcinoma can develop in major salivary glands and should be considered in the differential diagnosis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23184" xmlns="http://purl.org/rss/1.0/"><title>Isolation and genomic characterization of stem cells in head and neck cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23184</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Isolation and genomic characterization of stem cells in head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">George D. Wilson, Brian Marples, Sandra Galoforo, Timothy J. Geddes, Bryan J. Thibodeau, Reidar Grénman, Jan Akervall</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-29T04:41:26.543187-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23184</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23184</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23184</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>This study investigated the use of 3 different established cell-sorting strategies to isolate and characterize stem cells from head and neck cancer cell lines.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Five low-passage cell lines were subjected to cell sorting based on Hoechst side population, Aldefluor, and CD44 expression. Isolated cell populations were studied for gene expression, radiosensitivity, and chemosensitivity to cisplatin and paclitaxel.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Each sorting method identified a different set of genes associated with different gene ontology categories, with mitosis being the only common category. CD44-associated gene changes were almost exclusively associated with cell cycle and in particular mitosis. There were no significant differences in radiosensitivity or cisplatin sensitivity of stem or non–stem cells, but CD44-isolated stem cells were more resistant to paclitaxel.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>This study suggested that CD44 may be the most promising cell-sorting strategy to isolate and investigate the impact of stem cells in head and neck squamous cell cancer (HNSCC). © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
This study investigated the use of 3 different established cell-sorting strategies to isolate and characterize stem cells from head and neck cancer cell lines.


Methods
Five low-passage cell lines were subjected to cell sorting based on Hoechst side population, Aldefluor, and CD44 expression. Isolated cell populations were studied for gene expression, radiosensitivity, and chemosensitivity to cisplatin and paclitaxel.


Results
Each sorting method identified a different set of genes associated with different gene ontology categories, with mitosis being the only common category. CD44-associated gene changes were almost exclusively associated with cell cycle and in particular mitosis. There were no significant differences in radiosensitivity or cisplatin sensitivity of stem or non–stem cells, but CD44-isolated stem cells were more resistant to paclitaxel.


Conclusions
This study suggested that CD44 may be the most promising cell-sorting strategy to isolate and investigate the impact of stem cells in head and neck squamous cell cancer (HNSCC). © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23188" xmlns="http://purl.org/rss/1.0/"><title>p16 Expression in cutaneous squamous carcinomas with neck metastases: A potential pitfall in identifying unknown primaries of the head and neck</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23188</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">p16 Expression in cutaneous squamous carcinomas with neck metastases: A potential pitfall in identifying unknown primaries of the head and neck</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Beth M. Beadle, William N. William, Michael S. McLemore, Erich M. Sturgis, Michelle D. Williams</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-29T04:41:12.654022-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23188</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23188</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23188</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Human papillomavirus (HPV) positivity (+) has been used to identify oropharyngeal squamous carcinomas (SCCs) presenting as unknown primaries in the neck. p16 overexpression correlates with HPV+ in the oropharynx; however, the use of p16 alone as a surrogate marker of oropharyngeal HPV+ tumors has not been validated.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We immunohistochemically analyzed p16 expression in surgically resected aggressive cutaneous head and neck SCC primaries and their nodal metastases from 24 patients to determine the potential overlap of p16 expression outside of the oropharynx.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Five of 24 primary tumors (20.8%) and 3 lymph node metastases (12.5%) in levels II, III, and V, and the periparotid region diffusely expressed p16. HPV (high-risk types by in situ hybridization) was negative.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>p16 expression is relatively common in lymph node-positive cutaneous head and neck SCCs; thus, p16 expression as an independent biomarker and mechanism to determine the oropharyngeal source of an unknown primary is not advised. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Human papillomavirus (HPV) positivity (+) has been used to identify oropharyngeal squamous carcinomas (SCCs) presenting as unknown primaries in the neck. p16 overexpression correlates with HPV+ in the oropharynx; however, the use of p16 alone as a surrogate marker of oropharyngeal HPV+ tumors has not been validated.


Methods
We immunohistochemically analyzed p16 expression in surgically resected aggressive cutaneous head and neck SCC primaries and their nodal metastases from 24 patients to determine the potential overlap of p16 expression outside of the oropharynx.


Results
Five of 24 primary tumors (20.8%) and 3 lymph node metastases (12.5%) in levels II, III, and V, and the periparotid region diffusely expressed p16. HPV (high-risk types by in situ hybridization) was negative.


Conclusions
p16 expression is relatively common in lymph node-positive cutaneous head and neck SCCs; thus, p16 expression as an independent biomarker and mechanism to determine the oropharyngeal source of an unknown primary is not advised. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23189" xmlns="http://purl.org/rss/1.0/"><title>Evaluation of optical coherence tomography to discriminate lesions of the upper aerodigestive tract</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23189</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Evaluation of optical coherence tomography to discriminate lesions of the upper aerodigestive tract</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Veronika Volgger, Herbert Stepp, Stephan Ihrler, Marcel Kraft, Andreas Leunig, Parag M. Patel, Malavika Susarla, Kathleen Jackson, Christian S. Betz</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-29T04:40:58.307893-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23189</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23189</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23189</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>This study evaluated the capability of optical coherence tomography (OCT) to differentiate premalignant and early malignant lesions of the upper aerodigestive tract (UADT).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>An OCT screening was performed in 52 healthy volunteers. Epithelial thicknesses on 38 OCT images and histopathological slides were correlated. One hundred primary lesions were rated via OCT concerning invasiveness by an “unblinded” investigator, then biopsied, and the results correlated. All OCT images were evaluated by 3 “blinded” investigators. Forty-eight images underwent retrospective image analysis.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Screening showed large differences concerning epithelial thicknesses, but good correlation (κ = 0.63) between OCT and histopathological slides. In the unblinded evaluation, noninvasive and invasive lesions could be distinguished with a sensitivity of 88.9% and specificity of 89.0% whereas the blinded evaluations led to sensitivities of 100%, 66.7%, and 77.8% and specificities of 75.8%, 71.4%, and 70.3%. The difference of mean intraepithelial intensity reductions in dysplasias (38.7%) and hyperplasias (18.9%) was statistically significant.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>OCT complements visual inspection for differentiating UADT-lesions. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
This study evaluated the capability of optical coherence tomography (OCT) to differentiate premalignant and early malignant lesions of the upper aerodigestive tract (UADT).


Methods
An OCT screening was performed in 52 healthy volunteers. Epithelial thicknesses on 38 OCT images and histopathological slides were correlated. One hundred primary lesions were rated via OCT concerning invasiveness by an “unblinded” investigator, then biopsied, and the results correlated. All OCT images were evaluated by 3 “blinded” investigators. Forty-eight images underwent retrospective image analysis.


Results
Screening showed large differences concerning epithelial thicknesses, but good correlation (κ = 0.63) between OCT and histopathological slides. In the unblinded evaluation, noninvasive and invasive lesions could be distinguished with a sensitivity of 88.9% and specificity of 89.0% whereas the blinded evaluations led to sensitivities of 100%, 66.7%, and 77.8% and specificities of 75.8%, 71.4%, and 70.3%. The difference of mean intraepithelial intensity reductions in dysplasias (38.7%) and hyperplasias (18.9%) was statistically significant.


Conclusion
OCT complements visual inspection for differentiating UADT-lesions. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23193" xmlns="http://purl.org/rss/1.0/"><title>Comparison of ultrasound-guided core biopsy versus fine-needle aspiration biopsy in the evaluation of salivary gland lesions</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23193</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Comparison of ultrasound-guided core biopsy versus fine-needle aspiration biopsy in the evaluation of salivary gland lesions</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicholas J. Douville, Carol R. Bradford</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-29T04:40:32.770591-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23193</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23193</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23193</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Ultrasound-guided core biopsy provides many benefits compared with fine-needle aspiration cytology and has begun to emerge as part of the diagnostic work-up for a salivary gland lesion. Although the increased potential for tumor-seeding and capsule rupture has been extensively discussed, the safety of this procedure is widely accepted based on infrequent reports of tumor-seeding. In fact, a review of the literature shows only 2 cases of salivary tumor seeding following biopsy with larger-gauge needle characteristics, with 2 reported cases of salivary tumor seeding following fine-needle aspiration cytology. However, the follow-up interval of such studies (&lt;7 years) is substantially less than the 20-year follow-up typically necessary to detect remote recurrence. Studies on tumor recurrence of pleomorphic adenoma, the most common salivary gland lesion, suggest that as many as 16% of tumor recurrences occur at least 10 years following initial surgery, with average time to recurrence ranging anywhere from 6.1 to 11.8 years postoperatively. Despite the benefits of ultrasound-guided core biopsy over fine-needle aspiration biopsy, which include both improved consistency and diagnostic accuracy, current studies lack adequate patient numbers and follow-up duration to confirm comparable safety profile to currently accepted fine-needle aspiration cytology. In this report we: (1) compare the relative benefits of each procedure, (2) review evidence regarding tumor seeding in each procedure, (3) discuss time course and patient numbers necessary to detect tumor recurrence, and (4) describe how these uncertainties should be factored into clinical considerations. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div>
]]></content:encoded><description>

Ultrasound-guided core biopsy provides many benefits compared with fine-needle aspiration cytology and has begun to emerge as part of the diagnostic work-up for a salivary gland lesion. Although the increased potential for tumor-seeding and capsule rupture has been extensively discussed, the safety of this procedure is widely accepted based on infrequent reports of tumor-seeding. In fact, a review of the literature shows only 2 cases of salivary tumor seeding following biopsy with larger-gauge needle characteristics, with 2 reported cases of salivary tumor seeding following fine-needle aspiration cytology. However, the follow-up interval of such studies (&lt;7 years) is substantially less than the 20-year follow-up typically necessary to detect remote recurrence. Studies on tumor recurrence of pleomorphic adenoma, the most common salivary gland lesion, suggest that as many as 16% of tumor recurrences occur at least 10 years following initial surgery, with average time to recurrence ranging anywhere from 6.1 to 11.8 years postoperatively. Despite the benefits of ultrasound-guided core biopsy over fine-needle aspiration biopsy, which include both improved consistency and diagnostic accuracy, current studies lack adequate patient numbers and follow-up duration to confirm comparable safety profile to currently accepted fine-needle aspiration cytology. In this report we: (1) compare the relative benefits of each procedure, (2) review evidence regarding tumor seeding in each procedure, (3) discuss time course and patient numbers necessary to detect tumor recurrence, and (4) describe how these uncertainties should be factored into clinical considerations. © 2012 Wiley Periodicals, Inc. Head Neck, 2012
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23185" xmlns="http://purl.org/rss/1.0/"><title>Multiple craniocervical chordomas presenting as a parapharyngeal mass</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23185</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Multiple craniocervical chordomas presenting as a parapharyngeal mass</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andreas Anagiotos, Simon Florian Preuss, Uta Drebber, Masen Dirk Jumah</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-29T04:40:19.439043-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23185</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23185</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23185</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Chordomas are malignant neoplasms of the axial skeleton that have rarely been seen in the cervical area.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A 55-year-old woman presented to our department with a history of a left cervical mass protruding into the throat with the symptoms of dysphagia and hoarseness.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The radiological examination revealed 3 polycyclic masses in the neck, 2 on the left side and 1 small mass on the right side. After the neurosurgical excision of the intraspinal parts of the tumor, we performed the surgical resection of the cervical tumors via a lateral collotomy. The histological examination showed a chordoma. Because of the advanced stage of the tumor, a postoperative radiotherapy was performed.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Meticulous radiological workup is essential in order to identify the exact extension of the tumor and to reveal possible multifocal lesions. The current literature and treatment recommendations for this rare tumor at this localization are discussed. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Chordomas are malignant neoplasms of the axial skeleton that have rarely been seen in the cervical area.


Methods
A 55-year-old woman presented to our department with a history of a left cervical mass protruding into the throat with the symptoms of dysphagia and hoarseness.


Results
The radiological examination revealed 3 polycyclic masses in the neck, 2 on the left side and 1 small mass on the right side. After the neurosurgical excision of the intraspinal parts of the tumor, we performed the surgical resection of the cervical tumors via a lateral collotomy. The histological examination showed a chordoma. Because of the advanced stage of the tumor, a postoperative radiotherapy was performed.


Conclusions
Meticulous radiological workup is essential in order to identify the exact extension of the tumor and to reveal possible multifocal lesions. The current literature and treatment recommendations for this rare tumor at this localization are discussed. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23175" xmlns="http://purl.org/rss/1.0/"><title>Immunoglobulin G4–related sclerosing disease of the paranasal sinus</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23175</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Immunoglobulin G4–related sclerosing disease of the paranasal sinus</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert H. Lindau, Yungpo Bernard Su, Roger Kobayashi, Russell B. Smith</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-10T04:07:52.488677-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23175</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23175</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23175</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Immunoglobulin G4 (IgG4)–related sclerosing disease is a systemic disease characterized by extensive IgG4-positive plasma cells and T-lymphocyte infiltration of various organs. We present a case of a 69-year-old man with maxillary sinus IgG4 sclerosing disease, with orbital invasion treated with rituximab and dexamethasone pulse therapy. Surgery was used as well to debulk the disease and to obtain tissue for diagnosis.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A PubMed search using the key phrase “IgG4-related Sclerosing Disease” was performed. There were 304 different articles regarding the disease for a multitude of different organ sites. Of the 304 articles, there were 3 articles that reported this disease in the paranasal sinuses.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>IgG4-related sclerosing disease is a rare entity in the head and neck. There are documented reports of steroid therapy for this disease, but the patient presented here demonstrated clinical progression of disease with steroids alone. The use of combination therapy of surgery, dexamethasone, and rituximab provided clinical improvement and stable disease determined by radiographic means. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Immunoglobulin G4 (IgG4)–related sclerosing disease is a systemic disease characterized by extensive IgG4-positive plasma cells and T-lymphocyte infiltration of various organs. We present a case of a 69-year-old man with maxillary sinus IgG4 sclerosing disease, with orbital invasion treated with rituximab and dexamethasone pulse therapy. Surgery was used as well to debulk the disease and to obtain tissue for diagnosis.


Methods
A PubMed search using the key phrase “IgG4-related Sclerosing Disease” was performed. There were 304 different articles regarding the disease for a multitude of different organ sites. Of the 304 articles, there were 3 articles that reported this disease in the paranasal sinuses.


Conclusions
IgG4-related sclerosing disease is a rare entity in the head and neck. There are documented reports of steroid therapy for this disease, but the patient presented here demonstrated clinical progression of disease with steroids alone. The use of combination therapy of surgery, dexamethasone, and rituximab provided clinical improvement and stable disease determined by radiographic means. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23170" xmlns="http://purl.org/rss/1.0/"><title>Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23170</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paolo Bossi, Gabriela Kornek, Gaetano Lanzetta, Antonio Rozzi, Thorsten Füreder, Laura Locati, Lisa Licitra</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-06T02:46:15.149289-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23170</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23170</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23170</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>In patients with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC), there are no data about an every-other-week cetuximab maintenance schedule after chemotherapy plus cetuximab as first-line treatment.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We reviewed the safety and feasibility of every-other-week maintenance cetuximab administered at 3 different European centers.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Thirty-one patients with recurrent or metastatic HNSCC were treated from 2006 to 2010. Mean cetuximab dose intensity in the maintenance phase was 93%. The major toxicities reported during every-other-week maintenance cetuximab were skin rash (grade 3, 16%; grade 2, 23%), fatigue (grade 3, 3%; grade 2, 16%), diarrhea (grade 3, 7%; grade 2, 13%), hypomagnesemia (grade 4, 3%; grade 3, 3%; grade 2, 19%), and mucositis (grade 3, 3%; grade 2, 23%).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Every-other-week maintenance cetuximab schedule was well tolerated and did not worsen toxicity that occurred during chemotherapy. In daily practice, this simplified schedule could improve compliance and possibly improve quality of life in patients with recurrent or metastatic HNSCC that showed no progression during first-line chemotherapy. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
In patients with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC), there are no data about an every-other-week cetuximab maintenance schedule after chemotherapy plus cetuximab as first-line treatment.


Methods
We reviewed the safety and feasibility of every-other-week maintenance cetuximab administered at 3 different European centers.


Results
Thirty-one patients with recurrent or metastatic HNSCC were treated from 2006 to 2010. Mean cetuximab dose intensity in the maintenance phase was 93%. The major toxicities reported during every-other-week maintenance cetuximab were skin rash (grade 3, 16%; grade 2, 23%), fatigue (grade 3, 3%; grade 2, 16%), diarrhea (grade 3, 7%; grade 2, 13%), hypomagnesemia (grade 4, 3%; grade 3, 3%; grade 2, 19%), and mucositis (grade 3, 3%; grade 2, 23%).


Conclusions
Every-other-week maintenance cetuximab schedule was well tolerated and did not worsen toxicity that occurred during chemotherapy. In daily practice, this simplified schedule could improve compliance and possibly improve quality of life in patients with recurrent or metastatic HNSCC that showed no progression during first-line chemotherapy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23126" xmlns="http://purl.org/rss/1.0/"><title>Prognostic impact of human papillomavirus status, survivin, and epidermal growth-factor receptor expression on survival in patients treated with radiochemotherapy for very advanced nonresectable oropharyngeal cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23126</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prognostic impact of human papillomavirus status, survivin, and epidermal growth-factor receptor expression on survival in patients treated with radiochemotherapy for very advanced nonresectable oropharyngeal cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert Semrau, Helena Duerbaum, Susanne Temming, Christian Huebbers, Markus Stenner, Uta Drebber, Jens Peter Klussmann, Rolf-Peter Müller, Simon F. Preuss</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-05T04:57:06.709513-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23126</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23126</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23126</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The influence of human papillomavirus (HPV) status on survival for patients with very advanced inoperable oropharyngeal SCC treated with radiochemotherapy (RCT) was studied.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Patients received either 69.2 Gy with concomitant boost (ccb) or 70 Gy conventionally fractionated (cf), weekly paclitaxel 40 mg/m<sup>2</sup>, and carboplatin area under the concentration–time curve (AUC) 1. Tumor was analyzed for the presence of high-risk HPV-DNA using polymerase chain reaction (PCR) and direct DNA sequencing. p16-expression, survivin, and epidermal growth factor receptor (EGFR) expression were evaluated by immunohistochemistry and influence on survival was calculated.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Of 52 patients, 25.0% were HPV positive and 75.0% HPV negative. The 2-year progression-free survival (PFS) was 70.1% for p16-positive patients and 37.1% for p16-negative patients (<em>p</em> = .005). The 3-year overall survival (OS) rate was 43.9% for all patients and did not significantly differ between the groups. Neither survivin nor EGFR expression influenced PFS or OS significantly.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>HPV status influences PFS in patients with advanced, nonresectable tumor stages but not OS. Additional risk factors seem to have a stronger influence on survival than HPV status. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The influence of human papillomavirus (HPV) status on survival for patients with very advanced inoperable oropharyngeal SCC treated with radiochemotherapy (RCT) was studied.


Methods
Patients received either 69.2 Gy with concomitant boost (ccb) or 70 Gy conventionally fractionated (cf), weekly paclitaxel 40 mg/m2, and carboplatin area under the concentration–time curve (AUC) 1. Tumor was analyzed for the presence of high-risk HPV-DNA using polymerase chain reaction (PCR) and direct DNA sequencing. p16-expression, survivin, and epidermal growth factor receptor (EGFR) expression were evaluated by immunohistochemistry and influence on survival was calculated.


Results
Of 52 patients, 25.0% were HPV positive and 75.0% HPV negative. The 2-year progression-free survival (PFS) was 70.1% for p16-positive patients and 37.1% for p16-negative patients (p = .005). The 3-year overall survival (OS) rate was 43.9% for all patients and did not significantly differ between the groups. Neither survivin nor EGFR expression influenced PFS or OS significantly.


Conclusions
HPV status influences PFS in patients with advanced, nonresectable tumor stages but not OS. Additional risk factors seem to have a stronger influence on survival than HPV status. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23144" xmlns="http://purl.org/rss/1.0/"><title>Factors associated with supracricoid laryngectomy functional outcomes</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23144</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Factors associated with supracricoid laryngectomy functional outcomes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel R. Clayburgh, Donna J. Graville, Andrew D. Palmer, Joshua S. Schindler</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-10-05T04:56:55.592967-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23144</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23144</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23144</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Background</em></h4><div class="para"><p>Supracricoid partial laryngectomy (SCPL) is an option for laryngeal cancer resection that preserves laryngeal function; however, little information exists regarding factors that are associated with functional outcomes.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Methods</em></h4><div class="para"><p>A medical chart review was performed on patients that underwent SCPL at our institution between 2006 and 2011. Data were collected on surgical, voice, and swallowing outcomes.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Results</em></h4><div class="para"><p>Eighteen patients were identified. Thirteen underwent cricohyoidoepiglottopexy (CHEP) and 5 had a cricohyoidopexy (CHP). Mean follow-up was 737 days. On average, decannulation occurred at 27.4 days and feeding tube removal at 87.9 days postoperatively. Sixty-seven percent of patients tolerated an unrestricted diet at follow-up. Increased age and a CHP procedure were associated with negative outcomes. Age may be a proxy for more extensive disease and prior treatments.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Conclusion</em></h4><div class="para"><p>Patients who undergo an SCPL require extensive rehabilitation after surgery. Those who have undergone multiple cancer interventions and have more extensive surgery may be at risk for poorer outcomes. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Supracricoid partial laryngectomy (SCPL) is an option for laryngeal cancer resection that preserves laryngeal function; however, little information exists regarding factors that are associated with functional outcomes.


Methods
A medical chart review was performed on patients that underwent SCPL at our institution between 2006 and 2011. Data were collected on surgical, voice, and swallowing outcomes.


Results
Eighteen patients were identified. Thirteen underwent cricohyoidoepiglottopexy (CHEP) and 5 had a cricohyoidopexy (CHP). Mean follow-up was 737 days. On average, decannulation occurred at 27.4 days and feeding tube removal at 87.9 days postoperatively. Sixty-seven percent of patients tolerated an unrestricted diet at follow-up. Increased age and a CHP procedure were associated with negative outcomes. Age may be a proxy for more extensive disease and prior treatments.


Conclusion
Patients who undergo an SCPL require extensive rehabilitation after surgery. Those who have undergone multiple cancer interventions and have more extensive surgery may be at risk for poorer outcomes. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23104" xmlns="http://purl.org/rss/1.0/"><title>Factors predisposing to chyle leakage following thyroid cancer surgery without lateral neck dissection</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23104</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Factors predisposing to chyle leakage following thyroid cancer surgery without lateral neck dissection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yong Sang Lee, Bup-Woo Kim, Hang-Seok Chang, Cheong Soo Park</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-28T01:36:00.631251-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23104</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23104</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23104</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The aims of this study were to assess the clinicopathologic features of patients with chyle leakage following thyroid cancer surgery without lateral neck dissection and to evaluate the factors associated with chyle leakage.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Of 3137 patients who underwent thyroid surgery between January 2006 and December 2007, 2314 patients (73.8%) satisfied our inclusion criteria. Patients were divided into those with (group I, <em>n</em> = 14) and without (group II, <em>n</em> = 2300) chyle leakage.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>There were no significant differences between the 2 groups in clinicopathologic features including age, body mass index, extent of thyroidectomy, pathologic type, tumor size, multiplicity, capsular invasion, and coexisting thyroiditis. In univariate and multivariate analyses, male sex, age &gt;45 years, and number of harvested central nodes were significantly associated with chyle leakage.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>If extensive central compartment node dissection is needed, meticulous dissection is required, especially in male patients, and aged &gt;45 years, even without lateral neck dissection. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The aims of this study were to assess the clinicopathologic features of patients with chyle leakage following thyroid cancer surgery without lateral neck dissection and to evaluate the factors associated with chyle leakage.


Methods
Of 3137 patients who underwent thyroid surgery between January 2006 and December 2007, 2314 patients (73.8%) satisfied our inclusion criteria. Patients were divided into those with (group I, n = 14) and without (group II, n = 2300) chyle leakage.


Results
There were no significant differences between the 2 groups in clinicopathologic features including age, body mass index, extent of thyroidectomy, pathologic type, tumor size, multiplicity, capsular invasion, and coexisting thyroiditis. In univariate and multivariate analyses, male sex, age &gt;45 years, and number of harvested central nodes were significantly associated with chyle leakage.


Conclusions
If extensive central compartment node dissection is needed, meticulous dissection is required, especially in male patients, and aged &gt;45 years, even without lateral neck dissection. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23145" xmlns="http://purl.org/rss/1.0/"><title>The role of elective neck dissection in patients undergoing salvage laryngectomy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23145</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The role of elective neck dissection in patients undergoing salvage laryngectomy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Moran Amit, Ohad Hilly, Leonor Leider–Trejo, Aharon Popovtzer, Orit Gutfeld, Jacob Shvero, Dan M. Fliss, Jacob T. Cohen, Gideon Bachar, Ziv Gil</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-28T01:35:50.206897-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23145</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23145</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23145</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Background</em></h4><div class="para"><p>We investigated the risk of neck metastases in patients undergoing salvage total laryngectomy in association with previous radiotherapy.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Methods</em></h4><div class="para"><p>The medical records of 42 patients (51 neck specimens) with clinical N0 classification who underwent salvage total laryngectomy in 2 cancer centers were reviewed. Fourteen patients had previous radiotherapy to the central neck and 28 to the central and lateral neck.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Results</em></h4><div class="para"><p>Staging before salvage total laryngectomy was similar in both groups. The risk of neck metastases in the central and central/lateral radiation groups was 12% and 18%, respectively (<em>p</em> = .69). Subgroup analysis revealed that 4 of 8 patients initially presenting with clinically N+ had neck metastases before surgery, versus 2 of 26 for those with clinically N0 (<em>p</em> = .015; relative risk [RR] = 4.67). The risk or metastases in the contralateral neck was 0 of 9.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Conclusion</em></h4><div class="para"><p>The risk of neck metastases in patients who undergo either central or central/lateral neck radiotherapy is similar. Elective neck dissection seems appropriate in patients undergoing SLR. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
We investigated the risk of neck metastases in patients undergoing salvage total laryngectomy in association with previous radiotherapy.


Methods
The medical records of 42 patients (51 neck specimens) with clinical N0 classification who underwent salvage total laryngectomy in 2 cancer centers were reviewed. Fourteen patients had previous radiotherapy to the central neck and 28 to the central and lateral neck.


Results
Staging before salvage total laryngectomy was similar in both groups. The risk of neck metastases in the central and central/lateral radiation groups was 12% and 18%, respectively (p = .69). Subgroup analysis revealed that 4 of 8 patients initially presenting with clinically N+ had neck metastases before surgery, versus 2 of 26 for those with clinically N0 (p = .015; relative risk [RR] = 4.67). The risk or metastases in the contralateral neck was 0 of 9.


Conclusion
The risk of neck metastases in patients who undergo either central or central/lateral neck radiotherapy is similar. Elective neck dissection seems appropriate in patients undergoing SLR. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23160" xmlns="http://purl.org/rss/1.0/"><title>Case of high-risk epithelioid hemangioendothelioma of the neck</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23160</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Case of high-risk epithelioid hemangioendothelioma of the neck</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shingo Matsuzawa, Takeharu Kanazawa, Takehiko Yamaguchi, Hiroshi Nishino, Kazumi Kawada, Keiichi Ichimura</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-28T01:35:35.377519-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23160</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23160</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23160</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Epithelioid hemangioendotheliomas (EHEs) of the head and neck region are uncommon malignant neoplasms that exhibit various biologic behaviors characteristic of both low- and high-grade malignancy. A subgroup of EHEs identified as “high-risk” EHEs because of their size and mitotic activity is associated with an unfavorable clinical course and poor prognosis.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Materials and Results</h4><div class="para"><p>We describe the treatment of the first and, in terms of size, largest case of high-risk EHE arising from the neck. Despite wide excision, recurrence occurred 9 months after surgery, as had been expected. However, the tumor was found to express both vascular endothelial growth factor (VEGF) and VEGF receptor 2, indicating the potential of anti-VEGF therapy in the treatment of such cases.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>The finding that a high-risk EHE arising from the head and neck region is characterized by expression of VEGF and its receptor provides further support for the development of targeted molecular therapies. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Epithelioid hemangioendotheliomas (EHEs) of the head and neck region are uncommon malignant neoplasms that exhibit various biologic behaviors characteristic of both low- and high-grade malignancy. A subgroup of EHEs identified as “high-risk” EHEs because of their size and mitotic activity is associated with an unfavorable clinical course and poor prognosis.


Materials and Results
We describe the treatment of the first and, in terms of size, largest case of high-risk EHE arising from the neck. Despite wide excision, recurrence occurred 9 months after surgery, as had been expected. However, the tumor was found to express both vascular endothelial growth factor (VEGF) and VEGF receptor 2, indicating the potential of anti-VEGF therapy in the treatment of such cases.


Conclusion
The finding that a high-risk EHE arising from the head and neck region is characterized by expression of VEGF and its receptor provides further support for the development of targeted molecular therapies. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23173" xmlns="http://purl.org/rss/1.0/"><title>Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23173</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vlad C. Sandulache, Thomas J. Ow, Shiva P. Daram, Jackson Hamilton, Heath Skinner, Diana Bell, David I. Rosenthal, Beth M. Beadle, K. Kian Ang, Merrill S. Kies, Faye M. Johnson, Adel K. El-Naggar, Jeffrey N. Myers</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-28T01:34:42.327415-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23173</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23173</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23173</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Oropharyngeal squamous cell carcinoma (OPSCC) is increasing in frequency. We reviewed patients with advanced-stage OPSCC treated with chemoradiation to assess the impact of residual neck disease on survival.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We reviewed 202 patients with OPSCC between 1990 and 2010 treated with primary chemoradiation followed by neck dissection. Imaging was analyzed using RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 criteria. Survival was evaluated using both univariate and multivariate analyses.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Overall survival at 5 years was 89%. Forty-two patients (21%) had residual disease in the neck (pN+). pN+ was associated with greater locoregional recurrence (LRR) and distant metastasis (DM) and decreased survival. No clinicopathologic factors were predictive of pN+. Contrasted posttreatment CT had low sensitivity and specificity.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>In advanced OPSCC pN+, patients have higher rates of LRR and DM. Neither clinicopathologic factors nor posttreatment imaging was predictive of pN+, although increased use of modern imaging may reduce the rate of negative neck dissections. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Oropharyngeal squamous cell carcinoma (OPSCC) is increasing in frequency. We reviewed patients with advanced-stage OPSCC treated with chemoradiation to assess the impact of residual neck disease on survival.


Methods
We reviewed 202 patients with OPSCC between 1990 and 2010 treated with primary chemoradiation followed by neck dissection. Imaging was analyzed using RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 criteria. Survival was evaluated using both univariate and multivariate analyses.


Results
Overall survival at 5 years was 89%. Forty-two patients (21%) had residual disease in the neck (pN+). pN+ was associated with greater locoregional recurrence (LRR) and distant metastasis (DM) and decreased survival. No clinicopathologic factors were predictive of pN+. Contrasted posttreatment CT had low sensitivity and specificity.


Conclusions
In advanced OPSCC pN+, patients have higher rates of LRR and DM. Neither clinicopathologic factors nor posttreatment imaging was predictive of pN+, although increased use of modern imaging may reduce the rate of negative neck dissections. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23174" xmlns="http://purl.org/rss/1.0/"><title>Extended voice-sparing surgery in selected pyriform sinus carcinoma: Techniques and outcomes</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23174</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Extended voice-sparing surgery in selected pyriform sinus carcinoma: Techniques and outcomes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marc Hamoir, Juliette Fievez, Sandra Schmitz, Dorris Velasco, Benoît Lengele</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-28T01:34:16.105507-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23174</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23174</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23174</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Organ-preservation approaches are frequently favored in the treatment of advanced pyriform sinus carcinoma. In selected cases, use of free flaps allows voice-sparing surgery.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Thirteen patients underwent conservative extended laryngopharyngectomy. In 11 patients, the resection included the supraglottic larynx, whereas the whole hemilarynx was resected in 2. Reconstruction was achieved with a radial forearm free flap with the palmaris longus tendon. In hemilarynx resection, a costal graft was also used. Functional results were assessed by nasofibroscopy and swallowing videofluoroscopic tests.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>At 12 months, no patient was gastrostomy dependent, whereas 1 patient remained tracheostomy dependent. At 1, 3, and 5 years, the locoregional control was 100%, 100%, and 83%; overall survival was 69.4%, 46.3%, and 30.8%; and disease-specific survival was 81.2%, 54.5%, and 36.4%, respectively.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>In selected patients, extended conservative laryngopharyngectomy challenges the oncologic results of organ-preservation protocols and allows a good quality of life. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Organ-preservation approaches are frequently favored in the treatment of advanced pyriform sinus carcinoma. In selected cases, use of free flaps allows voice-sparing surgery.


Methods
Thirteen patients underwent conservative extended laryngopharyngectomy. In 11 patients, the resection included the supraglottic larynx, whereas the whole hemilarynx was resected in 2. Reconstruction was achieved with a radial forearm free flap with the palmaris longus tendon. In hemilarynx resection, a costal graft was also used. Functional results were assessed by nasofibroscopy and swallowing videofluoroscopic tests.


Results
At 12 months, no patient was gastrostomy dependent, whereas 1 patient remained tracheostomy dependent. At 1, 3, and 5 years, the locoregional control was 100%, 100%, and 83%; overall survival was 69.4%, 46.3%, and 30.8%; and disease-specific survival was 81.2%, 54.5%, and 36.4%, respectively.


Conclusions
In selected patients, extended conservative laryngopharyngectomy challenges the oncologic results of organ-preservation protocols and allows a good quality of life. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23172" xmlns="http://purl.org/rss/1.0/"><title>Neck metastases in oropharyngeal cancer: Necessity and extent of bilateral treatment</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23172</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Neck metastases in oropharyngeal cancer: Necessity and extent of bilateral treatment</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter T. Dziegielewski, Daniel A. O'Connell, Jacek Szudek, Brittany Barber, Arjun Joshi, Jeffrey R. Harris, Hadi Seikaly</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-25T05:41:00.250495-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23172</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23172</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23172</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Bilateral neck treatment in oropharyngeal squamous cell carcinoma (OPSCC) is controversial. This study determined the rate of bilateral neck metastases in OPSCC and formulated a neck treatment algorithrm for OPSCC.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In all, 212 consecutive patients with OPSCC underwent ipsilateral level I–V and contralateral I–III or I–V neck dissections. Pathology results were used to identify factors predicting bilateral neck metastases.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>A total of 171 patients (81%) had ipsilateral and 41 patients (24%) bilateral neck metastases. Multivariate logistic regression found cT4 and ≥cN<sub>2a</sub> significantly associated with contralateral neck metastases (<em>p</em> &lt; .05). However, tumor site was not predictive (<em>p</em> &gt; .05). High-risk pathology features predicted contralateral neck disease (<em>p</em> &lt; .05). cN0 and cN1 necks were unlikely to harbor disease in level V (&lt;5%). Both 2- and 5-year contralateral neck recurrence rates were 1% and 2%.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Bilateral neck disease in OPSCC is more common than once thought. Patients with OPSCC with cT4 or cN<sub>2a+</sub> would benefit from bilateral neck treatment. Posttreatment high-risk features should guide treatment escalation. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Bilateral neck treatment in oropharyngeal squamous cell carcinoma (OPSCC) is controversial. This study determined the rate of bilateral neck metastases in OPSCC and formulated a neck treatment algorithrm for OPSCC.


Methods
In all, 212 consecutive patients with OPSCC underwent ipsilateral level I–V and contralateral I–III or I–V neck dissections. Pathology results were used to identify factors predicting bilateral neck metastases.


Results
A total of 171 patients (81%) had ipsilateral and 41 patients (24%) bilateral neck metastases. Multivariate logistic regression found cT4 and ≥cN2a significantly associated with contralateral neck metastases (p &lt; .05). However, tumor site was not predictive (p &gt; .05). High-risk pathology features predicted contralateral neck disease (p &lt; .05). cN0 and cN1 necks were unlikely to harbor disease in level V (&lt;5%). Both 2- and 5-year contralateral neck recurrence rates were 1% and 2%.


Conclusions
Bilateral neck disease in OPSCC is more common than once thought. Patients with OPSCC with cT4 or cN2a+ would benefit from bilateral neck treatment. Posttreatment high-risk features should guide treatment escalation. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23050" xmlns="http://purl.org/rss/1.0/"><title>Tumors of the cervical sympathetic chain—Diagnosis and management</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23050</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Tumors of the cervical sympathetic chain—Diagnosis and management</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexander Langerman, Sanjeet V. Rangarajan, Sanjay M. Athavale, Michelle Q. Pham, Robert J. Sinard, James L. Netterville</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-24T02:05:22.810081-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23050</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23050</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23050</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Tumors originating from the cervical sympathetic chain are uncommon but important entities in the differential diagnosis of parapharyngeal space masses.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We conducted a retrospective review of patients presenting with tumors of the cervical sympathetic chain.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Twenty-four patients presented between 1994 and 2010. Presenting symptoms were dysphagia (<em>n</em> = 7.29%), neck mass (<em>n</em> = 7.29%), throat fullness (<em>n</em> = 4.17%), and Horner syndrome (<em>n</em> = 2.8%). Although radiologic images showed classic lateral displacement of the carotid arteries in 10 patients (42%), in 9 patients (38%) the radiologic findings demonstrated splaying of the carotid arteries similar to carotid body tumor, and in 5 patients (20%), the findings were indeterminate. Twenty-one patients underwent surgical removal of the tumors with pathology revealing 10 paragangliomas, 10 schwannomas, and 1 neurofibroma. Horner (57%) and first-bite (33%) syndromes were the most common complications.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Although anterolateral displacement of the carotids is suggestive of a sympathetic tumor, absence of these findings does not rule out this entity. To this end, we have included in this review a guide to preoperative radiologic diagnosis of parapharyngeal space lesions. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Tumors originating from the cervical sympathetic chain are uncommon but important entities in the differential diagnosis of parapharyngeal space masses.


Methods
We conducted a retrospective review of patients presenting with tumors of the cervical sympathetic chain.


Results
Twenty-four patients presented between 1994 and 2010. Presenting symptoms were dysphagia (n = 7.29%), neck mass (n = 7.29%), throat fullness (n = 4.17%), and Horner syndrome (n = 2.8%). Although radiologic images showed classic lateral displacement of the carotid arteries in 10 patients (42%), in 9 patients (38%) the radiologic findings demonstrated splaying of the carotid arteries similar to carotid body tumor, and in 5 patients (20%), the findings were indeterminate. Twenty-one patients underwent surgical removal of the tumors with pathology revealing 10 paragangliomas, 10 schwannomas, and 1 neurofibroma. Horner (57%) and first-bite (33%) syndromes were the most common complications.


Conclusions
Although anterolateral displacement of the carotids is suggestive of a sympathetic tumor, absence of these findings does not rule out this entity. To this end, we have included in this review a guide to preoperative radiologic diagnosis of parapharyngeal space lesions. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23152" xmlns="http://purl.org/rss/1.0/"><title>Primary squamous cell carcinoma of the thyroid gland: A case report and review</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23152</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Primary squamous cell carcinoma of the thyroid gland: A case report and review</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Merica Shrestha, Shankar K. Sridhara, Leonard J. Leo, George L. Coppit, Nicole M. Ehrhardt</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-24T02:04:56.729592-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23152</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23152</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23152</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Background</em></h4><div class="para"><p>Primary squamous cell carcinoma (SCC) of the thyroid gland is a rare malignancy that presents with advanced disease and poor prognosis.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Methods</em></h4><div class="para"><p>A 75-year-old woman with a history of Hashimoto thyroiditis presented with 6 months of dysphagia and stridor. Imaging revealed a thyroid mass invading the larynx. Primary SCC of the thyroid was diagnosed by histopathologic and immunohistochemical evaluation. Total thyroidectomy, total laryngectomy, bilateral modified neck dissection, and adjuvant radiotherapy (RT) were performed. Radiologic follow-up at 21 months demonstrated no disease and total length of survival was 31 months.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Results</em></h4><div class="para"><p>Despite an aggressive T4aN0M0 tumor, survival in this case was more than double the median survival rate previously reported. Concomitant Hashimoto thyroiditis is rare and histopathologic and immunohistochemical evaluation is imperative for an accurate diagnosis.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Conclusion</em></h4><div class="para"><p>The case and literature reported here support that a thorough diagnostic workup of primary SCC of the thyroid with aggressive locoregional surgery and adjuvant RT may improve the length of survival. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Primary squamous cell carcinoma (SCC) of the thyroid gland is a rare malignancy that presents with advanced disease and poor prognosis.


Methods
A 75-year-old woman with a history of Hashimoto thyroiditis presented with 6 months of dysphagia and stridor. Imaging revealed a thyroid mass invading the larynx. Primary SCC of the thyroid was diagnosed by histopathologic and immunohistochemical evaluation. Total thyroidectomy, total laryngectomy, bilateral modified neck dissection, and adjuvant radiotherapy (RT) were performed. Radiologic follow-up at 21 months demonstrated no disease and total length of survival was 31 months.


Results
Despite an aggressive T4aN0M0 tumor, survival in this case was more than double the median survival rate previously reported. Concomitant Hashimoto thyroiditis is rare and histopathologic and immunohistochemical evaluation is imperative for an accurate diagnosis.


Conclusion
The case and literature reported here support that a thorough diagnostic workup of primary SCC of the thyroid with aggressive locoregional surgery and adjuvant RT may improve the length of survival. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23159" xmlns="http://purl.org/rss/1.0/"><title>Surgical management of inverted papilloma: Approaching a new standard for surgery</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23159</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Surgical management of inverted papilloma: Approaching a new standard for surgery</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Filippo Carta, Jean-Philippe Blancal, Benjamin Verillaud, Hugo Tran, Elisabeth Sauvaget, Romain Kania, Philippe Herman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-24T02:04:44.330997-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23159</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23159</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23159</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Inverted papilloma surgery is currently performed primarily with an endoscopic approach, a technique that has a recurrence rate of 12%. However, a recent study reported a recurrence rate of 5% with a strategy based on subperiosteal dissection of the tumor, with limited indications for using an external approach. The aim of this work was to evaluate whether different teams using the same surgical concepts could reproduce the excellent results that were recently reported.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>This study is a retrospective chart review of 71 consecutive patients with inverted papilloma who were treated during the last 10 years.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In all, 80% of the patients were treated using a purely endoscopic approach. The mean follow-up period was 31.6 months. The recurrence rate was 3.3% for cases with at least a 12-month follow-up.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>This work confirms the results described in recent literature and further supports transnasal endoscopic surgery to manage inverted papilloma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Inverted papilloma surgery is currently performed primarily with an endoscopic approach, a technique that has a recurrence rate of 12%. However, a recent study reported a recurrence rate of 5% with a strategy based on subperiosteal dissection of the tumor, with limited indications for using an external approach. The aim of this work was to evaluate whether different teams using the same surgical concepts could reproduce the excellent results that were recently reported.


Methods
This study is a retrospective chart review of 71 consecutive patients with inverted papilloma who were treated during the last 10 years.


Results
In all, 80% of the patients were treated using a purely endoscopic approach. The mean follow-up period was 31.6 months. The recurrence rate was 3.3% for cases with at least a 12-month follow-up.


Conclusions
This work confirms the results described in recent literature and further supports transnasal endoscopic surgery to manage inverted papilloma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22950" xmlns="http://purl.org/rss/1.0/"><title>Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: Systematic review and meta-analysis </title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22950</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: Systematic review and meta-analysis </dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James W. Rainsbury, Waseem Ahmed, Hazel K. Williams, Sally Roberts, Vinidh Paleri, Hisham Mehanna</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-20T07:34:53.998029-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22950</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22950</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.22950</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Human papillomavirus (HPV) positivity improves prognosis in patients with oropharyngeal squamous cell carcinoma (OPSCC). Combining HPV status with other biomarkers may improve its prognostic power.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The approach was a literature search for longitudinal studies of biomarkers in OPSCC, with systematic review and meta-analysis.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In all, 3130 articles were identified; 32 satisfied the inclusion and exclusion criteria. On meta-analysis, there was a significant overall survival (OS) benefit for patients with HPV positive and p16 positive tumors. There was some evidence of improved OS of OPSCC patients with raised bcl2; amplification of 11q3 and loss of 16q genes; and low c-met, ki67, IMD, PLK, FHIT, nuclear surviving, or nuclear cyclin D1. However, none of these was suitable for meta-analysis.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Survival from OPSCC is associated with several biomarkers, which constitute potential targets for research into improving the prognostic power of HPV in OPSCC. Larger trials are needed, with standardization of cut-points and adherence to consensus reporting guidelines. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Human papillomavirus (HPV) positivity improves prognosis in patients with oropharyngeal squamous cell carcinoma (OPSCC). Combining HPV status with other biomarkers may improve its prognostic power.


Methods
The approach was a literature search for longitudinal studies of biomarkers in OPSCC, with systematic review and meta-analysis.


Results
In all, 3130 articles were identified; 32 satisfied the inclusion and exclusion criteria. On meta-analysis, there was a significant overall survival (OS) benefit for patients with HPV positive and p16 positive tumors. There was some evidence of improved OS of OPSCC patients with raised bcl2; amplification of 11q3 and loss of 16q genes; and low c-met, ki67, IMD, PLK, FHIT, nuclear surviving, or nuclear cyclin D1. However, none of these was suitable for meta-analysis.


Conclusion
Survival from OPSCC is associated with several biomarkers, which constitute potential targets for research into improving the prognostic power of HPV in OPSCC. Larger trials are needed, with standardization of cut-points and adherence to consensus reporting guidelines. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23147" xmlns="http://purl.org/rss/1.0/"><title>New genetic findings in parotid gland pleomorphic adenomas</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23147</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">New genetic findings in parotid gland pleomorphic adenomas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Silke Wemmert, Vivienne Willnecker, Christian Brunner, Gentiana Ioana Wenzel, Birgit Sauter, Heike Meinelt, Nadia Bartholmé, Carolin Saada, Rainer Maria Bohle, Steffi Urbschat, Bernhard Schick</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:34:36.642483-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23147</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23147</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23147</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Despite numerous studies, the tumor biology of pleomorphic adenomas, the most common salivary gland tumors, is still not completely defined. In order to identify further candidate genes important for tumor biology of pleomorphic adenomas, extended cytogenetic and molecular analysis are mandatory.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We performed a detailed molecular cytogenetic analysis using comparative genomic hybridization (CGH) followed by fluorescence in situ hybridization (FISH) with probes for chromosome X, 16p, 17, and 20 on a large cohort of pleomorphic adenomas (<em>n</em> = 29).</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>We could confirm previously described deletions in pleomorphic adenomas affecting 16p, 17, 20q, and 22 by FISH and/or CGH analysis. Moreover, our CGH study revealed novel candidate regions on 8p23.1pter, 9p, 10q25.1q25.3, and 11q24qter in the series of analyzed pleomorphic adenomas.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Our present study reveals new insights in novel candidate regions implicated in pleomorphic adenoma tumorigenesis which should be considered in further molecular studies. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Despite numerous studies, the tumor biology of pleomorphic adenomas, the most common salivary gland tumors, is still not completely defined. In order to identify further candidate genes important for tumor biology of pleomorphic adenomas, extended cytogenetic and molecular analysis are mandatory.


Methods
We performed a detailed molecular cytogenetic analysis using comparative genomic hybridization (CGH) followed by fluorescence in situ hybridization (FISH) with probes for chromosome X, 16p, 17, and 20 on a large cohort of pleomorphic adenomas (n = 29).


Results
We could confirm previously described deletions in pleomorphic adenomas affecting 16p, 17, 20q, and 22 by FISH and/or CGH analysis. Moreover, our CGH study revealed novel candidate regions on 8p23.1pter, 9p, 10q25.1q25.3, and 11q24qter in the series of analyzed pleomorphic adenomas.


Conclusion
Our present study reveals new insights in novel candidate regions implicated in pleomorphic adenoma tumorigenesis which should be considered in further molecular studies. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23164" xmlns="http://purl.org/rss/1.0/"><title>Hypopharyngeal paraganglioma with a paraneoplastic neurologic syndrome: A case report</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23164</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Hypopharyngeal paraganglioma with a paraneoplastic neurologic syndrome: A case report</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Huiqin Tian, Zhibin Chen, Cong Wang, Guangqian Xing</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:34:17.066748-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23164</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23164</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23164</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Background</em></h4><div class="para"><p>We report an extremely rare case of hypopharyngeal paraganglioma that was accompanied by a paraneoplastic neurologic syndrome (PNS).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Methods</em></h4><div class="para"><p>The clinical, radiological, and histopathologic findings of the patient are presented.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Results</em></h4><div class="para"><p>A 49-year-old woman presented with a history of progressive asthenia of the lower extremities persisting for 2 months. She also experienced numbness and sensory disturbance of the left lower limbs, 2 epileptic seizures, and constipation during the period. Clinical and radiological evaluations suggested the diagnosis of encephalomyelitis in combination with a left hypopharyngeal mass lesion. The patient underwent surgical excision of the lesion, which subsequently resolved her symptoms. Postoperative pathology was consistent with a paraganglioma. There was no evidence of local recurrence or distant metastasis of the tumor on recent follow-up.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Conclusions</em></h4><div class="para"><p>To the best of our knowledge, our patient represents the third reported case of hypopharyngeal paraganglioma, and the only one to have a paraneoplastic syndrome. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
We report an extremely rare case of hypopharyngeal paraganglioma that was accompanied by a paraneoplastic neurologic syndrome (PNS).


Methods
The clinical, radiological, and histopathologic findings of the patient are presented.


Results
A 49-year-old woman presented with a history of progressive asthenia of the lower extremities persisting for 2 months. She also experienced numbness and sensory disturbance of the left lower limbs, 2 epileptic seizures, and constipation during the period. Clinical and radiological evaluations suggested the diagnosis of encephalomyelitis in combination with a left hypopharyngeal mass lesion. The patient underwent surgical excision of the lesion, which subsequently resolved her symptoms. Postoperative pathology was consistent with a paraganglioma. There was no evidence of local recurrence or distant metastasis of the tumor on recent follow-up.


Conclusions
To the best of our knowledge, our patient represents the third reported case of hypopharyngeal paraganglioma, and the only one to have a paraneoplastic syndrome. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23088" xmlns="http://purl.org/rss/1.0/"><title>Osteocutaneous radial forearm reconstruction of large partial cricotracheal defects</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23088</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Osteocutaneous radial forearm reconstruction of large partial cricotracheal defects</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Samer Al–Khudari, Saurabh Sharma, William Young, Robert Stapp, Tamer A. Ghanem</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:34:00.507907-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23088</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23088</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23088</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Single-stage procedures for reconstruction of large cricotracheal defects have been limited in success and malignant immature teratomas in the larynx of an adult have never been reported.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>This was a case report and literature review. A 27-year-old man presented with 2 weeks of new-onset stridor and was found to have a mass obstructing 80% of the subglottis and trachea. He underwent a noncircumferential partial cricotracheal resection with a resultant 7-cm luminal defect, followed by osteocutaneous radial forearm flap semi-rigid reconstruction. A novel technique was used to allow a functional and patent airway, which may be applied to other partial luminal reconstructive defects. Postoperatively, the patient was decannulated and has good speech quality and swallowing function. This work was performed at the Henry Ford Health System. This project was reviewed and was granted full approval by the Henry Ford Health System Institutional Review Board.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>This is the first reported case of malignant immature teratoma to involve the larynx, trachea, and recurrent laryngeal nerve in an adult patient, and the first single-stage technique described to use free tissue transfer without prefabrication for a 7-cm airway defect. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Single-stage procedures for reconstruction of large cricotracheal defects have been limited in success and malignant immature teratomas in the larynx of an adult have never been reported.


Methods and Results
This was a case report and literature review. A 27-year-old man presented with 2 weeks of new-onset stridor and was found to have a mass obstructing 80% of the subglottis and trachea. He underwent a noncircumferential partial cricotracheal resection with a resultant 7-cm luminal defect, followed by osteocutaneous radial forearm flap semi-rigid reconstruction. A novel technique was used to allow a functional and patent airway, which may be applied to other partial luminal reconstructive defects. Postoperatively, the patient was decannulated and has good speech quality and swallowing function. This work was performed at the Henry Ford Health System. This project was reviewed and was granted full approval by the Henry Ford Health System Institutional Review Board.


Conclusions
This is the first reported case of malignant immature teratoma to involve the larynx, trachea, and recurrent laryngeal nerve in an adult patient, and the first single-stage technique described to use free tissue transfer without prefabrication for a 7-cm airway defect. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23105" xmlns="http://purl.org/rss/1.0/"><title>Orthotopic VX rabbit tongue cancer model with FDG–PET and histologic characterization</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23105</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Orthotopic VX rabbit tongue cancer model with FDG–PET and histologic characterization</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Brendan C. Stack, John Ye, Twyla B. Bartel, Gal Shafirstein, Chien Chen, Eric Siegel, Bipin Singh, Samta Thacker, Val J. Lowe, Vivek Nagarkar</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:33:46.203009-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23105</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23105</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23105</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>We present our experience with the use of an immunocompetent medium-sized animal model of tongue cancer that may be suitable for imaging and surgical studies.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A New Zealand white rabbit model of tongue cancer was created by injecting a VX tumor cell suspension grown in culture into the tongue of our model. The tumor was examined 7 days following implantation by physical examination, photography, and <sup>18</sup>fluoro 2-deoxyglucose–positron emission tomography (FDG-PET). At 12 days postimplantation, the model was again studied as described above prior to euthanization, and then tongue excision and bilateral neck dissections were performed. All tissue was examined by histology.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>We confirmed a successful orthotopic tongue cancer model that resulted in cervical nodal metastases.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>This model may be a useful model of orthotopic head and neck cancer for future surgical or imaging research. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
We present our experience with the use of an immunocompetent medium-sized animal model of tongue cancer that may be suitable for imaging and surgical studies.


Methods
A New Zealand white rabbit model of tongue cancer was created by injecting a VX tumor cell suspension grown in culture into the tongue of our model. The tumor was examined 7 days following implantation by physical examination, photography, and 18fluoro 2-deoxyglucose–positron emission tomography (FDG-PET). At 12 days postimplantation, the model was again studied as described above prior to euthanization, and then tongue excision and bilateral neck dissections were performed. All tissue was examined by histology.


Results
We confirmed a successful orthotopic tongue cancer model that resulted in cervical nodal metastases.


Conclusion
This model may be a useful model of orthotopic head and neck cancer for future surgical or imaging research. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23153" xmlns="http://purl.org/rss/1.0/"><title>Bcl-xL protein: Predictor of complete tumor response in patients with oral cancer treated with curative radiotherapy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23153</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Bcl-xL protein: Predictor of complete tumor response in patients with oral cancer treated with curative radiotherapy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sanchita Mallick, Jaiprakash Agarwal, Sadhana Kannan, Sagar Pawar, Shubhada Kane, Tanuja Teni</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:33:30.748006-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23153</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23153</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23153</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>We earlier observed altered expression of p53 and Bcl-xL in oral cancer cell lines/tissues and wanted to evaluate these proteins for prediction of radiotherapy response and outcome.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Thirty-nine paraffin-embedded, pretreatment oral cancer biopsies were analyzed for protein expression using immunohistochemistry and correlated with tumor response to radiotherapy and disease-free survival (DFS).</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Result</h4><div class="para"><p>High p53 (<em>p</em> = .040) was observed in female versus male patients. Increased p53 intensity (<em>p</em> = .063) was observed in tobacco habitués (chewers ± smokers) versus patients with no habits. In univariate analysis, nodal positivity (<em>p</em> = .044) and favorable/complete tumor response (<em>p</em> = .002) exhibited a significant correlation with DFS, whereas tumor response emerged as an independent predictor of DFS in multivariate analysis. Significantly high Bcl-xL (<em>p</em> = .048) was observed in the unfavorable versus favorable responders.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Our study suggests that Bcl-xL expression along with clinical parameters may be useful for identifying patients with oral cancer likely to draw maximum benefit from curative radiotherapy. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
We earlier observed altered expression of p53 and Bcl-xL in oral cancer cell lines/tissues and wanted to evaluate these proteins for prediction of radiotherapy response and outcome.


Methods
Thirty-nine paraffin-embedded, pretreatment oral cancer biopsies were analyzed for protein expression using immunohistochemistry and correlated with tumor response to radiotherapy and disease-free survival (DFS).


Result
High p53 (p = .040) was observed in female versus male patients. Increased p53 intensity (p = .063) was observed in tobacco habitués (chewers ± smokers) versus patients with no habits. In univariate analysis, nodal positivity (p = .044) and favorable/complete tumor response (p = .002) exhibited a significant correlation with DFS, whereas tumor response emerged as an independent predictor of DFS in multivariate analysis. Significantly high Bcl-xL (p = .048) was observed in the unfavorable versus favorable responders.


Conclusion
Our study suggests that Bcl-xL expression along with clinical parameters may be useful for identifying patients with oral cancer likely to draw maximum benefit from curative radiotherapy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23154" xmlns="http://purl.org/rss/1.0/"><title>Vagal nerve stimulation without dissecting the carotid sheath during intraoperative neuromonitoring of the recurrent laryngeal nerve in thyroid surgery</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23154</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Vagal nerve stimulation without dissecting the carotid sheath during intraoperative neuromonitoring of the recurrent laryngeal nerve in thyroid surgery</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Che-Wei Wu, Gianlorenzo Dionigi, Hui-Chun Chen, Hsiu-Ya Chen, Ka-Wo Lee, I-Cheng Lu, Pi-Ying Chang, Pi-Jung Hsiao, Kuen-Yao Ho, Feng-Yu Chiang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:33:14.304759-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23154</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23154</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23154</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Background</em></h4><div class="para"><p>Vagal nerve stimulation (VNS) has been recommended as a routine procedure during intraoperative neuromonitoring (IONM) of the recurrent laryngeal nerve (RLN). However, many surgeons have been discouraged from performing VNS because of the need for opening the carotid sheath. The purpose of this study was to investigate the feasibility and reliability of VNS without carotid sheath dissection.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Methods</em></h4><div class="para"><p>Two hundred twenty patients with 376 nerves at risk were enrolled in this study. VNS without nerve exposure during IONM was applied by simply pressing a ball-tip stimulator on the space between the carotid artery and jugular vein.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Results</em></h4><div class="para"><p>VNS without nerve exposure was feasible in all cases and did not result in any morbidity. All VNS signals were successfully obtained within 30 minutes of the start of the operation and all showed a clear and reliable laryngeal electromyography (EMG) response that was similar to that from the conventional method in which nerve exposure for VNS is applied.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Conclusions</em></h4><div class="para"><p>VNS without dissecting the carotid sheath is feasible and reliable, rendering it a simple, safe, and surgeon-friendly procedure during IONM. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Vagal nerve stimulation (VNS) has been recommended as a routine procedure during intraoperative neuromonitoring (IONM) of the recurrent laryngeal nerve (RLN). However, many surgeons have been discouraged from performing VNS because of the need for opening the carotid sheath. The purpose of this study was to investigate the feasibility and reliability of VNS without carotid sheath dissection.


Methods
Two hundred twenty patients with 376 nerves at risk were enrolled in this study. VNS without nerve exposure during IONM was applied by simply pressing a ball-tip stimulator on the space between the carotid artery and jugular vein.


Results
VNS without nerve exposure was feasible in all cases and did not result in any morbidity. All VNS signals were successfully obtained within 30 minutes of the start of the operation and all showed a clear and reliable laryngeal electromyography (EMG) response that was similar to that from the conventional method in which nerve exposure for VNS is applied.


Conclusions
VNS without dissecting the carotid sheath is feasible and reliable, rendering it a simple, safe, and surgeon-friendly procedure during IONM. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23156" xmlns="http://purl.org/rss/1.0/"><title>Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: A meta-analysis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23156</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: A meta-analysis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jian Zang, Chen Li, Li-Na Zhao, Mei Shi, Yong-Chun Zhou, Jian-Hua Wang, Xin Li</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:32:58.867044-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23156</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23156</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23156</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The correlation between vascular endothelial growth factor (VEGF) overexpression and the clinical outcome of head and neck cancer remains inconclusive. This meta-analysis aimed to evaluate the prognostic value of VEGF in patients with head and neck cancer.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We searched Ovid MEDLINE, EMBASE and 2 Chinese science databases in order to enroll all eligible articles. Forty-seven studies were included in this meta-analysis. All results were evaluated by the random-effects model.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>VEGF overexpression is significantly associated with worse overall survival (OS; hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.61–2.22) and progression-free survival (PFS; HR, 1.68; 95% CI, 1.33–2.12). Subgroup analysis reveals that VEGF overexpression is a significant poor predictor for nasopharyngeal cancer (HR, 1.66; 95% CI, 1.30–2.12) and salivary gland cancer (HR, 3.32; 95% CI, 1.61–6.84).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Our meta-analysis supports that VEGF overexpression is an available poor predictor for patients with head and neck cancer. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The correlation between vascular endothelial growth factor (VEGF) overexpression and the clinical outcome of head and neck cancer remains inconclusive. This meta-analysis aimed to evaluate the prognostic value of VEGF in patients with head and neck cancer.


Methods
We searched Ovid MEDLINE, EMBASE and 2 Chinese science databases in order to enroll all eligible articles. Forty-seven studies were included in this meta-analysis. All results were evaluated by the random-effects model.


Results
VEGF overexpression is significantly associated with worse overall survival (OS; hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.61–2.22) and progression-free survival (PFS; HR, 1.68; 95% CI, 1.33–2.12). Subgroup analysis reveals that VEGF overexpression is a significant poor predictor for nasopharyngeal cancer (HR, 1.66; 95% CI, 1.30–2.12) and salivary gland cancer (HR, 3.32; 95% CI, 1.61–6.84).


Conclusion
Our meta-analysis supports that VEGF overexpression is an available poor predictor for patients with head and neck cancer. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23169" xmlns="http://purl.org/rss/1.0/"><title>Identification of upregulated genes in oral squamous cell carcinomas</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23169</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Identification of upregulated genes in oral squamous cell carcinomas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roberta C. Lessa, Antonio Hugo J. F. M. Campos, Carlos Elias de Freitas, Felipe Rodrigues da Silva, Luiz Paulo Kowalski, André Lopes Carvalho, André Luiz Vettore</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:32:40.915577-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23169</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23169</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23169</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Oral cancer is the most common subset of head and neck squamous cell carcinomas (HNSCC). These tumors often have an aggressive clinical outcome hallmarked by a propensity for local invasion and regional nodal metastasis. Upregulated genes could be useful as markers for diagnosis, prognosis, and as new drug targets for these tumors.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>To identify upregulated genes in oral squamous cell carcinomas (OSSCs), we examined the ORESTES public database and used a quantitative reverse transcription–polymerase chain reaction (qRT-PCR) approach to determine the expression level of selected genes in tumor samples.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results and Conclusions</h4><div class="para"><p>The ORESTES data mining analysis indicated 40 upregulated genes in HNSCC. Nine of these candidate genes were selected for further qRT-PCR validation and 3 of them (<em>ALDOA</em>, <em>AHSA1</em>, and <em>POLQ</em>) were frequently found upregulated in OSCC samples, which may indicate an association of these genes with the carcinogenesis process in this tumor site and they can constitute potential new targets for therapy. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Oral cancer is the most common subset of head and neck squamous cell carcinomas (HNSCC). These tumors often have an aggressive clinical outcome hallmarked by a propensity for local invasion and regional nodal metastasis. Upregulated genes could be useful as markers for diagnosis, prognosis, and as new drug targets for these tumors.


Methods
To identify upregulated genes in oral squamous cell carcinomas (OSSCs), we examined the ORESTES public database and used a quantitative reverse transcription–polymerase chain reaction (qRT-PCR) approach to determine the expression level of selected genes in tumor samples.


Results and Conclusions
The ORESTES data mining analysis indicated 40 upregulated genes in HNSCC. Nine of these candidate genes were selected for further qRT-PCR validation and 3 of them (ALDOA, AHSA1, and POLQ) were frequently found upregulated in OSCC samples, which may indicate an association of these genes with the carcinogenesis process in this tumor site and they can constitute potential new targets for therapy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23138" xmlns="http://purl.org/rss/1.0/"><title>Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23138</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hao Wu, Huiming Xu, Shu Zhang, Xudong Wang, Huijun Zhu, Huilin Zhang, Jin Zhu, Jianfei Huang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:32:23.45986-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23138</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23138</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23138</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The human trophoblastic cell surface antigen 2 (TROP2) gene is associated with the development of malignancies, but its expression in laryngeal squamous cell carcinoma (SCC) and its relationship with clinical characteristics of the disease remain undetermined.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Expression of TROP2 protein was detected by immunohistochemistry with a self-made anti-TROP2 antibody in laryngeal SCC tissue microarrays.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Elevated expression of TROP2 was detected in laryngeal SCC tissues compared with adjacent noncancerous tissues. TROP2 expression in laryngeal SCC was related to tumor differentiation (<em>p</em> = .0001) and lymph node metastasis (<em>p</em> = .0352). Cox regression analyses confirmed that TROP2 expression (<em>p</em> = .015), lymph node metastasis (<em>p</em> = .001), degree of differentiation (<em>p</em> = .002), tumor site (<em>p</em> = .021), and T classification (<em>p</em> = .003) were independent prognostic factors.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>TROP2 can be used as an independent prognostic indicator for laryngeal SCC. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The human trophoblastic cell surface antigen 2 (TROP2) gene is associated with the development of malignancies, but its expression in laryngeal squamous cell carcinoma (SCC) and its relationship with clinical characteristics of the disease remain undetermined.


Methods
Expression of TROP2 protein was detected by immunohistochemistry with a self-made anti-TROP2 antibody in laryngeal SCC tissue microarrays.


Results
Elevated expression of TROP2 was detected in laryngeal SCC tissues compared with adjacent noncancerous tissues. TROP2 expression in laryngeal SCC was related to tumor differentiation (p = .0001) and lymph node metastasis (p = .0352). Cox regression analyses confirmed that TROP2 expression (p = .015), lymph node metastasis (p = .001), degree of differentiation (p = .002), tumor site (p = .021), and T classification (p = .003) were independent prognostic factors.


Conclusions
TROP2 can be used as an independent prognostic indicator for laryngeal SCC. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23139" xmlns="http://purl.org/rss/1.0/"><title>Multimodal nonlinear microscopic investigations on head and neck squamous cell carcinoma: Toward intraoperative imaging</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23139</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Multimodal nonlinear microscopic investigations on head and neck squamous cell carcinoma: Toward intraoperative imaging</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tobias Meyer, Orlando Guntinas-Lichius, Ferdinand von Eggeling, Günther Ernst, Denis Akimov, Michael Schmitt, Benjamin Dietzek, Jürgen Popp</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:32:07.802634-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23139</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23139</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23139</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Prognosis and appropriate treatment of head and neck squamous cell carcinoma (HNSCC) depend on the tumor type routinely derived by invasive histopathology. A promising noninvasive alternative is nonlinear optical imaging, which is capable of in vivo tissue visualization for tumor typing and grading.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>Thin tissue sections from 3 patients aged 56 to 60 years presenting advanced carcinoma of the hypopharynx, larynx, and left tonsil were investigated by coherent anti-Stokes Raman scattering (CARS), second-harmonic generation (SHG), and 2 photon excited fluorescence (TPEF) to study the morphochemistry of the tissues. Morphologic alterations of prognostic significance, such as cell density, nuclear to cytoplasm ratio, and keratinization as well as the underlying compositional changes during malignant transformation were determined, such as the distributions of lipids, collagen, and autofluorophors.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Nonlinear imaging provides a noninvasive optical biopsy of the epithelial layer comparable to staining microscopy. By integration into an operational microscope, routine screening of suspicious lesions and surgical guidance can be realized. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Prognosis and appropriate treatment of head and neck squamous cell carcinoma (HNSCC) depend on the tumor type routinely derived by invasive histopathology. A promising noninvasive alternative is nonlinear optical imaging, which is capable of in vivo tissue visualization for tumor typing and grading.


Methods and Results
Thin tissue sections from 3 patients aged 56 to 60 years presenting advanced carcinoma of the hypopharynx, larynx, and left tonsil were investigated by coherent anti-Stokes Raman scattering (CARS), second-harmonic generation (SHG), and 2 photon excited fluorescence (TPEF) to study the morphochemistry of the tissues. Morphologic alterations of prognostic significance, such as cell density, nuclear to cytoplasm ratio, and keratinization as well as the underlying compositional changes during malignant transformation were determined, such as the distributions of lipids, collagen, and autofluorophors.


Conclusions
Nonlinear imaging provides a noninvasive optical biopsy of the epithelial layer comparable to staining microscopy. By integration into an operational microscope, routine screening of suspicious lesions and surgical guidance can be realized. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23150" xmlns="http://purl.org/rss/1.0/"><title>First bite syndrome: Case report of 3 patients treated with botulinum toxin and review of other treatment modalities</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23150</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">First bite syndrome: Case report of 3 patients treated with botulinum toxin and review of other treatment modalities</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John R. Sims, James Y. Suen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:31:37.244531-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23150</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23150</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23150</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>First bite syndrome is an unexpected yet relatively common complication of surgeries involving the parapharyngeal space. It can have a significant effect on both the quality of life and physical health of affected patients. This study presents 3 cases of first bite syndrome treated with botulinum toxin and a review of the current literature on available treatment modalities for first bite syndrome.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Three patients with first bite syndrome were injected with 75 units of botulinum toxin into affected parotid glands, focusing on areas of greatest first bite pain.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Two of 3 patients experienced complete relief of symptoms for 4 to 6 months. The third patient had significant decrease in pain at 4-month follow-up.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Many treatments for first bite syndrome have been attempted including: dietary modification, pharmacological treatments, and surgical treatments. However, few have been successful. Botulinum toxin is a safe and effective treatment for this life altering and difficult to treat first bite syndrome. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
First bite syndrome is an unexpected yet relatively common complication of surgeries involving the parapharyngeal space. It can have a significant effect on both the quality of life and physical health of affected patients. This study presents 3 cases of first bite syndrome treated with botulinum toxin and a review of the current literature on available treatment modalities for first bite syndrome.


Methods
Three patients with first bite syndrome were injected with 75 units of botulinum toxin into affected parotid glands, focusing on areas of greatest first bite pain.


Results
Two of 3 patients experienced complete relief of symptoms for 4 to 6 months. The third patient had significant decrease in pain at 4-month follow-up.


Conclusions
Many treatments for first bite syndrome have been attempted including: dietary modification, pharmacological treatments, and surgical treatments. However, few have been successful. Botulinum toxin is a safe and effective treatment for this life altering and difficult to treat first bite syndrome. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23151" xmlns="http://purl.org/rss/1.0/"><title>Influence of study sponsorship on head and neck cancer randomized trial results</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23151</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Influence of study sponsorship on head and neck cancer randomized trial results</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gordon H. Sun, Jeffrey J. Houlton, Mark P. MacEachern, Carol R. Bradford, Rodney A. Hayward</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:31:14.586497-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23151</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23151</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23151</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to identify associations between study sponsorship and the methodological quality and published outcomes of head and neck cancer randomized controlled trials (RCTs).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We systematically searched MEDLINE, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials for qualified RCTs, evaluating journal impact factor (IF), Jadad score (measure of study quality), and results favoring or not favoring experimental therapy.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Of 118 RCTs, the most common sponsor was government (38; 32%), followed by nonprofit organizations (30; 25%) and industry (26; 22%). Industry-supported RCTs were associated with publication in journals with higher IF compared with RCTs without industry support (<em>p</em> = .013). Government-supported RCTs were associated with higher mean Jadad score (<em>p</em> = .026) and results favoring experimental therapy (<em>p</em> = .034).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Government-supported, but not industry-supported, RCTs were significantly associated with positive study results. These findings may be confounded by broadly applied definitions of sponsorship. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to identify associations between study sponsorship and the methodological quality and published outcomes of head and neck cancer randomized controlled trials (RCTs).


Methods
We systematically searched MEDLINE, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials for qualified RCTs, evaluating journal impact factor (IF), Jadad score (measure of study quality), and results favoring or not favoring experimental therapy.


Results
Of 118 RCTs, the most common sponsor was government (38; 32%), followed by nonprofit organizations (30; 25%) and industry (26; 22%). Industry-supported RCTs were associated with publication in journals with higher IF compared with RCTs without industry support (p = .013). Government-supported RCTs were associated with higher mean Jadad score (p = .026) and results favoring experimental therapy (p = .034).


Conclusions
Government-supported, but not industry-supported, RCTs were significantly associated with positive study results. These findings may be confounded by broadly applied definitions of sponsorship. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23108" xmlns="http://purl.org/rss/1.0/"><title>Economic analysis of FDG-PET–guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23108</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Economic analysis of FDG-PET–guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David I. Pryor, Sandro V. Porceddu, Paul A. Scuffham, Jennifer A. Whitty, Paul A. Thomas, Bryan H. Burmeister</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:30:59.800886-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23108</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23108</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23108</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The aim of this economic analysis was to model different strategies using pre-treatment nodal stage or nodal response assessment with CT or positron emission tomography (PET)/CT to determine the need for neck dissection.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A cost-minimization analysis was developed on the basis of probability data from a prospective study of PET-guided management of the neck in patients achieving a complete response at the primary site. Costs were derived from our institution's activity-based clinical costing system. The effect of uncertainty was tested with sensitivity and scenario analyses including nationally representative cost data.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Strategies incorporating PET had a 7% rate for neck dissection compared with 44% for CT-guided and 90% for planned neck dissection. The cost per patient was A$16,502 for planned neck dissection, A$8014 for CT-guided, and A$2573 for PET-guided. A policy with PET used only for incomplete response on CT was the least-cost strategy (A$2111). Policies incorporating PET remained the most efficient for all sensitivity/scenario analyses.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>The incorporation of PET/CT into nodal response assessment significantly reduced the number of unnecessary neck dissections and generated considerable cost savings in our cohort. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The aim of this economic analysis was to model different strategies using pre-treatment nodal stage or nodal response assessment with CT or positron emission tomography (PET)/CT to determine the need for neck dissection.


Methods
A cost-minimization analysis was developed on the basis of probability data from a prospective study of PET-guided management of the neck in patients achieving a complete response at the primary site. Costs were derived from our institution's activity-based clinical costing system. The effect of uncertainty was tested with sensitivity and scenario analyses including nationally representative cost data.


Results
Strategies incorporating PET had a 7% rate for neck dissection compared with 44% for CT-guided and 90% for planned neck dissection. The cost per patient was A$16,502 for planned neck dissection, A$8014 for CT-guided, and A$2573 for PET-guided. A policy with PET used only for incomplete response on CT was the least-cost strategy (A$2111). Policies incorporating PET remained the most efficient for all sensitivity/scenario analyses.


Conclusion
The incorporation of PET/CT into nodal response assessment significantly reduced the number of unnecessary neck dissections and generated considerable cost savings in our cohort. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23120" xmlns="http://purl.org/rss/1.0/"><title>Quality of life instruments for skull base pathology: Systematic review and methodologic appraisal</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23120</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Quality of life instruments for skull base pathology: Systematic review and methodologic appraisal</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John R. de Almeida, Ian J. Witterick, Patrick J. Gullane, Fred Gentili, Lynne Lohfeld, Jolie Ringash, Achilles Thoma, Allan D. Vescan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-18T05:30:45.51172-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23120</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23120</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23120</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Several quality of life (QOL) instruments exist for skull base pathology, however, there have been no attempts to appraise and systematically review these instruments.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We systematically reviewed MEDLINE, EMBASE, Central, AMED, Health and Psychosocial Instruments, and PsychoInfo for anterior or central skull base QOL instruments to January 2010. We queried experts, bibliographies, and meeting proceedings from the North American Skull Base Society from 2005 to 2009. Included instruments were evaluated for instrument characteristics, item generation and reduction, field testing, and measurement properties using predefined criteria.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>We identified 9 QOL instruments: 7 measuring QOL for pituitary pathology, 1 for midface pathology, and 1 for anterior skull base pathology. Eight of the 9 instruments have had some psychometric testing. None demonstrated all of the predefined psychometric properties.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>There are several QOL instruments for patients with skull base pathology. None of these instruments met all predefined requirements, and further instrument development is needed. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Several quality of life (QOL) instruments exist for skull base pathology, however, there have been no attempts to appraise and systematically review these instruments.


Methods
We systematically reviewed MEDLINE, EMBASE, Central, AMED, Health and Psychosocial Instruments, and PsychoInfo for anterior or central skull base QOL instruments to January 2010. We queried experts, bibliographies, and meeting proceedings from the North American Skull Base Society from 2005 to 2009. Included instruments were evaluated for instrument characteristics, item generation and reduction, field testing, and measurement properties using predefined criteria.


Results
We identified 9 QOL instruments: 7 measuring QOL for pituitary pathology, 1 for midface pathology, and 1 for anterior skull base pathology. Eight of the 9 instruments have had some psychometric testing. None demonstrated all of the predefined psychometric properties.


Conclusions
There are several QOL instruments for patients with skull base pathology. None of these instruments met all predefined requirements, and further instrument development is needed. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23094" xmlns="http://purl.org/rss/1.0/"><title>Transoral en bloc resection of superficial laryngeal and pharyngeal cancers</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23094</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Transoral en bloc resection of superficial laryngeal and pharyngeal cancers</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kenji Okami, Koji Ebisumoto, Akihiro Sakai, Ryousuke Sugimoto, Daisuke Maki, Kosuke Saito, Shoji Kaneda, Masahiro Iida, Go Ogura, Naoya Nakamura, Koichiro Nishiyama</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:55:48.416679-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23094</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23094</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23094</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The objective of this study was to evaluate the efficacy and safety of minimally invasive transoral en bloc resection of superficial pharyngeal and laryngeal cancers.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Forty-one superficial lesions (from 35 patients) were resected transorally under a surgical microscope using a monopolar cautery. Quality of life (QOL) was assessed using a questionnaire European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Cancer Module (EORTC QLQ-H&amp;N35) 1 year after the surgery.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Twenty-eight hypopharyngeal, 5 oropharyngeal, and 8 laryngeal cancers were operated on using this method. The surgical field was widely exposed with a wide-caliber scope or extending laryngoscope. A bimanual procedure under a surgical microscope enabled us to achieve en bloc resection. The local control rate was 98%. No postoperative dyspnea or dysphagia was observed. Postoperative QOL scores were favorable.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Our transoral en bloc resection technique can be easily adopted, and it effectively maintained QOL after treatment. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The objective of this study was to evaluate the efficacy and safety of minimally invasive transoral en bloc resection of superficial pharyngeal and laryngeal cancers.


Methods
Forty-one superficial lesions (from 35 patients) were resected transorally under a surgical microscope using a monopolar cautery. Quality of life (QOL) was assessed using a questionnaire European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Cancer Module (EORTC QLQ-H&amp;N35) 1 year after the surgery.


Results
Twenty-eight hypopharyngeal, 5 oropharyngeal, and 8 laryngeal cancers were operated on using this method. The surgical field was widely exposed with a wide-caliber scope or extending laryngoscope. A bimanual procedure under a surgical microscope enabled us to achieve en bloc resection. The local control rate was 98%. No postoperative dyspnea or dysphagia was observed. Postoperative QOL scores were favorable.


Conclusions
Our transoral en bloc resection technique can be easily adopted, and it effectively maintained QOL after treatment. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23116" xmlns="http://purl.org/rss/1.0/"><title>Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23116</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jianji Pan, Tianlan Tang, Luying Xu, Jiade J. Lu, Senan Lin, Sufang Qiu, Gang Chen, Ivan W. K. Tham</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:55:35.586849-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23116</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23116</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23116</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The association between expression of cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and the long-term outcomes in treated nasopharyngeal carcinoma (NPC) was studied.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Expression of COX-2, VEGF, and EGFR by immunohistochemical (IHC) staining was assessed in 128 patients with NPC. Overall survival (OS), disease-free survival (DFS), locoregional control, and distant metastasis-free survival rates were compared for different expression levels of each marker. Multivariate analysis was by the Cox regression model.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Median follow-up after radiation therapy ± chemotherapy was 116 months. Univariate and multivariate analyses demonstrated that COX-2, VEGF, EGFR, and clinical stage were all independent predictors for OS, DFS, locoregional control, and distant metastasis–free survival rates.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>High expression of COX-2, VEGF, and EGFR were independent adverse prognostic factors for long-term outcomes in nonmetastatic NPC independent of clinical stage. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The association between expression of cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and the long-term outcomes in treated nasopharyngeal carcinoma (NPC) was studied.


Methods
Expression of COX-2, VEGF, and EGFR by immunohistochemical (IHC) staining was assessed in 128 patients with NPC. Overall survival (OS), disease-free survival (DFS), locoregional control, and distant metastasis-free survival rates were compared for different expression levels of each marker. Multivariate analysis was by the Cox regression model.


Results
Median follow-up after radiation therapy ± chemotherapy was 116 months. Univariate and multivariate analyses demonstrated that COX-2, VEGF, EGFR, and clinical stage were all independent predictors for OS, DFS, locoregional control, and distant metastasis–free survival rates.


Conclusions
High expression of COX-2, VEGF, and EGFR were independent adverse prognostic factors for long-term outcomes in nonmetastatic NPC independent of clinical stage. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23131" xmlns="http://purl.org/rss/1.0/"><title>Neck and shoulder function in patients treated for oral malignancies: A 1-year prospective cohort study</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23131</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Neck and shoulder function in patients treated for oral malignancies: A 1-year prospective cohort study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Caroline M. Speksnijder, Andries van der Bilt, Margot Slappendel, Anton de Wijer, Matthias A.W. Merkx, Ron Koole</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:55:19.680211-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23131</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23131</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23131</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Neck and shoulder complaints can be a direct result of a neck dissection.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Maximal active lateral flexion of the neck, forward flexion and abduction of the shoulder, and self-perceived function were determined in 145 patients treated for oral cancer.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>No short-term influence of radiotherapy was found on measured range of motion and self-perceived neck and shoulder function (<em>p</em> &gt; .05). One year after a bilateral neck dissection, patients showed deteriorated lateral flexion of the neck, whereas patients treated with a unilateral modified radical neck dissection still reported pain during neck movements. Maximal forward flexion of the shoulder recovered to the level of healthy controls, but maximal abduction was still reduced in all patients.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Neck dissection, tumor site, and extensive reconstruction are related to deterioration of shoulder function shortly after intervention. Maximal active shoulder abduction was affected most. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Neck and shoulder complaints can be a direct result of a neck dissection.


Methods
Maximal active lateral flexion of the neck, forward flexion and abduction of the shoulder, and self-perceived function were determined in 145 patients treated for oral cancer.


Results
No short-term influence of radiotherapy was found on measured range of motion and self-perceived neck and shoulder function (p &gt; .05). One year after a bilateral neck dissection, patients showed deteriorated lateral flexion of the neck, whereas patients treated with a unilateral modified radical neck dissection still reported pain during neck movements. Maximal forward flexion of the shoulder recovered to the level of healthy controls, but maximal abduction was still reduced in all patients.


Conclusions
Neck dissection, tumor site, and extensive reconstruction are related to deterioration of shoulder function shortly after intervention. Maximal active shoulder abduction was affected most. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23137" xmlns="http://purl.org/rss/1.0/"><title>Oncologic and functional outcome of the preserved eye in malignant sinonasal tumors</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23137</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Oncologic and functional outcome of the preserved eye in malignant sinonasal tumors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mayuri Rajapurkar, Krishnakumar Thankappan, Leela Mohan C. S. Sampathirao, Moni Abraham Kuriakose, Subramania Iyer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:54:54.311893-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23137</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23137</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23137</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to analyze the oncologic and functional outcomes of the preserved eye in malignant sinonasal tumors with orbital involvement.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In a retrospective study of 19 consecutive patients who underwent craniofacial resection or maxillectomy with preservation of orbital contents and adjuvant radiotherapy, the oncological outcome in terms of local recurrence and survival was analyzed. The functional outcome in the preserved eye was analyzed for the cases that did not recur in the orbit.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Nineteen patients were analyzed for their oncologic and functional outcomes. Fifteen patients underwent immediate reconstruction of the orbital support. Eight patients had local recurrences; 11 patients were disease free at the end of the follow-up. Squamous cell carcinoma has a high propensity for local recurrences (ie, 5 of 8 local recurrences were squamous cell carcinoma). Sixteen patients, in whom a satisfactory orbital tumor clearance was obtained, remained recurrence free in the orbit. All the preserved eyes retained adequate function after adjuvant radiotherapy.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Adequate local control with preserved visual function can be obtained with surgery and adjuvant radiation in appropriately selected malignant sinonasal tumors with orbital involvement. The preserved eye, if reconstructed appropriately, maintains good overall function with acceptable morbidity. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to analyze the oncologic and functional outcomes of the preserved eye in malignant sinonasal tumors with orbital involvement.


Methods
In a retrospective study of 19 consecutive patients who underwent craniofacial resection or maxillectomy with preservation of orbital contents and adjuvant radiotherapy, the oncological outcome in terms of local recurrence and survival was analyzed. The functional outcome in the preserved eye was analyzed for the cases that did not recur in the orbit.


Results
Nineteen patients were analyzed for their oncologic and functional outcomes. Fifteen patients underwent immediate reconstruction of the orbital support. Eight patients had local recurrences; 11 patients were disease free at the end of the follow-up. Squamous cell carcinoma has a high propensity for local recurrences (ie, 5 of 8 local recurrences were squamous cell carcinoma). Sixteen patients, in whom a satisfactory orbital tumor clearance was obtained, remained recurrence free in the orbit. All the preserved eyes retained adequate function after adjuvant radiotherapy.


Conclusions
Adequate local control with preserved visual function can be obtained with surgery and adjuvant radiation in appropriately selected malignant sinonasal tumors with orbital involvement. The preserved eye, if reconstructed appropriately, maintains good overall function with acceptable morbidity. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23157" xmlns="http://purl.org/rss/1.0/"><title>Readability assessment of online thyroid surgery patient education materials</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23157</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Readability assessment of online thyroid surgery patient education materials</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chirag R. Patel, Deepa V. Cherla, Saurin Sanghvi, Soly Baredes, Jean Anderson Eloy</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:54:28.455748-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23157</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23157</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23157</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Published guidelines recommend written health information be written at or below the sixth-grade level. We evaluate the readability of online materials related to thyroid surgery.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Thyroid surgery materials were evaluated using Flesch Reading Ease Score (FRES), Flesch Kincaid Grade Level (FKGL), Gunning Frequency of Gobbledygook (GFOG), and Simple Measure of Gobbledygook (SMOG).</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Thirty-one documents were evaluated. FRES scores ranged from 29.3 to 67.8 (possible range = 0 to 100), and averaged 50.5. FKGL ranged from 6.9 to 14.9 (possible range = 3 to 12), and averaged 10.4. SMOG scores ranged from 11.8 to 14.5 (possible range = 3 to 19), and averaged 13.0. GFOG scores ranged from 10.6 to 18.0 (possible range = 3 to 19), and averaged 13.5.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Readability scores for online thyroid surgery materials are higher (i.e., more difficult) than the recommended levels. However, readability is only one aspect of comprehension. Written information should be designed with that fact in mind. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Published guidelines recommend written health information be written at or below the sixth-grade level. We evaluate the readability of online materials related to thyroid surgery.


Methods
Thyroid surgery materials were evaluated using Flesch Reading Ease Score (FRES), Flesch Kincaid Grade Level (FKGL), Gunning Frequency of Gobbledygook (GFOG), and Simple Measure of Gobbledygook (SMOG).


Results
Thirty-one documents were evaluated. FRES scores ranged from 29.3 to 67.8 (possible range = 0 to 100), and averaged 50.5. FKGL ranged from 6.9 to 14.9 (possible range = 3 to 12), and averaged 10.4. SMOG scores ranged from 11.8 to 14.5 (possible range = 3 to 19), and averaged 13.0. GFOG scores ranged from 10.6 to 18.0 (possible range = 3 to 19), and averaged 13.5.


Conclusions
Readability scores for online thyroid surgery materials are higher (i.e., more difficult) than the recommended levels. However, readability is only one aspect of comprehension. Written information should be designed with that fact in mind. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23161" xmlns="http://purl.org/rss/1.0/"><title>Metastasis over implantable venous access ports</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23161</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Metastasis over implantable venous access ports</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chun-Hong Lee, An-Shiou Day, Tzer-Zen Hwang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:54:16.562326-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23161</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23161</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23161</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The totally implantable venous access port (TIVAP) is an important device for patients receiving chemotherapy. We have reported, to our knowledge, the first case of a metastatic tumor over a TIVAP implanted via the Seldinger technique with a subclavian vein puncture.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Our patient, a 48-year-old man with hard palate cancer, had metastasis over the TIVAP. CT studies showed that the tumor had spread along the catheter from the neck to the chest wall.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The cause of death was multiple lung metastases and intractable tumor bleeding over the TIVAP.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>We present a novel case of metastasis over the TIVAP implanted by use of the Seldinger technique. This technique is used for patients receiving prolonged cytotoxic therapy for malignancy. Although the Seldinger technique is quick and more effective, we prefer the cephalic vein cut-down technique when an aggressive, advanced cancer of head and neck is involved. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The totally implantable venous access port (TIVAP) is an important device for patients receiving chemotherapy. We have reported, to our knowledge, the first case of a metastatic tumor over a TIVAP implanted via the Seldinger technique with a subclavian vein puncture.


Methods
Our patient, a 48-year-old man with hard palate cancer, had metastasis over the TIVAP. CT studies showed that the tumor had spread along the catheter from the neck to the chest wall.


Results
The cause of death was multiple lung metastases and intractable tumor bleeding over the TIVAP.


Conclusions
We present a novel case of metastasis over the TIVAP implanted by use of the Seldinger technique. This technique is used for patients receiving prolonged cytotoxic therapy for malignancy. Although the Seldinger technique is quick and more effective, we prefer the cephalic vein cut-down technique when an aggressive, advanced cancer of head and neck is involved. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23163" xmlns="http://purl.org/rss/1.0/"><title>Case of pediatric acute promyelocytic leukemia presenting as extramedullary tumor of the mandible</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23163</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Case of pediatric acute promyelocytic leukemia presenting as extramedullary tumor of the mandible</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yoshio Yamashita, Naoko Isomura, Yuhei Hamasaki, Masaaki Goto</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:54:00.559332-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23163</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23163</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23163</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Acute promyelocytic leukemia (APL) is a malignant subtype of acute myeloid leukemia caused by the <em>PML-retinoic acid receptor (RAR)α</em> fusion gene. APL may be discovered in adulthood and diagnosed after spontaneous gingival bleeding or difficulty in hemostasis after oral surgery such as tooth extraction. However, APL is extremely rare in children.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>A 1-year-old boy presented with a mass on the mentum of the mandible. The marked periosteal reaction was seen on CT and MRI, leading to strong suspicion of a malignant bone-derived tumor such as a sarcoma. Chromosome banding by fluorescence in situ hybridization (FISH) showed <em>PML-RAR</em>α, confirming the diagnosis of APL. Treatment with tretinoin was immediately initiated. No signs of recurrence have been noted 1 year after treatment.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>We report herein a rare case involving an infant with APL who presented with an extramedullary tumor of the mandible, whom we treated with good results. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Acute promyelocytic leukemia (APL) is a malignant subtype of acute myeloid leukemia caused by the PML-retinoic acid receptor (RAR)α fusion gene. APL may be discovered in adulthood and diagnosed after spontaneous gingival bleeding or difficulty in hemostasis after oral surgery such as tooth extraction. However, APL is extremely rare in children.


Methods and Results
A 1-year-old boy presented with a mass on the mentum of the mandible. The marked periosteal reaction was seen on CT and MRI, leading to strong suspicion of a malignant bone-derived tumor such as a sarcoma. Chromosome banding by fluorescence in situ hybridization (FISH) showed PML-RARα, confirming the diagnosis of APL. Treatment with tretinoin was immediately initiated. No signs of recurrence have been noted 1 year after treatment.


Conclusions
We report herein a rare case involving an infant with APL who presented with an extramedullary tumor of the mandible, whom we treated with good results. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23171" xmlns="http://purl.org/rss/1.0/"><title>Buried free flaps in head and neck surgery: Outcome analysis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23171</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Buried free flaps in head and neck surgery: Outcome analysis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert H. Lindau, Kara Detwiller, Mark K. Wax</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:53:47.089034-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23171</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23171</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23171</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Over the last several decades, reconstruction of the head and neck oncologic defect has been revolutionized by the use of microvascular free tissue transfer. The majority of these defects can be reconstructed with the ability to visually monitor the flap, to intervene as soon as vascular compromise becomes evident. Occasionally, it is necessary to use a flap that has no visual external monitor: a buried free flap. A belief has circulated within the microvascular community that buried free flaps do not do as well as visible flaps. By our review, there are no recent data in the literature to support this position. We present our data on the outcomes of buried free flaps in microvascular reconstruction.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A single institutional retrospective review of 1492 flaps was performed between January 1999 and December 2011. A total of 103 free flaps (7.2%) were identified as meeting the criteria for a buried flap. It should be noted that all flaps with or without an external segment were monitored with an implantable Doppler. The flap failure and complications are defined as those failures or complications occurring within 2 weeks of surgery and related to the operation or to the flap itself.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In all, 5 of the 103 patients (4.9%) had complications requiring reoperative intervention. There were no instances of flap failure within the first 2 weeks of surgery.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>In our series, there are no differences in flap failure rates comparing buried flaps to externally monitored flaps. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Over the last several decades, reconstruction of the head and neck oncologic defect has been revolutionized by the use of microvascular free tissue transfer. The majority of these defects can be reconstructed with the ability to visually monitor the flap, to intervene as soon as vascular compromise becomes evident. Occasionally, it is necessary to use a flap that has no visual external monitor: a buried free flap. A belief has circulated within the microvascular community that buried free flaps do not do as well as visible flaps. By our review, there are no recent data in the literature to support this position. We present our data on the outcomes of buried free flaps in microvascular reconstruction.


Methods
A single institutional retrospective review of 1492 flaps was performed between January 1999 and December 2011. A total of 103 free flaps (7.2%) were identified as meeting the criteria for a buried flap. It should be noted that all flaps with or without an external segment were monitored with an implantable Doppler. The flap failure and complications are defined as those failures or complications occurring within 2 weeks of surgery and related to the operation or to the flap itself.


Results
In all, 5 of the 103 patients (4.9%) had complications requiring reoperative intervention. There were no instances of flap failure within the first 2 weeks of surgery.


Conclusion
In our series, there are no differences in flap failure rates comparing buried flaps to externally monitored flaps. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23140" xmlns="http://purl.org/rss/1.0/"><title>Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23140</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vikas Mehta, Yuri E. Nikiforov, Robert L. Ferris</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:53:32.380499-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23140</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23140</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23140</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Accurate preoperative assessment of thyroid nodules with fine-needle aspiration biopsy (FNAB) continues to be a challenge, often resulting in unnecessary diagnostic surgical intervention. The detection of several novel gene mutations in differentiated thyroid cancer (DTC) over the last decade has led to the diagnostic use of these oncogenic alterations to improve FNAB sensitivity and specificity.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>Thyroid oncogene mutations including BRAF, RAS, and RET/PTC are reviewed. The potential benefit of using this panel on fine-needle aspiration (FNA) cytology samples will be described.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Our use of ‘‘reflexive’’ molecular testing demonstrates its clinical value in conjunction with FNAB cytology, representing an application of personalized molecular medicine to guide appropriate surgical therapy. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Accurate preoperative assessment of thyroid nodules with fine-needle aspiration biopsy (FNAB) continues to be a challenge, often resulting in unnecessary diagnostic surgical intervention. The detection of several novel gene mutations in differentiated thyroid cancer (DTC) over the last decade has led to the diagnostic use of these oncogenic alterations to improve FNAB sensitivity and specificity.


Methods and Results
Thyroid oncogene mutations including BRAF, RAS, and RET/PTC are reviewed. The potential benefit of using this panel on fine-needle aspiration (FNA) cytology samples will be described.


Conclusion
Our use of ‘‘reflexive’’ molecular testing demonstrates its clinical value in conjunction with FNAB cytology, representing an application of personalized molecular medicine to guide appropriate surgical therapy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23141" xmlns="http://purl.org/rss/1.0/"><title>Laryngeal leishmaniasis: Case report of a rare infection</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23141</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Laryngeal leishmaniasis: Case report of a rare infection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Trevor A. Teemul, Montserrat Giles-Lima, John Williams, Shane E. Lester</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:53:17.675458-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23141</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23141</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23141</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>We report a case of laryngeal leishmaniasis in a United Kingdom (UK) resident who lived in Spain for 5 years.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>The patient presented with a history of hoarseness. He had returned to the UK after spending 5 years in Spain as a retiree. His past medical history includes chronic obstructive pulmonary disease (COPD). Histology of a vocal cord biopsy was suggestive of leishmaniasis and polymerase chain reaction (PCR) test was positive for <em>Leishmania donovani</em>. His use of steroid inhaler probably contributed to his acquiring this extremely unusual infection. He was successfully treated with intravenous amphotericin.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Laryngeal leishmaniasis is an extremely rare infection and is rarely reported in the UK. The ease of travel ensures that many tropical infections may present to UK clinicians. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
We report a case of laryngeal leishmaniasis in a United Kingdom (UK) resident who lived in Spain for 5 years.


Methods and Results
The patient presented with a history of hoarseness. He had returned to the UK after spending 5 years in Spain as a retiree. His past medical history includes chronic obstructive pulmonary disease (COPD). Histology of a vocal cord biopsy was suggestive of leishmaniasis and polymerase chain reaction (PCR) test was positive for Leishmania donovani. His use of steroid inhaler probably contributed to his acquiring this extremely unusual infection. He was successfully treated with intravenous amphotericin.


Conclusions
Laryngeal leishmaniasis is an extremely rare infection and is rarely reported in the UK. The ease of travel ensures that many tropical infections may present to UK clinicians. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23143" xmlns="http://purl.org/rss/1.0/"><title>Oral squamous cell carcinoma arising in background of oral submucous fibrosis: A clinicopathologically distinct disease</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23143</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Oral squamous cell carcinoma arising in background of oral submucous fibrosis: A clinicopathologically distinct disease</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pankaj Chaturvedi, Sagar S. Vaishampayan, Sudhir Nair, Deepa Nair, J. P. Agarwal, S. V. Kane, Prashant Pawar, Sourav Datta</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:53:02.811812-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23143</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23143</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23143</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Oral cancer is the most common cancer in Indian males and is the third most common cancer in Indian females. Tobacco, alcohol, areca nut, and human papillomavirus (HPV) are the common etiologic factors. Each of these agents follows a unique model of carcinogenesis that leads to a certain distinct presentation and behavior. For example, HPV is strongly associated with oropharyngeal cancers in younger age and is known to have a better outcome and specific histopathologic characteristics. A high incidence of oral submucous fibrosis (OSMF) is linked to areca nut (group 1 human carcinogen) chewing in the Indian subcontinent.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We prospectively studied 371 consecutive patients with proven squamous cell carcinoma of the oral cavity. Of these, 112 patients had oral cancer with OSMF and 259 had oral cancer without OSMF. All patients underwent standard management and their clinicopathologic findings were recorded.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>We found that patients of oral cancer with OSMF are younger males with better prognostic factors such as better grade of tumor differentiation, lesser incidence of nodal metastases, and extracapsular spread. This difference was maintained even after matching for stage. We also report that presence of OSMF is an independent factor influencing nodal metastases.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Based on these findings we propose that oral cancers with OSMF constitute a clinicopathologically distinct disease. Since all patients with OSMF had chewed areca nut with or without smokeless tobacco, we believe that the differences in the 2 groups emanate from differential mechanisms of areca nut carcinogenesis. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Oral cancer is the most common cancer in Indian males and is the third most common cancer in Indian females. Tobacco, alcohol, areca nut, and human papillomavirus (HPV) are the common etiologic factors. Each of these agents follows a unique model of carcinogenesis that leads to a certain distinct presentation and behavior. For example, HPV is strongly associated with oropharyngeal cancers in younger age and is known to have a better outcome and specific histopathologic characteristics. A high incidence of oral submucous fibrosis (OSMF) is linked to areca nut (group 1 human carcinogen) chewing in the Indian subcontinent.


Methods
We prospectively studied 371 consecutive patients with proven squamous cell carcinoma of the oral cavity. Of these, 112 patients had oral cancer with OSMF and 259 had oral cancer without OSMF. All patients underwent standard management and their clinicopathologic findings were recorded.


Results
We found that patients of oral cancer with OSMF are younger males with better prognostic factors such as better grade of tumor differentiation, lesser incidence of nodal metastases, and extracapsular spread. This difference was maintained even after matching for stage. We also report that presence of OSMF is an independent factor influencing nodal metastases.


Conclusions
Based on these findings we propose that oral cancers with OSMF constitute a clinicopathologically distinct disease. Since all patients with OSMF had chewed areca nut with or without smokeless tobacco, we believe that the differences in the 2 groups emanate from differential mechanisms of areca nut carcinogenesis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23146" xmlns="http://purl.org/rss/1.0/"><title>Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high-risk patients for proactive gastrostomy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23146</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high-risk patients for proactive gastrostomy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Teresa E. Brown, Ann-Louise Spurgin, Lynda Ross, Lee Tripcony, Jacqui Keller, Brett G. M. Hughes, Rob Hodge, Quenten Walker, Merrilyn Banks, Lizbeth Moira Kenny, Jane Crombie</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-13T01:52:46.458651-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23146</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23146</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23146</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Background</em></h4><div class="para"><p>The “Swallowing and Nutrition Guidelines for Patients with Head and Neck Cancer” were developed to guide early identification and management of dysphagia and nutritional risk before, during, and after cancer treatment. The purpose of this study was to validate these guidelines.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Methods</em></h4><div class="para"><p>Patients attending a Combined Head and Neck Clinic at a major tertiary hospital in 2007 to 2008 were assessed using the guidelines, with high-risk category patients recommended for proactive gastrostomy. Data were collected on guideline adherence, gastrostomy tube insertion, and weight. Sensitivity, specificity, and positive predictive value were calculated for validation.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Results</em></h4><div class="para"><p>Proactive gastrostomy tubes were inserted in 173 of 501 patients (25%). Overall guideline adherence was 87%. High-risk category adherence was 75%. Validation outcomes were sensitivity 54%, specificity 93%, and positive predictive value 82%.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Conclusion</em></h4><div class="para"><p>The risk categories in the guidelines are valid to assist early identification of swallowing and nutritional risk and guide decision-making on proactive gastrostomy tube insertion. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The “Swallowing and Nutrition Guidelines for Patients with Head and Neck Cancer” were developed to guide early identification and management of dysphagia and nutritional risk before, during, and after cancer treatment. The purpose of this study was to validate these guidelines.


Methods
Patients attending a Combined Head and Neck Clinic at a major tertiary hospital in 2007 to 2008 were assessed using the guidelines, with high-risk category patients recommended for proactive gastrostomy. Data were collected on guideline adherence, gastrostomy tube insertion, and weight. Sensitivity, specificity, and positive predictive value were calculated for validation.


Results
Proactive gastrostomy tubes were inserted in 173 of 501 patients (25%). Overall guideline adherence was 87%. High-risk category adherence was 75%. Validation outcomes were sensitivity 54%, specificity 93%, and positive predictive value 82%.


Conclusion
The risk categories in the guidelines are valid to assist early identification of swallowing and nutritional risk and guide decision-making on proactive gastrostomy tube insertion. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23148" xmlns="http://purl.org/rss/1.0/"><title>Early-stage squamous cell carcinoma of the lip: The Australian experience and the benefits of radiotherapy in improving outcome in high-risk patients after resection</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23148</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Early-stage squamous cell carcinoma of the lip: The Australian experience and the benefits of radiotherapy in improving outcome in high-risk patients after resection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria Najim, Shamira Cross, Val Gebski, Carsten E. Palme, Gary J. Morgan, Michael J. Veness</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-10T08:32:00.570046-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23148</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23148</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23148</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to analyze the outcome of Australian patients treated for early lip cancer.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Data on 217 patients with T1 to T2 squamous cell carcinoma (SCC) of the lip and treated with radical intent were analyzed.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The addition of local adjuvant radiotherapy in patients with a close/positive margin was associated with a significant improvement in relapse-free survival (RFS; <em>p</em> = .008). Tumor thickness (≤4 mm vs &gt;4 mm) was also significantly associated with RFS (<em>p</em> = .01). The 5-year RFS was 51% after surgery, 87% after radiotherapy, and 92% after adjuvant radiotherapy.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Patients with a tumor thickness &gt;4 mm experienced an increased risk of recurrence, especially nodal. Compared with patients having any radiotherapy, those undergoing surgery experienced a higher rate of locoregional recurrence. The addition of adjuvant radiotherapy in patients with inadequate excision significantly decreased the risk of recurrence. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to analyze the outcome of Australian patients treated for early lip cancer.


Methods
Data on 217 patients with T1 to T2 squamous cell carcinoma (SCC) of the lip and treated with radical intent were analyzed.


Results
The addition of local adjuvant radiotherapy in patients with a close/positive margin was associated with a significant improvement in relapse-free survival (RFS; p = .008). Tumor thickness (≤4 mm vs &gt;4 mm) was also significantly associated with RFS (p = .01). The 5-year RFS was 51% after surgery, 87% after radiotherapy, and 92% after adjuvant radiotherapy.


Conclusions
Patients with a tumor thickness &gt;4 mm experienced an increased risk of recurrence, especially nodal. Compared with patients having any radiotherapy, those undergoing surgery experienced a higher rate of locoregional recurrence. The addition of adjuvant radiotherapy in patients with inadequate excision significantly decreased the risk of recurrence. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23149" xmlns="http://purl.org/rss/1.0/"><title>Metastatic papillary thyroid cancer with lateral neck disease: Pattern of spread by level</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23149</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Metastatic papillary thyroid cancer with lateral neck disease: Pattern of spread by level</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mazin Merdad, Antoine Eskander, Teresa Kroeker, Jeremy L. Freeman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-10T08:31:49.632746-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23149</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23149</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23149</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Currently, there is no clear consensus on the extent of this lateral neck dissection required in papillary thyroid cancer (PTC) with lateral neck metastasis. The purpose of this study was to review our experience with metastatic PTC, and identify the pattern of lymphatic spread to the lateral neck.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective medical chart review of PTC patients treated with lateral neck dissection (levels II–Vb) at our institution between January 2004 and 2011. A total of 185 patients underwent 248 selective lateral neck dissections.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Levels II, III, IV, and Vb were respectively involved in 49.3%, 76.6%, 61.6%, and 29.2% of cases.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>We advocate for a routine excision of levels II, III, IV, and Vb in PTC with metastasize to any lateral neck level. Although we have routinely dissected level IIb, it may be appropriate to omit its dissection, as well as level Va, when there are no clinical, radiologic, or intraoperative evidence of disease involving these sublevels. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Currently, there is no clear consensus on the extent of this lateral neck dissection required in papillary thyroid cancer (PTC) with lateral neck metastasis. The purpose of this study was to review our experience with metastatic PTC, and identify the pattern of lymphatic spread to the lateral neck.


Methods
A retrospective medical chart review of PTC patients treated with lateral neck dissection (levels II–Vb) at our institution between January 2004 and 2011. A total of 185 patients underwent 248 selective lateral neck dissections.


Results
Levels II, III, IV, and Vb were respectively involved in 49.3%, 76.6%, 61.6%, and 29.2% of cases.


Conclusion
We advocate for a routine excision of levels II, III, IV, and Vb in PTC with metastasize to any lateral neck level. Although we have routinely dissected level IIb, it may be appropriate to omit its dissection, as well as level Va, when there are no clinical, radiologic, or intraoperative evidence of disease involving these sublevels. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23155" xmlns="http://purl.org/rss/1.0/"><title>Squamous cell carcinoma of the oral tongue in a patient with Fanconi anemia treated with radiotherapy and concurrent cetuximab: A case report and review of the literature</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23155</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Squamous cell carcinoma of the oral tongue in a patient with Fanconi anemia treated with radiotherapy and concurrent cetuximab: A case report and review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Winnifred M. Wong, Upendra Parvathaneni, Patrick D. Jewell, Renato G. Martins, Neal D. Futran, George E. Laramore, Jay J. Liao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-10T08:31:39.024422-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23155</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23155</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23155</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Fanconi anemia (FA) is a rare autosomal recessive genetic disorder characterized by bone marrow failure and increased risk of cancers including acute myelogenous leukemia and various solid tumors, especially head and neck cancer. Management of head and neck cancer in the setting of FA is complicated by pancytopenia, poor tolerance of chemotherapy, and potentially increased radiosensitivity. There are limited reports on tolerance of radiotherapy (RT) in patients with FA.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We report a case of a patient with FA who presented with a small oral tongue cancer that was excised. He rapidly developed extensive locoregional recurrence and underwent surgical resection followed by postoperative RT with concurrent cetuximab.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Both RT and cetuximab were well tolerated with manageable toxicities. Unfortunately, the patient died of early locoregional disease progression.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>RT with concurrent cetuximab was well tolerated and may be an appropriate option in patients with FA. However, many patients have a poor prognosis due to aggressive disease. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Fanconi anemia (FA) is a rare autosomal recessive genetic disorder characterized by bone marrow failure and increased risk of cancers including acute myelogenous leukemia and various solid tumors, especially head and neck cancer. Management of head and neck cancer in the setting of FA is complicated by pancytopenia, poor tolerance of chemotherapy, and potentially increased radiosensitivity. There are limited reports on tolerance of radiotherapy (RT) in patients with FA.


Methods
We report a case of a patient with FA who presented with a small oral tongue cancer that was excised. He rapidly developed extensive locoregional recurrence and underwent surgical resection followed by postoperative RT with concurrent cetuximab.


Results
Both RT and cetuximab were well tolerated with manageable toxicities. Unfortunately, the patient died of early locoregional disease progression.


Conclusions
RT with concurrent cetuximab was well tolerated and may be an appropriate option in patients with FA. However, many patients have a poor prognosis due to aggressive disease. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23162" xmlns="http://purl.org/rss/1.0/"><title>Giant papillary carcinoma arising in the ectopic buccal thyroid tissue</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23162</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Giant papillary carcinoma arising in the ectopic buccal thyroid tissue</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cagdas Elsurer, Kayhan Ozturk, Fusun Baba, Cagdas Yavas, Serap Bulut</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-10T08:31:29.397326-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23162</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23162</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23162</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Ectopic thyroid tissue very rarely occurs in the buccal region. Even more rarely encountered is the papillary carcinoma arising in the ectopic tissue.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>We herein present a 78-year-old female patient admitted with a giant, buccal mass that developed within the previous 2 years. Physical examination revealed a vegetative mass on the left buccal region without any cervical lymphadenopathy. Magnetic resonance imaging scan showed an 8- × 6-cm solid mass with cystic components in the left buccal region and thoracic computed tomography scanning revealed pulmonary metastasis. A successful surgery including lower lip splitting was performed, and the mass was totally excised with its surrounding capsule. Histopathologic examination revealed follicular variant of papillary carcinoma of the ectopic thyroid tissue.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>To our knowledge, our case is the first case of papillary carcinoma arising from ectopic thyroid tissue in the buccal region in the literature. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Ectopic thyroid tissue very rarely occurs in the buccal region. Even more rarely encountered is the papillary carcinoma arising in the ectopic tissue.


Methods and Results
We herein present a 78-year-old female patient admitted with a giant, buccal mass that developed within the previous 2 years. Physical examination revealed a vegetative mass on the left buccal region without any cervical lymphadenopathy. Magnetic resonance imaging scan showed an 8- × 6-cm solid mass with cystic components in the left buccal region and thoracic computed tomography scanning revealed pulmonary metastasis. A successful surgery including lower lip splitting was performed, and the mass was totally excised with its surrounding capsule. Histopathologic examination revealed follicular variant of papillary carcinoma of the ectopic thyroid tissue.


Conclusions
To our knowledge, our case is the first case of papillary carcinoma arising from ectopic thyroid tissue in the buccal region in the literature. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23093" xmlns="http://purl.org/rss/1.0/"><title>Targeting EGFR-positive cancer cells with cetuximab–ZZ-PE38: Results of in vitro and in vivo studies</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23093</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Targeting EGFR-positive cancer cells with cetuximab–ZZ-PE38: Results of in vitro and in vivo studies</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Itay Barnea, Rahamim Ben-Yosef, Victoria Karaush, Itai Benhar, Akiva Vexler</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-10T07:50:10.992136-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23093</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23093</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23093</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Arming antibody with toxins is a new approach in cancer therapy. We evaluated the efficacy of cetuximab–ZZ-PE38 immunocomplex in killing cancer cells in vitro and inhibiting tumor growth in nude mice.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Several cancer cell lines and human foreskin fibroblasts were tested for epidermal growth factor receptor (EGFR) expression and cetuximab binding using Western blot assay, enzyme-linked immunosorbent assay (ELISA), and flow cytometry. Cell survival in vitro was estimated by XTT assay. Tumor size was measured twice a week.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Cetuximab–ZZ-PE38 immunocomplex was significantly more effective in killing head and neck cancer cells than nonspecific IgG-ZZ-PE38 complex or free ZZ-PE38, whereas normal cells were not affected. Tumor treatment with immunocomplex resulted in tumor shrinkage. The immunocomplex was safe to mice at a therapeutic dosage of 0.25 mg/mL, whereas the dosage of 0.50 mg/mL induced liver toxicity.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Cetuximab–ZZ-PE38 immunocomplex is a highly effective agent in killing EGFR-positive cancer cells and in tumor shrinkage. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Arming antibody with toxins is a new approach in cancer therapy. We evaluated the efficacy of cetuximab–ZZ-PE38 immunocomplex in killing cancer cells in vitro and inhibiting tumor growth in nude mice.


Methods
Several cancer cell lines and human foreskin fibroblasts were tested for epidermal growth factor receptor (EGFR) expression and cetuximab binding using Western blot assay, enzyme-linked immunosorbent assay (ELISA), and flow cytometry. Cell survival in vitro was estimated by XTT assay. Tumor size was measured twice a week.


Results
Cetuximab–ZZ-PE38 immunocomplex was significantly more effective in killing head and neck cancer cells than nonspecific IgG-ZZ-PE38 complex or free ZZ-PE38, whereas normal cells were not affected. Tumor treatment with immunocomplex resulted in tumor shrinkage. The immunocomplex was safe to mice at a therapeutic dosage of 0.25 mg/mL, whereas the dosage of 0.50 mg/mL induced liver toxicity.


Conclusions
Cetuximab–ZZ-PE38 immunocomplex is a highly effective agent in killing EGFR-positive cancer cells and in tumor shrinkage. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23130" xmlns="http://purl.org/rss/1.0/"><title>Regulation of protease-activated receptor-1 expression in human buccal fibroblasts stimulated with arecoline</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23130</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Regulation of protease-activated receptor-1 expression in human buccal fibroblasts stimulated with arecoline</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chung-Hung Tsai, Shiuan-Shinn Lee, Fu-Mei Huang, Yu-Chao Chang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-10T07:49:54.831933-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23130</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23130</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23130</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to compare the major thrombin receptor protease-activated receptor-1 (PAR-1) expression in normal human buccal mucosa and oral submucous fibrosis (OSF) specimens and further explore the potential mechanisms that may lead to induce PAR-1 expression.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Thirty OSF and 10 normal buccal mucosa specimens were examined by immunohistochemistry. Buccal mucosal fibroblasts (BMFs) were challenged with arecoline by using Western blot analysis. <em>N</em>-acetyl-<em>L</em>-cysteine (NAC), LY294002, herbimycin A, NS-398, and PD98059 were added to find the possible regulatory mechanisms.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>PAR-1 expression was significantly higher in OSF specimens (<em>p</em> &lt; .05). Arecoline was found to elevate PAR-1 expression in a dose-dependent and time-dependent manner (<em>p</em> &lt; .05). The addition of NAC, LY294002, herbimycin A, NS398, and PD98059 markedly inhibited the arecoline-induced PAR-1 expression (<em>p</em> &lt; .05).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4><em>Conclusion</em></h4><div class="para"><p>PAR-1 expression is significantly upregulated in areca quid chewing-associated OSF. Arecoline-induced PAR-1 expression was downregulated by NAC, LY294002, herbimycin A, NS398, and PD98059. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to compare the major thrombin receptor protease-activated receptor-1 (PAR-1) expression in normal human buccal mucosa and oral submucous fibrosis (OSF) specimens and further explore the potential mechanisms that may lead to induce PAR-1 expression.


Methods
Thirty OSF and 10 normal buccal mucosa specimens were examined by immunohistochemistry. Buccal mucosal fibroblasts (BMFs) were challenged with arecoline by using Western blot analysis. N-acetyl-L-cysteine (NAC), LY294002, herbimycin A, NS-398, and PD98059 were added to find the possible regulatory mechanisms.


Results
PAR-1 expression was significantly higher in OSF specimens (p &lt; .05). Arecoline was found to elevate PAR-1 expression in a dose-dependent and time-dependent manner (p &lt; .05). The addition of NAC, LY294002, herbimycin A, NS398, and PD98059 markedly inhibited the arecoline-induced PAR-1 expression (p &lt; .05).


Conclusion
PAR-1 expression is significantly upregulated in areca quid chewing-associated OSF. Arecoline-induced PAR-1 expression was downregulated by NAC, LY294002, herbimycin A, NS398, and PD98059. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23142" xmlns="http://purl.org/rss/1.0/"><title>Large trigeminal schwannoma of the infratemporal fossa: Evaluation of neoangiogenesis in this rare neoplasm</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23142</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Large trigeminal schwannoma of the infratemporal fossa: Evaluation of neoangiogenesis in this rare neoplasm</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Concetta Alafaci, Maria Caffo, Valeria Barresi, Mariano Cutugno, Maria A. Pino, Francesca Granata, Francesco S. De Ponte, Francesco M. Salpietro, Francesco Tomasello</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-10T07:49:08.315982-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23142</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23142</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23142</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Trigeminal schwannomas are uncommon intracranial tumors. Extracranial trigeminal schwannomas in the infratemporal fossa are rare.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We present a case with a clinical history of facial pain. MRI and CT scans showed a mass arising from the infratemporal fossa extending into the intracranial space.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>We performed a combined neurosurgical and maxillofacial approach with preoperative endovascular embolization. Complete removal of the parasellar component was achieved with a minimal extracranial neoplastic residual. High microvessel density, reflecting intense neoangiogenesis, was detected through the immunohistochemical staining with endoglin.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Due to the unique development pattern of trigeminal schwannoma involving multiple intracranial fossae and extracranial compartment, we chose a combined neurosurgical and maxillofacial approach with preoperative embolization of the tumor. Immunohistochemical findings suggest that the extensive growth observed may be related to an intense neoangiogenesis, opening the perspective to novel therapeutic options based on the inhibition of neoangiogenesis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Trigeminal schwannomas are uncommon intracranial tumors. Extracranial trigeminal schwannomas in the infratemporal fossa are rare.


Methods
We present a case with a clinical history of facial pain. MRI and CT scans showed a mass arising from the infratemporal fossa extending into the intracranial space.


Results
We performed a combined neurosurgical and maxillofacial approach with preoperative endovascular embolization. Complete removal of the parasellar component was achieved with a minimal extracranial neoplastic residual. High microvessel density, reflecting intense neoangiogenesis, was detected through the immunohistochemical staining with endoglin.


Conclusions
Due to the unique development pattern of trigeminal schwannoma involving multiple intracranial fossae and extracranial compartment, we chose a combined neurosurgical and maxillofacial approach with preoperative embolization of the tumor. Immunohistochemical findings suggest that the extensive growth observed may be related to an intense neoangiogenesis, opening the perspective to novel therapeutic options based on the inhibition of neoangiogenesis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23110" xmlns="http://purl.org/rss/1.0/"><title>Surgical margins in head and neck cancer: A contemporary review</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23110</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Surgical margins in head and neck cancer: A contemporary review</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael L. Hinni, Alfio Ferlito, Margaret S. Brandwein-Gensler, Robert P. Takes, Carl E. Silver, William H. Westra, Raja R. Seethala, Juan P. Rodrigo, June Corry, Carol R. Bradford, Jennifer L. Hunt, Primož Strojan, Kenneth O. Devaney, Douglas R. Gnepp, Dana M. Hartl, Luiz P. Kowalski, Alessandra Rinaldo, Leon Barnes</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-03T01:59:47.177968-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23110</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23110</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23110</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Adequate resection margins are critical to the treatment decisions and prognosis of patients with head and neck squamous cell carcinoma (HNSCC). However, there are numerous controversies regarding reporting and interpretation of the status of resection margins. Fundamental issues relating to the basic definition of margin adequacy, uniform reporting standards for margins, optimal method of specimen dissection, and the role of intraoperative frozen section evaluation, all require further clarification and standardization. Future horizons for margin surveillance offer the possible use of novel methods such as “molecular margins” and contact microscopic endoscopy, However, the limitations of these approaches need to be understood. The goal of this review was to evaluate these issues to define a more rational, standardized approach for achieving resection margin adequacy for patients with HNSCC undergoing curative resection. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div>
]]></content:encoded><description>

Adequate resection margins are critical to the treatment decisions and prognosis of patients with head and neck squamous cell carcinoma (HNSCC). However, there are numerous controversies regarding reporting and interpretation of the status of resection margins. Fundamental issues relating to the basic definition of margin adequacy, uniform reporting standards for margins, optimal method of specimen dissection, and the role of intraoperative frozen section evaluation, all require further clarification and standardization. Future horizons for margin surveillance offer the possible use of novel methods such as “molecular margins” and contact microscopic endoscopy, However, the limitations of these approaches need to be understood. The goal of this review was to evaluate these issues to define a more rational, standardized approach for achieving resection margin adequacy for patients with HNSCC undergoing curative resection. © 2012 Wiley Periodicals, Inc. Head Neck, 2012
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23106" xmlns="http://purl.org/rss/1.0/"><title>Clinical outcomes of endoscopic mucosal resection and endoscopic submucosal dissection as a transoral treatment for superficial pharyngeal cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23106</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clinical outcomes of endoscopic mucosal resection and endoscopic submucosal dissection as a transoral treatment for superficial pharyngeal cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Noboru Hanaoka, Ryu Ishihara, Yoji Takeuchi, Motoyuki Suzuki, Hirokazu Uemura, Takashi Fujii, Kunitoshi Yoshino, Noriya Uedo, Koji Higashino, Takashi Ohta, Hiromitsu Kanzaki, Masao Hanafusa, Kengo Nagai, Fumi Matsui, Hiroyasu Iishi, Masaharu Tatsuta, Yasuhiko Tomita</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-09-01T07:52:26.634227-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23106</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23106</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23106</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been introduced for the treatment of superficial pharyngeal cancer.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Sixty superficial pharyngeal cancers in 45 patients were treated by EMR or ESD. Resectability and curability, complications, and survival were analyzed retrospectively.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The en bloc resection and curative resection rate were higher with ESD (100; 81.6%) than with EMR (59; 50%). In subgroup analysis with regard to tumor size ≤10 mm, both resection rates were comparative. All the patients had preserved larynx and swallowing, speech, and airway function. Two of the 45 patients died of other diseases, local recurrence was observed in 4 of 18 patients with noncurative resection with a median observation period of 38 months. No recurrence was observed in patients with curative resection.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>ESD or EMR for superficial pharyngeal cancer is minimally invasive treatment and lesions larger than 10 mm should be referred for ESD. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been introduced for the treatment of superficial pharyngeal cancer.


Methods
Sixty superficial pharyngeal cancers in 45 patients were treated by EMR or ESD. Resectability and curability, complications, and survival were analyzed retrospectively.


Results
The en bloc resection and curative resection rate were higher with ESD (100; 81.6%) than with EMR (59; 50%). In subgroup analysis with regard to tumor size ≤10 mm, both resection rates were comparative. All the patients had preserved larynx and swallowing, speech, and airway function. Two of the 45 patients died of other diseases, local recurrence was observed in 4 of 18 patients with noncurative resection with a median observation period of 38 months. No recurrence was observed in patients with curative resection.


Conclusions
ESD or EMR for superficial pharyngeal cancer is minimally invasive treatment and lesions larger than 10 mm should be referred for ESD. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23099" xmlns="http://purl.org/rss/1.0/"><title>Lymph node metastasis between sternocleidomastoid and sternohyoid muscle in clinically node-positive papillary thyroid carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23099</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Lymph node metastasis between sternocleidomastoid and sternohyoid muscle in clinically node-positive papillary thyroid carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guohua Sun, Yu Wang, Yongxue Zhu, Yulong Wang, Kuan Xu, Wenjun Wei, Hui Li, Zhongwu Lu, Qinghai Ji</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-28T02:00:21.429833-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23099</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23099</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23099</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>There have been few reports on lymph node metastasis between sternocleidomastoid and sternohyoid muscle (originally LNSS) in clinically node positive (cN+) papillary thyroid carcinoma (PTC). Therefore, our objective was to investigate the significance of LNSS metastasis.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A total of 115 patients with cN+ PTC underwent a neck dissection with LNSS, as a separate pathologic specimen to be analyzed for the correlation between LNSS and sex, age, tumor size, tumor site, initial or reoperative treatment, lateral cervical lymph nodes, and central compartment metastasis.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The positive rate of LNSS was 22.6%. LNSS metastasis was correlated with a primary site in the inferior pole, the lateral nodal metastasis, level III and level IV nodal metastasis, but not with other clinical parameters.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>In cN+ PTC, especially a primary site in the inferior pole, level III and/or level IV metastasis, attention should be given to excising the nodal tissue in LNSS. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
There have been few reports on lymph node metastasis between sternocleidomastoid and sternohyoid muscle (originally LNSS) in clinically node positive (cN+) papillary thyroid carcinoma (PTC). Therefore, our objective was to investigate the significance of LNSS metastasis.


Methods
A total of 115 patients with cN+ PTC underwent a neck dissection with LNSS, as a separate pathologic specimen to be analyzed for the correlation between LNSS and sex, age, tumor size, tumor site, initial or reoperative treatment, lateral cervical lymph nodes, and central compartment metastasis.


Results
The positive rate of LNSS was 22.6%. LNSS metastasis was correlated with a primary site in the inferior pole, the lateral nodal metastasis, level III and level IV nodal metastasis, but not with other clinical parameters.


Conclusion
In cN+ PTC, especially a primary site in the inferior pole, level III and/or level IV metastasis, attention should be given to excising the nodal tissue in LNSS. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23123" xmlns="http://purl.org/rss/1.0/"><title>Acute multiple arterial thrombosis after cisplatin in base of tongue carcinoma: Case report</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23123</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Acute multiple arterial thrombosis after cisplatin in base of tongue carcinoma: Case report</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anupam Rishi, Sushmita Ghoshal</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-23T02:40:39.181168-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23123</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23123</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23123</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Arterial thromboses following cisplatin-based chemotherapy in head and neck cancers are extremely rare and devastating complication.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>A 54-year-old male smoker had an acute history of left lower limb pain and calf claudication 3 days following the first cycle of cisplatin-based chemotherapy given concurrently with radiotherapy for squamous cell carcinoma of the base of tongue. CT angiography showed extensive abdominal aortic thrombus along with involvement of left common iliac, saphenopopliteal, and tibeal arteries as well as moderate stenosis in the proximal segments of left anterior descending and right coronary artery. We suggest that endothelial damage and hypercoaguable state secondary to cisplatin may have induced severe arterial and coronary thrombosis.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>This is the first reported case of acute multiple arterial thrombosis following cisplatin in head and neck cancer. It is a dreaded complication and has a dismal prognosis if not promptly recognized and treated. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Arterial thromboses following cisplatin-based chemotherapy in head and neck cancers are extremely rare and devastating complication.


Methods and Results
A 54-year-old male smoker had an acute history of left lower limb pain and calf claudication 3 days following the first cycle of cisplatin-based chemotherapy given concurrently with radiotherapy for squamous cell carcinoma of the base of tongue. CT angiography showed extensive abdominal aortic thrombus along with involvement of left common iliac, saphenopopliteal, and tibeal arteries as well as moderate stenosis in the proximal segments of left anterior descending and right coronary artery. We suggest that endothelial damage and hypercoaguable state secondary to cisplatin may have induced severe arterial and coronary thrombosis.


Conclusions
This is the first reported case of acute multiple arterial thrombosis following cisplatin in head and neck cancer. It is a dreaded complication and has a dismal prognosis if not promptly recognized and treated. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23124" xmlns="http://purl.org/rss/1.0/"><title>Uncommon presentations of parathyroid adenoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23124</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Uncommon presentations of parathyroid adenoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel J. Givens, Jason P. Hunt, Brandon G. Bentz</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T03:59:13.282606-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23124</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23124</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23124</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Patients with parathyroid adenomas (PAs) are commonly encountered in otolaryngology and may present with asymptomatic hypercalcemia. Retropharyngeal hematoma and recurrent laryngeal nerve (RLN) paralysis are less commonly encountered presentations and may be harbingers of a malignant process.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>We present 2 patients with rare presentations of parathyroid adenoma. The first is a 57-year-old man with retropharyngeal hemorrhage and progressive airway compromise. The second is a 51-year-old woman presenting with dysphonia who was found to have RLN paralysis. Both of these patients were found to have benign disease.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Although most patients with PA present with asymptomatic hypercalcemia, this disease entity must be considered in patients with other unusual presentations including hemorrhagic neck masses and dysphonia. The importance of a broad differential diagnosis and thorough workup is emphasized. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Patients with parathyroid adenomas (PAs) are commonly encountered in otolaryngology and may present with asymptomatic hypercalcemia. Retropharyngeal hematoma and recurrent laryngeal nerve (RLN) paralysis are less commonly encountered presentations and may be harbingers of a malignant process.


Methods and Results
We present 2 patients with rare presentations of parathyroid adenoma. The first is a 57-year-old man with retropharyngeal hemorrhage and progressive airway compromise. The second is a 51-year-old woman presenting with dysphonia who was found to have RLN paralysis. Both of these patients were found to have benign disease.


Conclusions
Although most patients with PA present with asymptomatic hypercalcemia, this disease entity must be considered in patients with other unusual presentations including hemorrhagic neck masses and dysphonia. The importance of a broad differential diagnosis and thorough workup is emphasized. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23125" xmlns="http://purl.org/rss/1.0/"><title>Feasibility and safety of minimal-incision thyroidectomy for Graves' disease: A prospective, single-center study</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23125</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Feasibility and safety of minimal-incision thyroidectomy for Graves' disease: A prospective, single-center study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuliano Perigli, Etleva Qirici, Benedetta Badii, Aurora Kokomani, Fabio Staderini, Michaela Luconi, Clara Crescioli, Massimo Mannelli, Mario Maggi, Fabio Cianchi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T03:58:55.084687-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23125</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23125</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23125</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The role of minimally invasive surgery in Graves' disease is still controversial. The aim of this study was to compare the clinical outcomes of patients undergoing minimal-incision thyroidectomy with those undergoing conventional thyroidectomy for Graves' disease.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A prospective study was performed on 148 patients undergoing total thyroidectomy. Seventy-one patients underwent minimal-incision thyroidectomy and 77 underwent conventional thyroidectomy. Minimal-incision thyroidectomy was proposed if the thyroid volume was ≤50 mL.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>There were no significant differences in the operative time between minimal-incision thyroidectomy and conventional thyroidectomy. The length of skin incision was significantly shorter in the minimal-incision thyroidectomy than that in the conventional thyroidectomy group. The incidence of postoperative complications was similar in the 2 groups. Patients undergoing minimal-incision thyroidectomy experienced significantly less postoperative pain and were more satisfied with the cosmetic result than patients who underwent conventional thyroidectomy.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Minimal-incision thyroidectomy is a feasible and safe option for the surgical treatment of selected patients with Graves' disease. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The role of minimally invasive surgery in Graves' disease is still controversial. The aim of this study was to compare the clinical outcomes of patients undergoing minimal-incision thyroidectomy with those undergoing conventional thyroidectomy for Graves' disease.


Methods
A prospective study was performed on 148 patients undergoing total thyroidectomy. Seventy-one patients underwent minimal-incision thyroidectomy and 77 underwent conventional thyroidectomy. Minimal-incision thyroidectomy was proposed if the thyroid volume was ≤50 mL.


Results
There were no significant differences in the operative time between minimal-incision thyroidectomy and conventional thyroidectomy. The length of skin incision was significantly shorter in the minimal-incision thyroidectomy than that in the conventional thyroidectomy group. The incidence of postoperative complications was similar in the 2 groups. Patients undergoing minimal-incision thyroidectomy experienced significantly less postoperative pain and were more satisfied with the cosmetic result than patients who underwent conventional thyroidectomy.


Conclusions
Minimal-incision thyroidectomy is a feasible and safe option for the surgical treatment of selected patients with Graves' disease. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23127" xmlns="http://purl.org/rss/1.0/"><title>Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy — Update of the EORTC QLQ-H&amp;N35, Phase I</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23127</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy — Update of the EORTC QLQ-H&amp;N35, Phase I</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susanne Singer, Juan I. Arraras, Ingo Baumann, Andreas Boehm, Wei-Chu Chie, Razvan Galalae, Johannes A. Langendijk, Orlando Guntinas–Lichius, Eva Hammerlid, Monica Pinto, Ourania Nicolatou–Galitis, Claudia Schmalz, Mehmet Sen, Allen C. Sherman, Karin Spiegel, Irma Verdonck–de Leeuw, Noam Yarom, Paola Zotti, Dirk Hofmeister, </dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T03:58:28.886972-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23127</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23127</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23127</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies.


Methods
The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers.


Results
Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer.


Conclusions
Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23128" xmlns="http://purl.org/rss/1.0/"><title>Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23128</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christina I. Tsien, Mukesh K. Nyati, Aarif Ahsan, Susmita G. Ramanand, Douglas B. Chepeha, Francis P. Worden, Joseph I. Helman, Nisha D'Silva, Carol R. Bradford, Gregory T. Wolf, Theodore S. Lawrence, Avraham Eisbruch</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T03:58:12.768668-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23128</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23128</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23128</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to determine if there are differences in biomarker modulation and epidermal growth factor receptor (EGFR) degradation between the tumor and the normal mucosa after treatment with an EGFR inhibitor, erlotinib, in head and neck cancer.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Patients with primary oral cavity squamous cell cancers received a course of erlotinib, 150 mg every day for 7 days before surgical resection. Tumor and normal mucosa biopsies were obtained both pre-erlotinib and post-erlotinib. Changes in known markers of EGFR activity (phospho, AKT, STAT3) were measured by immunoblotting, whereas changes in tissue distribution were analyzed by immunohistochemical analysis.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Twelve patients were enrolled; 7 had evaluable paired tumors and normal mucosa biopsies pretreatment and posttreatment. Expression of EGFR was higher in tumors compared to the normal mucosa (<em>p</em> = .005). Erlotinib administration was associated with marked inhibition of phosphorylated epidermal growth factor receptor (pEGFR) and reduction in total EGFR protein (<em>p</em> = .004, <em>p</em> = .007) in tumors, whereas there was heterogeneity in EGFR inhibition in the normal mucosa (<em>p</em> = .10 [pEGFR], and <em>p</em> = .07 [EGFR]). Reduced levels of pSrc and pSTAT3 and enhanced p27 levels were noted in tumors after erlotinib. Cell culture studies confirmed that EGFR is degraded in tumor cells after prolonged treatment with erlotinib.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Our results show that EGFR inhibition by erlotinib led to a marked reduction in EGFR protein levels in patients. Differential effects of erlotinib on tumors compared to the normal mucosa suggest there may be individual patient heterogeneity. These preliminary data suggest EGFR degradation should be further analyzed as a potential biomarker in selecting patients likely to benefit from EGFR inhibitors. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to determine if there are differences in biomarker modulation and epidermal growth factor receptor (EGFR) degradation between the tumor and the normal mucosa after treatment with an EGFR inhibitor, erlotinib, in head and neck cancer.


Methods
Patients with primary oral cavity squamous cell cancers received a course of erlotinib, 150 mg every day for 7 days before surgical resection. Tumor and normal mucosa biopsies were obtained both pre-erlotinib and post-erlotinib. Changes in known markers of EGFR activity (phospho, AKT, STAT3) were measured by immunoblotting, whereas changes in tissue distribution were analyzed by immunohistochemical analysis.


Results
Twelve patients were enrolled; 7 had evaluable paired tumors and normal mucosa biopsies pretreatment and posttreatment. Expression of EGFR was higher in tumors compared to the normal mucosa (p = .005). Erlotinib administration was associated with marked inhibition of phosphorylated epidermal growth factor receptor (pEGFR) and reduction in total EGFR protein (p = .004, p = .007) in tumors, whereas there was heterogeneity in EGFR inhibition in the normal mucosa (p = .10 [pEGFR], and p = .07 [EGFR]). Reduced levels of pSrc and pSTAT3 and enhanced p27 levels were noted in tumors after erlotinib. Cell culture studies confirmed that EGFR is degraded in tumor cells after prolonged treatment with erlotinib.


Conclusion
Our results show that EGFR inhibition by erlotinib led to a marked reduction in EGFR protein levels in patients. Differential effects of erlotinib on tumors compared to the normal mucosa suggest there may be individual patient heterogeneity. These preliminary data suggest EGFR degradation should be further analyzed as a potential biomarker in selecting patients likely to benefit from EGFR inhibitors. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23129" xmlns="http://purl.org/rss/1.0/"><title>Frozen biopsy of central compartment in papillary thyroid cancer: Quantitative nodal analysis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23129</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Frozen biopsy of central compartment in papillary thyroid cancer: Quantitative nodal analysis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yun-Sung Lim, Sung-Won Choi, Yoon Se Lee, Jin-Choon Lee, Byung-Joo Lee, Soo-Geun Wang, Seok-Man Son, In-Ju Kim, Dong-Hoon Shin</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T03:57:56.050243-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23129</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23129</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23129</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Nodal metastasis in papillary thyroid cancer (PTC) usually occurs in the central compartment of the ipsilateral neck and spreads laterally. The purpose of this study was to evaluate the diagnostic accuracy of frozen biopsy for quantitative nodal evaluation of central neck metastasis in PTC.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In all, 252 patients with PTC underwent total thyroidectomy with bilateral central neck dissection (CND). All tissues from ipsilateral CND were examined by frozen biopsy.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Among them, 53% of patients had central neck metastasis. The sensitivity and specificity of frozen biopsy for central neck metastasis were 92% and 99%, respectively. The positive predictive value and the negative predictive value were 99% and 84%, respectively. The diagnostic accuracy for the exact number of metastatic nodes was 91% compared to permanent biopsy.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Frozen biopsy for quantitative analysis of central compartment is a useful tool for the precise evaluation of central lymphatic status intraoperatively with a high sensitivity and specificity. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Nodal metastasis in papillary thyroid cancer (PTC) usually occurs in the central compartment of the ipsilateral neck and spreads laterally. The purpose of this study was to evaluate the diagnostic accuracy of frozen biopsy for quantitative nodal evaluation of central neck metastasis in PTC.


Methods
In all, 252 patients with PTC underwent total thyroidectomy with bilateral central neck dissection (CND). All tissues from ipsilateral CND were examined by frozen biopsy.


Results
Among them, 53% of patients had central neck metastasis. The sensitivity and specificity of frozen biopsy for central neck metastasis were 92% and 99%, respectively. The positive predictive value and the negative predictive value were 99% and 84%, respectively. The diagnostic accuracy for the exact number of metastatic nodes was 91% compared to permanent biopsy.


Conclusions
Frozen biopsy for quantitative analysis of central compartment is a useful tool for the precise evaluation of central lymphatic status intraoperatively with a high sensitivity and specificity. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23097" xmlns="http://purl.org/rss/1.0/"><title>Angiogenesis and lymphangiogenesis in early-stage laryngeal carcinoma: Prognostic implications</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23097</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Angiogenesis and lymphangiogenesis in early-stage laryngeal carcinoma: Prognostic implications</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrea Bolzoni Villaret, Diego Barbieri, Giorgio Peretti, Alberto Schreiber, Simona Fisogni, Silvia Lonardi, Fabio Facchetti, Piero Nicolai</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T03:57:08.424513-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23097</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23097</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23097</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Many studies have recently emphasized the role of tumor angiogenesis and lymphangiogenesis in regional and distant spread of disease. Although early laryngeal cancer has a favorable oncologic outcome after conservative surgery or radiation therapy, we observed few cases with poor prognosis in terms of locoregional relapse, organ preservation, and survival. The aim of our study was to evaluate the immunohistochemical expression of CD31 and podoplanin to define angiogenic and lymphangiogenic patterns and their possible prognostic implications in previously untreated T1–T2 glottic squamous cell carcinoma.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Four hundred twenty-eight patients with previously untreated early-stage laryngeal cancer underwent a laser surgical resection in the period between January 1994 and December 2007. Twenty-seven cases with poor outcome were identified and compared with a selected sample of 28 patients. All specimens were negative for the presence of high-risk human papillomavirus genotypes. Patients were followed up until death or for at least 24 months after treatment. Three-micrometer sections were obtained from formalin-fixed and paraffin-embedded tumoral tissues, and an immunohistochemical evaluation was performed. Monoclonal antibodies against CD31 and podoplanin were used for the detection of blood and lymphatic vessels, respectively. A morphometric measurement was used for the analysis of angiogenesis whereas lymphangiogenesis was studied with a semiquantitative technique. The data were analyzed by use of chi-square and Mann-Whitney tests as appropriate.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>An increased tumor angiogenesis correlated with local relapse (<em>p</em> = .01), locoregional relapse (<em>p</em> = .01), and death of disease (<em>p</em> = .03). The presence of lymphatic vessels in peritumoral fields had an impact on local (<em>p</em> = .004) and locoregional recurrence (<em>p</em> = .01).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Evaluation of angiogenesis and lymphangiogenesis in early-stage laryngeal cancer could be useful to identify patients at higher risk of recurrence and consequently to modulate treatment planning and follow-up strategy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Many studies have recently emphasized the role of tumor angiogenesis and lymphangiogenesis in regional and distant spread of disease. Although early laryngeal cancer has a favorable oncologic outcome after conservative surgery or radiation therapy, we observed few cases with poor prognosis in terms of locoregional relapse, organ preservation, and survival. The aim of our study was to evaluate the immunohistochemical expression of CD31 and podoplanin to define angiogenic and lymphangiogenic patterns and their possible prognostic implications in previously untreated T1–T2 glottic squamous cell carcinoma.


Methods
Four hundred twenty-eight patients with previously untreated early-stage laryngeal cancer underwent a laser surgical resection in the period between January 1994 and December 2007. Twenty-seven cases with poor outcome were identified and compared with a selected sample of 28 patients. All specimens were negative for the presence of high-risk human papillomavirus genotypes. Patients were followed up until death or for at least 24 months after treatment. Three-micrometer sections were obtained from formalin-fixed and paraffin-embedded tumoral tissues, and an immunohistochemical evaluation was performed. Monoclonal antibodies against CD31 and podoplanin were used for the detection of blood and lymphatic vessels, respectively. A morphometric measurement was used for the analysis of angiogenesis whereas lymphangiogenesis was studied with a semiquantitative technique. The data were analyzed by use of chi-square and Mann-Whitney tests as appropriate.


Results
An increased tumor angiogenesis correlated with local relapse (p = .01), locoregional relapse (p = .01), and death of disease (p = .03). The presence of lymphatic vessels in peritumoral fields had an impact on local (p = .004) and locoregional recurrence (p = .01).


Conclusions
Evaluation of angiogenesis and lymphangiogenesis in early-stage laryngeal cancer could be useful to identify patients at higher risk of recurrence and consequently to modulate treatment planning and follow-up strategy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23112" xmlns="http://purl.org/rss/1.0/"><title>Analysis of risk factors for retropharyngeal lymph node metastasis in carcinoma of the hypopharynx</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23112</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Analysis of risk factors for retropharyngeal lymph node metastasis in carcinoma of the hypopharynx</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zheng Wu, Xue-Ying Deng, Rui-Fang Zeng, Yong Su, Mo-Fa Gu, Yun Zhang, Chuan-Miao Xie, Lie Zheng</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T03:56:55.042758-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23112</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23112</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23112</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to investigate the incidence of retropharyngeal lymph node (RPLN) metastasis and to explore the associated risk factors using CT and MRI, to direct clinical radiotherapy in hypopharyngeal carcinoma (HPC).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The CT and MRI images of 218 patients with pathologically confirmed HPC were analyzed retrospectively. The chi-square test and logistic regression were used for statistical analysis.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The incidence of RPLN metastasis in HPC was 17.0%, and the highest rate of 36.4% was found in pharyngeal wall carcinoma. None of the patients with N0 classification exhibited RPLN metastasis. Univariate and multivariate analyses demonstrated that primary tumor subsites, bilateral cervical lymph node metastasis, the number and size of cervical lymph nodes, and level V metastasis were significantly associated with RPLN metastasis.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Our findings demonstrated that primary carcinoma subsites and multiple metastatic cervical lymph nodes are the principal risk factors for RPLN metastasis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to investigate the incidence of retropharyngeal lymph node (RPLN) metastasis and to explore the associated risk factors using CT and MRI, to direct clinical radiotherapy in hypopharyngeal carcinoma (HPC).


Methods
The CT and MRI images of 218 patients with pathologically confirmed HPC were analyzed retrospectively. The chi-square test and logistic regression were used for statistical analysis.


Results
The incidence of RPLN metastasis in HPC was 17.0%, and the highest rate of 36.4% was found in pharyngeal wall carcinoma. None of the patients with N0 classification exhibited RPLN metastasis. Univariate and multivariate analyses demonstrated that primary tumor subsites, bilateral cervical lymph node metastasis, the number and size of cervical lymph nodes, and level V metastasis were significantly associated with RPLN metastasis.


Conclusions
Our findings demonstrated that primary carcinoma subsites and multiple metastatic cervical lymph nodes are the principal risk factors for RPLN metastasis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23115" xmlns="http://purl.org/rss/1.0/"><title>Health-related quality of life differences between African Americans and non-Hispanic whites with head and neck cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23115</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Health-related quality of life differences between African Americans and non-Hispanic whites with head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bryce B. Reeve, Jianwen Cai, Hongtao Zhang, Jaeun Choi, Mark C. Weissler, David Cella, Andrew F. Olshan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T03:56:42.534519-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23115</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23115</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23115</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Cancers of the head and neck are associated with detriments in health-related quality of life (HRQOL); however, little is known about different experiences between African Americans and non-Hispanic whites.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>HRQOL was measured by the Functional Assessment of Cancer Therapy – Head and Neck (FACT-H&amp;N) approximately 5 months postdiagnosis among 222 patients with cancer from North Carolina. Higher scores represent better HRQOL. Regression models included sociodemographic characteristics and clinical factors.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>African Americans reported higher physical well-being than whites (adjusted means, 23.1 vs 20.9). African Americans with incomes &lt;$20,000 reported higher emotional well-being (21.4) and fewer head and neck symptoms (22.0). Non-Hispanic whites making &lt;$20,000 reported the poorest emotional well-being (17.3), whereas African Americans making &gt;$20,000 reported the most head and neck symptoms (18.7).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Further investigation is needed to explore variation in HRQOL experiences among different race and socioeconomic groups that may inform resource allocation to improve cancer care. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Cancers of the head and neck are associated with detriments in health-related quality of life (HRQOL); however, little is known about different experiences between African Americans and non-Hispanic whites.


Methods
HRQOL was measured by the Functional Assessment of Cancer Therapy – Head and Neck (FACT-H&amp;N) approximately 5 months postdiagnosis among 222 patients with cancer from North Carolina. Higher scores represent better HRQOL. Regression models included sociodemographic characteristics and clinical factors.


Results
African Americans reported higher physical well-being than whites (adjusted means, 23.1 vs 20.9). African Americans with incomes &lt;$20,000 reported higher emotional well-being (21.4) and fewer head and neck symptoms (22.0). Non-Hispanic whites making &lt;$20,000 reported the poorest emotional well-being (17.3), whereas African Americans making &gt;$20,000 reported the most head and neck symptoms (18.7).


Conclusions
Further investigation is needed to explore variation in HRQOL experiences among different race and socioeconomic groups that may inform resource allocation to improve cancer care. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23119" xmlns="http://purl.org/rss/1.0/"><title>Toxicity of areca nut ingredients: Activation of CHK1/CHK2. induction of cell cycle arrest, and regulation of MMP-9 and TIMPs production in SAS epithelial cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23119</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Toxicity of areca nut ingredients: Activation of CHK1/CHK2. induction of cell cycle arrest, and regulation of MMP-9 and TIMPs production in SAS epithelial cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mei-Chi Chang, Chiu-Po Chan, Wei-Ting Wang, Bei-En Chang, Jang-Jaer Lee, Shuei-Kuen Tseng, Sin-Yuet Yeung, Liang-Jiunn Hahn, Jiiang-Huei Jeng</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T03:56:27.431398-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23119</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23119</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23119</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>There are 600 million betel quid chewers around the world. betel quid chewing is a major risk factor of oral cancer. Why betel quid components induce oral cancer is not clear.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Cytotoxicity of areca nut extract and arecoline (an areca nut alkaloid) to SAS oral epithelial cell line was evaluated by trypan blue dye exclusion and MTT assays. Cell cycle distribution and apoptosis was analyzed by propidium iodide staining flow cytometry. Chk1 and chk2 activation was analyzed by Pathscan phospho-enzyme-linked immunosorbent assay. Metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase (TIMPs) production was measured by enzyme-linked immunosorbent assay.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Areca nut extract (800 μg/mL) and arecoline (&gt;0.4 mmol/L) caused cell death, apoptosis, and cell cycle arrest of SAS cells. Areca nut extract and arecoline stimulated Chk1 and Chk2 phosphorylation in SAS cells. Areca nut extract stimulated cellular MMP-9 but suppressed TIMP-1 and TIMP-2 production.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Areca nut components activate Chk1/Chk2, alter cell cycle regulation/apoptosis, MMP-9, and TIMPs production, contributing to the pathogenesis of oral carcinogenesis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
There are 600 million betel quid chewers around the world. betel quid chewing is a major risk factor of oral cancer. Why betel quid components induce oral cancer is not clear.


Methods
Cytotoxicity of areca nut extract and arecoline (an areca nut alkaloid) to SAS oral epithelial cell line was evaluated by trypan blue dye exclusion and MTT assays. Cell cycle distribution and apoptosis was analyzed by propidium iodide staining flow cytometry. Chk1 and chk2 activation was analyzed by Pathscan phospho-enzyme-linked immunosorbent assay. Metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase (TIMPs) production was measured by enzyme-linked immunosorbent assay.


Results
Areca nut extract (800 μg/mL) and arecoline (&gt;0.4 mmol/L) caused cell death, apoptosis, and cell cycle arrest of SAS cells. Areca nut extract and arecoline stimulated Chk1 and Chk2 phosphorylation in SAS cells. Areca nut extract stimulated cellular MMP-9 but suppressed TIMP-1 and TIMP-2 production.


Conclusions
Areca nut components activate Chk1/Chk2, alter cell cycle regulation/apoptosis, MMP-9, and TIMPs production, contributing to the pathogenesis of oral carcinogenesis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23082" xmlns="http://purl.org/rss/1.0/"><title>Airway management after maxillectomy with free flap reconstruction</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23082</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Airway management after maxillectomy with free flap reconstruction</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel S. Brickman, Douglas D. Reh, Daniel S. Schneider, Ben Bush, Eben L. Rosenthal, Mark K. Wax</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:27:18.14963-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23082</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23082</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23082</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Maxillectomy defects require complex 3-dimensional reconstructions often best suited to microvascular free tissue transfer. Postoperative airway management during this procedure has little discussion in the literature and is often dictated by surgical dogma. The purpose of this article was to review our experience in order to evaluate the effect of airway management on perioperative outcomes in patients undergoing maxillectomy with free flap reconstruction.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective chart review was performed on patients receiving maxillectomy with microvascular reconstruction at 2 institutions between 1999 and 2011. Patient's airways were managed with or without elective tracheotomy at the surgical team's discretion and different perioperative outcomes were measured. The primary outcome was incidence of airway complication including pneumonia and need for further airway intervention. Secondary outcome was measured as factors leading to perioperative performance of the tracheotomy.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Seventy-nine of 143 patients received elective tracheotomy perioperatively. The incidence of airway complication was equivalent between groups (10.1% vs 9.4%; <em>p</em> = .89). Patients with cardiopulmonary comorbidities were more likely to receive perioperative tracheotomy (74.1% vs 50.9%; <em>p</em> = .03) without a difference in airway complications. Other patient cofactors did not have an impact on perioperative tracheotomy or airway complication rate.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Elective tracheotomy may safely be avoided in a subset of patients undergoing maxillectomy with microvascular reconstruction. Elective tracheotomy should be considered in patients with cardiopulmonary risk factors. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Maxillectomy defects require complex 3-dimensional reconstructions often best suited to microvascular free tissue transfer. Postoperative airway management during this procedure has little discussion in the literature and is often dictated by surgical dogma. The purpose of this article was to review our experience in order to evaluate the effect of airway management on perioperative outcomes in patients undergoing maxillectomy with free flap reconstruction.


Methods
A retrospective chart review was performed on patients receiving maxillectomy with microvascular reconstruction at 2 institutions between 1999 and 2011. Patient's airways were managed with or without elective tracheotomy at the surgical team's discretion and different perioperative outcomes were measured. The primary outcome was incidence of airway complication including pneumonia and need for further airway intervention. Secondary outcome was measured as factors leading to perioperative performance of the tracheotomy.


Results
Seventy-nine of 143 patients received elective tracheotomy perioperatively. The incidence of airway complication was equivalent between groups (10.1% vs 9.4%; p = .89). Patients with cardiopulmonary comorbidities were more likely to receive perioperative tracheotomy (74.1% vs 50.9%; p = .03) without a difference in airway complications. Other patient cofactors did not have an impact on perioperative tracheotomy or airway complication rate.


Conclusions
Elective tracheotomy may safely be avoided in a subset of patients undergoing maxillectomy with microvascular reconstruction. Elective tracheotomy should be considered in patients with cardiopulmonary risk factors. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23101" xmlns="http://purl.org/rss/1.0/"><title>Clinical outcomes of transoral robotic supraglottic laryngectomy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23101</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clinical outcomes of transoral robotic supraglottic laryngectomy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Enver Ozer, Bianca Alvarez, Kiran Kakarala, Kasim Durmus, Theodoros N. Teknos, Ricardo L. Carrau</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:11:55.562047-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23101</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23101</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23101</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Transoral, minimally invasive organ preservation surgeries are being increasingly used for laryngopharyngeal carcinomas to avoid the toxicities of combined chemotherapy and radiation therapy regimens. This study investigates the efficiency, safety, and functional outcomes of transoral robotic surgery (TORS) supraglottic laryngectomy.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Patients with laryngeal cancer who underwent TORS supraglottic laryngectomy and participated in a prospective TORS study between 2008 and 2011 at an academic medical center are presented.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Thirteen of 126 patients underwent TORS supraglottic laryngectomy for laryngeal cancer. Average robotic operative time and estimated blood loss were 25.3 minutes and 15.4 mL, respectively. Negative surgical margins were achieved in all patients. Eleven patients were started on an oral diet within 24 hours of surgery with no evidence of immediate airway compromise. Two patients (15.4%) received adjuvant radiation therapy based on pathology.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>In this preliminary study, TORS supraglottic laryngectomy was a safe procedure with good functional outcomes. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Transoral, minimally invasive organ preservation surgeries are being increasingly used for laryngopharyngeal carcinomas to avoid the toxicities of combined chemotherapy and radiation therapy regimens. This study investigates the efficiency, safety, and functional outcomes of transoral robotic surgery (TORS) supraglottic laryngectomy.


Methods
Patients with laryngeal cancer who underwent TORS supraglottic laryngectomy and participated in a prospective TORS study between 2008 and 2011 at an academic medical center are presented.


Results
Thirteen of 126 patients underwent TORS supraglottic laryngectomy for laryngeal cancer. Average robotic operative time and estimated blood loss were 25.3 minutes and 15.4 mL, respectively. Negative surgical margins were achieved in all patients. Eleven patients were started on an oral diet within 24 hours of surgery with no evidence of immediate airway compromise. Two patients (15.4%) received adjuvant radiation therapy based on pathology.


Conclusion
In this preliminary study, TORS supraglottic laryngectomy was a safe procedure with good functional outcomes. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23102" xmlns="http://purl.org/rss/1.0/"><title>Concurrent primary and metastatic cutaneous head and neck squamous cell carcinoma: Analysis of prognostic factors</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23102</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Concurrent primary and metastatic cutaneous head and neck squamous cell carcinoma: Analysis of prognostic factors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Timothy McLean, Markus Brunner, Ardalan Ebrahimi, Kan Gao, Sydney Ch'ng, Michael J. Veness, Jonathan R. Clark</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:11:40.825682-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23102</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23102</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23102</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>There is a small subgroup of patients with head and neck cutaneous squamous cell carcinoma (cSCC) in which nodal metastases present concurrently with the primary lesion. There is evidence that these tumors may represent a more aggressive subset of cSCC. The aim of this study was to determine whether alternative clinicopathologic prognostic factors should be applied to this patient cohort.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective analysis of data from prospective databases of 2 large head and neck cancer units in Sydney, Australia, was performed. Ninety-five patients with concurrent primary and nodal metastatic head and neck cSCC were suitable for inclusion in the study.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Univariable analysis was performed for overall survival (OS) and disease-specific survival (DSS). OS was adversely affected by immunosuppression (<em>p</em> = .011) and nodal extracapsular spread (ECS) (<em>p</em> = .006). Similarly, immunosuppression (<em>p</em> = .005) and ECS (<em>p</em> = .005) indicated a worse outcome for DSS. ECS and immunosuppression remained significant in the multivariable analysis.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>This study found that adverse prognostic factors were similar to the current evidence for nonconcurrent metastatic cSCC. In particular, the primary lesion had no significant influence on survival. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
There is a small subgroup of patients with head and neck cutaneous squamous cell carcinoma (cSCC) in which nodal metastases present concurrently with the primary lesion. There is evidence that these tumors may represent a more aggressive subset of cSCC. The aim of this study was to determine whether alternative clinicopathologic prognostic factors should be applied to this patient cohort.


Methods
A retrospective analysis of data from prospective databases of 2 large head and neck cancer units in Sydney, Australia, was performed. Ninety-five patients with concurrent primary and nodal metastatic head and neck cSCC were suitable for inclusion in the study.


Results
Univariable analysis was performed for overall survival (OS) and disease-specific survival (DSS). OS was adversely affected by immunosuppression (p = .011) and nodal extracapsular spread (ECS) (p = .006). Similarly, immunosuppression (p = .005) and ECS (p = .005) indicated a worse outcome for DSS. ECS and immunosuppression remained significant in the multivariable analysis.


Conclusions
This study found that adverse prognostic factors were similar to the current evidence for nonconcurrent metastatic cSCC. In particular, the primary lesion had no significant influence on survival. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23103" xmlns="http://purl.org/rss/1.0/"><title>Novel differential diagnostic method for superficial/deep tumor of the parotid gland using ultrasonography</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23103</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Novel differential diagnostic method for superficial/deep tumor of the parotid gland using ultrasonography</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Masaaki Higashino, Ryo Kawata, Shin-Ichi Haginomori, Koutetsu Lee, Katsuhiro Yoshimura, Takaki Inui, Shuji Nishikawa</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:11:26.508808-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23103</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23103</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23103</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to prepare the ultrasonographic diagnostic criteria on parotid tumors for preoperative differentiation of superficial and deep tumors.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We evaluated 154 patients with a benign parotid tumor who underwent surgery. The minimum thickness of normal parotid gland tissue between the parotideomasseteric fascia and tumor (minimum fascia–tumor distance [MFTD]) was measured on preoperative ultrasonography and compared among tumors at different locations, and the optimum cutoff value to differentiate a deep tumor was identified.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The MFTD showed significant differences between superficial and deep tumors and between inferior pole and deep tumors. The sensitivity, specificity, and accuracy of an MFTD ≥3 mm for the differentiation of deep tumors were 85%, 91%, and 89%.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>A tumor with an MFTD ≥3 mm on preoperative ultrasonography is very likely to be a deep tumor based on a new differentiation method for deep parotid tumors considering those present at other locations. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to prepare the ultrasonographic diagnostic criteria on parotid tumors for preoperative differentiation of superficial and deep tumors.


Methods
We evaluated 154 patients with a benign parotid tumor who underwent surgery. The minimum thickness of normal parotid gland tissue between the parotideomasseteric fascia and tumor (minimum fascia–tumor distance [MFTD]) was measured on preoperative ultrasonography and compared among tumors at different locations, and the optimum cutoff value to differentiate a deep tumor was identified.


Results
The MFTD showed significant differences between superficial and deep tumors and between inferior pole and deep tumors. The sensitivity, specificity, and accuracy of an MFTD ≥3 mm for the differentiation of deep tumors were 85%, 91%, and 89%.


Conclusion
A tumor with an MFTD ≥3 mm on preoperative ultrasonography is very likely to be a deep tumor based on a new differentiation method for deep parotid tumors considering those present at other locations. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23107" xmlns="http://purl.org/rss/1.0/"><title>Paclitaxel-based chemotherapy for aggressive kaposiform hemangioendothelioma of the temporomastoid region: Case report and review of the literature</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23107</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Paclitaxel-based chemotherapy for aggressive kaposiform hemangioendothelioma of the temporomastoid region: Case report and review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michinori Funato, Toshiyuki Fukao, Hideo Sasai, Tomohiro Hori, Daisuke Terazawa, Kaori Kanda, Michio Ozeki, Keisuke Mizuta, Yoshinobu Hirose, Hideo Kaneko, Naomi Kondo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:11:11.878218-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23107</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23107</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23107</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor of infancy and childhood. This tumor results in poor prognosis, and therefore, development of a more effective treatment is needed.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>We describe an 11-year-old boy presenting with left facial palsy caused by aggressive KHE of the left temporomastoid region. He was treated with paclitaxel-based chemotherapy, because of the difficulty with complete surgical resection for anatomic factor, multiple lung metastases on diagnosis, and no response to conventional treatments. This treatment reduced the volume of primary tumor and lung metastatic lesions, but the efficacy was transitory.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Paclitaxel-based chemotherapy for aggressive KHE may be effective, therefore the multimodality therapy including paclitaxel of aggressive KHE, particularly in the head and neck, needs to be investigated in further studies. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor of infancy and childhood. This tumor results in poor prognosis, and therefore, development of a more effective treatment is needed.


Methods and Results
We describe an 11-year-old boy presenting with left facial palsy caused by aggressive KHE of the left temporomastoid region. He was treated with paclitaxel-based chemotherapy, because of the difficulty with complete surgical resection for anatomic factor, multiple lung metastases on diagnosis, and no response to conventional treatments. This treatment reduced the volume of primary tumor and lung metastatic lesions, but the efficacy was transitory.


Conclusions
Paclitaxel-based chemotherapy for aggressive KHE may be effective, therefore the multimodality therapy including paclitaxel of aggressive KHE, particularly in the head and neck, needs to be investigated in further studies. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23109" xmlns="http://purl.org/rss/1.0/"><title>Node-positive hypopharyngeal cancer treated by (chemo)radiotherapy: Impact of up-front neck dissection on outcome, toxicity, and quality of life</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23109</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Node-positive hypopharyngeal cancer treated by (chemo)radiotherapy: Impact of up-front neck dissection on outcome, toxicity, and quality of life</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Abrahim Al-Mamgani, Cees A. Meeuwis, Peter H. van Rooij, Robert Mehilal, Harie Basdew, Aniel Sewnaik, Peter C. Levendag</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:10:55.705065-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23109</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23109</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23109</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>To investigate the impact of up-front neck dissection on the outcome of patients with node-positive hypopharyngeal cancer (HPC) treated with (chemo)radiation.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Of 135 consecutive patients with node-positive HPC, 32 patients underwent up-front neck dissection followed by (chemo)radiation (group 1), and 103 patients received definitive (chemo)radiation (group 2).</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The 3-year regional, local and distant control for groups 1 and 2 were 92% versus 87% (<em>p</em> = .37), 84% versus 72% (<em>p</em> = .15), and 80% versus 62% (<em>p</em> = .08), respectively. High T classification was the only significant predictor for poor overall survival on multivariate analysis (OR = 3.0, <em>p</em> = .02). Acute and late toxicities and the prospectively assessed quality of life were comparable in both groups.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Upfront neck dissection followed by (chemo)radiation did not negatively impact on oncologic outcomes, toxicity, or quality of life and therefore is to be regarded as a safe and effective treatment option for small HPC with bulky nodal disease, especially in busy radiation departments with unacceptably long waiting time for definitive (chemo)radiation. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
To investigate the impact of up-front neck dissection on the outcome of patients with node-positive hypopharyngeal cancer (HPC) treated with (chemo)radiation.


Methods
Of 135 consecutive patients with node-positive HPC, 32 patients underwent up-front neck dissection followed by (chemo)radiation (group 1), and 103 patients received definitive (chemo)radiation (group 2).


Results
The 3-year regional, local and distant control for groups 1 and 2 were 92% versus 87% (p = .37), 84% versus 72% (p = .15), and 80% versus 62% (p = .08), respectively. High T classification was the only significant predictor for poor overall survival on multivariate analysis (OR = 3.0, p = .02). Acute and late toxicities and the prospectively assessed quality of life were comparable in both groups.


Conclusion
Upfront neck dissection followed by (chemo)radiation did not negatively impact on oncologic outcomes, toxicity, or quality of life and therefore is to be regarded as a safe and effective treatment option for small HPC with bulky nodal disease, especially in busy radiation departments with unacceptably long waiting time for definitive (chemo)radiation. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23111" xmlns="http://purl.org/rss/1.0/"><title>Abnormal anatomy of the superficial branch of the radial nerve</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23111</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Abnormal anatomy of the superficial branch of the radial nerve</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert H. Lindau, Mark K. Wax</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:10:42.511781-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23111</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23111</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23111</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The superficial branch of the radial nerve is frequently encountered when performing the harvest for a radial forearm free tissue transfer.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>We present an abnormal course of this nerve which has not been described in the literature. During a harvest of a radial forearm free flap, we encountered a nerve that was not deep to the brachioradialis muscle in the proximal arm; rather, the superficial branch of the radial nerve was found to be superficial to this muscle through its entire course. An in-depth literature review was performed, and there was no documented abnormality identified resembling the abnormality we encountered.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Knowledge of the normal and abnormal anatomy is essential for the microvascular surgeon to assure the safety of this nerve. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The superficial branch of the radial nerve is frequently encountered when performing the harvest for a radial forearm free tissue transfer.


Methods and Results
We present an abnormal course of this nerve which has not been described in the literature. During a harvest of a radial forearm free flap, we encountered a nerve that was not deep to the brachioradialis muscle in the proximal arm; rather, the superficial branch of the radial nerve was found to be superficial to this muscle through its entire course. An in-depth literature review was performed, and there was no documented abnormality identified resembling the abnormality we encountered.


Conclusion
Knowledge of the normal and abnormal anatomy is essential for the microvascular surgeon to assure the safety of this nerve. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23113" xmlns="http://purl.org/rss/1.0/"><title>Aggressive multimodality management of locally advanced retromolar trigone tumors</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23113</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Aggressive multimodality management of locally advanced retromolar trigone tumors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S. V. Suryanarayana Deo, Nootan K. Shukla, Ashwin A. Kallianpur, Bidhu K. Mohanti, Sanjay P. Thulkar</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:10:26.559684-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23113</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23113</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23113</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Retromolar trigone tumors are rare and aggressive malignancies. There is lack of quality evidence pertaining to their management due to the heterogeneity in treatment policies adopted. We retrospectively reviewed the patients of locally advanced retromolar trigone tumors treated with a standard and uniform multimodality management.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective review of patients with locally advanced retromolar trigone tumors was performed and an analysis of clinicopathologic profile, treatment details, and survival outcomes was carried out.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Forty-two patients of locally advanced retromolar trigone tumors underwent the standard multimodality treatment. The majority of them presented with stage IVa disease. Margin negative resection could be achieved in 93% of patients. Histopathologically proven bone and node involvement was seen in 20 patients (47.6%) and 21 patients (50%), respectively. The 3-year disease-free and overall survival rates were 64% and 71%, respectively.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Treatment of patients with locally advanced retromolar trigone tumors is challenging. However, good oncologic outcomes can be achieved by advocating an aggressive surgical approach with postoperative radiation therapy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Retromolar trigone tumors are rare and aggressive malignancies. There is lack of quality evidence pertaining to their management due to the heterogeneity in treatment policies adopted. We retrospectively reviewed the patients of locally advanced retromolar trigone tumors treated with a standard and uniform multimodality management.


Methods
A retrospective review of patients with locally advanced retromolar trigone tumors was performed and an analysis of clinicopathologic profile, treatment details, and survival outcomes was carried out.


Results
Forty-two patients of locally advanced retromolar trigone tumors underwent the standard multimodality treatment. The majority of them presented with stage IVa disease. Margin negative resection could be achieved in 93% of patients. Histopathologically proven bone and node involvement was seen in 20 patients (47.6%) and 21 patients (50%), respectively. The 3-year disease-free and overall survival rates were 64% and 71%, respectively.


Conclusions
Treatment of patients with locally advanced retromolar trigone tumors is challenging. However, good oncologic outcomes can be achieved by advocating an aggressive surgical approach with postoperative radiation therapy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23114" xmlns="http://purl.org/rss/1.0/"><title>Effect of intradermal human recombinant copper-zinc superoxide dismutase on random pattern flaps in rats</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23114</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effect of intradermal human recombinant copper-zinc superoxide dismutase on random pattern flaps in rats</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ophir Schein, Melvyn Westreich, Avshalom Shalom</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:07:35.023836-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23114</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23114</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23114</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Studies have focused on enhancing flap viability using superoxide dismutase (SOD), but only a few used SOD from human origin, and most gave the compound systemically. We evaluated the ability of SOD to improve random skin flap survival using human recombinant copper-zinc superoxide dismutase (Hr-CuZnSOD) in variable doses, injected intradermally into the flap.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Seventy male Sprague Dawley rats were randomly assigned into 4 groups. Cephalic random pattern flaps were elevated on their backs and intradermal injections of different dosages of Hr-CuZnSOD were given 15 minutes before surgery. Flap survival was evaluated by fluorescein fluorescence. Analysis of variance (ANOVA) and <em>t</em> test statistical analyses were performed.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Flap survival in all treated groups was significantly better than in the controls.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The beneficial effect of HR-CuZnSOD on flap survival is attained when it is given intradermally into the flap tissue. Theoretically, Hr-CuZnSOD delivered with local anesthetics used in flap elevation may be a valuable clinical tool. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Studies have focused on enhancing flap viability using superoxide dismutase (SOD), but only a few used SOD from human origin, and most gave the compound systemically. We evaluated the ability of SOD to improve random skin flap survival using human recombinant copper-zinc superoxide dismutase (Hr-CuZnSOD) in variable doses, injected intradermally into the flap.


Methods
Seventy male Sprague Dawley rats were randomly assigned into 4 groups. Cephalic random pattern flaps were elevated on their backs and intradermal injections of different dosages of Hr-CuZnSOD were given 15 minutes before surgery. Flap survival was evaluated by fluorescein fluorescence. Analysis of variance (ANOVA) and t test statistical analyses were performed.


Results
Flap survival in all treated groups was significantly better than in the controls.


Conclusions
The beneficial effect of HR-CuZnSOD on flap survival is attained when it is given intradermally into the flap tissue. Theoretically, Hr-CuZnSOD delivered with local anesthetics used in flap elevation may be a valuable clinical tool. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23002" xmlns="http://purl.org/rss/1.0/"><title>Hypopharyngeal paraganglioma: Case report and review of the literature</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23002</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Hypopharyngeal paraganglioma: Case report and review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vikas Mehta, Tova Fischer, Gabe Levi, Beverly Wang, Mark L. Urken</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:06:57.18806-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23002</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23002</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23002</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Paragangliomas are rare, vascular, and predominantly benign neoplasms of neural crest origin. They typically arise in the head and neck from the carotid body, jugulotympanic, or vagal paraganglia. Rarely, paragangliomas occur in the larynx. Only 2 cases of hypopharyngeal paraganglioma have been reported. We discuss the case of a hypopharyngeal paraganglioma and review the literature concerning laryngopharyngeal paragangliomas.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>We present the case of a woman with 2 months of dysphagia and hoarseness that was found to have a hypopharyngeal paraganglioma. The patient underwent embolization and resection of the mass via a lateral thyrotomy approach. Pathologic analysis and selective staining confirmed the presence of a paraganglioma.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Proper histopathologic identification of these tumors is tantamount to guiding treatment. The preferred operative approach is a lateral thyrotomy to minimize patient morbidity. We present the third documented case of a hypopharyngeal paraganglioma and the first in the English-language literature. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Paragangliomas are rare, vascular, and predominantly benign neoplasms of neural crest origin. They typically arise in the head and neck from the carotid body, jugulotympanic, or vagal paraganglia. Rarely, paragangliomas occur in the larynx. Only 2 cases of hypopharyngeal paraganglioma have been reported. We discuss the case of a hypopharyngeal paraganglioma and review the literature concerning laryngopharyngeal paragangliomas.


Methods and Results
We present the case of a woman with 2 months of dysphagia and hoarseness that was found to have a hypopharyngeal paraganglioma. The patient underwent embolization and resection of the mass via a lateral thyrotomy approach. Pathologic analysis and selective staining confirmed the presence of a paraganglioma.


Conclusions
Proper histopathologic identification of these tumors is tantamount to guiding treatment. The preferred operative approach is a lateral thyrotomy to minimize patient morbidity. We present the third documented case of a hypopharyngeal paraganglioma and the first in the English-language literature. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23086" xmlns="http://purl.org/rss/1.0/"><title>Effects of enhanced bolus flavors on oropharyngeal swallow in patients treated for head and neck cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23086</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effects of enhanced bolus flavors on oropharyngeal swallow in patients treated for head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Barbara Roa Pauloski, Jerilyn A. Logemann, Alfred W. Rademaker, Donna Lundy, Paula A. Sullivan, Lisa A. Newman, Cathy Lazarus, Mary Bacon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:06:39.858107-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23086</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23086</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23086</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Treatment for head and neck cancer can reduce peripheral sensory input and impair oropharyngeal swallow. This study examined the effect of enhanced bolus flavor on liquid swallows in these patients.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Fifty-one patients treated for head and neck cancer with chemoradiation or surgery and 64 healthy adult control subjects served as subjects. All were randomized to receive sour, sweet, or salty bolus flavor. Patients were evaluated at 7–10 days, 1 month, and 3 months after completion of tumor treatment. Control subjects received 1 assessment.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>All bolus flavors affected oropharyngeal swallow; sour flavor significantly shortened pharyngeal transit time across all evaluations.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Sour flavor influenced the swallow of patients treated for head and neck cancer, as well as that of control subjects in a manner similar to those with neurologic impairment observed in an earlier study. Sour flavor may improve the speed of pharyngeal transit regardless of whether a patient has suffered peripheral or central sensory damage. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Treatment for head and neck cancer can reduce peripheral sensory input and impair oropharyngeal swallow. This study examined the effect of enhanced bolus flavor on liquid swallows in these patients.


Methods
Fifty-one patients treated for head and neck cancer with chemoradiation or surgery and 64 healthy adult control subjects served as subjects. All were randomized to receive sour, sweet, or salty bolus flavor. Patients were evaluated at 7–10 days, 1 month, and 3 months after completion of tumor treatment. Control subjects received 1 assessment.


Results
All bolus flavors affected oropharyngeal swallow; sour flavor significantly shortened pharyngeal transit time across all evaluations.


Conclusions
Sour flavor influenced the swallow of patients treated for head and neck cancer, as well as that of control subjects in a manner similar to those with neurologic impairment observed in an earlier study. Sour flavor may improve the speed of pharyngeal transit regardless of whether a patient has suffered peripheral or central sensory damage. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23087" xmlns="http://purl.org/rss/1.0/"><title>Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23087</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shamir P. Chandarana, Julia S. Lee, Eric J. P. Chanowski, Assuntina G. Sacco, Carol R. Bradford, Gregory T. Wolf, Mark E. Prince, Jeffrey S. Moyer, Avraham Eisbruch, Francis P. Worden, Thomas J. Giordano, Bhavna Kumar, Katrina G. Cordell, Thomas E. Carey, Douglas B. Chepeha</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:06:25.777427-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23087</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23087</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23087</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to describe the relationship of p16 and epidermal growth factor receptor (EGFR) expression with survival in surgically treated patients who had oropharyngeal or oral cavity squamous cell carcinoma (SCC).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Tissue from 36 patients with oropharyngeal SCC and 49 patients with oral cavity SCC treated between 1997 and 2001 was imbedded and immunostained using a tissue microarray.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The p16 was positive in 57% and 13% of patients with oropharyngeal SCC and oral cavity SCC, respectively. EGFR was positive in 60% and 63% of patients with oropharyngeal SCC and oral cavity SCC, respectively. In patients with oropharyngeal SCC, p16 expression was associated with improved disease-specific survival (DSS), overall survival (OS), and time to recurrence (TTR) (<em>p</em> &lt; .01, &lt; .01, and &lt;.01, respectively). EGFR expression was associated with poorer DSS, OS, and TTR (<em>p</em> &lt; .01, = .01, and &lt; .01, respectively). For oropharyngeal SCC, when examining both p16 and EGFR expression as combined biomarkers, high p16 expression coupled with low EGFR expression was associated with improved DSS (<em>p</em> p16 = .01; <em>p</em> EGFR = .01). Patients with oral cavity SCC showed no association between biomarker and outcome.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>For patients with oropharyngeal SCC, high p16 and low EGFR were associated with improved outcome, suggesting a predictive role in surgically treated patients. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to describe the relationship of p16 and epidermal growth factor receptor (EGFR) expression with survival in surgically treated patients who had oropharyngeal or oral cavity squamous cell carcinoma (SCC).


Methods
Tissue from 36 patients with oropharyngeal SCC and 49 patients with oral cavity SCC treated between 1997 and 2001 was imbedded and immunostained using a tissue microarray.


Results
The p16 was positive in 57% and 13% of patients with oropharyngeal SCC and oral cavity SCC, respectively. EGFR was positive in 60% and 63% of patients with oropharyngeal SCC and oral cavity SCC, respectively. In patients with oropharyngeal SCC, p16 expression was associated with improved disease-specific survival (DSS), overall survival (OS), and time to recurrence (TTR) (p &lt; .01, &lt; .01, and &lt;.01, respectively). EGFR expression was associated with poorer DSS, OS, and TTR (p &lt; .01, = .01, and &lt; .01, respectively). For oropharyngeal SCC, when examining both p16 and EGFR expression as combined biomarkers, high p16 expression coupled with low EGFR expression was associated with improved DSS (p p16 = .01; p EGFR = .01). Patients with oral cavity SCC showed no association between biomarker and outcome.


Conclusions
For patients with oropharyngeal SCC, high p16 and low EGFR were associated with improved outcome, suggesting a predictive role in surgically treated patients. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23092" xmlns="http://purl.org/rss/1.0/"><title>Aggressive fibromatosis in the head and neck region: Benign tumor with often mutilating effects</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23092</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Aggressive fibromatosis in the head and neck region: Benign tumor with often mutilating effects</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mathijs P. Hendriks, Chantal M. L. Driessen, Hanneke W. M. van Laarhoven, Geert O. R. J. Janssens, Berit M. Verbist, Winette T. A. van der Graaf, Piet J. Slootweg, Matthias A. W. Merkx, Carla M. L. van Herpen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:06:11.876376-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23092</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23092</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23092</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Aggressive fibromatosis (AF) or desmoid tumor of the head and neck region is a rare, usually unresectable, benign soft tissue tumor with locally aggressive behavior.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>A 31-year-old woman presented with a progressive trismus, a swelling in the retromandibular area, as well as loss of sensibility of the maxillary and mandibular branch of the trigeminal nerve. MRI of the head and neck revealed an infiltrative mass involving the masticator, parapharyngeal, and prevertebral and paravertebral space on the left with intracranial extension through the orbital fissure. After the fifth biopsy, 15 months after presentation, the diagnosis of AF was made. The tumor was unresectable, so intensity-modulated radiotherapy was given with curative intent using a total dose of 60 Gy in 30 fractions of 2 Gy. After 16 months, she showed progressive disease, for which tamoxifen 40 mg twice daily was started with a good response for 2 years. After that, she started with sorafinib, on which she has stable disease now.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>The often long delay in proper diagnosis and the treatment challenges of a desmoid tumor are illustrated in this case. Furthermore, this article reviews the literature concerning AF, especially of the head and neck region. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Aggressive fibromatosis (AF) or desmoid tumor of the head and neck region is a rare, usually unresectable, benign soft tissue tumor with locally aggressive behavior.


Methods and Results
A 31-year-old woman presented with a progressive trismus, a swelling in the retromandibular area, as well as loss of sensibility of the maxillary and mandibular branch of the trigeminal nerve. MRI of the head and neck revealed an infiltrative mass involving the masticator, parapharyngeal, and prevertebral and paravertebral space on the left with intracranial extension through the orbital fissure. After the fifth biopsy, 15 months after presentation, the diagnosis of AF was made. The tumor was unresectable, so intensity-modulated radiotherapy was given with curative intent using a total dose of 60 Gy in 30 fractions of 2 Gy. After 16 months, she showed progressive disease, for which tamoxifen 40 mg twice daily was started with a good response for 2 years. After that, she started with sorafinib, on which she has stable disease now.


Conclusion
The often long delay in proper diagnosis and the treatment challenges of a desmoid tumor are illustrated in this case. Furthermore, this article reviews the literature concerning AF, especially of the head and neck region. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23095" xmlns="http://purl.org/rss/1.0/"><title>Rehabilitation of a parotidectomy patient—A systematic approach</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23095</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Rehabilitation of a parotidectomy patient—A systematic approach</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Oleg N. Militsakh, Jeremy A. Sanderson, Derrick Lin, Mark K. Wax</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:05:58.6345-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23095</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23095</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23095</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Parotidectomy is a common surgical procedure. Resultant contour defect, Frey's syndrome, and facial nerve rehabilitation deserve special consideration. Microsurgical techniques provide unparallel advantage for reconstruction of large-volume defects. Same-stage reconstruction of the defect is advocated and often beneficial to the patient. The importance of full communication between the extirpative and reconstructive surgeon cannot be underscored. Often, institutional and personal biases must be overcome to provide best quality care for the patient. This article provides a comprehensive review of the medical literature on the subject and contrives a systematic approach to the use of various reconstructive techniques. Head Neck, 2012</p></div>
]]></content:encoded><description>

Parotidectomy is a common surgical procedure. Resultant contour defect, Frey's syndrome, and facial nerve rehabilitation deserve special consideration. Microsurgical techniques provide unparallel advantage for reconstruction of large-volume defects. Same-stage reconstruction of the defect is advocated and often beneficial to the patient. The importance of full communication between the extirpative and reconstructive surgeon cannot be underscored. Often, institutional and personal biases must be overcome to provide best quality care for the patient. This article provides a comprehensive review of the medical literature on the subject and contrives a systematic approach to the use of various reconstructive techniques. Head Neck, 2012
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23098" xmlns="http://purl.org/rss/1.0/"><title>Intrapericardial paraganglioma associated with succinate dehydrogenase complex subunit C mutation syndrome</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23098</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Intrapericardial paraganglioma associated with succinate dehydrogenase complex subunit C mutation syndrome</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeremiah C. Tracy, Richard O. Wein</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-21T02:05:44.129137-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23098</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23098</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23098</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Paragangliomas are benign neoplasms of neuroendocrine origin. It is estimated that from 20% to 50% of these tumors are familial. Mutations in the succinate dehydrogenase (SDH) gene family have been found to be responsible for a significant percentage of familial paragangliomas.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A 33-year-old man who was found to have 3 synchronous primary tumors including a catecholamine-secreting intrapericardial paraganglioma is presented.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Genetic workup diagnosed this patient with an underlying germ-line mutation in the succinate dehydrogenase complex subunit C (SDHC) gene; consistent with a diagnosis of hereditary paraganglioma/pheochromocytoma syndrome (PGL/PCC). Current knowledge regarding the clinical implications of an SDHC gene mutation is reviewed.</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Modern molecular techniques have identified that a significantly greater proportion of paragangliomas are due to underlying hereditary conditions than was previously thought. Appropriate screening in these individuals and their immediate family members may allow for early tumor diagnosis and improved disease outcomes. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
Paragangliomas are benign neoplasms of neuroendocrine origin. It is estimated that from 20% to 50% of these tumors are familial. Mutations in the succinate dehydrogenase (SDH) gene family have been found to be responsible for a significant percentage of familial paragangliomas.


Methods
A 33-year-old man who was found to have 3 synchronous primary tumors including a catecholamine-secreting intrapericardial paraganglioma is presented.


Results
Genetic workup diagnosed this patient with an underlying germ-line mutation in the succinate dehydrogenase complex subunit C (SDHC) gene; consistent with a diagnosis of hereditary paraganglioma/pheochromocytoma syndrome (PGL/PCC). Current knowledge regarding the clinical implications of an SDHC gene mutation is reviewed.


Conclusion
Modern molecular techniques have identified that a significantly greater proportion of paragangliomas are due to underlying hereditary conditions than was previously thought. Appropriate screening in these individuals and their immediate family members may allow for early tumor diagnosis and improved disease outcomes. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23089" xmlns="http://purl.org/rss/1.0/"><title>Survival differences among American Indians/Alaska natives with head and neck squamous cell carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23089</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Survival differences among American Indians/Alaska natives with head and neck squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sunshine M. Dwojak, Thomas D. Sequist, Kevin Emerick, Daniel G. Deschler</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-08T05:36:10.802889-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23089</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23089</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23089</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>American Indians/Alaska Natives experience poor overall survival. Data are limited on American Indians/Alaska Natives with head and neck squamous cell carcinoma (HNSCC).</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We identified all cases of HNSCC among American Indians/Alaska Natives, and white patients from 1996 to 2007 using the Surveillance, Epidemiology, and End Results (SEER) database. Univariate, multivariate, and Cox models were fit to analyze racial differences in sex, age, stage, treatment, and survival.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>American Indians/Alaska Natives experienced decreased survival for oropharyngeal cancer (hazard ratio [HR] = 1.4; <em>p</em> = .008). After adjusting for demographic factors, survival was decreased for oral cavity cancer (HR = 1.3; <em>p</em> = .05) and hypopharyngeal/laryngeal cancer (HR = 1.6; <em>p</em> = .04). These disparities were eliminated after adjusting for treatment for oral cavity cancer (HR = 1.2; <em>p</em> = .17) and stage for hypopharyngeal/laryngeal cancer (HR = 1.4; <em>p</em> = .12). American Indians/Alaska Natives received less surgery for oral cavity cancer (78% vs 85%; <em>p</em> = .02).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Disparities in survival exist among American Indians/Alaska Natives patients with HNSCC. They are related to stage and differential treatment patterns. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
American Indians/Alaska Natives experience poor overall survival. Data are limited on American Indians/Alaska Natives with head and neck squamous cell carcinoma (HNSCC).


Methods
We identified all cases of HNSCC among American Indians/Alaska Natives, and white patients from 1996 to 2007 using the Surveillance, Epidemiology, and End Results (SEER) database. Univariate, multivariate, and Cox models were fit to analyze racial differences in sex, age, stage, treatment, and survival.


Results
American Indians/Alaska Natives experienced decreased survival for oropharyngeal cancer (hazard ratio [HR] = 1.4; p = .008). After adjusting for demographic factors, survival was decreased for oral cavity cancer (HR = 1.3; p = .05) and hypopharyngeal/laryngeal cancer (HR = 1.6; p = .04). These disparities were eliminated after adjusting for treatment for oral cavity cancer (HR = 1.2; p = .17) and stage for hypopharyngeal/laryngeal cancer (HR = 1.4; p = .12). American Indians/Alaska Natives received less surgery for oral cavity cancer (78% vs 85%; p = .02).


Conclusion
Disparities in survival exist among American Indians/Alaska Natives patients with HNSCC. They are related to stage and differential treatment patterns. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23080" xmlns="http://purl.org/rss/1.0/"><title>Maté consumption and risk of oral cancer: Case-control study in Uruguay</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23080</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Maté consumption and risk of oral cancer: Case-control study in Uruguay</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hugo Deneo–Pellegrini, Eduardo De Stefani, Paolo Boffetta, Alvaro L. Ronco, Gisele Acosta, Pelayo Correa, María Mendilaharsu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-08T05:05:18.911667-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23080</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23080</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23080</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>In the period 1990 to 2001, a case-control study on oral cancer and maté consumption was conducted at the Cancer Institute of Uruguay.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The study included 696 newly diagnosed cases with squamous cell carcinoma and 696 controls afflicted with nonneoplastic conditions not related to tobacco smoking and alcohol drinking. The participants were matched on age and residence and the study was restricted to men.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In order to control confounding for tobacco and alcohol, we fitted 2 models. According to model 1, the odds ratio (OR) for maté consumption was 1.15 (95% confidence interval [CI], 0.76–1.73), whereas the results for model 2 showed an OR of 3.47 (95% CI, 1.60–7.52).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The inclusion of a term for the interaction between maté and smoking (or drinking) was rewarding and the ORs were even higher than those observed with the crude estimates. Head Neck, 2012</p></div></div>
]]></content:encoded><description>


Background
In the period 1990 to 2001, a case-control study on oral cancer and maté consumption was conducted at the Cancer Institute of Uruguay.


Methods
The study included 696 newly diagnosed cases with squamous cell carcinoma and 696 controls afflicted with nonneoplastic conditions not related to tobacco smoking and alcohol drinking. The participants were matched on age and residence and the study was restricted to men.


Results
In order to control confounding for tobacco and alcohol, we fitted 2 models. According to model 1, the odds ratio (OR) for maté consumption was 1.15 (95% confidence interval [CI], 0.76–1.73), whereas the results for model 2 showed an OR of 3.47 (95% CI, 1.60–7.52).


Conclusions
The inclusion of a term for the interaction between maté and smoking (or drinking) was rewarding and the ORs were even higher than those observed with the crude estimates. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23090" xmlns="http://purl.org/rss/1.0/"><title>Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23090</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tae Mi Yoon, Sun-Ae Kim, Young-Lan Park, Kyung-Hwa Lee, Myung-Whun Sung, Joon Kyoo Lee, Sang Chul Lim, Ik-Joo Chung, Young-Eun Joo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-06T05:05:33.119377-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23090</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23090</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23090</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to investigate expression of recepteur d'origine nantais (RON) in human hypopharyngeal squamous cell carcinoma (SCC) and to determine whether RON affects tumor cell behavior in hypopharyngeal SCC cell line and if this would serve as a target for molecular therapy in a preclinical model.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Reverse transcriptase-polymerase chain reaction, immunohistochemistry, Western blotting, cell invasion, migration, proliferation, and apoptosis assays were used to assess alteration of RON expression and its impact to cancer progression in human hypopharyngeal SCC.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Immunoreactivity of RON was observed in hypopharyngeal SCC tissues relative to adjacent normal mucosa in all cases. RON protein expression was significantly increased in metastatic lymph nodes than nonmetastatic lymph nodes by Western blotting. Knockdown of RON resulted in significantly reduced cell invasion, migration, and proliferation in human hypopharyngeal SCC cells. Knockdown of RON enhanced cell apoptosis through activation of caspase 3, caspase 7, and poly ADP-ribose polymerase (PARP).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>These results indicate that knockdown of RON expression may be associated with the reversal of invasive phenotype in hypopharyngeal SCC. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
The purpose of this study was to investigate expression of recepteur d'origine nantais (RON) in human hypopharyngeal squamous cell carcinoma (SCC) and to determine whether RON affects tumor cell behavior in hypopharyngeal SCC cell line and if this would serve as a target for molecular therapy in a preclinical model.


Methods
Reverse transcriptase-polymerase chain reaction, immunohistochemistry, Western blotting, cell invasion, migration, proliferation, and apoptosis assays were used to assess alteration of RON expression and its impact to cancer progression in human hypopharyngeal SCC.


Results
Immunoreactivity of RON was observed in hypopharyngeal SCC tissues relative to adjacent normal mucosa in all cases. RON protein expression was significantly increased in metastatic lymph nodes than nonmetastatic lymph nodes by Western blotting. Knockdown of RON resulted in significantly reduced cell invasion, migration, and proliferation in human hypopharyngeal SCC cells. Knockdown of RON enhanced cell apoptosis through activation of caspase 3, caspase 7, and poly ADP-ribose polymerase (PARP).


Conclusion
These results indicate that knockdown of RON expression may be associated with the reversal of invasive phenotype in hypopharyngeal SCC. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23051" xmlns="http://purl.org/rss/1.0/"><title>Dynamic contrast-enhanced MR perfusion imaging of head and neck tumors at 3 Tesla</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23051</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Dynamic contrast-enhanced MR perfusion imaging of head and neck tumors at 3 Tesla</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matakazu Furukawa, Upendra Parvathaneni, Kenneth Maravilla, Todd L. Richards, Yoshimi Anzai</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-06T05:05:12.401795-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23051</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23051</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23051</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Dynamic contrast-enhanced (DCE) MR perfusion imaging allows assessment of vascular density and integrity of tumors. The purpose of this study was to determine the diagnostic efficacy of time intensity curve analysis on DCE MRI for characterization of head and neck tumors.</p></div></div>
<div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Twenty patients underwent T1-weighted fast field echo DCE MRI with temporal resolution of 2.6 seconds. In total, 100 dynamic phases covering 20 slices were obtained in 4.5 minutes. Time to peak (TTP), relative maximum enhancement (RME) ratio, and relative washout ratio (RWO) were calculated.</p></div></div>
<div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Malignant tumors had a significantly lower RME (<em>p</em> = .025) and prolonged TTP with lower RWO than benign lesions. Postradiation changes had a significantly longer TTP (<em>p</em> = .024) and lower RWO (<em>p</em> = .007) than did postradiation recurrent tumors. Receiver operating characteristic (ROC) analysis revealed RWO had highest accuracy (area under the curve [AUC] = 1.0).</p></div></div>
<div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>DCE MR perfusion imaging provides pivotal information regarding microcirculation, potentially improves differentiation of malignant tumor from postradiation changes. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>
]]></content:encoded><description>


Background
Dynamic contrast-enhanced (DCE) MR perfusion imaging allows assessment of vascular density and integrity of tumors. The purpose of this study was to determine the diagnostic efficacy of time intensity curve analysis on DCE MRI for characterization of head and neck tumors.


Methods
Twenty patients underwent T1-weighted fast field echo DCE MRI with temporal resolution of 2.6 seconds. In total, 100 dynamic phases covering 20 slices were obtained in 4.5 minutes. Time to peak (TTP), relative maximum enhancement (RME) ratio, and relative washout ratio (RWO) were calculated.


Results
Malignant tumors had a significantly lower RME (p = .025) and prolonged TTP with lower RWO than benign lesions. Postradiation changes had a significantly longer TTP (p = .024) and lower RWO (p = .007) than did postradiation recurrent tumors. Receiver operating characteristic (ROC) analysis revealed RWO had highest accuracy (area under the curve [AUC] = 1.0).


Conclusions
DCE MR perfusion imaging provides pivotal information regarding microcirculation, potentially improves differentiation of malignant tumor from postradiation changes. © 2012 Wiley Periodicals, Inc. Head Neck, 2012

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23055" xmlns="http://purl.org/rss/1.0/"><title>Dysphonia as an unusual debut of parsonage–Turner syndrome</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23055</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Dysphonia as an unusual debut of parsonage–Turner syndrome</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laura Samarà, Josep Valls–Sole, Miguel Caballero</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-06T02:26:05.842313-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23055</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23055</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23055</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Parsonage–Turner syndrome is a rare and painful peripheral neuropathy that usually presents as brachial plexus neuritis and also has other nerve involvement.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods and Results</h4><div class="para"><p>Herein, we report the case of a patient with right recurrent nerve palsy as the first clinically isolated manifestation of underlying Parsonage–Turner syndrome. Idiopathic dysphonia was the only symptom presenting during a week for a patient that later developed a more conventional neurological deficit in her right shoulder.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The case illustrates the need for a careful clinical-neurologic examination beyond the larynx in patients presenting with idiopathic dysphonia. Parsonage–Turner syndrome should be considered as one of the rare causes in the differential diagnosis of isolated and otherwise unexplained dysphonia. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundParsonage–Turner syndrome is a rare and painful peripheral neuropathy that usually presents as brachial plexus neuritis and also has other nerve involvement.Methods and ResultsHerein, we report the case of a patient with right recurrent nerve palsy as the first clinically isolated manifestation of underlying Parsonage–Turner syndrome. Idiopathic dysphonia was the only symptom presenting during a week for a patient that later developed a more conventional neurological deficit in her right shoulder.ConclusionsThe case illustrates the need for a careful clinical-neurologic examination beyond the larynx in patients presenting with idiopathic dysphonia. Parsonage–Turner syndrome should be considered as one of the rare causes in the differential diagnosis of isolated and otherwise unexplained dysphonia. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23091" xmlns="http://purl.org/rss/1.0/"><title>Altered tissue electrical properties in squamous cell carcinoma in head and neck tumors: Preliminary observations</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23091</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Altered tissue electrical properties in squamous cell carcinoma in head and neck tumors: Preliminary observations</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Teresa Małecka–Massalska, Agata Smolen, Kamal Morshed</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-08-01T06:58:42.649807-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23091</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23091</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23091</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to investigate tissue electrical properties in patients with head and neck cancer.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>In the cross-sectional study direct bioimpedance measures (resistance, reactance, and phase angle) determined by bioelectrical impedance analysis (BIA) were performed on 31 patients with head and neck cancer and 31 healthy volunteers matched by age and sex as a control group.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Phase angle at 50 kHz was found to be significantly lower (<em>p</em> = .000006) in patients with head and neck cancer than in the control group (4.69° ± 0.71 vs 5.59° ± 0.70, respectively). Resistance was significantly (<em>p</em> = .0002) greater in patients with head and neck cancer than in the control group (596.24 ± 96.31 ohm vs 513.73 ± 65.79 ohm, respectively).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Presurgical patients diagnosed with head and neck cancer have altered tissue electrical properties. Further observations would be valuable to calculate survival, validate the prognostic significance of phase angle, and monitor nutritional and therapeutic interventions in this patient population. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to investigate tissue electrical properties in patients with head and neck cancer.MethodsIn the cross-sectional study direct bioimpedance measures (resistance, reactance, and phase angle) determined by bioelectrical impedance analysis (BIA) were performed on 31 patients with head and neck cancer and 31 healthy volunteers matched by age and sex as a control group.ResultsPhase angle at 50 kHz was found to be significantly lower (p = .000006) in patients with head and neck cancer than in the control group (4.69° ± 0.71 vs 5.59° ± 0.70, respectively). Resistance was significantly (p = .0002) greater in patients with head and neck cancer than in the control group (596.24 ± 96.31 ohm vs 513.73 ± 65.79 ohm, respectively).ConclusionPresurgical patients diagnosed with head and neck cancer have altered tissue electrical properties. Further observations would be valuable to calculate survival, validate the prognostic significance of phase angle, and monitor nutritional and therapeutic interventions in this patient population. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23117" xmlns="http://purl.org/rss/1.0/"><title>Update and external validation of a head and neck cancer prognostic model</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23117</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Update and external validation of a head and neck cancer prognostic model</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Frank R. Datema, Marciano B. Ferrier, Yvonne Vergouwe, Ana Moya, Jan Molenaar, Jay F. Piccirillo, Robert J. Baatenburg de Jong</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-30T01:20:00.142107-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23117</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23117</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23117</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to update and external validation of a prognostic model that is able to predict the survival probability of newly diagnosed patients with head and neck cancer.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Our original prognostic model is based on historical data of 1371 patients with primary head and neck cancer, diagnosed and treated in the Leiden University Medical Center, between 1981 and 1999. The model contains the predictors age, sex, tumor site, TNM-classification, prior tumors, and comorbidity. We updated the model with follow-up data until January 2010. The updated model was then externally validated in 598 patients with head and neck cancer from the Siteman Cancer Center/Barnes-Jewish Hospital, St. Louis, Missouri.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Median follow-up was 5.5 years (range, 0–25.5). Only 2.5% of patients were lost to follow-up. During follow-up 1099 patients (80.2%) passed away. Discrimination of the updated prognostic model was good, with a C-index of 0.73 after internal validation. The discrimination was slightly lower in the external validation set (C-index, 0.69). The predicted 2-year and 5-year survival rates correlated satisfactorily with some slight deviations from the perfect calibration line.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>We used recent follow-up information to update the Leiden prognostic model for newly diagnosed patients with head and neck cancer. The model showed acceptably good calibration and discrimination results in internal and external validation procedures. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to update and external validation of a prognostic model that is able to predict the survival probability of newly diagnosed patients with head and neck cancer.MethodsOur original prognostic model is based on historical data of 1371 patients with primary head and neck cancer, diagnosed and treated in the Leiden University Medical Center, between 1981 and 1999. The model contains the predictors age, sex, tumor site, TNM-classification, prior tumors, and comorbidity. We updated the model with follow-up data until January 2010. The updated model was then externally validated in 598 patients with head and neck cancer from the Siteman Cancer Center/Barnes-Jewish Hospital, St. Louis, Missouri.ResultsMedian follow-up was 5.5 years (range, 0–25.5). Only 2.5% of patients were lost to follow-up. During follow-up 1099 patients (80.2%) passed away. Discrimination of the updated prognostic model was good, with a C-index of 0.73 after internal validation. The discrimination was slightly lower in the external validation set (C-index, 0.69). The predicted 2-year and 5-year survival rates correlated satisfactorily with some slight deviations from the perfect calibration line.ConclusionsWe used recent follow-up information to update the Leiden prognostic model for newly diagnosed patients with head and neck cancer. The model showed acceptably good calibration and discrimination results in internal and external validation procedures. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23118" xmlns="http://purl.org/rss/1.0/"><title>Pilot, randomized trial of resistance exercise during radiation therapy for head and neck cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23118</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pilot, randomized trial of resistance exercise during radiation therapy for head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laura Q. Rogers, Philip M. Anton, Amanda Fogleman, Patricia Hopkins–Price, Steven Verhulst, Krishna Rao, James Malone, Randy Robbs, Kerry S. Courneya, Parashar Nanavati, Sara Mansfield, K. Thomas Robbins</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-30T01:19:47.842392-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23118</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23118</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23118</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to determine the feasibility of a randomized trial of resistance exercise in patients with head and neck cancer receiving radiation.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Fifteen patients with head and neck cancer receiving radiation were randomized to resistance exercise (using resistance bands) or control group. Resistance exercise occurred at the radiation therapy site (weeks 1–6) and home (weeks 7–12).</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>No serious adverse events occurred related to resistance exercise. Medium to large effect size differences favoring resistance exercise versus control group were noted for perceived fatigue at 6 weeks (smaller increase in fatigue for resistance exercise group; 7.4 vs 15.4, effect size [<em>d</em>] = −0.64), quality of life at 6 weeks (−7.0 vs −14.4, <em>d</em> = 0.52), and chair rise time (seconds) at 6 and 12 weeks (−1.6 vs 0.4, <em>d</em> = −.63 and −1.9 vs 0.1, <em>d</em> = −0.60, respectively).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Resistance exercise is safe and feasible in patients with head and neck cancer receiving radiation; a definitive trial is warranted. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to determine the feasibility of a randomized trial of resistance exercise in patients with head and neck cancer receiving radiation.MethodsFifteen patients with head and neck cancer receiving radiation were randomized to resistance exercise (using resistance bands) or control group. Resistance exercise occurred at the radiation therapy site (weeks 1–6) and home (weeks 7–12).ResultsNo serious adverse events occurred related to resistance exercise. Medium to large effect size differences favoring resistance exercise versus control group were noted for perceived fatigue at 6 weeks (smaller increase in fatigue for resistance exercise group; 7.4 vs 15.4, effect size [d] = −0.64), quality of life at 6 weeks (−7.0 vs −14.4, d = 0.52), and chair rise time (seconds) at 6 and 12 weeks (−1.6 vs 0.4, d = −.63 and −1.9 vs 0.1, d = −0.60, respectively).ConclusionsResistance exercise is safe and feasible in patients with head and neck cancer receiving radiation; a definitive trial is warranted. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23121" xmlns="http://purl.org/rss/1.0/"><title>Surgical management of bilateral parotid lipomatosis in a patient with HIV</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23121</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Surgical management of bilateral parotid lipomatosis in a patient with HIV</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aileen L. Cunningham, Ali S. Taghi, Gurmit Kaur Jagjit Singh, Ann Sandison, Charlotte E. Cohen, William E. Grant</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-30T01:19:33.796424-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23121</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23121</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23121</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The long-term use of highly active antiretroviral therapy (HAART) in patients with human immunodeficiency virus (HIV) has led to sequelae including lipodystrophy syndrome (LDS). We present the first published case of surgical management of bilateral parotid lipomatosis in a patient with HIV on long-term HAART.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We undertook review of the case notes from the time of diagnosis with HIV and literature review of this topic.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>A 45-year-old man with HIV on HAART presented with a 4-year history of increasing bilateral facial swelling. He was asymptomatic apart from the stigmatizing cosmetic deformity. MRI revealed the parotid glands had been replaced by fat. He elected for surgery and parotid lipomatosis was diagnosed on histopathological examination.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Lipohypertrophy in LDS is rare in the literature and this presentation of bilateral parotid lipomatosis secondary to HAART is only the third reported case, and the first to undergo surgical resection. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe long-term use of highly active antiretroviral therapy (HAART) in patients with human immunodeficiency virus (HIV) has led to sequelae including lipodystrophy syndrome (LDS). We present the first published case of surgical management of bilateral parotid lipomatosis in a patient with HIV on long-term HAART.MethodsWe undertook review of the case notes from the time of diagnosis with HIV and literature review of this topic.ResultsA 45-year-old man with HIV on HAART presented with a 4-year history of increasing bilateral facial swelling. He was asymptomatic apart from the stigmatizing cosmetic deformity. MRI revealed the parotid glands had been replaced by fat. He elected for surgery and parotid lipomatosis was diagnosed on histopathological examination.ConclusionLipohypertrophy in LDS is rare in the literature and this presentation of bilateral parotid lipomatosis secondary to HAART is only the third reported case, and the first to undergo surgical resection. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23065" xmlns="http://purl.org/rss/1.0/"><title>A new angle to mandibular reconstruction: The scapular tip free flap</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23065</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A new angle to mandibular reconstruction: The scapular tip free flap</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John Yoo, Samuel A. Dowthwaite, Kevin Fung, Jason Franklin, Anthony Nichols</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-29T23:50:00.460857-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23065</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23065</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23065</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to review our experience with the scapular tip free flap for mandibular reconstruction, describe the surgical approach, and highlight specific clinical applications.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A retrospective review of all patients undergoing oromandibular reconstruction using a scapular tip free flap at the London Health Sciences Centre was undertaken. Patient demographics, surgical data, and early outcomes were collated.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Twenty patients were identified. The majority involved mandibular angle and short segment defects (16 of 20). Average length of the segmental defect was 6.2 cm with the longest measuring 8 cm. A single patient required an osteotomy. Six were revision cases. No vein grafts were required. One complete flap failure occurred.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The natural scapular angle makes the scapular tip flap ideal for mandibular angle reconstruction. Short bone segments can be harvested with little donor-site morbidity. The long pedicle length may obviate vein grafts. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to review our experience with the scapular tip free flap for mandibular reconstruction, describe the surgical approach, and highlight specific clinical applications.MethodsA retrospective review of all patients undergoing oromandibular reconstruction using a scapular tip free flap at the London Health Sciences Centre was undertaken. Patient demographics, surgical data, and early outcomes were collated.ResultsTwenty patients were identified. The majority involved mandibular angle and short segment defects (16 of 20). Average length of the segmental defect was 6.2 cm with the longest measuring 8 cm. A single patient required an osteotomy. Six were revision cases. No vein grafts were required. One complete flap failure occurred.ConclusionsThe natural scapular angle makes the scapular tip flap ideal for mandibular angle reconstruction. Short bone segments can be harvested with little donor-site morbidity. The long pedicle length may obviate vein grafts. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23048" xmlns="http://purl.org/rss/1.0/"><title>“Mystic” transient recurrent nerve palsy after thyroid surgery</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23048</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">“Mystic” transient recurrent nerve palsy after thyroid surgery</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Áron Altorjay, Miklós Rüll, Balázs Paál, Géza Csáti, Anna Szilágyi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-29T23:49:44.095196-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23048</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23048</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23048</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The mechanism of transient recurrent laryngeal nerve (RLN) palsy remains unclear.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Samples were harvested from the RLN adjacent thyroid capsule and perineural fascia during 223 lobectomies and 89 RLNs from cadavers were used for histologic and immunohistologic evaluation. Intraoperative chromoendoscopic features of the RLN were compared with postoperative ear, nose, and throat examinations.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Those nerves that macroscopically seem to be single-branched (35 of 89 = 39.3%), microscopically consist of multiple fascicles in most of the cases (23 of 35 = 65.7%), resembling a plexus more than a single cord. Chronic lymphocytic infiltration of the thyroid capsule adjacent to the RLN was present in 29% (65 of 223) of the cases. The perineural fascia showed lymphocytic (18 of 223 = 8.1%) or granulocytic (7 of 223 = 3.1%) infiltration.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The origin of transient RLN palsy is multifactorial: plexus shaped microscopic nerve structure with or without branches, frame-like adventitial tissue, variable epineurium, inflammatory changes that involve not only the thyroid capsule but the perineural fascia, resultant nerve edema, and diffuse microhemorrhages by injury of fragile capillaries. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe mechanism of transient recurrent laryngeal nerve (RLN) palsy remains unclear.MethodsSamples were harvested from the RLN adjacent thyroid capsule and perineural fascia during 223 lobectomies and 89 RLNs from cadavers were used for histologic and immunohistologic evaluation. Intraoperative chromoendoscopic features of the RLN were compared with postoperative ear, nose, and throat examinations.ResultsThose nerves that macroscopically seem to be single-branched (35 of 89 = 39.3%), microscopically consist of multiple fascicles in most of the cases (23 of 35 = 65.7%), resembling a plexus more than a single cord. Chronic lymphocytic infiltration of the thyroid capsule adjacent to the RLN was present in 29% (65 of 223) of the cases. The perineural fascia showed lymphocytic (18 of 223 = 8.1%) or granulocytic (7 of 223 = 3.1%) infiltration.ConclusionsThe origin of transient RLN palsy is multifactorial: plexus shaped microscopic nerve structure with or without branches, frame-like adventitial tissue, variable epineurium, inflammatory changes that involve not only the thyroid capsule but the perineural fascia, resultant nerve edema, and diffuse microhemorrhages by injury of fragile capillaries. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23063" xmlns="http://purl.org/rss/1.0/"><title>Utility of multiple sampling in reducing variation of salivary interleukin-8 and interleukin-1β mRNA levels in healthy adults</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23063</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Utility of multiple sampling in reducing variation of salivary interleukin-8 and interleukin-1β mRNA levels in healthy adults</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeong Kyu Kim, Hui Zhou, Vishad Nabili, Marilene B. Wang, Elliot Abemayor, David T. W. Wong</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-17T00:31:39.875545-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23063</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23063</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23063</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Salivary mRNA biomarkers can exhibit significant variation over time. The purpose of this study was to investigate the pattern and magnitude of variation of salivary mRNA biomarkers and to explore the effect of performing replicate assays and multiple sampling on the dispersion of salivary biomarkers.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Salivary interleukin-8 (IL-8) and interleukin-1β (IL-1β) mRNAs, developed as biomarkers for oral cancer detection, were selected and measured from 15 healthy subjects at 4 different time points on the same day.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Salivary IL-8 and IL-1β mRNA levels fluctuated randomly over time without predictable rhythm and showed higher within-subject biological variation than analytical variation. The dispersion of salivary IL-8 and IL-1β mRNAs was more effectively reduced by taking multiple saliva sample measurements than by performing replicative assays.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Taking multiple saliva samples can effectively reduce variation of salivary IL-8 and IL-1β mRNA levels in healthy adults. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundSalivary mRNA biomarkers can exhibit significant variation over time. The purpose of this study was to investigate the pattern and magnitude of variation of salivary mRNA biomarkers and to explore the effect of performing replicate assays and multiple sampling on the dispersion of salivary biomarkers.MethodsSalivary interleukin-8 (IL-8) and interleukin-1β (IL-1β) mRNAs, developed as biomarkers for oral cancer detection, were selected and measured from 15 healthy subjects at 4 different time points on the same day.ResultsSalivary IL-8 and IL-1β mRNA levels fluctuated randomly over time without predictable rhythm and showed higher within-subject biological variation than analytical variation. The dispersion of salivary IL-8 and IL-1β mRNAs was more effectively reduced by taking multiple saliva sample measurements than by performing replicative assays.ConclusionTaking multiple saliva samples can effectively reduce variation of salivary IL-8 and IL-1β mRNA levels in healthy adults. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23085" xmlns="http://purl.org/rss/1.0/"><title>Elevated levels of 1-hydroxypyrene and N′-nitrosonornicotine in smokers with head and neck cancer: A matched control study</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23085</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Elevated levels of 1-hydroxypyrene and N′-nitrosonornicotine in smokers with head and neck cancer: A matched control study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Samir S. Khariwala, Steven G. Carmella, Irina Stepanov, Patricia Fernandes, Amy Anne Lassig, Bevan Yueh, Dorothy Hatsukami, Stephen S. Hecht</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-17T00:31:27.317861-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23085</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23085</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23085</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Head and neck squamous cell carcinoma (HNSCC) is associated with tobacco use. Still, most smokers do not develop HNSCC. The mechanisms of varying susceptibility to HNSCC are poorly studied to date. Tobacco metabolite research provides insight regarding the innate metabolism and excretion of carcinogens.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Smokers with HNSCC (cases) were compared with smokers without HNSCC (controls) in a matched cohort. The tobacco metabolites studied were: 1-hydroxypyrene (1-HOP), <em>N′</em>-nitrosonornicotine (NNN), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL).</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In 33 subjects, mean 1-HOP was 1.82 pmol/mg creatinine versus 1.08 pmol/mg creatinine (<em>p</em> = .004) and mean NNN was 0.10 pmol/mg creatinine versus 0.04 pmol/mg creatinine (<em>p</em> = .01) in cases and controls, respectively. NNAL did not differ between groups.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Smokers with HNSCC have elevated urinary levels of 1-HOP and total NNN compared with matched controls, suggesting an increased effective exposure to these carcinogens. Tobacco constituent metabolites may be useful in understanding tobacco-related carcinogenesis in HNSCC. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundHead and neck squamous cell carcinoma (HNSCC) is associated with tobacco use. Still, most smokers do not develop HNSCC. The mechanisms of varying susceptibility to HNSCC are poorly studied to date. Tobacco metabolite research provides insight regarding the innate metabolism and excretion of carcinogens.MethodsSmokers with HNSCC (cases) were compared with smokers without HNSCC (controls) in a matched cohort. The tobacco metabolites studied were: 1-hydroxypyrene (1-HOP), N′-nitrosonornicotine (NNN), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL).ResultsIn 33 subjects, mean 1-HOP was 1.82 pmol/mg creatinine versus 1.08 pmol/mg creatinine (p = .004) and mean NNN was 0.10 pmol/mg creatinine versus 0.04 pmol/mg creatinine (p = .01) in cases and controls, respectively. NNAL did not differ between groups.ConclusionsSmokers with HNSCC have elevated urinary levels of 1-HOP and total NNN compared with matched controls, suggesting an increased effective exposure to these carcinogens. Tobacco constituent metabolites may be useful in understanding tobacco-related carcinogenesis in HNSCC. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23046" xmlns="http://purl.org/rss/1.0/"><title>Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23046</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jill Gilbert, Ju Whei Lee, Athanassios Argiris, Missak Haigentz, Lawrence Eric Feldman, Minyoung Jang, Pattatheyil Arun, Carter Van Waes, Arlene A. Forastiere</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-13T05:09:06.542383-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23046</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23046</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23046</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Constitutive activation of nuclear factor κB (NF-κB) is associated with poor prognosis. Irinotecan demonstrates single-agent activity in head and neck cancer but activates NF-κB, promoting cell survival and resistance. Bortezomib is a proteasome inhibitor that inactivates NF-κB.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Patients and Methods</h4><div class="para"><p>We performed a randomized phase II trial of bortezomib on days 1, 4, 8, and 11 and irinotecan on days 1 and 8 of each 21-day cycle or single-agent bortezomib on days 1, 4, 8, and 11 on a 21-day cycle. The addition of irinotecan to bortezomib was allowed in patients who progressed on bortezomib alone.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The response rate of bortezomib and irinotecan was 13%. One patient had a partial response to bortezomib alone (response rate 3%). No responses were seen in patients with addition of irinotecan at time of progression on bortezomib.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The bortezomib-based regimens evaluated in this study have minimal activity in recurrent or metastatic head and neck cancer. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundConstitutive activation of nuclear factor κB (NF-κB) is associated with poor prognosis. Irinotecan demonstrates single-agent activity in head and neck cancer but activates NF-κB, promoting cell survival and resistance. Bortezomib is a proteasome inhibitor that inactivates NF-κB.Patients and MethodsWe performed a randomized phase II trial of bortezomib on days 1, 4, 8, and 11 and irinotecan on days 1 and 8 of each 21-day cycle or single-agent bortezomib on days 1, 4, 8, and 11 on a 21-day cycle. The addition of irinotecan to bortezomib was allowed in patients who progressed on bortezomib alone.ResultsThe response rate of bortezomib and irinotecan was 13%. One patient had a partial response to bortezomib alone (response rate 3%). No responses were seen in patients with addition of irinotecan at time of progression on bortezomib.ConclusionsThe bortezomib-based regimens evaluated in this study have minimal activity in recurrent or metastatic head and neck cancer. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23076" xmlns="http://purl.org/rss/1.0/"><title>Orosphere assay: A method for propagation of head and neck cancer stem cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23076</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Orosphere assay: A method for propagation of head and neck cancer stem cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sudha Krishnamurthy, Jacques E. Nör</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-13T05:07:13.181251-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23076</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23076</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23076</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Recent evidence suggests that head and neck squamous cell carcinomas (HNSCCs) harbor a small subpopulation of highly tumorigenic cells, designated cancer stem cells. A limiting factor in cancer stem cell research is the intrinsic difficulty of expanding cells in an undifferentiated state in vitro.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Here, we describe the development of the orosphere assay, a method for the study of putative head and neck cancer stem cells. An orosphere is defined as a nonadherent colony of cells sorted from primary HNSCCs or from HNSCC cell lines and cultured in 3-dimensional soft agar or ultralow attachment plates. Aldehyde dehydrogenase activity and CD44 expression were used here as stem cell markers.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>This assay allowed for the propagation of head and neck cancer cells that retained stemness and self-renewal.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>The orosphere assay is well suited for studies designed to understand the pathobiology of head and neck cancer stem cells. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundRecent evidence suggests that head and neck squamous cell carcinomas (HNSCCs) harbor a small subpopulation of highly tumorigenic cells, designated cancer stem cells. A limiting factor in cancer stem cell research is the intrinsic difficulty of expanding cells in an undifferentiated state in vitro.MethodsHere, we describe the development of the orosphere assay, a method for the study of putative head and neck cancer stem cells. An orosphere is defined as a nonadherent colony of cells sorted from primary HNSCCs or from HNSCC cell lines and cultured in 3-dimensional soft agar or ultralow attachment plates. Aldehyde dehydrogenase activity and CD44 expression were used here as stem cell markers.ResultsThis assay allowed for the propagation of head and neck cancer cells that retained stemness and self-renewal.ConclusionThe orosphere assay is well suited for studies designed to understand the pathobiology of head and neck cancer stem cells. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23077" xmlns="http://purl.org/rss/1.0/"><title>Interruption of nuclear localization of ATBF1 during the histopathologic progression of head and neck squamous cell carcinoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23077</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Interruption of nuclear localization of ATBF1 during the histopathologic progression of head and neck squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiaodong Sun, Jie Li, Gabriel Sica, Song-Qing Fan, Yuxiang Wang, Zhengjia Chen, Susan Muller, Zhuo (Georgia) Chen, Xiaoying Fu, Xue-Yuan Dong, Peng Guo, Dong M. Shin, Jin-Tang Dong</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-13T05:07:01.791226-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23077</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23077</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23077</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The AT-motif binding factor 1 (ATBF1) gene is frequently altered at the genetic level in several types of cancer, but its protein expression and subcellular localization have not been well studied in human cancers, including head and neck squamous cell carcinomas (HNSCCs).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>ATBF1 expression and localization were examined in 5 cell lines and 197 clinical specimens of HNSCC, and correlated with pathologic and clinical characteristics.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>ATBF1 was predominantly localized in the nucleus of hyperplastic squamous epithelium. Whereas nuclear ATBF1 dramatically decreased in invasive tumors (<em>p</em> = .0012), cytoplasmic ATBF1 levels progressively increased from dysplasia to invasive tumors (<em>p</em> &lt; .0001), and the increase correlated with poor survival. Reduced nuclear ATBF1 level was also detected in HNSCC cell lines.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Nuclear localization of ATBF1 is frequently interrupted in HNSCC, and the interruption is significantly associated with the progression of HNSCC. The cytoplasmic ATBF1 level could be useful for predicting patient survival. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe AT-motif binding factor 1 (ATBF1) gene is frequently altered at the genetic level in several types of cancer, but its protein expression and subcellular localization have not been well studied in human cancers, including head and neck squamous cell carcinomas (HNSCCs).MethodsATBF1 expression and localization were examined in 5 cell lines and 197 clinical specimens of HNSCC, and correlated with pathologic and clinical characteristics.ResultsATBF1 was predominantly localized in the nucleus of hyperplastic squamous epithelium. Whereas nuclear ATBF1 dramatically decreased in invasive tumors (p = .0012), cytoplasmic ATBF1 levels progressively increased from dysplasia to invasive tumors (p &lt; .0001), and the increase correlated with poor survival. Reduced nuclear ATBF1 level was also detected in HNSCC cell lines.ConclusionsNuclear localization of ATBF1 is frequently interrupted in HNSCC, and the interruption is significantly associated with the progression of HNSCC. The cytoplasmic ATBF1 level could be useful for predicting patient survival. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23079" xmlns="http://purl.org/rss/1.0/"><title>Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23079</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mario Turri–Zanoni, Daniela Medicina, Davide Lombardi, Marco Ungari, Piera Balzarini, Cristina Rossini, Wilma Pellegrini, Paolo Battaglia, Carlo Capella, Paolo Castelnuovo, Gabriele Palmedo, Fabio Facchetti, Heinz Kutzner, Piero Nicolai, William Vermi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-12T07:53:20.360709-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23079</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23079</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23079</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Primary sinonasal mucosal melanomas are aggressive tumors with a poor clinical control by current treatments, raising the urgent need of novel strategies.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>By fluorescence in situ hybridization (FISH), direct sequencing, and immunohistochemistry, we investigate the spectrum of molecular abnormalities in a cohort of 32 cases of primary sinonasal mucosal melanomas.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>We found that all primary sinonasal mucosal melanomas lack BRAF V600E mutation; in addition, they are characterized by somatic mutations of NRAS (22%) and KIT (12.5%), together with amplification of <em>RREB1</em> (100%) and loss of <em>MYB</em> (76%). The large majority of cases showed KIT protein expression (96.9%). Among tumor suppressor genes, primary sinonasal mucosal melanomas showed loss of PTEN (48.1%) and p16/INK4a (55.2%). All tested cases showed expression of pAkt and pErk, suggesting a combined activation of PI3K/Akt and RAS-mitogen-activated protein kinase (MAPK) pathways.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>This molecular fingerprint strongly argues against the clinical efficacy of BRAF-inhibitors, but could candidate primary sinonasal mucosal melanomas to therapeutic strategies targeting RAS and KIT mutations or inhibiting PI3K-Akt-mTOR pathway. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundPrimary sinonasal mucosal melanomas are aggressive tumors with a poor clinical control by current treatments, raising the urgent need of novel strategies.MethodsBy fluorescence in situ hybridization (FISH), direct sequencing, and immunohistochemistry, we investigate the spectrum of molecular abnormalities in a cohort of 32 cases of primary sinonasal mucosal melanomas.ResultsWe found that all primary sinonasal mucosal melanomas lack BRAF V600E mutation; in addition, they are characterized by somatic mutations of NRAS (22%) and KIT (12.5%), together with amplification of RREB1 (100%) and loss of MYB (76%). The large majority of cases showed KIT protein expression (96.9%). Among tumor suppressor genes, primary sinonasal mucosal melanomas showed loss of PTEN (48.1%) and p16/INK4a (55.2%). All tested cases showed expression of pAkt and pErk, suggesting a combined activation of PI3K/Akt and RAS-mitogen-activated protein kinase (MAPK) pathways.ConclusionsThis molecular fingerprint strongly argues against the clinical efficacy of BRAF-inhibitors, but could candidate primary sinonasal mucosal melanomas to therapeutic strategies targeting RAS and KIT mutations or inhibiting PI3K-Akt-mTOR pathway. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23081" xmlns="http://purl.org/rss/1.0/"><title>Minimally invasive video-assisted thyroidectomy: Learning curve in terms of mean operative time and conversion and complication rates</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23081</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Minimally invasive video-assisted thyroidectomy: Learning curve in terms of mean operative time and conversion and complication rates</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yoann Pons, Benjamin Vérillaud, Jean–Philippe Blancal, Elisabeth Sauvaget, Tam Cloutier, Nicolas Le Clerc, Philippe Herman, Romain Kania</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-12T07:53:09.543941-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23081</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23081</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23081</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The purpose of this study was to evaluate the learning curve for minimally invasive video-assisted thyroidectomy (MIVAT).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Fifty consecutive patients were prospectively included in groups corresponding to their surgical order (10 patients in each group).</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The mean operation times between 2 neighboring groups were 33.9 minutes longer in group 1 than in group 2 (<em>p</em> = .01) and 25.8 minutes longer in group 3 than in group 4 (<em>p</em> = .002). The conversion rate for technical difficulties in group 1 was 6% (3 of 50). The definitive complication rate was 2% (1 of 50).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>In terms of operative time, 10 patients represented the early stage of the learning curve, and 30 patients represented the number of procedures required to reach an advanced level of skill. Considering the low conversion and complication rates, improved aesthetic results and postoperative course, MIVAT should become a tool in the repertoire of high-volume thyroid surgeons. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to evaluate the learning curve for minimally invasive video-assisted thyroidectomy (MIVAT).MethodsFifty consecutive patients were prospectively included in groups corresponding to their surgical order (10 patients in each group).ResultsThe mean operation times between 2 neighboring groups were 33.9 minutes longer in group 1 than in group 2 (p = .01) and 25.8 minutes longer in group 3 than in group 4 (p = .002). The conversion rate for technical difficulties in group 1 was 6% (3 of 50). The definitive complication rate was 2% (1 of 50).ConclusionsIn terms of operative time, 10 patients represented the early stage of the learning curve, and 30 patients represented the number of procedures required to reach an advanced level of skill. Considering the low conversion and complication rates, improved aesthetic results and postoperative course, MIVAT should become a tool in the repertoire of high-volume thyroid surgeons. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23083" xmlns="http://purl.org/rss/1.0/"><title>Tenascin-C, GLUT-1, and syndecan-2 expression in juvenile nasopharyngeal angiofibroma: Correlations to vessel density and tumor stage</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23083</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Tenascin-C, GLUT-1, and syndecan-2 expression in juvenile nasopharyngeal angiofibroma: Correlations to vessel density and tumor stage</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Suvi Renkonen, Päivi Heikkilä, Caj Haglund, Antti A. Mäkitie, Jaana Hagström</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-12T07:52:58.976558-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23083</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23083</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23083</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Juvenile nasopharyngeal angiofibroma (JNA) is a highly vascular tumor with some characteristics resembling those of vascular malformations. The significance of different growth and angiogenesis promoting factors for the etiology of JNA remains unsolved.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>We analyzed the immunoexpressions of glucose transporter 1 (GLUT-1), tenascin-C (TNC), and syndecan-2 in a series of 27 patients with JNA and compared these with each other and the clinical data to investigate their possible connections and role in the angiogenesis and growth of JNA.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>We found that frequent stromal TNC expression had a strong correlation with vessel density and tumor stage and endothelial GLUT-1 expression, when present, correlated with higher tumor stage. Stromal TNC and stromal GLUT-1 expressions were also found to correlate with each other.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>The immunoexpression of stromal TNC correlated with vascular density and higher tumors stage, which supports the idea of TNC having a role in the tumorigenesis of JNA putatively by promoting angiogenesis. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundJuvenile nasopharyngeal angiofibroma (JNA) is a highly vascular tumor with some characteristics resembling those of vascular malformations. The significance of different growth and angiogenesis promoting factors for the etiology of JNA remains unsolved.MethodsWe analyzed the immunoexpressions of glucose transporter 1 (GLUT-1), tenascin-C (TNC), and syndecan-2 in a series of 27 patients with JNA and compared these with each other and the clinical data to investigate their possible connections and role in the angiogenesis and growth of JNA.ResultsWe found that frequent stromal TNC expression had a strong correlation with vessel density and tumor stage and endothelial GLUT-1 expression, when present, correlated with higher tumor stage. Stromal TNC and stromal GLUT-1 expressions were also found to correlate with each other.ConclusionsThe immunoexpression of stromal TNC correlated with vascular density and higher tumors stage, which supports the idea of TNC having a role in the tumorigenesis of JNA putatively by promoting angiogenesis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23084" xmlns="http://purl.org/rss/1.0/"><title>Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23084</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jie Deng, Barbara A. Murphy, Mary S. Dietrich, Nancy Wells, Kenneth A. Wallston, Robert J. Sinard, Anthony J. Cmelak, Jill Gilbert, Sheila H. Ridner</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-12T07:52:38.542046-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23084</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23084</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23084</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Lymphedema may disrupt local function and affect quality of life (QOL) in patients with head and neck cancer. The purpose of this study was to examine the associations among severity of internal and external lymphedema, symptoms, functional status, and QOL in patients with head and neck cancer.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The sample included 103 patients who were ≥3 months after head and neck cancer treatment. Variables assessed included severity of internal and external lymphedema, physical/psychological symptoms, functional status, and QOL.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Severity of internal and external lymphedema was associated with physical symptoms and psychological symptoms. Patients with more severe external lymphedema were more likely to have a decrease in neck left/right rotation. The combined effects of external and internal lymphedema severity were associated with hearing impairment and decreased QOL.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Lymphedema severity correlates with symptom burden, functional status, and QOL in patients after head and neck cancer treatment. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundLymphedema may disrupt local function and affect quality of life (QOL) in patients with head and neck cancer. The purpose of this study was to examine the associations among severity of internal and external lymphedema, symptoms, functional status, and QOL in patients with head and neck cancer.MethodsThe sample included 103 patients who were ≥3 months after head and neck cancer treatment. Variables assessed included severity of internal and external lymphedema, physical/psychological symptoms, functional status, and QOL.ResultsSeverity of internal and external lymphedema was associated with physical symptoms and psychological symptoms. Patients with more severe external lymphedema were more likely to have a decrease in neck left/right rotation. The combined effects of external and internal lymphedema severity were associated with hearing impairment and decreased QOL.ConclusionsLymphedema severity correlates with symptom burden, functional status, and QOL in patients after head and neck cancer treatment. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23039" xmlns="http://purl.org/rss/1.0/"><title>Tonsillar carcinoma metastatic to the spleen presenting as trauma: A case report</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23039</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Tonsillar carcinoma metastatic to the spleen presenting as trauma: A case report</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Janet T. Lee, Vladimir Hugec, Warren McGuire, Kristin Gendron, Steven Semmler, Frederick W. Endorf</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-12T07:52:27.625068-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23039</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23039</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23039</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Background</em>. Cancers of the head and neck rarely metastasize to the spleen. To the best of our knowledge, there is no reported case of a tonsillar carcinoma metastasizing to the spleen. <em>Method and Results</em>. This patient had a splenic capsular rupture likely related to his metastases that presented as a traumatic splenic injury. The patient had received neoadjuvant chemotherapy followed by concurrent chemoradiotherapy. Two months after completion of radiotherapy, he fell out of bed. The next day he had acute abdominal pain and hypotension. CT findings were consistent with splenic rupture, and he underwent splenectomy. Pathologic assessment of the specimen showed metastatic SCC. <em>Conclusion</em>. New splemic lesions in patients with head and neck cancer should be investigated. Head Neck, 2012</p></div>]]></content:encoded><description>Background. Cancers of the head and neck rarely metastasize to the spleen. To the best of our knowledge, there is no reported case of a tonsillar carcinoma metastasizing to the spleen. Method and Results. This patient had a splenic capsular rupture likely related to his metastases that presented as a traumatic splenic injury. The patient had received neoadjuvant chemotherapy followed by concurrent chemoradiotherapy. Two months after completion of radiotherapy, he fell out of bed. The next day he had acute abdominal pain and hypotension. CT findings were consistent with splenic rupture, and he underwent splenectomy. Pathologic assessment of the specimen showed metastatic SCC. Conclusion. New splemic lesions in patients with head and neck cancer should be investigated. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23060" xmlns="http://purl.org/rss/1.0/"><title>Intraoperative cone-beam CT for head and neck surgery: Feasibility of clinical implementation using a prototype mobile C-arm</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23060</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Intraoperative cone-beam CT for head and neck surgery: Feasibility of clinical implementation using a prototype mobile C-arm</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Emma King, Michael J. Daly, Harley Chan, Gideon Bachar, Benjamin J. Dixon, Jeffrey H. Siewerdsen, Jonathan C. Irish</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-07-12T07:52:14.4912-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23060</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23060</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23060</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Intraoperative 3-dimensional (3D) imaging in head and neck surgery was developed using a prototype mobile C-arm for cone-beam CT (CBCT). This article summarizes its implementation in a prospective pilot and feasibility study.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The CBCT C-arm was used in 12 head and neck surgical oncology cases. Human-factors engineering methods and expert feedback from surgeons, nurses, and anesthetists were used to evaluate the impact of intraoperative imaging on the surgical environment and clinical workflow. Image quality of CBCT and the perceived clinical utility were evaluated.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>The CBCT C-arm was successfully incorporated in 12 head and neck cases and streamlined into the surgical environment. Reviewed 3D-CBCT images were qualitatively sufficient for intraoperative-guidance for bony detail. Additional artifact management is required to improve soft-tissue visualization.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Intraoperative CBCT provides high-quality images for visualization of bony detail and is feasible during major head and neck surgery with acceptable workflow interruptions. Operations with significant bone ablation and/or reconstruction involving complex 3D anatomical structures are likely to benefit from the updated imaging. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundIntraoperative 3-dimensional (3D) imaging in head and neck surgery was developed using a prototype mobile C-arm for cone-beam CT (CBCT). This article summarizes its implementation in a prospective pilot and feasibility study.MethodsThe CBCT C-arm was used in 12 head and neck surgical oncology cases. Human-factors engineering methods and expert feedback from surgeons, nurses, and anesthetists were used to evaluate the impact of intraoperative imaging on the surgical environment and clinical workflow. Image quality of CBCT and the perceived clinical utility were evaluated.ResultsThe CBCT C-arm was successfully incorporated in 12 head and neck cases and streamlined into the surgical environment. Reviewed 3D-CBCT images were qualitatively sufficient for intraoperative-guidance for bony detail. Additional artifact management is required to improve soft-tissue visualization.ConclusionsIntraoperative CBCT provides high-quality images for visualization of bony detail and is feasible during major head and neck surgery with acceptable workflow interruptions. Operations with significant bone ablation and/or reconstruction involving complex 3D anatomical structures are likely to benefit from the updated imaging. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23073" xmlns="http://purl.org/rss/1.0/"><title>Synchronous bilateral inverted papilloma of the temporal bone: Case report and review of the literature</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23073</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Synchronous bilateral inverted papilloma of the temporal bone: Case report and review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stephen J. Ramey, J. Kyle Russo, Jack M. Condrey, Benjamin Coulter, Anand K. Sharma</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-06-28T01:41:54.087326-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23073</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23073</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23073</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Temporal bone inverted papilloma (IP) is an extremely rare tumor. Its etiology is unknown and represents a source of debate. Only 2 previous cases of bilateral temporal bone IP have been reported. A case report and review of the literature via PubMed database search are presented.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Mathods and Results</h4><div class="para"><p>A 52-year-old African-American man who initially underwent medial maxillectomy for right-sided nasal IP returned with bilateral temporal bone IP 7 months later without evidence of extension through the Eustachian tubes. Despite multiple resections and adjuvant radiation, the tumor transformed into squamous cell carcinoma and progressed to involve the intracranial dura, temporal lobe, and cervical dura.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Multiple origins may exist for temporal IP: direct extension, iatrogenic seeding, or development from ectopic Schneiderian epithelium. Temporal bone IP appears to represent a much more aggressive tumor than its nasal counterpart, necessitating aggressive early surgical intervention to decrease recurrence and transformation risk. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundTemporal bone inverted papilloma (IP) is an extremely rare tumor. Its etiology is unknown and represents a source of debate. Only 2 previous cases of bilateral temporal bone IP have been reported. A case report and review of the literature via PubMed database search are presented.Mathods and ResultsA 52-year-old African-American man who initially underwent medial maxillectomy for right-sided nasal IP returned with bilateral temporal bone IP 7 months later without evidence of extension through the Eustachian tubes. Despite multiple resections and adjuvant radiation, the tumor transformed into squamous cell carcinoma and progressed to involve the intracranial dura, temporal lobe, and cervical dura.ConclusionsMultiple origins may exist for temporal IP: direct extension, iatrogenic seeding, or development from ectopic Schneiderian epithelium. Temporal bone IP appears to represent a much more aggressive tumor than its nasal counterpart, necessitating aggressive early surgical intervention to decrease recurrence and transformation risk. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23071" xmlns="http://purl.org/rss/1.0/"><title>Outcome of patients with early T1 and T2 squamous cell carcinoma of the base of tongue managed by conventional surgery with adjuvant postoperative radiation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23071</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Outcome of patients with early T1 and T2 squamous cell carcinoma of the base of tongue managed by conventional surgery with adjuvant postoperative radiation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">N. Gopalakrishna Iyer, Leslie Kim, Iain J. Nixon, Frank Palmer, Jatin P. Shah, Snehal G. Patel, Ian Ganly</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-06-25T07:36:50.565462-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23071</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23071</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23071</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>Existing treatment regimens for squamous cell carcinoma (SCC) of the base of tongue (BOT) favor chemoradiation. However, there is a shifting paradigm toward minimally invasive surgery with adjuvant radiatiotherapy for select tumors. The aim was to report our experience in conventional surgical management with particular focus on T1/T2 tumors, which may be candidates for minimally invasive techniques.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>Between 1985 and 2005, 128 patients were treated with primary surgery. Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) rates were calculated using Kaplan–Meier method, and predictive factors analyzed by univariate and multivariate analyses.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Five-year OS, DSS, and RFS rates were 60%, 70%, and 61%, respectively. Multivariate analysis showed pathologic T classification and extracapsular extension (ECE) were significant predictors for DSS, whereas T classification remained significant for local recurrence. DSS for T1/T2 tumors ranged from 77% (node-positive) to 84% (node-negative).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>T classification and ECE are independent predictors of outcome for BOT SCC. Patients with cT1/T2 tumors had excellent outcome and may be suitable for transoral robotic or endoscopic surgical procedures. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundExisting treatment regimens for squamous cell carcinoma (SCC) of the base of tongue (BOT) favor chemoradiation. However, there is a shifting paradigm toward minimally invasive surgery with adjuvant radiatiotherapy for select tumors. The aim was to report our experience in conventional surgical management with particular focus on T1/T2 tumors, which may be candidates for minimally invasive techniques.MethodsBetween 1985 and 2005, 128 patients were treated with primary surgery. Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) rates were calculated using Kaplan–Meier method, and predictive factors analyzed by univariate and multivariate analyses.ResultsFive-year OS, DSS, and RFS rates were 60%, 70%, and 61%, respectively. Multivariate analysis showed pathologic T classification and extracapsular extension (ECE) were significant predictors for DSS, whereas T classification remained significant for local recurrence. DSS for T1/T2 tumors ranged from 77% (node-positive) to 84% (node-negative).ConclusionT classification and ECE are independent predictors of outcome for BOT SCC. Patients with cT1/T2 tumors had excellent outcome and may be suitable for transoral robotic or endoscopic surgical procedures. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23072" xmlns="http://purl.org/rss/1.0/"><title>In vitro apoptotic effects of methanol extracts of Dianthus chinensis and Acalypha australis L. targeting specificity protein 1 in human oral cancer cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23072</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">In vitro apoptotic effects of methanol extracts of Dianthus chinensis and Acalypha australis L. targeting specificity protein 1 in human oral cancer cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ji-Ae Shin, Jae-Jin Kim, Eun-Sun Choi, Jung-Hyun Shim, Mi Heon Ryu, Ki Han Kwon, Hee-Min Park, Jin-Young Seo, Soo-Yeon Lee, Do-Won Lim, Nam-Pyo Cho, Sung-Dae Cho</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-06-25T07:36:24.680959-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23072</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23072</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23072</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>The aims of this study were to evaluate the apoptotic activities and molecular mechanisms of methanol extracts of <em>Dianthus chinensis</em> (MEDC) and <em>Acalypha australis</em> L. (MEAL) in human oral cancer cells.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>The apoptotic effects and related molecular mechanisms of MEDC and MEAL on oral cancer cells were evaluated using MTS assay, DAPI staining, immunostaining, Western blotting, and reverse transcriptase–polymerase chain reaction.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>Sp1 was overexpressed in oral tumor tissues compared with normal oral mucosa. Downregulation of Sp1 inhibited the growth of SCC-15 and YD-15 oral cancer cells. MEDC and MEAL inhibited cell growth and induced apoptosis in both cell lines by decreasing the expression of Sp1. In addition, treatment of cells with MEDC and MEAL decreased Mcl-1 expression, which is a downstream target of Sp1.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusion</h4><div class="para"><p>Our results indicate that MEDC and MEAL are bioactive natural products that can potentially induce apoptosis of tumor cells that overexpress the Sp1 protein. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe aims of this study were to evaluate the apoptotic activities and molecular mechanisms of methanol extracts of Dianthus chinensis (MEDC) and Acalypha australis L. (MEAL) in human oral cancer cells.MethodsThe apoptotic effects and related molecular mechanisms of MEDC and MEAL on oral cancer cells were evaluated using MTS assay, DAPI staining, immunostaining, Western blotting, and reverse transcriptase–polymerase chain reaction.ResultsSp1 was overexpressed in oral tumor tissues compared with normal oral mucosa. Downregulation of Sp1 inhibited the growth of SCC-15 and YD-15 oral cancer cells. MEDC and MEAL inhibited cell growth and induced apoptosis in both cell lines by decreasing the expression of Sp1. In addition, treatment of cells with MEDC and MEAL decreased Mcl-1 expression, which is a downstream target of Sp1.ConclusionOur results indicate that MEDC and MEAL are bioactive natural products that can potentially induce apoptosis of tumor cells that overexpress the Sp1 protein. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23074" xmlns="http://purl.org/rss/1.0/"><title>Systematic review of treatment and prognosis of sinonasal hemangiopericytoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23074</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Systematic review of treatment and prognosis of sinonasal hemangiopericytoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Melanie Duval, Euna Hwang, Shaun J. Kilty</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-06-25T07:36:13.021546-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.23074</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.23074</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23074</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h4>Background</h4><div class="para"><p>This study was undertaken to determine the recurrence rate for open and endoscopic surgery and the clinical prognosis of this sinonasal tumor.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h4>Methods</h4><div class="para"><p>A systematic review of individual cases of sinonasal hemangiopericytoma was performed. A total of 97 articles were included in the study and reviewed to extract the relevant information about each case.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h4>Results</h4><div class="para"><p>In all, 194 cases of sinonasal hemangiopericytoma were identified. There were 53 recurrences (27.3%), 6 tumor-related deaths (3.1%), and 4 cases of metastases (2.1%). There was no significant difference between rate of recurrence for endoscopic or open resection (<em>p</em> = .06). Incomplete excision was the most important predictor of recurrence (odds ratio = 11.50, 95% confidence interval 3.76–36.82, <em>p</em> &lt; .001). Radiotherapy may be advantageous in cases of incomplete surgical resection (<em>p</em> = .03).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h4>Conclusions</h4><div class="para"><p>Complete excision is essential to minimize tumor recurrence and radiotherapy may decrease the rate of recurrence in the case of incomplete resection. Current evidence does not suggest that open resection is superior to endoscopic resection. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThis study was undertaken to determine the recurrence rate for open and endoscopic surgery and the clinical prognosis of this sinonasal tumor.MethodsA systematic review of individual cases of sinonasal hemangiopericytoma was performed. A total of 97 articles were included in the study and reviewed to extract the relevant information about each case.ResultsIn all, 194 cases of sinonasal hemangiopericytoma were identified. There were 53 recurrences (27.3%), 6 tumor-related deaths (3.1%), and 4 cases of metastases (2.1%). There was no significant difference between rate of recurrence for endoscopic or open resection (p = .06). Incomplete excision was the most important predictor of recurrence (odds ratio = 11.50, 95% confidence interval 3.76–36.82, p &lt; .001). Radiotherapy may be advantageous in cases of incomplete surgical resection (p = .03).ConclusionsComplete excision is essential to minimize tumor recurrence and radiotherapy may decrease the rate of recurrence in the case of incomplete resection. Current evidence does not suggest that open resection is superior to endoscopic resection. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23040" xmlns="http://purl.org/rss/1.0/"><title>Emerging understanding of dosimetric factors impacting on dysphagia and nutrition following radiotherapy for oropharyngeal cancer</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fhed.23040</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Emerging understanding of dosimetric factors impacting on dysphagia and nutrition following radiotherapy for oropharyngeal cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bena Cartmill, Petrea Cornwell, Elizabeth Ward, Wendy Davidson, Rebecca Nund, Catherine Bettington, Reza Masoud Rahbari, Michael Poulsen, Sandro Porceddu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-06-22T23:22:10.6730